0001193125-23-206204.txt : 20230808 0001193125-23-206204.hdr.sgml : 20230808 20230808161041 ACCESSION NUMBER: 0001193125-23-206204 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SCP Private Credit Income BDC LLC CENTRAL INDEX KEY: 0001743415 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 814-01294 FILM NUMBER: 231151386 BUSINESS ADDRESS: STREET 1: 500 PARK AVENUE STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 993-1670 MAIL ADDRESS: STREET 1: 500 PARK AVENUE STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 10-Q 1 d530243d10q.htm 10-Q 10-Q
Table of Contents
false0001743415Q2--12-31NYIncludes the impact of the different unit amounts used in calculating per unit data as a result of calculating certain per unit data based upon the weighted average units outstanding during the period and certain per unit data based on the units outstanding as of a period end. Not annualized for periods less than one year. Calculated as the change in NAV per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load.Indicates an investment that is wholly or partially held by SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”) through its wholly-owned financing subsidiary SCP Private Credit Income BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of June 30, 2023, on a fair value basis, non-qualifying assets in the portfolio represented 11.9% of the total assets of the Company.Non-income producing security.Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (“1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2022, on a fair value basis, non-qualifying assets in the portfolio represented 11.2% of the total assets of the Company.Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the LIBOR, SOFR or PRIME rate. These instruments are often subject to a LIBOR, SOFR or PRIME rate floor.Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (PRIME or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment we have provided the current interest rate in effect as of December 31, 2022.Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (PRIME or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment we have provided the current interest rate in effect as of June 30, 2023.Vapotherm, Inc. may elect to defer up to 9.00% of the coupon as PIK.Investment is on non-accrual status.Denotes investments in which we are an “Affiliated Person” but not exercising a controlling influence, as defined in the Investment Company Act of 1940, as amended (the “1940 Act”), due to beneficially owning, either directly or through one or more controlled companies, more than 5% but less than 25% of the outstanding voting securities of the investment.AmeriMark Interactive, LLC, AmeriMark Direct LLC, AmeriMark Intermediate Sub, Inc., L.T.D. Commodities LLC, Dr. Leonard’s Healthcare Corp. and Amerimark Intermediate Holdings, LLC are each co-Borrowers.BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK.iCIMS, Inc. may elect to defer up to 3.875% of the coupon as PIK.Kaseya, Inc. may elect to defer up to 2.50% of the coupon as PIK.AmeriMark Interactive, LLC, AmeriMark Direct LLC, AmeriMark Intermediate Sub, Inc., L.T.D. Commodities LLC, Dr. Leonard’s Healthcare Corp. and Amerimark Intermediate Holdings, LLC are each co-Borrowers. Amerimark may elect to defer up to 8.00% of the coupon as PIK.Through this entity and other intermediate entities, the Company owns approximately 6.5% of the underlying common units of ASC Holdco, LLC, a joint venture which owns certain assets of the former Amerimark Interactive, LLC.Vapotherm, Inc. may elect to defer up to 8.00% of the coupon as PIK.Aggregate net unrealized depreciation for U.S. federal income tax purposes is $9,108; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $6,687 and $15,795, respectively, based on a tax cost of $531,577. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.Aggregate net unrealized depreciation for U.S. federal income tax purposes is $927; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $5,202 and $6,129, respectively, based on a tax cost of $533,822. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated. 0001743415 2023-01-01 2023-06-30 0001743415 2023-08-04 0001743415 2022-12-31 0001743415 2023-06-30 0001743415 2022-01-01 2022-06-30 0001743415 2022-04-01 2022-06-30 0001743415 2023-04-01 2023-06-30 0001743415 2018-10-05 2018-10-05 0001743415 2019-03-12 2019-03-12 0001743415 2019-03-12 0001743415 2019-03-31 0001743415 2022-01-01 2022-12-31 0001743415 2021-12-31 0001743415 2022-03-31 0001743415 2023-03-31 0001743415 2022-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2023-06-30 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2023-06-30 0001743415 ck0001743415:SubscriptionFacilityMember 2023-06-30 0001743415 ck0001743415:SpvFacilityMember 2023-06-30 0001743415 ck0001743415:GlookoIncMember 2023-06-30 0001743415 ck0001743415:ArcutisBiotherapeuticsIncMember 2023-06-30 0001743415 ck0001743415:SpectrumPharmaceuticalsInc.Member 2023-06-30 0001743415 ck0001743415:CcSagHoldingsCorpMember 2023-06-30 0001743415 ck0001743415:VesscoMidcoHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:IcimsInc.Member 2023-06-30 0001743415 ck0001743415:OutsetMedicalInc.Member 2023-06-30 0001743415 ck0001743415:RscAcquisitionIncMember 2023-06-30 0001743415 ck0001743415:HumanInterestIncMember 2023-06-30 0001743415 ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:NacHoldingsCorporationMember 2023-06-30 0001743415 ck0001743415:IvyFertilityServicesLlcMember 2023-06-30 0001743415 ck0001743415:BaymarkHealthServicesIncMember 2023-06-30 0001743415 ck0001743415:AllStatesAgPartsLlcMember 2023-06-30 0001743415 ck0001743415:PlasticsManagementLlcMember 2023-06-30 0001743415 ck0001743415:PinnacleTreatmentCentersIncMember 2023-06-30 0001743415 ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember 2023-06-30 0001743415 ck0001743415:WorldInsuranceAssociatesLlcMember 2023-06-30 0001743415 ck0001743415:ApexServicePartnersLlcMember 2023-06-30 0001743415 ck0001743415:TaucManagementLlcMember 2023-06-30 0001743415 ck0001743415:SunmedGroupHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:OralSurgeryPartnersHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:MriSoftwareLlcMember 2023-06-30 0001743415 ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember 2023-06-30 0001743415 ck0001743415:FoundationConsumerBrandsLlcMember 2023-06-30 0001743415 ck0001743415:TilleyChemicalBuyerIncMember 2023-06-30 0001743415 ck0001743415:UltimateBakedGoodsMidcoLlcMember 2023-06-30 0001743415 ck0001743415:KidDistroHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:GsmAcquisitionCorpMember 2023-06-30 0001743415 ck0001743415:TransportationInsightLlcMember 2023-06-30 0001743415 ck0001743415:EnverusHoldingsIncMember 2023-06-30 0001743415 ck0001743415:MeditrinaInc.Member 2023-06-30 0001743415 ck0001743415:BasicFunIncMember 2023-06-30 0001743415 ck0001743415:OrthopedicCarePartnersManagementLlcMember 2023-06-30 0001743415 ck0001743415:KaseyaIncMember 2023-06-30 0001743415 ck0001743415:NexusIntermediateIiiLlcVortexMember 2023-06-30 0001743415 ck0001743415:MauricesIncorporatedMember 2023-06-30 0001743415 ck0001743415:ErieConstructionMidWestLlcMember 2023-06-30 0001743415 ck0001743415:RxsenseHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:PediatricHomeRespiratoryServicesLlcMember 2023-06-30 0001743415 ck0001743415:CerapedicsInc.Member 2023-06-30 0001743415 ck0001743415:SouthernOrthodonticPartnersManagementLlcMember 2023-06-30 0001743415 ck0001743415:HighStreetBuyerIncMember 2023-06-30 0001743415 ck0001743415:ArdelyxIncMember 2023-06-30 0001743415 ck0001743415:CapitalCommitmentConditionOneMember 2023-06-30 0001743415 ck0001743415:CapitalCommitmentConditionTwoMember 2023-06-30 0001743415 ck0001743415:RevolvingTermLoansMember 2023-06-30 0001743415 ck0001743415:JpmorganChaseBankMember ck0001743415:ScpPrivateCreditIncomeBdcSpvLlcMember ck0001743415:SpvFacilityMember 2023-06-30 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member ck0001743415:BankDebtSeniorSecuredLoansMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member ck0001743415:BankDebtSeniorSecuredLoansMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member ck0001743415:BankDebtSeniorSecuredLoansMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember ck0001743415:BankDebtSeniorSecuredLoansMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-06-30 0001743415 ck0001743415:SeniorSecuredLoansMember us-gaap:FairValueInputsLevel3Member us-gaap:IncomeApproachValuationTechniqueMember ck0001743415:MeasurementInputMarketYieldMember 2023-06-30 0001743415 ck0001743415:MeasurementInputRecoverableAmountMember ck0001743415:ValuationTechniqueRecoveryAnalysisModelMember us-gaap:FairValueInputsLevel3Member ck0001743415:BankDebtSeniorSecuredLoansMember 2023-06-30 0001743415 ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputEbitdaMultipleMember ck0001743415:MeasurementInputComparableMultipleMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member us-gaap:MarketApproachValuationTechniqueMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputEbitdaMultipleMember ck0001743415:MeasurementInputComparableMultipleMember srt:MinimumMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputEbitdaMultipleMember ck0001743415:MeasurementInputComparableMultipleMember srt:MaximumMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputEbitdaMultipleMember ck0001743415:MeasurementInputComparableMultipleMember srt:WeightedAverageMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member srt:MinimumMember ck0001743415:SeniorSecuredLoansMember us-gaap:IncomeApproachValuationTechniqueMember ck0001743415:MeasurementInputMarketYieldMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member srt:MaximumMember ck0001743415:SeniorSecuredLoansMember us-gaap:IncomeApproachValuationTechniqueMember ck0001743415:MeasurementInputMarketYieldMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member srt:WeightedAverageMember ck0001743415:SeniorSecuredLoansMember us-gaap:IncomeApproachValuationTechniqueMember ck0001743415:MeasurementInputMarketYieldMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member srt:MinimumMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MarketApproachValuationTechniqueMember us-gaap:MeasurementInputPriceVolatilityMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member srt:MaximumMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MarketApproachValuationTechniqueMember us-gaap:MeasurementInputPriceVolatilityMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member srt:WeightedAverageMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MarketApproachValuationTechniqueMember us-gaap:MeasurementInputPriceVolatilityMember 2023-06-30 0001743415 ck0001743415:SpectrumPharmaceuticalsIncMember ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SunmedGroupHoldingsLlcMember ck0001743415:HealthCareProvidersAndServicesMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:TaucManagementLlcMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:UltimateBakedGoodsMidcoLlcMember ck0001743415:PackagedFoodsAndMeatsMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:VapothermIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:RoadAndRailMember ck0001743415:TransportationInsightLlcMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:VesscoMidcoHoldingsLlcMember ck0001743415:WaterUtilitiesMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:WorldInsuranceAssociatesLlcMember ck0001743415:InsuranceMember 2023-06-30 0001743415 ck0001743415:SouthernOrthodonticPartnersManagementLlcMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:TilleyDistributionIncMember ck0001743415:TradingCompaniesAndDistributorsMember 2023-06-30 0001743415 ck0001743415:EnverusHoldingsIncMember ck0001743415:ItServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:KaseyaIncMember ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:HighStreetBuyerIncMember ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:GlookoIncMember ck0001743415:HealthCareTechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:CerapedicsIncMember ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:AlimeraSciencesIncMember ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:AllStateAgPartsLlcMember ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:ApexServicePartnersLlcMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:ArcutisBiotherapeuticsIncMember ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:PediatricHomeRespiratoryServicesLlcMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:OrthopedicCarePartnersManagementLlcMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:NeuroneticsIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:MriSoftwareLlcMember ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:MauricesIncorporatedMember ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:BasicFunIncMember ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:BaymarkHealthServicesIncMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:CcSagHoldingsCorpMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:EnhancedPermanentCapitalLlcMember ck0001743415:CapitalMarketsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:ErieConstructionMidWestLlcMember ck0001743415:BuildingProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:PlasticsManagementLlcMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:AmeriMarkIntermediateHoldingsLlcOneMember ck0001743415:InternetAndCatalogRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:AcresCommercialMortgageLlcMember ck0001743415:DiversifiedFinancialServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:KoreWirelessGroupIncMember ck0001743415:WirelessTelecommunicationServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:AmerimarkIntermediateHoldingsLlcMember ck0001743415:InternetAndCatalogRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:IcimsIncMember ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:OutsetMedicalIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:HigginbothamInsuranceAgencyMember ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:ArdelyxIncMember ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:CentrexionTherapeuticsIncMember ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:FertilityInvestmentHoldcoLlcMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:FoundationConsumerBrandsLlcMember ck0001743415:PersonalProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:PinnacleTreatmentCentersIncMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:BridgebioPharmaIncMember ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:RscAcquisitionIncMember ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:RxsenseHoldingsLlcMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:KidDistroHoldingsLlcMember ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:MeditrinaIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:NexusIntermediateIiiLlcVortexMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:GsmAcquisitionCorpMember ck0001743415:LeisureEquipmentAndProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:RqmPlusCorpMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:HumanInterestIncMember ck0001743415:InternetSoftwareAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SunmedGroupHoldingsLlcMember ck0001743415:HealthCareEquipmentAndSuppliesMember 2023-06-30 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:InternetAndCatalogRetailMember ck0001743415:SlrAmiTopcoBlockerLlcMember 2023-06-30 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:SpectrumPharmaceuticalsInc.WarrantsMember ck0001743415:BiotechnologyMember 2023-06-30 0001743415 ck0001743415:VapothermIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember 2023-06-30 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:SenseonicsHoldingsInc.CommonStockMember ck0001743415:HealthCareEquipmentAndSuppliesMember 2023-06-30 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:MeditrinaInc.WarrantsMember ck0001743415:HealthCareEquipmentAndSuppliesMember 2023-06-30 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:CentrexionTherapeuticsInc.WarrantsMember ck0001743415:PharmaceuticalsMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:InvestmentsOneHundredAndNinetyFivePointFivePercentageMember 2023-06-30 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember 2023-06-30 0001743415 ck0001743415:LiabilitiesInExcessOfOtherAssetsNinetyFivePointFivePercentageMember 2023-06-30 0001743415 ck0001743415:NetAssetsOneHundredPercentageMember 2023-06-30 0001743415 ck0001743415:SpecialtyRetailMember 2023-06-30 0001743415 ck0001743415:ProfessionalServicesMember 2023-06-30 0001743415 ck0001743415:RoadAndRailMember 2023-06-30 0001743415 ck0001743415:HealthCareTechnologyMember 2023-06-30 0001743415 ck0001743415:WaterUtilitiesMember 2023-06-30 0001743415 ck0001743415:DiversifiedFinancialServicesMember 2023-06-30 0001743415 ck0001743415:LeisureEquipmentAndProductsMember 2023-06-30 0001743415 ck0001743415:InternetAndCatalogRetailMember 2023-06-30 0001743415 ck0001743415:BuildingProductsMember 2023-06-30 0001743415 ck0001743415:CapitalMarketsMember 2023-06-30 0001743415 ck0001743415:PackagedFoodsAndMeatsMember 2023-06-30 0001743415 ck0001743415:InternetSoftwareServicesMember 2023-06-30 0001743415 ck0001743415:BiotechnologyMember 2023-06-30 0001743415 ck0001743415:PersonalProductsMember 2023-06-30 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember 2023-06-30 0001743415 ck0001743415:LifeSciencesToolsAndServicesMember 2023-06-30 0001743415 ck0001743415:ItServicesMember 2023-06-30 0001743415 ck0001743415:WirelessTelecommunicationServicesMember 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember 2023-06-30 0001743415 ck0001743415:InsuranceMember 2023-06-30 0001743415 ck0001743415:SoftwareMember 2023-06-30 0001743415 ck0001743415:DiversifiedConsumerServicesMember 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember 2023-06-30 0001743415 us-gaap:InvestmentsMember srt:MaximumMember 2023-06-30 0001743415 us-gaap:InvestmentsMember srt:MinimumMember 2023-06-30 0001743415 ck0001743415:AdvisorMember 2023-06-30 0001743415 ck0001743415:AscHoldcoLlcMember 2023-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2022-12-31 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2022-12-31 0001743415 ck0001743415:SubscriptionFacilityMember 2022-12-31 0001743415 ck0001743415:SpvFacilityMember 2022-12-31 0001743415 ck0001743415:ArdelyxIncMember 2022-12-31 0001743415 ck0001743415:GlookoIncMember 2022-12-31 0001743415 ck0001743415:ArcutisBiotherapeuticsIncMember 2022-12-31 0001743415 ck0001743415:SpectrumPharmaceuticalsInc.Member 2022-12-31 0001743415 ck0001743415:CcSagHoldingsCorpMember 2022-12-31 0001743415 ck0001743415:VesscoMidcoHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:IcimsInc.Member 2022-12-31 0001743415 ck0001743415:OutsetMedicalInc.Member 2022-12-31 0001743415 ck0001743415:RscAcquisitionIncMember 2022-12-31 0001743415 ck0001743415:HumanInterestIncMember 2022-12-31 0001743415 ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:BaymarkHealthServicesIncMember 2022-12-31 0001743415 ck0001743415:NacHoldingsCorporationMember 2022-12-31 0001743415 ck0001743415:PlasticsManagementLlcMember 2022-12-31 0001743415 ck0001743415:IvyFertilityServicesLlcMember 2022-12-31 0001743415 ck0001743415:AllStatesAgPartsLlcMember 2022-12-31 0001743415 ck0001743415:PinnacleTreatmentCentersIncMember 2022-12-31 0001743415 ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember 2022-12-31 0001743415 ck0001743415:WorldInsuranceAssociatesLlcMember 2022-12-31 0001743415 ck0001743415:ApexServicePartnersLlcMember 2022-12-31 0001743415 ck0001743415:TaucManagementLlcMember 2022-12-31 0001743415 ck0001743415:SunmedGroupHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:OralSurgeryPartnersHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:MriSoftwareLlcMember 2022-12-31 0001743415 ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember 2022-12-31 0001743415 ck0001743415:FoundationConsumerBrandsLlcMember 2022-12-31 0001743415 ck0001743415:TilleyChemicalBuyerIncMember 2022-12-31 0001743415 ck0001743415:UltimateBakedGoodsMidcoLlcMember 2022-12-31 0001743415 ck0001743415:KidDistroHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:GsmAcquisitionCorpMember 2022-12-31 0001743415 ck0001743415:TransportationInsightLlcMember 2022-12-31 0001743415 ck0001743415:EnverusHoldingsIncMember 2022-12-31 0001743415 ck0001743415:MeditrinaInc.Member 2022-12-31 0001743415 ck0001743415:BasicFunIncMember 2022-12-31 0001743415 ck0001743415:OrthopedicCarePartnersManagementLlcMember 2022-12-31 0001743415 ck0001743415:KaseyaIncMember 2022-12-31 0001743415 ck0001743415:NexusIntermediateIiiLlcVortexMember 2022-12-31 0001743415 ck0001743415:MauricesIncorporatedMember 2022-12-31 0001743415 ck0001743415:ErieConstructionMidWestLlcMember 2022-12-31 0001743415 ck0001743415:RxsenseHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:PediatricHomeRespiratoryServicesLlcMember 2022-12-31 0001743415 ck0001743415:CerapedicsInc.Member 2022-12-31 0001743415 ck0001743415:SouthernOrthodonticPartnersManagementLlcMember 2022-12-31 0001743415 ck0001743415:HighStreetBuyerIncMember 2022-12-31 0001743415 ck0001743415:RevolvingTermLoansMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member ck0001743415:BankDebtSeniorSecuredLoansMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member ck0001743415:BankDebtSeniorSecuredLoansMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member ck0001743415:BankDebtSeniorSecuredLoansMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember ck0001743415:BankDebtSeniorSecuredLoansMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2022-12-31 0001743415 ck0001743415:MeasurementInputMarketYieldMember ck0001743415:SeniorSecuredLoansMember us-gaap:IncomeApproachValuationTechniqueMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member us-gaap:MarketApproachValuationTechniqueMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member srt:MinimumMember ck0001743415:SeniorSecuredLoansMember us-gaap:IncomeApproachValuationTechniqueMember ck0001743415:MeasurementInputMarketYieldMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member srt:MaximumMember ck0001743415:SeniorSecuredLoansMember us-gaap:IncomeApproachValuationTechniqueMember ck0001743415:MeasurementInputMarketYieldMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member srt:WeightedAverageMember ck0001743415:SeniorSecuredLoansMember us-gaap:IncomeApproachValuationTechniqueMember ck0001743415:MeasurementInputMarketYieldMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member srt:MinimumMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MarketApproachValuationTechniqueMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member srt:MaximumMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MarketApproachValuationTechniqueMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member srt:WeightedAverageMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MarketApproachValuationTechniqueMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:VapothermIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:WaterUtilitiesMember ck0001743415:VesscoMidcoHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:WorldInsuranceAssociatesLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BiotechnologyMember ck0001743415:SpectrumPharmaceuticalsIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SunmedGroupHoldingsLlcMember ck0001743415:HealthCareEquipmentAndSuppliesMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PackagedFoodsAndMeatsMember ck0001743415:UltimateBakedGoodsMidcoLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:TilleyDistributionIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:RoadAndRailMember ck0001743415:TransportationInsightLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:TaucManagementLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:PediatricHomeRespiratoryServicesLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BiotechnologyMember ck0001743415:BridgebioPharmaIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:NeuroneticsIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:OutsetMedicalIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareTechnologyMember ck0001743415:GlookoIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:PlasticsManagementLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:LifeSciencesToolsAndServicesMember ck0001743415:RqmPlusCorpMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:RxsenseHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ItServicesMember ck0001743415:EnverusHoldingsIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PharmaceuticalsMember ck0001743415:CentrexionTherapeuticsIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:HigginbothamInsuranceAgencyMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SoftwareMember ck0001743415:IcimsIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:MeditrinaIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InternetAndCatalogRetailMember ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:SouthernOrthodonticPartnersManagementLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:WirelessTelecommunicationServicesMember ck0001743415:KoreWirelessGroupIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PersonalProductsMember ck0001743415:FoundationConsumerBrandsLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:LeisureEquipmentAndProductsMember ck0001743415:GsmAcquisitionCorpMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BuildingProductsMember ck0001743415:ErieConstructionMidWestLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:RscAcquisitionIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SpecialtyRetailMember ck0001743415:MauricesIncorporatedMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SpecialtyRetailMember ck0001743415:BasicFunIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BaymarkHealthServicesIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InternetSoftwareAndServicesMember ck0001743415:HumanInterestIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:IvyFertilityServicesLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SoftwareMember ck0001743415:KaseyaIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SoftwareMember ck0001743415:KidDistroHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PharmaceuticalsMember ck0001743415:ArdelyxIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:ApexServicePartnersLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PharmaceuticalsMember ck0001743415:ArcutisBiotherapeuticsIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:CcSagHoldingsCorpMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BiotechnologyMember ck0001743415:CerapedicsIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:CapitalMarketsMember ck0001743415:EnhancedPermanentCapitalLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:OrthopedicCarePartnersManagementLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ProfessionalServicesMember ck0001743415:NexusIntermediateIiiLlcVortexMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:AllStateAgPartsLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:PinnacleTreatmentCentersIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PersonalProductsMember ck0001743415:RevlonConsumerProductsCorporationMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:OralSurgeryPartnersHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:NACHoldingCorporationJaguarMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SoftwareMember ck0001743415:MriSoftwareLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:HighStreetBuyerIncMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:DiversifiedFinancialServicesMember ck0001743415:AcresCommercialMortgageLlcMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PharmaceuticalsMember ck0001743415:AlimeraSciencesIncMember 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:PharmaceuticalsMember ck0001743415:CentrexionTherapeuticsInc.WarrantsMember 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:VapothermIncMember 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:BiotechnologyMember ck0001743415:SpectrumPharmaceuticalsInc.WarrantsMember 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:SenseonicsHoldingsInc.CommonStockMember 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:MeditrinaInc.WarrantsMember 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember 2022-12-31 0001743415 ck0001743415:InvestmentsTwoHundredSeventyOnePointFivePercentageMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember 2022-12-31 0001743415 ck0001743415:LiabilitiesInExcessOfOtherAssetsOneHundredSeventyOnePointFivePercentageMember 2022-12-31 0001743415 ck0001743415:NetAssetsOneHundredPercentageMember 2022-12-31 0001743415 ck0001743415:InsuranceMember 2022-12-31 0001743415 ck0001743415:BiotechnologyMember 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember 2022-12-31 0001743415 ck0001743415:DiversifiedConsumerServicesMember 2022-12-31 0001743415 ck0001743415:SoftwareMember 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember 2022-12-31 0001743415 ck0001743415:WirelessTelecommunicationServicesMember 2022-12-31 0001743415 ck0001743415:ItServicesMember 2022-12-31 0001743415 ck0001743415:LifeSciencesToolsAndServicesMember 2022-12-31 0001743415 ck0001743415:InternetAndCatalogRetailMember 2022-12-31 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember 2022-12-31 0001743415 ck0001743415:PersonalProductsMember 2022-12-31 0001743415 ck0001743415:InternetSoftwareServicesMember 2022-12-31 0001743415 ck0001743415:CapitalMarketsMember 2022-12-31 0001743415 ck0001743415:PackagedFoodsAndMeatsMember 2022-12-31 0001743415 ck0001743415:BuildingProductsMember 2022-12-31 0001743415 ck0001743415:DiversifiedFinancialServicesMember 2022-12-31 0001743415 ck0001743415:LeisureEquipmentAndProductsMember 2022-12-31 0001743415 ck0001743415:WaterUtilitiesMember 2022-12-31 0001743415 ck0001743415:HealthCareTechnologyMember 2022-12-31 0001743415 ck0001743415:RoadAndRailMember 2022-12-31 0001743415 ck0001743415:SpecialtyRetailMember 2022-12-31 0001743415 ck0001743415:ProfessionalServicesMember 2022-12-31 0001743415 ck0001743415:AdvisorMember 2022-01-01 2022-06-30 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2022-01-01 2022-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2022-01-01 2022-06-30 0001743415 ck0001743415:KaseyaIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BridgebioPharmaIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:IcimsIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:VapothermIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AdministrationFeeMember ck0001743415:AdvisorMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AdvisorMember ck0001743415:ManagementFeeMember 2023-01-01 2023-06-30 0001743415 ck0001743415:SecondUnitholderPreferredReturnMember 2023-01-01 2023-06-30 0001743415 ck0001743415:FirstReturnOfCapitalContributionsMember 2023-01-01 2023-06-30 0001743415 srt:MinimumMember ck0001743415:SecondUnitholderPreferredReturnMember 2023-01-01 2023-06-30 0001743415 ck0001743415:ThirdAdviserCatchUpMember 2023-01-01 2023-06-30 0001743415 ck0001743415:Second.AdviserCatchUpMember 2023-01-01 2023-06-30 0001743415 ck0001743415:FirstUnitholderPreferredReturnMember 2023-01-01 2023-06-30 0001743415 ck0001743415:FourthOrderOfPriorityReturnOfCapitalContributionsMember 2023-01-01 2023-06-30 0001743415 ck0001743415:ThirdOrderOfPriorityReturnOfCapitalContributionsMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AdvisorMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CapitalCommitmentConditionOneMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CapitalCommitmentConditionTwoMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001743415 ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001743415 ck0001743415:CerapedicsIncMember ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:EnhancedPermanentCapitalLlcMember ck0001743415:CapitalMarketsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:EnverusHoldingsIncMember ck0001743415:ItServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:ErieConstructionMidWestLlcMember ck0001743415:BuildingProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:FoundationConsumerBrandsLlcMember ck0001743415:PersonalProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:PinnacleTreatmentCentersIncMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:PlasticsManagementLlcMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:RqmPlusCorpMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HumanInterestIncMember ck0001743415:InternetSoftwareAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:MeditrinaIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:NeuroneticsIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:OrthopedicCarePartnersManagementLlcMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:OutsetMedicalIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:PediatricHomeRespiratoryServicesLlcMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BaymarkHealthServicesIncMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:FertilityInvestmentHoldcoLlcMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:GsmAcquisitionCorpMember ck0001743415:LeisureEquipmentAndProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AllStateAgPartsLlcMember ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AmerimarkIntermediateHoldingsLlcMember ck0001743415:InternetAndCatalogRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AmeriMarkIntermediateHoldingsLlcOneMember ck0001743415:InternetAndCatalogRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AcresCommercialMortgageLlcMember ck0001743415:DiversifiedFinancialServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AlimeraSciencesIncMember ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:ApexServicePartnersLlcMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:ArcutisBiotherapeuticsIncMember ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:ArdelyxIncMember ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BasicFunIncMember ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:IcimsIncMember ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HighStreetBuyerIncMember ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HigginbothamInsuranceAgencyMember ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:GlookoIncMember ck0001743415:HealthCareTechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:RscAcquisitionIncMember ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:RxsenseHoldingsLlcMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:NexusIntermediateIiiLlcVortexMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:MriSoftwareLlcMember ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:MauricesIncorporatedMember ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:KoreWirelessGroupIncMember ck0001743415:WirelessTelecommunicationServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:KidDistroHoldingsLlcMember ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:KaseyaIncMember ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SpectrumPharmaceuticalsIncMember ck0001743415:BiotechnologyMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:CentrexionTherapeuticsInc.WarrantsMember ck0001743415:PharmaceuticalsMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:WorldInsuranceAssociatesLlcMember ck0001743415:InsuranceMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:VesscoMidcoHoldingsLlcMember ck0001743415:WaterUtilitiesMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:SpectrumPharmaceuticalsInc.WarrantsMember ck0001743415:BiotechnologyMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BridgebioPharmaIncMember ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CcSagHoldingsCorpMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CentrexionTherapeuticsIncMember ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:InternetAndCatalogRetailMember ck0001743415:SlrAmiTopcoBlockerLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:VapothermIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:UltimateBakedGoodsMidcoLlcMember ck0001743415:PackagedFoodsAndMeatsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:VapothermIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:MeditrinaInc.WarrantsMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:HealthCareEquipmentAndSuppliesMember 2023-01-01 2023-06-30 0001743415 ck0001743415:SenseonicsHoldingsInc.CommonStockMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:HealthCareEquipmentAndSuppliesMember 2023-01-01 2023-06-30 0001743415 ck0001743415:SunmedGroupHoldingsLlcMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:TaucManagementLlcMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:TilleyDistributionIncMember ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:TransportationInsightLlcMember ck0001743415:RoadAndRailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SouthernOrthodonticPartnersManagementLlcMember ck0001743415:HealthCareProvidersAndServicesMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SunmedGroupHoldingsLlcMember ck0001743415:HealthCareProvidersAndServicesMember 2023-01-01 2023-06-30 0001743415 us-gaap:InvestmentsMember srt:MaximumMember 2023-01-01 2023-06-30 0001743415 us-gaap:InvestmentsMember srt:MinimumMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AdvisorMember 2023-04-01 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansMember us-gaap:FairValueInputsLevel3Member 2023-04-01 2023-06-30 0001743415 ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-04-01 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member 2023-04-01 2023-06-30 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2023-04-01 2023-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2023-04-01 2023-06-30 0001743415 ck0001743415:AdvisorMember 2022-04-01 2022-06-30 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2022-04-01 2022-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2022-04-01 2022-06-30 0001743415 ck0001743415:AmerimarkInteractiveLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BridgebioPharmaIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:IcimsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:VapothermIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansMember us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SpecialtyRetailMember ck0001743415:MauricesIncorporatedMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SoftwareMember ck0001743415:MriSoftwareLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:NACHoldingCorporationJaguarMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:RxsenseHoldingsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SoftwareMember ck0001743415:KaseyaIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareTechnologyMember ck0001743415:GlookoIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PersonalProductsMember ck0001743415:FoundationConsumerBrandsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ItServicesMember ck0001743415:EnverusHoldingsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:HigginbothamInsuranceAgencyMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SoftwareMember ck0001743415:IcimsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:HighStreetBuyerIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:ApexServicePartnersLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ProfessionalServicesMember ck0001743415:NexusIntermediateIiiLlcVortexMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:WirelessTelecommunicationServicesMember ck0001743415:KoreWirelessGroupIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PharmaceuticalsMember ck0001743415:AlimeraSciencesIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PharmaceuticalsMember ck0001743415:ArdelyxIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BiotechnologyMember ck0001743415:BridgebioPharmaIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:DiversifiedConsumerServicesMember ck0001743415:CcSagHoldingsCorpMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:CapitalMarketsMember ck0001743415:EnhancedPermanentCapitalLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BiotechnologyMember ck0001743415:CerapedicsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:TilleyDistributionIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:RoadAndRailMember ck0001743415:TransportationInsightLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PackagedFoodsAndMeatsMember ck0001743415:UltimateBakedGoodsMidcoLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:VapothermIncMember ck0001743415:HealthCareEquipmentAndSuppliesMember 2022-01-01 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:MeditrinaInc.WarrantsMember 2022-01-01 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:SenseonicsHoldingsInc.CommonStockMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:PinnacleTreatmentCentersIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:PlasticsManagementLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:LifeSciencesToolsAndServicesMember ck0001743415:RqmPlusCorpMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:SouthernOrthodonticPartnersManagementLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SunmedGroupHoldingsLlcMember ck0001743415:HealthCareEquipmentAndSuppliesMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:TaucManagementLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:MeditrinaIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:NeuroneticsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:OralSurgeryPartnersHoldingsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:OrthopedicCarePartnersManagementLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:OutsetMedicalIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:PediatricHomeRespiratoryServicesLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InternetAndCatalogRetailMember ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BaymarkHealthServicesIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:LeisureEquipmentAndProductsMember ck0001743415:GsmAcquisitionCorpMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InternetSoftwareAndServicesMember ck0001743415:HumanInterestIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:IvyFertilityServicesLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:VapothermIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:AllStateAgPartsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:PharmaceuticalsMember ck0001743415:CentrexionTherapeuticsInc.WarrantsMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:WorldInsuranceAssociatesLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:WaterUtilitiesMember ck0001743415:VesscoMidcoHoldingsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SpecialtyRetailMember ck0001743415:BasicFunIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BiotechnologyMember ck0001743415:SpectrumPharmaceuticalsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:BiotechnologyMember ck0001743415:SpectrumPharmaceuticalsInc.WarrantsMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:DiversifiedFinancialServicesMember ck0001743415:AcresCommercialMortgageLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PharmaceuticalsMember ck0001743415:ArcutisBiotherapeuticsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SoftwareMember ck0001743415:KidDistroHoldingsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PersonalProductsMember ck0001743415:RevlonConsumerProductsCorporationMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BuildingProductsMember ck0001743415:ErieConstructionMidWestLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:InsuranceMember ck0001743415:RscAcquisitionIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PharmaceuticalsMember ck0001743415:CentrexionTherapeuticsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:JpmorganChaseBankMember ck0001743415:ScpPrivateCreditIncomeBdcSpvLlcMember ck0001743415:SpvFacilityMember 2019-01-01 2019-03-31 0001743415 ck0001743415:SpvFacilityMember ck0001743415:LondonInterbankOfferedRateMember 2019-03-31 2019-03-31 0001743415 ck0001743415:ScpPrivateCreditIncomeBdcSpvLlcMember ck0001743415:SpvFacilityMember ck0001743415:JpmorganChaseBankMember 2019-03-31 2019-03-31 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2019-03-31 0001743415 srt:MinimumMember ck0001743415:SpvFacilityMember 2019-03-31 0001743415 srt:MaximumMember ck0001743415:SpvFacilityMember 2019-03-31 0001743415 ck0001743415:SpvFacilityMember 2019-11-18 0001743415 ck0001743415:SpvFacilityMember 2021-02-27 0001743415 ck0001743415:SpvFacilityMember 2021-07-16 0001743415 ck0001743415:SpvFacilityMember 2021-08-18 0001743415 ck0001743415:SpvFacilityMember 2021-11-02 0001743415 ck0001743415:SpvFacilityMember 2022-08-03 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2019-06-24 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2021-03-05 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2021-10-04 0001743415 ck0001743415:EastWestBankMember ck0001743415:SubscriptionFacilityMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-12-28 2022-12-28 0001743415 ck0001743415:EastWestBankMember ck0001743415:SubscriptionFacilityMember 2022-12-28 2022-12-28 0001743415 ck0001743415:EastWestBankMember ck0001743415:SubscriptionFacilityMember 2022-12-28 0001743415 ck0001743415:ScpPrivateCreditIncomeBdcSpvLlcMember ck0001743415:SpvFacilityMember ck0001743415:JpmorganChaseBankMember 2021-08-18 2021-08-18 0001743415 ck0001743415:AmerimarkIntermediateHoldingsLlcMember us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-16 2023-06-30 0001743415 ck0001743415:SlrAmiTopcoBlockerLlcMember us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-16 2023-06-30 0001743415 ck0001743415:AmeriMarkIntermediateHoldingsLlcOneMember us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-16 2023-06-30 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-16 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001743415 ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001743415 ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001743415 ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-03-31 0001743415 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansMember us-gaap:FairValueInputsLevel3Member 2023-03-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001743415 ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001743415 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001743415 ck0001743415:AmeriMarkIntermediateHoldingsLlcOneMember us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-15 0001743415 ck0001743415:SlrAmiTopcoBlockerLlcMember us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-15 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-15 0001743415 ck0001743415:AmerimarkIntermediateHoldingsLlcMember us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-15 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-30 0001743415 ck0001743415:SlrAmiTopcoBlockerLlcMember us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-30 0001743415 ck0001743415:AmeriMarkIntermediateHoldingsLlcOneMember us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-30 0001743415 ck0001743415:AmerimarkIntermediateHoldingsLlcMember us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-30 xbrli:pure xbrli:shares iso4217:USD iso4217:USD xbrli:shares
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
 
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Quarter Ended June 30, 2023
 
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission File Number:
814-01294
 
 
SCP Private Credit Income BDC LLC
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
 
83-0634992
(State of Incorporation)
 
(I.R.S. Employer
Identification No.)
500 Park Avenue
New York, N.Y.
 
10022
(Address of principal executive offices)
 
(Zip Code)
(212993-1670
(Registrant’s telephone number, including area code)
 
 
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
 
Title of Each Class
 
Trading
Symbol
 
Name of Each Exchange
on Which Registered
N/A
 
N/A
 
N/A
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer      Accelerated filer  
Non-accelerated
filer
     Smaller Reporting company  
Emerging growth company       
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act).    Yes  ☐    No  
As of June 30, 2023, there was no established public market for the registrant’s units. The issuer had 25,190,253 units outstanding as of August 4, 2023.
 
 
 


Table of Contents

SCP PRIVATE CREDIT INCOME BDC LLC

FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2023

TABLE OF CONTENTS

 

    Index    Page
No.
 

PART I.

  FINANCIAL INFORMATION   

Item 1.

  Financial Statements   
  Consolidated Statements of Assets and Liabilities as of June 30, 2023 (unaudited) and December 31, 2022      3  
  Consolidated Statements of Operations for the three and six months ended June 30, 2023 (unaudited) and the three and six months ended June 30, 2022 (unaudited)      4  
  Consolidated Statements of Changes in Unitholders’ Capital for the three and six months ended June 30, 2023 (unaudited) and the three and six months ended June 30, 2022 (unaudited)      5  
  Consolidated Statements of Cash Flows for the six months ended June 30, 2023 (unaudited) and the six months ended June 30, 2022 (unaudited)      6  
  Consolidated Schedule of Investments as of June 30, 2023 (unaudited)      7  
  Consolidated Schedule of Investments as of December 31, 2022      11  
  Notes to Consolidated Financial Statements (unaudited)      14  
  Report of Independent Registered Public Accounting Firm      31  

Item 2.

  Management’s Discussion and Analysis of Financial Condition and Results of Operations      32  

Item 3.

  Quantitative and Qualitative Disclosures About Market Risk      43  

Item 4.

  Controls and Procedures      44  

PART II.

  OTHER INFORMATION   

Item 1.

  Legal Proceedings      44  

Item 1a.

  Risk Factors      44  

Item 2.

  Unregistered Sales of Equity Securities and Use of Proceeds      45  

Item 3.

  Defaults Upon Senior Securities      45  

Item 4.

  Mine Safety Disclosures      45  

Item 5.

  Other Information      45  

Item 6.

  Exhibits      46  

SIGNATURES

     47  

 

2


Table of Contents
PART I. FINANCIAL INFORMATION
In this Quarterly Report, “Company”, “we”, “us”, and “our” refer to SCP Private Credit Income BDC LLC unless the context states otherwise.
Item 1. Financial Statements
SCP Private Credit Income BDC LLC
Consolidated Statements of Assets and Liabilities
(in thousands, except unit amounts)
 
    
June 30, 2023
(unaudited)
    
December 31,
2022
 
Assets
                 
Investments at fair value:
                 
Companies less than 5% owned (cost: $505,230 and $529,070, respectively)
   $ 509,719      $ 532,895  
Companies 5% to 25% owned (
cost: $
21,595 and $0, respectively)
     12,750            
Cash
     13,060        16,697  
Interest receivable
     3,625        3,647  
Receivable for investments sold
     99            
Prepaid expenses
     86        22  
    
 
 
    
 
 
 
Total assets
   $ 539,339      $ 553,261  
    
 
 
    
 
 
 
Liabilities
                 
Revolving credit facility due December 2023 (the “SPV Facility”) ($236,500 and $267,726 face amounts, respectively, reported net of unamortized debt issuance costs of $700 and $1,392, respectively. See note 5)
   $ 235,800      $ 266,334  
Revolving credit facility due December 2023 (the “Subscription Facility”) ($26,800 and $70,400 face amounts, respectively, reported net of unamortized debt issuance costs of $115 and $185, respectively. See note 5)
     26,685        70,215  
Distributions payable
               10,825  
Management fee payable (see note 3)
     2,136        519  
Incentive fee payable (see note 3)
     2,039        4,025  
Administration fee payable (see note 3)
     105        108  
Interest payable (see note 5)
     4,731        4,041  
Other liabilities and accrued expenses
     617        940  
    
 
 
    
 
 
 
Total liabilities
   $ 272,113      $ 357,007  
    
 
 
    
 
 
 
Commitments and contingencies (see note 6)
             
Unitholders’ Capital
                 
Common Unitholders’ capital (25,190,253 and 18,992,563 units, respectively, issued and outstanding)
     261,160        196,160  
Accumulated distributable earnings
     6,066        94  
    
 
 
    
 
 
 
Total unitholders’ capital
   $ 267,226      $ 196,254  
    
 
 
    
 
 
 
Total liabilities and unitholders’ capital
   $ 539,339      $ 553,261  
    
 
 
    
 
 
 
Net asset value per unit
   $ 10.61      $ 10.33  
    
 
 
    
 
 
 
See notes to consolidated financial statements.
 
3

SCP Private Credit Income BDC LLC
Consolidated Statement of Operations (unaudited)
(in thousands, except unit amounts)
 
    
Three months ended
   
Six months ended
 
    
June 30, 2023
   
June 30, 2022
   
June 30, 2023
   
June 30, 2022
 
Investment Income:
        
Interest:
        
Companies less than 5% owned ,,
   $ 15,248     $ 9,573     $ 29,636     $ 18,095  
Other income:
        
Companies less than 5% owned
     63       45       467       170  
  
 
 
   
 
 
   
 
 
   
 
 
 
Total investment income
     15,311       9,618       30,103       18,265  
  
 
 
   
 
 
   
 
 
   
 
 
 
Expenses:
        
Management fees (see note 3)
   $ 1,078     $ 889     $ 2,136     $ 1,760  
Incentive fees (see note 3)
     1,582       736       1,054       1,586  
Administration fees (see note 3)
     105       93       210       181  
Interest and other credit facility expenses (see note 5)
     5,694       3,215       12,102       5,804  
Other general and administrative expenses
     256       246       522       451  
  
 
 
   
 
 
   
 
 
   
 
 
 
Total expenses
     8,715       5,179       16,024       9,782  
  
 
 
   
 
 
   
 
 
   
 
 
 
Net investment income
   $ 6,596     $ 4,439     $ 14,079     $ 8,483  
  
 
 
   
 
 
   
 
 
   
 
 
 
Realized and unrealized gain (loss) on investments:
        
Net realized gain on companies less than 5% owned
   $ 74     $        $ 74     $     
  
 
 
   
 
 
   
 
 
   
 
 
 
Net change in unrealized gain (loss) on investments:
        
Companies less than 5% owned
     4,362       (264     (6,110     507  
Companies 5% to 25% owned
     (2,071              (2,071         
  
 
 
   
 
 
   
 
 
   
 
 
 
Net change in unrealized gain (loss) on investments
     2,291       (264     (8,181     507  
  
 
 
   
 
 
   
 
 
   
 
 
 
Net realized and unrealized gain (loss) on investments
     2,365       (264     (8,107     507  
  
 
 
   
 
 
   
 
 
   
 
 
 
Net Increase in Unitholders’ Capital Resulting From Operations
   $ 8,961     $ 4,175     $ 5,972     $ 8,990  
  
 
 
   
 
 
   
 
 
   
 
 
 
Net Income Per Unit
   $ 0.36     $ 0.24     $ 0.25     $ 0.52  
  
 
 
   
 
 
   
 
 
   
 
 
 
See notes to consolidated financial statements.
 
4

SCP Private Credit Income BDC LLC
Consolidated Statement of Changes in Unitholders’ Capital (unaudited)
(in thousands, except unit amounts)
 
    
Three months ended
   
Six months ended
 
    
June 30, 2023
    
June 30, 2022
   
June 30, 2023
   
June 30, 2022
 
Increase (decrease) in unitholders’ capital resulting from operations:
         
Net investment income
   $ 6,596      $ 4,439     $ 14,079     $ 8,483  
Net realized gain
     74                 74           
Net change in unrealized gain (loss)
     2,291        (264     (8,181     507  
  
 
 
    
 
 
   
 
 
   
 
 
 
Net increase in unitholders’ capital resulting from operations
     8,961        4,175       5,972       8,990  
  
 
 
    
 
 
   
 
 
   
 
 
 
Distributions to unitholders:
         
From net investment
income
                                     
  
 
 
    
 
 
   
 
 
   
 
 
 
Increase in unitholders’ capital resulting from capital activity:
         
Contributions
               20,000       65,000       20,000  
  
 
 
    
 
 
   
 
 
   
 
 
 
Net increase in unitholders’ capital resulting from capital activity
               20,000       65,000       20,000  
  
 
 
    
 
 
   
 
 
   
 
 
 
Total increase in unitholders’ capital
     8,961        24,175       70,972       28,990  
Unitholders’ capital, beginning of period
     258,265        180,928       196,254       176,113  
  
 
 
    
 
 
   
 
 
   
 
 
 
Unitholders’ capital, end of period
   $ 267,226      $ 205,103     $ 267,226     $ 205,103  
  
 
 
    
 
 
   
 
 
   
 
 
 
Capital unit activity
(see note 7):
         
Units issued
               1,855,288       6,197,690       1,855,288  
  
 
 
    
 
 
   
 
 
   
 
 
 
Net increase from capital unit activity
               1,855,288       6,197,690       1,855,288  
  
 
 
    
 
 
   
 
 
   
 
 
 
See notes to consolidated financial statements.
 
5
SCP Private Credit Income BDC LLC
Consolidated Statement of Cash Flows (unaudited)
(in thousands)
 
    
Six months ended
June 30, 2023
   
Six months ended
June 30, 2022
 
Cash Flows from Operating Activities:
    
Net increase in unitholders’ capital resulting from operations
   $ 5,972     $ 8,990  
Adjustments to reconcile net increase in unitholders’ capital resulting from operations to net cash provided by (used in) operating activities:
    
Net realized gain on investments
     (74      
Net change in unrealized (gain) loss on investments
     8,181       (507
(Increase) decrease in operating assets:
    
Purchase of investments
     (63,726     (71,185
Net accretion of discount on investments
     (1,578     (1,121
Proceeds from disposition of investments
     68,597       33,514  
Capitalization of
payment-in-kind
income
     (974     (239
Receivable for investments sold
     (99     (78
Interest receivable
     22       (376
Prepaid expenses
     (64     (74
Increase (decrease) in operating liabilities:
    
Management fee payable
     1,617       1,760  
Incentive fee payable
     (1,986     (739
Administration fee payable
     (3     14  
Interest payable
     690       802  
Other liabilities and accrued expenses
     (323     264  
Deferred financing costs
     794       838  
  
 
 
   
 
 
 
Net Cash Provided by (Used in) Operating Activities
     17,046       (28,137
  
 
 
   
 
 
 
Cash Flows from Financing Activities:
    
Contributions from unitholders
     65,000       20,000  
Cash distributions paid
     (10,825     (7,277
Proceeds from borrowings
     35,168       72,500  
Repayments of borrowings
     (110,026     (57,200
  
 
 
   
 
 
 
Net Cash Provided by (Used in) Financing Activities
     (20,683     28,023  
  
 
 
   
 
 
 
NET DECREASE IN CASH
     (3,637     (114
CASH AT BEGINNING OF PERIOD
     16,697       11,181  
  
 
 
   
 
 
 
CASH AT END OF PERIOD
   $ 13,060     $ 11,067  
  
 
 
   
 
 
 
Supplemental disclosure of cash flow information:
    
Cash paid for interest
   $ 11,412     $ 5,002  
  
 
 
   
 
 
 
See notes to consolidated financial statements.
 
6

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (unaudited)
June 30, 2023
(in thousands, except share/unit amounts)
 
Description
 
 
Industry
 
Spread above
Index
(3)
   
Floor
 
   
Interest

Rate 
(1)
   
Acquisition
Date
   
Maturity

Date
   
Par Amount
   
Cost
   
Fair
Value
 
Bank Debt/Senior Secured Loans — 192.5%
                 
ACRES Commercial Mortgage, LLC
(2)
  Diversified Financial Services     S+705       1.00     12.31     12/24/2021       8/21/2028     $  12,660     $  12,453     $  12,660  
Alimera Sciences, Inc.
(2)
  Pharmaceuticals     S+515       4.60     10.32     12/31/2019       5/1/2028       5,893       5,905       5,893  
All State Ag Parts, LLC
(2)
  Trading Companies & Distributors     S+575       1.00     11.25     9/1/2021       9/1/2026       5,191       5,124       5,191  
AmeriMark Intermediate Holdings,
LLC
(2)(5)(11)*
  Internet & Catalog Retail     S+800       1.00              7/28/2021       10/15/2026       16,488       15,017       4,516  
AmeriMark Intermediate Holdings, LLC
(5)(11)
  Internet & Catalog Retail     P+475       1.00     13.00     6/16/2023       8/4/2023       408       408       408  
Apex Service Partners, LLC
(2)
  Diversified Consumer Services     S+525       1.00     10.55     11/5/2021       7/31/2025       20,699       20,449       20,699  
Arcutis Biotherapeutics, Inc.
(2)(4)
  Pharmaceuticals     L+745       0.10     12.61     12/22/2021       1/1/2027       24,520       24,847       24,827  
Ardelyx, Inc.
(2)(4)
  Pharmaceuticals     S+795       1.00     13.15     2/23/2022       3/1/2027       3,319       3,346       3,352  
Basic Fun, Inc.
(2)
  Specialty Retail     S+650       1.00     12.04     10/30/2020       10/30/2023       960       959       960  
BayMark Health Services, Inc.
(2)
  Health Care Providers & Services     S+500       1.00     10.50     6/29/2021       6/11/2027       15,782       15,666       15,782  
BridgeBio Pharma, Inc.
(2)(4)
  Biotechnology                       9.00 %
(6)
 
    11/17/2021       11/17/2026       14,581       14,523       14,581  
CC SAG Holdings Corp. (Spectrum Automotive)
(2)
  Diversified Consumer Services     S+575       0.75     11.25     6/29/2021       6/29/2028       12,609       12,441       12,609  
Centrexion Therapeutics, Inc.
  Pharmaceuticals     L+725       2.45     12.41     6/28/2019       1/1/2024       1,246       1,371       1,401  
Cerapedics, Inc.
(2)
  Biotechnology     S+620       2.75     11.37     12/27/2022       1/1/2028       9,698       9,704       9,722  
Enhanced Permanent Capital, LLC
(2)(4)
  Capital Markets     S+700       1.00     11.93     12/29/2020       12/29/2025       9,257       9,083       9,257  
ENS Holdings III Corp. & ES Opco USA LLC (BlueFin)
(2)
  Trading Companies & Distributors     S+475       1.00     10.09     12/31/2019       12/31/2025       7,143       7,079       7,143  
Enverus Holdings, Inc. (fka Drilling Info Holdings)
(2)
  IT Services     S+450                9.70     1/31/2020       7/30/2025       14,096       13,936       14,096  
Erie Construction
Mid-west,
LLC
(2)
  Building Products     S+475       1.00     10.34     8/5/2021       7/30/2027       11,089       10,949       11,089  
Fertility (ITC) Investment Holdco, LLC
(2)
  Health Care Providers & Services     S+650       1.00     11.63     1/4/2023       1/3/2029       10,330       10,038       10,330  
Foundation Consumer Brands, LLC
(2)
  Personal Products     S+625       1.00     11.47     2/12/2021       2/12/2027       11,876       11,680       11,876  
Glooko, Inc.
(2)
  Health Care Technology     L+790       0.10     13.06     9/30/2021       10/1/2026       2,831       2,850       2,852  
GSM Acquisition Corp.
(2)
  Leisure Equipment & Products     S+500       1.00     10.50     4/20/2021       11/16/2026       13,998       13,904       13,858  
Higginbotham Insurance Agency, Inc.
(2)
  Insurance     S+525       1.00     10.45     11/25/2020       11/25/2026       8,089       8,012       8,089  
High Street Buyer, Inc.
(2)
  Insurance     S+600       0.75     10.79     4/16/2021       4/16/2028       11,886       11,698       11,886  
Human Interest Inc.
(2)
  Internet Software & Services     S+785       1.00     13.01     6/30/2022       7/1/2027       6,799       6,717       6,799  
iCIMS, Inc.
(2)
  Software     S+725       0.75     12.38 %
(7)
 
    8/18/2022       8/18/2028       13,974       13,759       13,974  
Kaseya, Inc.
(2)
  Software     S+575       0.75     11.35 %
(12)
 
    6/22/2022       6/23/2029       11,006       10,860       11,006  
Kid Distro Holdings, LLC (Distro Kid)
(2)
  Software     S+575       1.00     11.14     9/24/2021       10/1/2027       12,394       12,207       12,394  
KORE Wireless Group, Inc.
(2)
  Wireless Telecommunication Services     S+550                10.84     3/12/2019       12/21/2024       14,030       13,945       14,030  
Maurices, Incorporated
(2)
  Specialty Retail     S+675       1.00     9.78     8/27/2021       6/1/2024       5,286       5,265       5,286  
Meditrina, Inc.
(2)
  Health Care Equipment & Supplies     S+550       3.45     10.67     12/20/2022       12/1/2027       1,212       1,208       1,212  
MRI Software LLC
(2)
  Software     S+550       1.00     10.83     7/23/2019       2/10/2026       15,230       15,120       15,230  
Neuronetics, Inc.
(2)
  Health Care Equipment & Supplies     S+565       3.95     10.82     3/2/2020       3/29/2028       3,274       3,272       3,282  
Nexus Intermediate III, LLC (Vortex)
(2)
  Professional Services     L+550       0.75     10.82     12/13/2021       12/6/2027       5,411       5,338       5,411  
Orthopedic Care Partners Management, LLC
(2)
  Health Care Providers & Services     S+650       1.00     11.66     8/17/2022       5/16/2024       5,672       5,646       5,672  
Outset Medical, Inc.
(2)(4)
  Health Care Equipment & Supplies     S+515       2.75     10.32     11/3/2022       11/1/2027       11,865       11,859       11,865  
Pediatric Home Respiratory Services, LLC
(2)
  Health Care Providers & Services     S+625       1.00     11.45     8/19/2022       12/4/2024       2,685       2,653       2,685  
Peter C. Foy & Associates Insurance Services, LLC
(2)
  Insurance     S+600       0.75     11.22     10/29/2021       11/1/2028       15,500       15,375       15,500  
Pinnacle Treatment Centers, Inc.
(2)
  Health Care Providers & Services     S+675       1.00     12.16     1/22/2020       1/2/2026       8,297       8,208       8,297  
Plastics Management, LLC
(2)
  Health Care Providers & Services     S+500       1.00     10.44     8/26/2021       8/18/2027       15,135       14,971       15,135  
RQM+ Corp.
(2)
  Life Sciences Tools & Services     S+575       1.00     11.51     8/20/2021       8/12/2026       15,601       15,443       15,601  
RSC Acquisition, Inc.
(2)
  Insurance     S+550       0.75     10.64     10/5/2020       11/1/2026       18,183       17,962       18,183  
RxSense Holdings LLC
(2)
  Diversified Consumer Services     S+500       1.00     10.15     3/17/2020       3/13/2026       14,562       14,432       14,562  
 
See notes to consolidated financial statements.
 
 
7
SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (unaudited) (continued)
June 30, 2023
(in thousands)
 
Description
 
 
Industry
 
Spread above
Index
(3)
   
Floor
 
   
Interest

Rate 
(1)
   
Acquisition
Date
   
Maturity

Date
   
Par Amount
   
Cost
   
Fair
Value
 
Bank Debt/Senior Secured Loans (continued)
                 
Southern Orthodontic Partners Management, LLC
(2)
  Health Care Providers & Services     S+600       1.00     11.50     6/3/2022       1/27/2026     $ 3,791     $ 3,758     $ 3,791  
Spectrum Pharmaceuticals, Inc.
(2)
  Biotechnology     S+570       2.30     10.87     9/21/2022       9/1/2027       3,559       3,776       3,835  
SunMed Group Holdings, LLC
(2)
  Health Care Equipment & Supplies     S+575       0.75     11.09     6/16/2021       6/16/2028       7,643       7,542       7,643  
TAUC Management, LLC
(2)
  Health Care Providers & Services     L+525       1.00     10.59     2/12/2021       2/12/2027       9,008       8,918       8,557  
Tilley Distribution, Inc.
(2)
  Trading Companies & Distributors     S+600       1.00     11.39     12/8/2021       12/31/2026       12,557       12,443       12,557  
Transportation Insight, LLC
(2)
  Road & Rail     S+450       1.00     9.64     10/27/2021       12/18/2024       5,581       5,528       5,581  
Ultimate Baked Goods Midco LLC (Rise Baking)
(2)
  Packaged Foods & Meats     S+625       1.00     11.45     8/12/2021       8/13/2027       7,593       7,454       7,593  
Vapotherm, Inc.
(2)
  Health Care Equipment & Supplies     S+930       1.00     14.57 %
(8)
 
    2/18/2022       2/1/2027       12,608       12,709       12,766  
Vessco Midco Holdings, LLC
(2)
  Water Utilities     S+450       1.00     9.56     9/3/2021       11/2/2026       3,742       3,711       3,742  
World Insurance Associates, LLC
(2)
  Insurance     S+575       1.00     10.99     10/12/2020       4/1/2026       19,265       18,966       19,265  
               
 
 
   
 
 
 
Total Bank Debt/Senior Secured Loans
 
   
$
 520,487
 
 
$
 514,531
 
   
 
 
   
 
 
 
                                     
Shares/
Units
             
Common Equity/Equity Interests/Warrants — 3.0%
                 
Centrexion Therapeutics, Inc. Warrants†
  Pharmaceuticals           6/28/2019         56,483       27       10  
Meditrina, Inc. Warrants†
  Health Care Equipment & Supplies           12/20/2022         10,572       8       7  
Senseonics Holdings, Inc. Common Stock†
(4)
  Health Care Equipment & Supplies           7/25/2019         79,501       23       61  
SLR-AMI
Topco Blocker, LLC†
(10)(11)
  Internet & Catalog Retail           6/16/2023                  6,170       7,826  
Spectrum Pharmaceuticals, Inc. Warrants†
  Biotechnology           9/21/2022         53,930       17       27  
Vapotherm, Inc.†
  Health Care Equipment & Supplies           2/18/2022         72,556       93       7  
               
 
 
   
 
 
 
Total Common Equity/Equity Interests/Warrants
 
   
$
6,338
 
 
$
7,938
 
   
 
 
   
 
 
 
Total Investments
(9)
— 195.5%
 
   
$
526,825
 
 
$
522,469
 
Liabilities in Excess of Other Assets — (95.5%)
 
          (255,243
                 
 
 
 
Net Assets — 100.0%
 
       
$
267,226
 
                 
 
 
 
 
(1)
Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (PRIME or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment we have provided the current interest rate in effect as of June 30, 2023.
(2)
Indicates an investment that is wholly or partially held by SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”) through its wholly-owned financing subsidiary SCP Private Credit Income BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.
(3)
Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the LIBOR, SOFR or PRIME rate. These instruments are often subject to a LIBOR, SOFR or PRIME rate floor.
(4)
Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making
follow-on
investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of June 30, 2023, on a fair value basis,
non-qualifying
assets in the portfolio represented 11.9% of the total assets of the Company.
(5)
AmeriMark Interactive, LLC, AmeriMark Direct LLC, AmeriMark Intermediate Sub, Inc., L.T.D. Commodities LLC, Dr. Leonard’s Healthcare Corp. and Amerimark Intermediate Holdings, LLC are each
co-Borrowers.
(6)
BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK.
(7)
iCIMS, Inc. may elect to defer up to 3.875% of the coupon as PIK.
(8)
Vapotherm, Inc. may elect to defer up to 9.00% of the coupon as PIK.
(9)
Aggregate net unrealized depreciation for U.S. federal income tax purposes is $9,108; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $6,687 and $15,795, respectively, based on a tax cost of $531,577. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.
 
See notes to consolidated financial statements.
 
8

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (unaudited) (continued)
June 30, 2023
(in thousands)
 
(10)
Through this entity and other intermediate entities, the Company owns approximately 6.5% of the underlying common units of ASC Holdco, LLC, a joint venture which owns certain assets of the former Amerimark Interactive, LLC.
(11)
Denotes investments in which we are an “Affiliated Person” but not exercising a controlling influence, as defined in the Investment Company Act of 1940, as amended (the “1940 Act”), due to beneficially owning, either directly or through one or more controlled companies, more than 5% but less than 25% of the outstanding voting securities of the investment. Transactions during the period June 16, 2023 (date at which the Company became an Affiliated Person) through June 30, 2023 in these affiliated investments are as follows:
 
Name of Issuer
  
Fair Value at
June 16,
2023
    
Gross
Additions
    
Gross
Reductions
    
Realized
Gain
(Loss)
    
Change in
Unrealized
Gain
(Loss)
   
Interest/
Dividend
Income
    
Fair Value at
June 30, 2023
 
AmeriMark Intermediate Holdings, LLC
   $  8,243      $          $         $          $ (3,727   $         $ 4,516  
AmeriMark Intermediate Holdings, LLC
               408                                               408  
SLR-AMI
Topco Blocker, LLC
     6,170                                      1,656                 7,826  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
 
   $  14,413      $ 408      $         $         $ (2,071   $          $ 12,750  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
   
 
 
    
 
 
 
 
(12)
Kaseya, Inc. may elect to defer up to 2.50% of the coupon as PIK.
*
Investment is on
non-accrual
status.
Non-income
producing security.
See notes to consolidated financial statements.
 
9

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (unaudited) (continued)
June 30, 2023
(in thousands)
 
Industry Classification
  
Percentage of Total
Investments (at
fair value) as of

June 30, 2023
 
Insurance
     14.0
Health Care Providers & Services
     13.4
Software
     10.1
Diversified Consumer Services
     9.2
Health Care Equipment & Supplies
     7.0
Pharmaceuticals
     6.8
Biotechnology
     5.4
Trading Companies & Distributors
     4.8
Life Sciences Tools & Services
     3.0
IT Services
     2.7
Wireless Telecommunication Services
     2.7
Leisure Equipment & Products
     2.6
Internet & Catalog Retail
     2.4
Diversified Financial Services
     2.4
Personal Products
     2.3
Building Products
     2.1
Capital Markets
     1.8
Packaged Foods & Meats
     1.5
Internet Software & Services
     1.3
Specialty Retail
     1.2
Road & Rail
     1.1
Professional Services
     1.0
Water Utilities
     0.7
Health Care Technology
     0.5
  
 
 
 
Total Investments
     100.0
  
 
 
 
See notes to consolidated financial statements.
 
10
SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments
December 31, 2022
(in thousands, except share/unit amounts)
 
Description
 
 
Industry
 
Spread above
Index
(3)
   
Floor
 
   
Interest
Rate
(1)
   
Acquisition
Date
   
Maturity
Date
   
Par Amount
   
Cost
   
Fair
Value
 
Bank Debt/Senior Secured Loans — 271.5%
                 
ACRES Commercial Mortgage, LLC
(2)
  Diversified Financial Services     S+705       1.00     11.38     12/24/2021       8/21/2028     $ 12,660     $ 12,437     $ 12,660  
Alimera Sciences, Inc.
(2)
  Pharmaceuticals     L+765       1.78     11.82     12/31/2019       7/1/2024       3,929       4,059       4,145  
All State Ag Parts, LLC
(2)
  Trading Companies & Distributors     S+575       1.00     10.19     9/1/2021       9/1/2026       5,358       5,279       5,358  
AmeriMark Intermediate Holdings, LLC
(2)(5)
  Internet & Catalog Retail     L+800       1.00     14.77     7/28/2021       10/15/2026       21,189       20,858       20,129  
Apex Service Partners, LLC
(2)
  Diversified Consumer Services     S+525       1.00     9.42     11/5/2021       7/31/2025       21,450       21,134       21,450  
Arcutis Biotherapeutics, Inc.
(2)(4)
  Pharmaceuticals     L+745       0.10     11.62     12/22/2021       1/1/2027       24,520       24,654       24,827  
Ardelyx, Inc.
(2)(4)
  Pharmaceuticals     L+795       0.10     12.12     2/23/2022       3/1/2027       3,319       3,328       3,328  
Basic Fun, Inc.
(2)
  Specialty Retail     L+550       1.00     10.27     10/30/2020       10/30/2023       966       961       966  
BayMark Health Services, Inc.
(2)
  Health Care Providers & Services     L+500       1.00     9.73     6/29/2021       6/11/2027       15,861       15,733       15,861  
BridgeBio Pharma, Inc.
(2)(4)
  Biotechnology                       9.00 %
(6)
 
    11/17/2021       11/17/2026       14,362       14,257       14,362  
CC SAG Holdings Corp. (Spectrum Automotive)
(2)
  Diversified Consumer Services     L+575       0.75     10.48     6/29/2021       6/29/2028       6,491       6,407       6,491  
Centrexion Therapeutics, Inc.
  Pharmaceuticals     L+725       2.45     11.42     6/28/2019       1/1/2024       2,314       2,417       2,453  
Cerapedics, Inc.
(2)
  Biotechnology     S+620       2.75     10.52     12/27/2022       1/1/2028       9,698       9,674       9,673  
Enhanced Permanent Capital, LLC
(2)(4)
  Capital Markets     L+700       1.00     10.13     12/29/2020       12/29/2025       7,503       7,352       7,503  
ENS Holdings III Corp. & ES Opco USA LLC (BlueFin)
(2)
  Trading Companies & Distributors     S+475       1.00     9.43     12/31/2019       12/31/2025       7,570       7,490       7,570  
Enverus Holdings, Inc. (fka Drilling Info Holdings)
(2)
  IT Services     L+450                8.88     1/31/2020       7/30/2025       14,454       14,252       14,454  
Erie Construction
Mid-west,
LLC
(2)
  Building Products     S+475       1.00     9.79     8/5/2021       7/30/2027       11,381       11,222       11,381  
Foundation Consumer Brands, LLC
(2)
  Personal Products     L+550       1.00     10.15     2/12/2021       2/12/2027       12,288       12,063       12,288  
Glooko, Inc.
(2)
  Health Care Technology     L+790       0.10     12.07     9/30/2021       10/1/2026       2,831       2,838       2,838  
GSM Acquisition Corp.
(2)
  Leisure Equipment & Products     S+500       1.00     9.03     4/20/2021       11/16/2026       14,069       13,961       13,928  
Higginbotham Insurance Agency, Inc.
(2)
  Insurance     L+525       0.75     9.63     11/25/2020       11/25/2026       8,130       8,043       8,130  
High Street Buyer, Inc.
(2)
  Insurance     L+600       0.75     8.75     4/16/2021       4/16/2028       11,606       11,408       11,606  
Human Interest Inc.
(2)
  Internet Software & Services     S+785       1.00     11.97     6/30/2022       7/1/2027       6,799       6,690       6,799  
iCIMS, Inc.
(2)
  Software     S+725       0.75     11.52 %
(7)
 
    8/18/2022       8/18/2028       13,757       13,527       13,517  
Ivy Fertility Services, LLC
(2)
  Health Care Providers & Services     L+625       1.00     10.39     12/22/2021       2/25/2026       10,515       10,369       10,620  
Kaseya, Inc.
(2)
  Software     S+575       0.75     10.33     6/22/2022       6/23/2029       10,966       10,810       10,966  
Kid Distro Holdings, LLC (Distro Kid)
(2)
  Software     L+575       1.00     10.48     9/24/2021       10/1/2027       12,457       12,251       12,457  
KORE Wireless Group, Inc.
(2)
  Wireless Telecommunication Services     S+550                10.08     3/12/2019       12/21/2024       14,104       13,992       14,104  
Maurices, Incorporated
(2)
  Specialty Retail     S+675       1.00     8.74     8/27/2021       6/1/2024       4,947       4,891       4,947  
Meditrina, Inc.
(2)
  Health Care Equipment & Supplies     S+550       3.45     9.82     12/20/2022       12/1/2027       1,212       1,201       1,209  
MRI Software LLC
(2)
  Software     L+550       1.00     10.23     7/23/2019       2/10/2026       15,308       15,180       15,308  
NAC Holding Corporation (Jaguar)
(2)
  Insurance     S+525       1.00     9.45     7/30/2021       9/28/2024       12,461       12,355       12,461  
Neuronetics, Inc.
(2)
  Health Care Equipment & Supplies     L+765       1.66     11.82     3/2/2020       2/28/2025       3,056       3,143       3,224  
Nexus Intermediate III, LLC (Vortex)
(2)
  Professional Services     L+550       0.75     10.22     12/13/2021       12/6/2027       5,947       5,858       5,947  
Oral Surgery Partners Holdings, LLC
  Health Care Providers & Services     S+625       1.00     10.92     11/29/2022       5/10/2024       2,206       2,164       2,162  
Orthopedic Care Partners Management, LLC
(2)
  Health Care Providers & Services     S+650       1.00     10.91     8/17/2022       5/16/2024       4,226       4,200       4,226  
Outset Medical, Inc.
(2)(4)
  Health Care Equipment & Supplies     S+515       2.75     9.33     11/3/2022       11/1/2027       11,865       11,796       11,775  
Pediatric Home Respiratory Services, LLC
(2)
  Health Care Providers & Services     S+625       1.00     10.67     8/19/2022       12/4/2024       1,802       1,778       1,784  
Peter C. Foy & Associates Insurance Services, LLC
(2)
  Insurance     S+600       0.75     11.21     10/29/2021       11/1/2028       15,579       15,444       15,579  
Pinnacle Treatment Centers, Inc.
(2)
  Health Care Providers & Services     S+650       1.00     10.57     1/22/2020       1/2/2026       8,339       8,233       8,152  
Plastics Management, LLC
(2)
  Health Care Providers & Services     S+500       1.00     9.89     8/26/2021       8/18/2027       12,117       11,967       12,117  
Revlon Consumer Products Corporation
(2)
  Personal Products     P+475       2.75     12.25     5/7/2021       6/17/2023       13,905       13,876       13,974  
RQM+ Corp.
(2)
  Life Sciences Tools & Services     S+575       1.00     10.59     8/20/2021       8/12/2026       15,680       15,499       15,680  
RSC Acquisition, Inc.
(2)
  Insurance     S+550       0.75     9.26     10/5/2020       11/1/2026       9,345       9,191       9,345  
RxSense Holdings LLC
(2)
  Diversified Consumer Services     L+500       1.00     9.41     3/17/2020       3/13/2026       14,674       14,522       14,674  
 
See notes to consolidated financial statements.
 
 
11

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (continued)
December 31, 2022
(in thousands)
 
Description
 
 
Industry
 
Spread above
Index
(3)
   
Floor
 
   
Interest
Rate
(1)
   
Acquisition
Date
   
Maturity
Date
   
Par Amount
   
Cost
   
Fair
Value
 
Bank Debt/Senior Secured Loans (continued)
                 
Southern Orthodontic Partners Management, LLC
(2)
  Health Care Providers & Services     S+600       1.00     10.84     6/3/2022       1/27/2026     $ 1,901     $ 1,884     $ 1,901  
Spectrum Pharmaceuticals, Inc.
(2)
  Biotechnology     S+570       2.30     9.88     9/21/2022       9/1/2027       3,559       3,519       3,524  
SunMed Group Holdings, LLC
(2)
  Health Care Equipment & Supplies     L+575       0.75     10.48     6/16/2021       6/16/2028       7,929       7,815       7,929  
TAUC Management, LLC
(2)
  Health Care Providers & Services     L+525       1.00     9.98     2/12/2021       2/12/2027       9,013       8,912       8,968  
Tilley Distribution, Inc.
(2)
  Trading Companies & Distributors     S+550       1.00     10.14     12/8/2021       12/31/2026       12,762       12,633       12,762  
Transportation Insight, LLC
(2)
  Road & Rail     L+450       1.00     8.91     10/27/2021       12/18/2024       4,198       4,150       4,198  
Ultimate Baked Goods Midco LLC (Rise Baking)
(2)
  Packaged Foods & Meats     L+650       1.00     10.88     8/12/2021       8/13/2027       7,877       7,717       7,877  
Vapotherm, Inc.
(2)
  Health Care Equipment & Supplies     S+830       1.00     12.58 %
(8)
 
    2/18/2022       2/1/2027       12,070       12,076       12,131  
Vessco Midco Holdings, LLC
(2)
  Water Utilities     L+450       1.00     7.87     9/3/2021       11/2/2026       2,207       2,189       2,206  
World Insurance Associates, LLC
(2)
  Insurance     S+575       1.00     10.07     10/12/2020       4/1/2026       19,614       19,261       18,829  
               
 
 
   
 
 
 
Total Bank Debt/Senior Secured Loans
 
   
$
528,920
 
 
$
532,753
 
   
 
 
   
 
 
 
                                     
Shares/
Units
             
Common Equity/Equity Interests/Warrants — 0.0%
                 
Centrexion Therapeutics, Inc. Warrants†
  Pharmaceuticals           6/28/2019         56,483       27       16  
Meditrina, Inc. Warrants†
  Health Care Equipment & Supplies           12/20/2022         10,572       8       8  
Senseonics Holdings, Inc. Common Stock†
(4)
  Health Care Equipment & Supplies           7/25/2019         79,501       23       82  
Spectrum Pharmaceuticals, Inc. Warrants†
  Biotechnology           9/21/2022         53,930       17       5  
Vapotherm, Inc.†
  Health Care Equipment & Supplies           2/18/2022         12,960       75       31  
               
 
 
   
 
 
 
Total Common Equity/Equity Interests/Warrants
 
   
$
150
 
 
$
142
 
   
 
 
   
 
 
 
Total Investments
(9)
— 271.5%
 
   
$
 529,070
 
 
$
 532,895
 
Liabilities in Excess of Other Assets — (171.5%)
 
          (336,641
                 
 
 
 
Net Assets — 100.0%
 
       
$
196,254
 
                 
 
 
 
 
(1)
Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (PRIME or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment we have provided the current interest rate in effect as of December 31, 2022.
(2)
Indicates an investment that is wholly or partially held by SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”) through its wholly-owned financing subsidiary SCP Private Credit Income BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.
(3)
Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the LIBOR, SOFR or PRIME rate. These instruments are often subject to a LIBOR, SOFR or PRIME rate floor.
(4)
Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (“1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making
follow-on
investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2022, on a fair value basis,
non-qualifying
assets in the portfolio represented
11.2
% of the total assets of the Company.
(5)
AmeriMark Interactive, LLC, AmeriMark Direct LLC, AmeriMark Intermediate Sub, Inc., L.T.D. Commodities LLC, Dr. Leonard’s Healthcare Corp. and Amerimark Intermediate Holdings, LLC are each
co-Borrowers.
Amerimark may elect to defer up to 8.00% of the coupon as PIK.
(6)
BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK.
(7)
iCIMS, Inc. may elect to defer up to 3.875% of the coupon as PIK.
(8)
Vapotherm, Inc. may elect to defer up to 8.00% of the coupon as PIK.
(9)
Aggregate net unrealized depreciation for U.S. federal income tax purposes is $927; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $5,202 and $6,129, respectively, based on a tax cost of $533,822. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.
Non-income
producing security.
See notes to consolidated financial statements.
 
12

SCP Private Credit Income BDC LLC
Consolidated Schedule of Investments (continued)
December 31, 2022
(in thousands)
 
Industry Classification
  
Percentage of Total
Investments (at
fair value) as of

December 31, 2022
 
Insurance
     14.3
Health Care Providers & Services
     12.4
Software
     9.8
Diversified Consumer Services
     8.0
Health Care Equipment & Supplies
     6.8
Pharmaceuticals
     6.5
Biotechnology
     5.2
Personal Products
     4.9
Trading Companies & Distributors
     4.8
Internet & Catalog Retail
     3.8
Life Sciences Tools & Services
     2.9
IT Services
     2.7
Wireless Telecommunication Services
     2.7
Leisure Equipment & Products
     2.6
Diversified Financial Services
     2.4
Building Products
     2.1
Packaged Foods & Meats
     1.5
Capital Markets
     1.4
Internet Software & Services
     1.3
Professional Services
     1.1
Specialty Retail
     1.1
Road & Rail
     0.8
Health Care Technology
     0.5
Water Utilities
     0.4
    
 
 
 
Total Investments
     100.0
    
 
 
 
See notes to consolidated financial statements.
 
13

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited)
June 30, 2023
(in thousands, except unit amounts)
Note 1. Organization
SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”) is a Delaware limited liability company formed on
May 18, 2018
. The Company has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (“the 1940 Act”). Furthermore, as the Company is an investment company, it applies the guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 946. In addition, for U.S. federal income tax purposes, the Company has elected to be treated, and intends to qualify annually, as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). The Company was formed primarily to provide investors with attractive long-term returns through investments made pursuant to the investment strategy of the Company described below (the Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”).
On October 5, 2018 (the “Initial Closing Date”), the Company closed on $326,000 in capital commitments. On March 12, 2019, the sale and issuance of 2,800,000 units, at an aggregate purchase price of $28,000 ($10.00 per unit) occurred and the Company commenced operations. As of June 30, 2023, $261,500 of capital commitments were drawn and $64,500 were unfunded.
The Company has implemented a corporate lending strategy focused on sourcing, underwriting and managing a diverse portfolio of private senior secured loans primarily to upper middle market companies (generally,
 
aggregate
 
loan sizes of $100,000 to $300,000 to companies with earnings before interest, tax, depreciation and amortization (“EBITDA”) between approximately $25,000 and $100,000) across the United States. In addition to senior secured loans to upper middle market companies, the Company intends to invest a portion of its assets in
non-traditional
asset-based loans and first lien loans to rapidly growing healthcare companies. The Company also expects that some of its investments will contain delayed-draw term loan type features and/or other types of unfunded commitments.
The offering period of the Company ended on April 5, 2019 (the “Offering Period”). The investment period of the Company ended on December 31, 2022. The term of the Company will be six years from the end of the Offering Period unless the Company is liquidated earlier as set forth in the Limited Liability Company Agreement of the Company (as amended, restated or otherwise modified from time to time, the “LLC Agreement”), but may be extended by the board of directors for up to two consecutive one year periods upon approval of the Company’s independent directors and the approval of unitholders of the Company (“Unitholders”), which approval will be obtained through a
non-1940
Act vote as described in the LLC Agreement. The Company may be dissolved and its affairs wound up prior to the end of the term under the circumstances set forth in the LLC Agreement. The fiscal year end of the Company is December 31.
Note 2. Summary of Significant Accounting Policies
The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles (“GAAP”), and include the accounts of the Company and certain wholly-owned subsidiaries. The consolidated financial statements reflect all adjustments and reclassifications which, in the opinion of management, are necessary for the fair presentation of the results of the operations and financial condition for the periods presented. All significant intercompany balances and transactions have been eliminated. Certain prior period amounts may have been reclassified to conform to current period presentation.
 
14

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
Interim consolidated financial statements are prepared in accordance with GAAP for interim financial information and pursuant to the requirements for reporting on Form
10-Q
and Regulation
S-X,
as appropriate. Accordingly, they may not include all of the information and notes required by GAAP for annual consolidated financial statements. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported periods. Changes in the economic environment, financial markets and any other parameters used in determining these estimates could cause actual results to differ materially. The current period’s results of operations will not necessarily be indicative of results that ultimately may be achieved for the fiscal year ending on December 31, 2023.
In the opinion of management, all adjustments which are of a normal recurring nature considered necessary for the fair presentation of financial statements, have been included.
The significant accounting policies consistently followed by the Company are:
 
  (a)
Investment transactions are accounted for on the trade date;
 
  (b)
In accordance with GAAP and the 1940 Act, the Company’s assets will generally be valued as follows:
 
  (i)
securities or other instruments (other than as referred to in clauses (ii) and (iii) below) for which market quotes are readily available and deemed to represent fair value under GAAP will be valued based on quotes obtained from a quotation reporting system, market makers or pricing services (when deemed to represent fair value under GAAP). A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation;
 
  (ii)
exchange-traded options, futures and options on futures will be valued at the settlement price determined by the exchange or through the use of a model such as Black-Scholes;
 
  (iii)
short-term investments with maturities of sixty (60) days or less generally will be valued at amortized cost; and
 
  (iv)
securities, loans or other instruments for which market quotes are not readily available or reliable under GAAP will be valued as described below:
 
  a.
the quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals of SLR responsible for the Portfolio Investment; 
 
  b.
preliminary valuation conclusions are then documented and discussed with senior management of the Adviser;
 
  c.
the audit committee of the Board of Directors ( the “Board”) reviews the preliminary valuations of the Adviser and third party valuation specialist, if any, and responds to the valuation recommendations to reflect any comments; and
 
15

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
  d.
the Board discusses valuations and determines the fair value of each investment in the Company’s portfolio in good faith based on the input of the Adviser, the audit committee, and third party valuation specialist, if any, which may from time to time be engaged by the Board.
The valuation principles set forth above may be modified from time to time without notice to Unitholders, in whole or in part, as determined by the Board in its sole discretion.
The Board will also (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule
2a-5
under the 1940 Act; and (6) maintain recordkeeping requirements under Rule
2a-5.
When an external event such as a purchase transaction, public offering or subsequent equity sale occurs, the Company will consider the pricing indicated by the external event to corroborate the valuation. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material.
Investments are valued utilizing a market approach, an income approach, or both approaches, as appropriate. However, in accordance with ASC
820-10,
certain investments that qualify as investment companies in accordance with ASC 946, may be valued using net asset value as a practical expedient for fair value. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities (including a business). The income approach uses valuation approaches to convert future amounts (for example, cash flows or earnings) to a single present amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that we may take into account in fair value pricing our investments include, as relevant: available current market data, including relevant and applicable market trading and transaction comparables, applicable market yields and multiples, security covenants, call protection provisions, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, the markets in which the portfolio company does business, comparisons of financial ratios of peer companies that are public, M&A comparables, and enterprise values, among other factors. When available, broker quotations and/or quotations provided by pricing services are considered as an input in the valuation process. For the six months ended June 30, 2023, there has been no change to the Company’s valuation approaches or techniques and the nature of the related inputs considered in the valuation process.
ASC Topic 820 classifies the inputs used to measure these fair values into the following hierarchy:
Level
 1
: Unadjusted quoted prices in active markets for identical assets or liabilities, accessible by the Company at the measurement date.
Level
 2
: Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable inputs other than quoted prices.
Level
 3
: Unobservable inputs for the asset or liability.
In all cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to each investment. The exercise of judgment is based in part on our knowledge of the asset class and our prior experience.
 
  (c)
Gains or losses on investments are calculated by using the specific identification method.
 
16
SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
  (d)
The Company records dividend income and interest, adjusted for amortization of premium and accretion of discount, on an accrual basis. Loan origination fees, original issue discount, and market discounts are capitalized and we amortize such amounts into income using the effective interest method. Upon the prepayment of a loan, any unamortized loan origination fees are recorded as interest income. We record call premiums on loans repaid as interest income when we receive such amounts. Capital structuring fees, amendment fees, consent fees, and any other
non-recurring
fee income as well as management fee and other fee income for services rendered, if any, are recorded as other income when earned.
 
  (e)
The Company intends to comply with the applicable provisions of the Code pertaining to
RICs
to make distributions of taxable income sufficient to relieve it of substantially all U.S. federal income taxes. The Company, at its discretion, may carry forward taxable income in excess of calendar year distributions and pay a 4% excise tax on this income. The Company will accrue excise tax on such estimated excess taxable income as appropriate.
 
  (f)
Book and tax basis differences relating to Unitholder distributions and other permanent book and tax differences are typically reclassified among the Company’s capital accounts annually. In addition, the character of income and gains to be distributed is determined in accordance with income tax regulations that may differ from GAAP.
 
  (g)
Distributions to Unitholders are recorded as of the record date. The amount to be paid out as a distribution is determined by the Board. Net realized capital gains, if any, are generally distributed or deemed distributed at least annually.
 
  (h)
In accordance with Regulation
S-X
and ASC Topic 810—
Consolidation
, the Company consolidates its interest in controlled investment company subsidiaries, financing subsidiaries and certain wholly-owned holding companies that serve to facilitate investment in portfolio companies. In addition, the Company may also consolidate any controlled operating companies substantially all of whose business consists of providing services to the Company.
 
  (i)
The accounting records of the Company are maintained in U.S. dollars. Any assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rate of exchange of such currencies against the U.S. dollar on the date of valuation. The Company will not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations would be included with the net unrealized gain or loss from investments. The Company’s investments in foreign securities, if any, may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments in terms of U.S. dollars and therefore the earnings of the Company.
 
  (j)
In accordance with ASC
835-30,
the Company reports origination and other expenses related to certain debt issuances, if any, as a direct deduction from the carrying amount of the debt liability. Applicable expenses are deferred and amortized using either the effective interest method or the straight-line method over the stated life. The straight-line method may be used on revolving facilities and/or when it approximates the effective yield method.
 
  (k)
The Company records expenses related to applicable equity offering costs as a charge to capital upon the sale of units, in accordance with ASC
946-20-25.
 
17

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
  (l)
Investments that are expected to pay regularly scheduled interest in cash are generally placed on
non-accrual
status when principal or interest cash payments are past due 30 days or more and/or when it is no longer probable that principal or interest cash payments will be collected. Such
non-accrual
investments are restored to accrual status if past due principal and interest are paid in cash, and in management’s judgment, are likely to continue timely payment of their remaining principal and interest obligations. Cash interest payments received on such investments may be recognized as income or applied to principal depending on management’s judgment.
 
  (m)
The Company records expenses directly related to its organization as incurred.
 
  (n)
The Company defines cash equivalents as securities that are readily convertible into known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only securities with a maturity of three months or less would qualify, with limited exceptions. The Company believes that certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities would qualify as cash equivalents.
Note 3. Agreements and Related Party Transactions
The Company has entered into an investment management agreement with the Adviser (the “Investment Management Agreement”) pursuant to which it will pay management fees, administrative coordinator fees and incentive fees to the Adviser. The Company will pay the Adviser a fee for investment advisory and management services consisting of two components: a base management fee and an incentive fee. The Company will also pay the Adviser (in its capacity as Administrative Coordinator, defined herein) an administration fee for administrative and coordination services. The cost of the base management fee, the incentive fee, and the administration fee will be borne by the Unitholders.
Management Fees and Administration Fees
The Company will pay the Adviser a management fee (the “Management Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (each such date, the “Management Fee Calculation Date”), in an amount equal to 1.5% per annum of Invested Capital (defined as, as of any date, the sum of (i) capital contributions to the Company plus (ii) the total amount of credit drawn on subscription credit facilities), and payable quarterly in arrears after such Management Fee Calculation Date.
Pursuant to the Investment Management Agreement, the Adviser has also been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Company will pay the Administrative Coordinator, a fee (the “Administration Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (the “Administration Fee Calculation Date”), in an amount equal to 0.08% per annum of the average Cost Basis (defined as the aggregate accreted and amortized cost of all
Portfolio Investments
, including any amounts reinvested in investments and the cost of investments acquired using leverage), as measured on the last day of the preceding quarter and the last day of the current quarter for the period ended and payable quarterly in arrears after such Administration Fee Calculation Date. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain
on-going,
routine,
non-investment-related
administrative services for the Company, (ii) the coordination of various third party services needed or required by the Company and (iii) certain Unitholder servicing functions.
 
18

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
Each of the Management Fee and the Administration Fee will be appropriately adjusted for any stub period. Such fees will be paid out of net current income and/or disposition proceeds or, to the extent such amounts are not available, from unfunded capital commitments that will be drawn down, or borrowings of the Company. In the event that the Adviser arranges for the Company to pay any portion of a placement fee to a placement agent, the amount of
Management Fees
otherwise payable shall be reduced by an amount equal to 100% of such payment to the placement agent.
Incentive Fee
The Company will make distributions out of two categories: Current Proceeds and Disposition Proceeds (collectively referred to as “Investment Proceeds”). “Disposition Proceeds” means all amounts received by the Company upon the disposition of an investment, including full or partial repayments or amortization of principal (but excluding Current Proceeds). “Current Proceeds” means all proceeds from investments, including interest income, fee income, warrant gains, prepayment fees and exit fees, other than Disposition Proceeds. The Adviser will apportion each Unitholder’s pro rata share of Investment Proceeds between Disposition Proceeds and Current Proceeds. Amounts of Investment Proceeds apportioned to Unitholders will be divided between and distributed to Unitholders, on the one hand, and the Adviser, on the other hand, in the following amounts and order of priority:
(i) Disposition Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as an
incentive fee
, on the other hand, in the following amounts and order of priority:
(A)
Return of Capital Contributions
. First, 100% to such Unitholder until such Unitholder has received cumulative distributions of Investment Proceeds pursuant to this clause (i)(A) equal to such Unitholder’s total Capital Contributions to the Company (including amounts contributed to pay Management Fees, Administration Fees, Organizational Expenses (as defined below) and other Company expenses);
(B)
Unitholder Preferred Return
. Second, 100% of all remaining Disposition Proceeds to Unitholders until they have each received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (B) and clause (D) below and pursuant to clause (ii)(A) and clause (ii)(C) below equal to 6% per annum, compounded annually, on such Unitholder’s unreturned capital contributions to the Company (including amounts contributed to pay Management Fees, Administration Fees, Organizational Expenses and other Company expenses) (the “
Preferred Return”);
(C)
Adviser Catch Up to 15%
. Third, 80% of all remaining Disposition Proceeds paid to the Adviser as an
incentive fee
until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (C) and clause (ii)(B) equal to 15% of the total amounts distributed to Unitholders and paid to the Adviser pursuant to clause (B) above and this clause (C) and pursuant to clause (ii)(A) and clause (ii)(B); and
 
19

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
(D)
85%/15%
 Shares
. Thereafter, 85% to Unitholders and 15% paid to the Adviser as an
incentive fee.
(ii) Current Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as an
incentive fee
, on the other hand, in the following amounts and order of priority:
(A)
Unitholder Preferred Return
. First, 100% of all Current Proceeds to Unitholders until Unitholders have received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (A) and clause (C) below and pursuant to clause (i)(B) and clause (i)(D) equal to the Preferred Return;
(B)
Adviser Catch Up to 15%
. Second, 80% of all remaining Current Proceeds paid to the Adviser as an
incentive fee
until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (B) and clause (i)(C) equal to 15% of the total amounts distributed to Unitholders and paid to the Adviser pursuant to clause (A) above and this clause (B) and pursuant to Section clause (i)(B) and clause (i)(C); and
(C)
85%/15% Units
. Thereafter, 85% to Unitholders and 15% paid to the Adviser as an
incentive fee.
In no event will the Adviser receive amounts attributable to Disposition Proceeds that, as of any distribution or payment date, exceeds 20% of cumulative realized capital gains net of all cumulative realized capital losses and unrealized capital depreciation.
The Adviser has the right with respect to all Unitholders, upon approval of the Company’s independent directors, to waive or reduce the incentive fee to which it is entitled. The Adviser may also elect not to receive all or any portion of the incentive fee that would otherwise be distributed to it, and may cause any or all amounts subsequently available for distribution to the Unitholders to be distributed to the Adviser until it has received the same aggregate amount of incentive fees had it not previously waived receipt of incentive fees.
The Adviser will be entitled to withhold from any distributions, in its discretion, any required tax withholdings. Amounts of taxes paid or withheld from amounts otherwise distributable to a Unitholder will be deemed distributed for purposes of the calculations above.
Upon liquidation of the Company, the Adviser will be required to restore funds to the Company for distribution to the Unitholders if and to the extent that the Adviser has received cumulative incentive fees in excess of the incentive fees that would have been payable to the Adviser on an aggregate basis covering all transactions of the Company; provided, however, that in no event will the Adviser be required to contribute an aggregate amount in excess of 100% of the net amount distributed to the Adviser (net of taxes) on account of its incentive fees. In addition, the Adviser will apply an interim incentive fee adjustment at the end of each fiscal year so that, in the event of any over-distribution of incentive fee to the Adviser (measured with respect to each Unitholder using the fair value of the Company’s portfolio at the end of the applicable fiscal year as if the Company were to liquidate on such date), future distributions that would, absent such interim incentive fee adjustment, otherwise be distributed to the Adviser as an incentive fee, shall be distributed to such Unitholder until such over-distribution (net of taxes payable by the Adviser with respect to such incentive fee) has been eliminated.
For the three and six months ended June 30, 2023, the Company incurred $1,078 and $2,136, respectively, in Management Fees, $105 and $210, respectively, in Administration Fees and $1,582 and $1,054, respectively, in
incentive fees
. For the three and six months ended June 30, 2022, the Company incurred $889 and $1,760, respectively, in Management Fees, $93 and $181, respectively, in Administration Fees and $736 and $1,586, respectively, in
incentive fees.
 
20

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
The aggregate amount of certain operating expenses relating to Unitholders investing directly in the Company will not exceed the Operating Expense Cap, calculated as follows: (A) if the Company has less than or equal to $400,000 in capital commitments, an amount equal to the sum of (x) the product of the capital commitments and 0.0025 and (y) $1,250, or (B) if the Company has greater than $400,000 in capital commitments, $2,250. Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. For the avoidance of doubt, the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder.
The Adviser or Administrative Coordinator and/or their affiliates has advanced organizational and offering expenses to the Company, which include organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company (“Organizational Expenses”). The Adviser or Administrative Coordinator (or such affiliate) has been reimbursed by the Company for such advanced costs and expenses in an amount not to exceed $500. $308 of offering expenses were charged to capital and $84 of organizational costs were expensed in 2019.
Note 4. Fair Value
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The levels of the fair value hierarchy are as follows:
Level
 1.
 Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the Company has the ability to access.
Level
 2.
 Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following:
 
  a)
Quoted prices for similar assets or liabilities in active markets;
 
  b)
Quoted prices for identical or similar assets or liabilities in
non-active
markets;
 
  c)
Pricing models whose inputs are observable for substantially the full term of the asset or liability; and
 
  d)
Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the asset or liability.
Level
 3.
Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s and, if applicable, an independent third-party valuation firm’s own assumptions about the assumptions a market participant would use in pricing the asset or liability.
When the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3).
 
21

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
Gains and losses for assets and liabilities categorized within the Level 3 table below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3).
A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. Such reclassifications involving Level 3 assets and liabilities are reported as transfers in/out of Level 3 as of the end of the quarter in which the reclassifications occur. Within the fair value hierarchy tables below, cash and cash equivalents are excluded but could be classified as Level 1.
The following tables present the balances of assets measured at fair value on a recurring basis, as of June 30, 2023 and December 31, 2022:
Fair Value Measurements
As of June 30, 2023
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $       $       $ 514,531      $ 514,531  
Common Equity/Equity Interests/Warrants
     61                  7,877        7,938  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $ 61    $         $ 522,408      $ 522,469  
  
 
 
    
 
 
    
 
 
    
 
 
 
While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at June 30, 2023, the fair value of the SPV Facility and the Subscription Facility would be $236,500 and $26,800, respectively.
Fair Value Measurements
As of December 31, 2022
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $       $       $ 532,753      $ 532,753  
Common Equity/Equity Interests/Warrants
     82                  60        142  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $ 82    $         $ 532,813      $ 532,895  
  
 
 
    
 
 
    
 
 
    
 
 
 
 
22

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 31, 2022, the fair value of the SPV Facility and the Subscription Facility would be $267,726 and $70,400, respectively.
The following table provides a summary of the changes in fair value of Level 3 assets for the three and six months ended June 30, 2023, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at June 30, 2023:
 
    
Bank Debt/Senior
Secured Loans
    
Common Equity/Equity
Interests/Warrants
    
Total
 
Fair value, March 31, 2023
   $ 524,025      $ 44      $ 524,069  
Total gains or losses included in earnings:
        
Net realized gain
     6                  6  
Net change in unrealized gain
     635        1,652        2,287  
Purchase of investment securities
     31,071        6,181        37,252  
Proceeds from dispositions of investment securities
     (41,206                (41,206
Transfers into Level 3
                             
Transfers out of Level 3
                             
  
 
 
    
 
 
    
 
 
 
Fair value, June 30, 2023
   $ 514,531      $ 7,877      $ 522,408  
  
 
 
    
 
 
    
 
 
 
Unrealized gains for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain
   $ 731      $ 1,652      $ 2,383  
  
 
 
    
 
 
    
 
 
 
    
Bank Debt/Senior
Secured Loans
    
Common Equity/Equity
Interests/Warrants
    
Total
 
Fair value, December 31, 2022
   $ 532,753      $ 60      $ 532,813  
Total gains or losses included in earnings:
        
Net realized gain
     6                  6  
Net change in unrealized gain (loss)
     (9,788      1,629        (8,159
Purchase of investment securities
     60,089        6,188        66,277  
Proceeds from dispositions of investment securities
     (68,529                (68,529
Transfers into Level 3
                             
Transfers out of Level 3
                             
  
 
 
    
 
 
    
 
 
 
Fair value, June 30, 2023
   $ 514,531      $ 7,877      $ 522,408  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ (9,563    $ 1,629      $ (7,934
  
 
 
    
 
 
    
 
 
 
 
23

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
The following table provides a summary of the changes in fair value of Level 3 assets for the year ended December 31, 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2022:
 
    
Bank Debt/Senior
Secured Loans
    
Common Equity/Equity
Interests/Warrants
    
Total
 
Fair value, December 31, 2021
   $ 439,661      $ 13      $ 439,674  
Total gains or losses included in earnings:
        
Net realized gain (loss)
                             
Net change in unrealized gain (loss)
     340        (53      287  
Purchase of investment securities
     188,107        100        188,207  
Proceeds from dispositions of investment securities
     (95,355                (95,355
Transfers into Level 3
                             
Transfers out of Level 3
                             
  
 
 
    
 
 
    
 
 
 
Fair value, December 31, 2022
   $ 532,753      $ 60      $ 532,813  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ 744      $ (53    $ 691  
  
 
 
    
 
 
    
 
 
 
Quantitative Information about Level 3 Fair Value Measurements
The Company typically determines the fair value of its performing debt investments utilizing a yield analysis. In a yield analysis, a price is ascribed for each investment based upon an assessment of current and expected market yields for similar investments and risk profiles. Additional consideration is given to current contractual interest rates, relative maturities and other key terms and risks associated with an investment. Among other factors, a significant determinant of risk is the amount of leverage used by the portfolio company relative to the total enterprise value of the company, and the rights and remedies of our investment within each portfolio company.
Significant unobservable quantitative inputs typically used in the fair value measurement of the Company’s Level 3 assets and liabilities primarily reflect current market yields, including indices, and readily available quotes from brokers, dealers, and pricing services as indicated by comparable assets and liabilities, as well as enterprise values, returns on equity and earnings before income taxes, depreciation and amortization (“EBITDA”) multiples of similar companies, and comparable market transactions for equity securities.
 
24
SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
Quantitative information about the Company’s Level 3 asset fair value measurements as of June 30, 2023 is summarized in the table below:
 
    
Asset or
Liability
  
Fair Value at
June 30, 2023
    
Principal Valuation
Technique/Methodology
  
Unobservable
Input
  
Range (Weighted
Average)
Senior Secured Loans
   Asset    $ 510,015      Income Approach    Market Yield    9.9% – 20.8% (12.0%)
      $ 4,516      Recovery Analysis    Recoverable Amount    N/A
Common Equity/Equity Interests/Warrants
   Asset    $ 51      Market Approach    Volatility   
17.3% - 17.3% (17.3%)
      $ 7,826      EBITDA Multiple    Comparable Multiple   
6.25x-7.25x (6.75x)
Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving
bid-ask
spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments.
Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below:
 
    
Asset or
Liability
  
Fair Value at
December 31, 2022
    
Principal Valuation
Technique/Methodology
  
Unobservable
Input
  
Range (Weighted
Average)
Senior Secured Loans
   Asset    $ 532,753      Income Approach    Market Yield    9.4% – 16.2% (11.4%)
Common Equity/Equity Interests/Warrants
   Asset    $ 60      Market Approach    Volatility   
26.0% - 26.0% (26.0%)
Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving
bid-ask
spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments.
 
25

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
Note 5. Debt
SPV Facility
—During the first quarter of 2019, the Company, through its wholly-owned subsidiary, SCP Private Credit Income BDC SPV LLC (the “SPV”), entered into the $100,000 SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. The commitment can also be expanded up to $400,000. The stated interest rate on the SPV Facility is SOFR plus 2.90% with no floor requirement and the current final maturity date is December 31, 2023. The fee on undrawn commitments is generally 0.875%. The SPV Facility is secured by all of the assets held by the SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV also includes usual and customary events of default for credit facilities of this nature. On November 18, 2019, the Company amended the SPV Facility, reducing commitments to $75,000. On February 27, 2021, the Company again amended the SPV Facility, increasing commitments to $100,000. On July 16, 2021, the Company entered into an amended SPV Facility, which increased commitments to $125,000, and on August 18, 2021 entered into a second amended SPV Facility which increased commitments to $200,000 and extended the final maturity date to December 31, 2023. On November 2, 2021, the Company entered into Amendment No. 1 to the second amended SPV Facility, which increased commitments to $275,000. On August 3, 2022, the Company entered into Amendment No. 2 to the second amended SPV Facility, which increased commitments to $300,000 and changed the interest rate to a SOFR-based calculation. There were $236,500 of borrowings outstanding as of June 30, 2023 under the SPV Facility. Effective with the end of the Investment Period on December 31, 2022, future advances are no longer permitted.
Subscription Facility
—During the first quarter of 2019, the Company established the $35,000 Subscription Facility with East West Bank, and subsequently entered into an amendment on June 24, 2019, which increased commitments from $35,000 to $50,000. On March 5, 2021, the Company entered into a second amendment. Under the second amendment, commitments were increased from $50,000 to $75,000 and the maturity date was extended. On October 4, 2021, the Company entered into an amended and restated loan and security agreement, which increased commitments to $100,000 and the maturity date was extended. On December 28, 2022, the Company entered into the first amendment to the amended and restated loan and security agreement, extending the maturity date to December 31, 2023, reducing commitments to $75,000 and the stated interest rate is SOFR plus 2.80%. Under the terms of the Subscription Facility, the Company has made certain customary representations and warranties, and is required to comply with various covenants, including reporting requirements and other customary requirements for similar credit facilities. The Subscription Facility also includes usual and customary events of default for credit facilities of this nature. There were $26,800 of borrowings outstanding as of June 30, 2023 under the Subscription Facility.
The average annualized interest cost for borrowings for the six months ended June 30, 2023 and the year ended December 31, 2022 was 7.93% and 4.67%, respectively. These costs are exclusive of other credit facility expenses such as unused fees and fees paid to the
back-up
servicer, if any. The maximum amount borrowed on the credit facilities during the six months ended June 30, 2023 and the year ended December 31, 2022 was $338,126 and $343,350, respectively.
 
26

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
Note 6. Commitments and Contingencies
The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of June 30, 2023 and December 31, 2022 is $59,616 and $98,214, respectively, comprised of the following:
 
    
June 30,
2023
    
December 31,
2022
 
Outset Medical, Inc.
   $ 11,865      $ 11,865  
Human Interest Inc.
     6,799        6,799  
Vessco Midco Holdings, LLC
     3,417        4,969  
Glooko, Inc.
     3,185        3,185  
Arcutis Biotherapeutics, Inc.
     3,065        3,065  
Ardelyx, Inc.
     2,716        2,716  
iCIMS, Inc.
     2,665        3,867  
Cerapedics, Inc.
     2,424        2,424  
High Street Buyer, Inc.
     2,040        2,797  
RxSense Holdings, LLC
     1,558        1,558  
Pediatric Home Respiratory Services, LLC
     1,557        2,451  
Enverus Holdings, Inc.
     1,537        1,251  
Maurices, Incorporated
     1,491        2,733  
RSC Acquisition, Inc.
     1,419        10,328  
Nexus Intermediate III, LLC (Vortex)
     1,264        1,264  
Meditrina, Inc.
     1,212        1,212  
Spectrum Pharmaceuticals, Inc.
     1,186        2,966  
Kid Distro Holdings, LLC
     1,121        1,121  
GSM Acquisition Corp.
     1,101        1,101  
Foundation Consumer Brands, LLC
     967        967  
Basic Fun, Inc.
     960        1,195  
Ultimate Baked Goods Midco LLC
     750        578  
Orthopedic Care Partners Management, LLC
     729        2,200  
Southern Orthodontic Partners Management, LLC
     705        2,605  
Kaseya, Inc.
     625        1,315  
MRI Software LLC
     577        577  
ENS Holdings III Corp. & ES Opco USA LLC
     574        179  
SunMed Group Holdings, LLC
     515        268  
Transportation Insight, LLC
     454        1,860  
World Insurance Associates, LLC
     385        135  
TAUC Management, LLC
     385        385  
Amerimark Intermediate Holdings, LLC
     194            
CC SAG Holdings Corp. (Spectrum Automotive)
     174        6,568  
Oral Surgery Partners Holdings, LLC
               3,277  
Plastics Management, LLC
               3,095  
Erie Construction
Mid-west,
LLC
               1,593  
Tilley Chemical Buyer, Inc.
               670  
Peter C. Foy & Associates Insurance Services, LLC
               570  
Pinnacle Treatment Centers, Inc.
               520  
Ivy Fertility Services, LLC
               499  
BayMark Health Services, Inc.
               499  
NAC Holdings Corporation
               470  
Apex Service Partners, LLC
               345  
All States Ag Parts, LLC
               172  
  
 
 
    
 
 
 
Total Commitments
   $ 59,616      $ 98,214  
  
 
 
    
 
 
 
 
27

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
The credit agreements of the above loan commitments contain customary lending provisions and/or are subject to the portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of June 30, 2023 and December 31, 2022, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment.
In the normal course of its business, we invest or trade in various financial instruments and may enter into various investment activities with
off-balance
sheet risk, which may include forward foreign currency contracts. Generally, these financial instruments represent future commitments to purchase or sell other financial instruments at specific terms at future dates. These financial instruments contain varying degrees of
off-balance
sheet risk whereby changes in the market value or our satisfaction of the obligations may exceed the amount recognized in our Consolidated Statements of Assets and Liabilities.
Note 7. Unitholders’ Capital
Transactions in Unitholders’ capital were as follows:
 
    
Three months
ended
June 30, 2023
    
Three months
ended
June 30, 2022
 
Units at beginning of period
     25,190,253        17,137,275  
Units issued
               1,855,288  
  
 
 
    
 
 
 
Units issued and outstanding at end of period
     25,190,253        18,992,563  
  
 
 
    
 
 
 
 
    
Six months
ended
June 30, 2023
    
Six months
ended
June 30, 2022
 
Units at beginning of period
     18,992,563        17,137,275  
Units issued
     6,197,690        1,855,288  
  
 
 
    
 
 
 
Units issued and outstanding at end of period
     25,190,253        18,992,563  
  
 
 
    
 
 
 
 
28

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
Note 8. Financial Highlights
The following is a schedule of financial highlights for the six months ended June 30, 2023 and June 30, 2022:
 
    
Six months ended
June 30, 2023
   
Six months ended
June 30, 2022
 
Per Share Data: (a)
    
Net asset value per unit, beginning of period
   $ 10.33     $ 10.28  
  
 
 
   
 
 
 
Net investment income
     0.60       0.49  
Net realized and unrealized gain (loss)
     (0.32 )*      0.03  
  
 
 
   
 
 
 
Net increase in Unitholders’ capital resulting from operations
     0.28       0.52  
Distributions to Unitholders:
    
From distributable earnings
                  
  
 
 
   
 
 
 
Net asset value per unit, end of period
   $ 10.61     $ 10.80  
  
 
 
   
 
 
 
Total Return (b)(c)
     2.71     5.06
Unitholders’ capital, end of period
   $ 267,226     $ 205,103  
Units outstanding, end of period
     25,190,253       18,992,563  
  
 
 
   
 
 
 
Ratios to average net assets of Unitholders’ Capital (c):
    
Net investment income
     5.82     4.69
  
 
 
   
 
 
 
Operating expenses
     1.62     2.20
Interest and other credit facility expenses
     5.00     3.21
  
 
 
   
 
 
 
Total expenses
     6.62     5.41
  
 
 
   
 
 
 
Average debt outstanding
   $ 285,613     $ 280,590  
Portfolio turnover ratio
     12.1     7.4
 
(a)
Calculated using the average units outstanding method. Weighted average units outstanding for the six months ended June 30, 2023 and June 30, 2022 were 23,512,651 and 17,342,279, respectively.
(b)
Calculated as the change in NAV per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load.
(c)
Not annualized for periods less than one year.
*
Includes the impact of the different unit amounts used in calculating per unit data as a result of calculating certain per unit data based upon the weighted average units outstanding during the period and certain per unit data based on the units outstanding as of a period end.
 
29

SCP Private Credit Income BDC LLC
Notes to Consolidated Financial Statements (unaudited) (continued)
June 30, 2023
(in thousands, except unit amounts)
 
Note 9. Subsequent Events
The Company has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date the consolidated financial statements were issued. There have been no subsequent events that require recognition or disclosure in these consolidated financial statements.
 
30

Report of Independent Registered Public Accounting Firm
To the Unitholders’ and Board of Directors
SCP Private Credit Income BDC LLC:
Results of Review of Interim Financial Information
We have reviewed the consolidated statement of assets and liabilities of SCP Private Credit Income BDC LLC (and subsidiaries) (the Company), including the consolidated schedule of investments, as of June 30, 2023, the related consolidated statements of operations and changes in unitholders’ capital for the three-month and
six-month
periods ended June 30, 2023 and 2022, the related consolidated statements of cash flows for the
six-month
periods ended June 30, 2023 and 2022, and the related notes (collectively, the consolidated interim financial information). Based on our reviews, we are not aware of any material modifications that should be made to the consolidated interim financial information for it to be in conformity with U.S. generally accepted accounting principles.
We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statement of assets and liabilities, including the consolidated schedule of investments, of the Company as of December 31, 2022, and the related consolidated statements of operations, changes in unitholders’ capital, and cash flows for the year then ended (not presented herein); and in our report dated February 28, 2023, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated statement of assets and liabilities, including the consolidated schedule of investments, as of December 31, 2022, is fairly stated, in all material respects, in relation to the consolidated statement of assets and liabilities, including the consolidated schedule of investments, from which it has been derived.
Basis for Review Results
This consolidated interim financial information is the responsibility of the Company’s management. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our reviews in accordance with the standards of the PCAOB. A review of consolidated interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the PCAOB, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.
/s/ KPMG LLP
New York, New York
August 8, 2023
 
31


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Such statements involve known and unknown risks, uncertainties and other factors and undue reliance should not be placed thereon. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about SCP Private Credit Income BDC LLC, our current and prospective Portfolio Investments (as defined below), our industry, our beliefs and opinions, and our assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “will,” “may,” “continue,” “believes,” “seeks,” “estimates,” “would,” “could,” “should,” “targets,” “projects,” “outlook,” “potential,” “predicts” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including without limitation:

 

   

our future operating results, including our ability to achieve objectives;

 

   

our business prospects and the prospects of our portfolio companies;

 

   

the impact of investments that we expect to make;

 

   

our contractual arrangements and relationships with third parties;

 

   

the dependence of our future success on the general economy and its impact on the industries in which we invest;

 

   

the impact of any protracted decline in the liquidity of credit markets on our business;

 

   

the ability of our portfolio companies to achieve their objectives;

 

   

the valuation of our investments in portfolio companies, particularly those having no liquid trading market;

 

   

market conditions and our ability to access alternative debt markets and additional debt and equity capital;

 

   

our expected financings and investments;

 

   

the adequacy of our cash resources and working capital;

 

   

the timing of cash flows, if any, from the operations of our portfolio companies;

 

   

the ability of our investment adviser to locate suitable investments for us and to monitor and administer our investments;

 

   

the ability of our investment adviser to attract and retain highly talented professionals;

 

   

the ability of our investment adviser to adequately allocate investment opportunities among the Company and its other advisory clients;

 

   

any conflicts of interest posed by the structure of the management fee and incentive fee to be paid to the Adviser;

 

   

changes in political, economic or industry conditions, relations between the United States, Russia, Ukraine and other nations, the interest rate environment or conditions affecting the financial and capital markets;

 

   

changes in the general economy, slowing economy, rising inflation, risk of recession and risks in respect of a failure to increase the U.S. debt ceiling; and

 

   

our ability to anticipate and identify evolving market expectations with respect to environmental, social and governance matters, including the environmental impacts of our portfolio companies’ supply chain and operations.

These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including without limitation:

 

   

an economic downturn could impair our portfolio companies’ ability to continue to operate, which could lead to the loss of some or all of our investments in such portfolio companies;

 

32


Table of Contents
   

a contraction of available credit and/or an inability to access the equity markets could impair our lending and investment activities;

 

   

interest rate volatility could adversely affect our results, particularly because we use leverage as part of our investment strategy;

 

   

currency fluctuations could adversely affect the results of our investments in foreign companies, particularly to the extent that we receive payments denominated in foreign currency rather than U.S. dollars; and

 

   

the risks, uncertainties and other factors we identify in Item 1A. — Risk Factors contained in our Annual Report on Form 10-K for the year ended December 31, 2022, elsewhere in this Quarterly Report on Form 10-Q and in our other filings with the SEC.

Although we believe that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate, and as a result, the forward-looking statements based on those assumptions also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans and objectives will be achieved. These risks and uncertainties include those described or identified in the section entitled “Item 1A. Risk Factors” and elsewhere in this report. These forward-looking statements apply only as of the date of this report. Moreover, we assume no duty and do not undertake to update the forward-looking statements.

The following analysis of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes thereto contained elsewhere in this Quarterly Report on Form 10-Q.

Overview

SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”) was formed as a limited liability company under the laws of the State of Delaware on May 18, 2018. We have elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”), and have elected to be treated as a regulated investment company (“RIC”) for U.S. federal income tax purposes. As such, we are required to comply with various regulatory requirements, such as the requirement to invest at least 70% of our assets in “qualifying assets,” source of income limitations, RIC asset diversification requirements, and the requirement to distribute annually at least 90% of our taxable income and tax-exempt interest. In addition, we expect that all of the Company’s total portfolio will be comprised of investments in the U.S. The Company was formed primarily to provide investors with attractive long-term returns through investments made pursuant to the investment strategy of the Company described below (the Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”).

SLR Capital Partners, LLC (the “Adviser”) serves as the Company’s investment adviser pursuant to an investment management agreement between the Company and the Adviser (as amended, restated or otherwise modified from time to time, the “Investment Management Agreement”). Subject to the overall supervision of the Company’s Board of Directors (the “Board”), the Adviser is responsible for managing the Company’s business and activities, including sourcing investment opportunities, conducting research, performing diligence on potential investments, structuring our investments, and monitoring our portfolio companies on an ongoing basis through a team of investment professionals. The managing members of the Adviser are Michael Gross and Bruce Spohler, who also oversee the Adviser’s investment committee. Pursuant to the Investment Management Agreement, the Adviser has also been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Administrative Coordinator supervises or provides the Company’s administrative services, including operational trade support, net asset value calculations, financial reporting, fund accounting, registrar and transfer agent services. The Administrative Coordinator also provides assistance to the Adviser in connection with communicating with investors and other persons with respect to the Company.

The Company is organized primarily for investors who may invest through one or more investment funds created by one or more financial institutions unaffiliated with the Company (collectively, the “Access Fund”). Certain other investors may also invest directly in the Company. For those investors who invest through the Access Fund, we expect the Access Fund will issue a pro rata interest to each investor in the Access Fund (the “Access Fund Investors”) that, with respect to each Access Fund Investor’s investment in the Access Fund, corresponds to the pro rata share of the units issued by the Company to the Access Fund. We also expect that units will only be sold (i) in the U.S. only to U.S. persons who are “accredited investors” within the meaning of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”) and (ii) outside the U.S. in accordance with Regulation S under the Securities Act. Upon a sale of units to an investor, we expect the Access Fund will pass its voting rights in the Company through to the Access Fund Investors.

 

33


Table of Contents

The Company’s principal focus is to invest in first lien secured floating rate loans primarily to upper middle market private leveraged companies (generally, loan sizes of $100 million to $300 million to companies with earnings before interest, tax, depreciation and amortization (“EBITDA”) between approximately $25 million and $100 million) that have significant free cash flow and are in non-cyclical industries in which the Adviser has direct experience. In addition to senior secured loans to upper middle market companies, the Company intends to invest a portion of its assets in non-traditional asset-based loans and first lien loans to rapidly growing healthcare companies. The Company also expects that some of its investments will contain delayed-draw term loan type features (which is a legally binding commitment by the Company to fund additional term loans to a borrower in the future) and/or other types of unfunded commitments. The Company expects to co-invest with other vehicles managed by the Adviser. There can be no assurance that the Company will be able to co-invest with such other funds, including as a result of legal restrictions and contractual restrictions and, as a result, the Company may not be able to meet its investment objective. The Company believes the potential scale resulting from co-investments with vehicles managed by the Adviser will provide the Company a significant advantage to source loans over other lenders that do not have the capital base to provide significant debt financing.

The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and the Company may from time to time take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act.

Recent Developments

None.

Revenues

The Company’s principal focus is to invest in first lien secured floating rate loans primarily to upper middle market private leveraged companies (generally, loan sizes of $100 million to $300 million to companies with EBITDA between approximately $25 million and $100 million) that have significant free cash flow and are in non-cyclical industries in which we have direct experience. In addition to senior secured loans to upper middle market companies, the Company intends to invest a portion of its assets in non-traditional asset-based loans and first lien loans to rapidly growing healthcare companies.

Expenses

The Company will (directly or indirectly) bear:

 

  (i)

all of its fees, costs, expenses and liabilities, all of its investment-related fees, costs, expenses and liabilities (including with respect to amounts incurred prior to the Company’s initial closing) and all of its other operating fees, costs, expenses and liabilities, including all fees, due diligence costs and other fees, costs, expenses and liabilities related to the identification, sourcing, evaluation, pursuit, acquisition, holding, appraisals, asset management, restructuring and disposing of investments, including all reasonable travel-related fees, costs, expenses and liabilities, including lodging and meals, all fees, costs, expenses and liabilities of legal counsel and financial and other advisers incurred in connection therewith, all fees, costs, expenses and liabilities of information technology services relating to the ongoing management of investments, and all other investment-related fees, costs, expenses and liabilities (to the extent not reimbursed by the relevant portfolio company);

 

  (ii)

all fees, costs, expenses and liabilities related to any audits or agreed upon procedures, tax forms and return preparations and filings, custodian fees and expenses, fund accounting, administrator services, financial statement preparation and reporting, web services for the benefit of Unitholders, delivery costs and expenses in connection with reporting obligations and communications and compliance services;

 

34


Table of Contents
  (iii)

all fees, costs, expenses and liabilities relating to insurance policies (including director and officer liability insurance) maintained by or for the Company, including in respect of Portfolio Investments and/or personnel of the Adviser, the Administrative Coordinator and their affiliates;

 

  (iv)

other administrative fees, costs, and liabilities;

 

  (v)

all fees, costs, expenses and liabilities of brokers, transaction finders and other intermediaries, including brokerage commissions and spreads, and all other transaction-related fees, costs, expenses and liabilities, including reverse break-up fees;

 

  (vi)

all fees, costs, expenses and liabilities relating to derivatives and hedging transactions;

 

  (vii)

all principal amounts of, and interest expense on, borrowings and guarantees, and all other fees, costs, expenses and liabilities arising out of borrowings and guarantees, including the arranging and maintenance thereof, whether incurred by the Company or incurred or facilitated by a special purpose vehicle that makes Portfolio Investments;

 

  (viii)

Management Fees;

 

  (ix)

Administration Fees;

 

  (x)

all fees, costs, expenses and liabilities incurred through the use or engagement of Service Providers;

 

  (xi)

all taxes, fees, penalties and other governmental charges levied against the Company and all fees, costs, expenses, penalties and liabilities related to tax compliance;

 

  (xii)

all fees, costs, expenses and liabilities of the Company’s legal counsel related to extraordinary matters, including expenses for any dispute resolution (including litigation and regulatory-related legal expenses);

 

  (xiii)

all fees, costs, expenses and liabilities relating to legal and regulatory filings, including securities law filings relating to Portfolio Investments;

 

  (xiv)

all fees, costs, expenses and liabilities related to the Company’s indemnification or contribution obligations;

 

  (xv)

all fees, costs, expenses and liabilities for subscription services (to the extent such subscription is required by the general partner of the Access Fund);

 

  (xvi)

any required regulatory filings and related legal fees;

 

  (xvii)

all fees, costs, expenses and liabilities of liquidating the Company;

 

  (xviii)

transfer agent services; and

 

  (xix)

any other fees, costs, expenses and liabilities not specifically assumed by the Adviser or the Administrative Coordinator.

In addition, the aggregate amount of the operating expenses relating to Unitholders investing directly in the Company set forth in clauses (ii)-(iv) and the operating expenses included in sub-clauses (xiii) and (xvi) related to U.S. regulatory bodies above borne by the Company (directly or indirectly) will not exceed the Operating Expense Cap, calculated as follows: (A) if the Company has less than or equal to $400 million in Commitments, an amount equal to the sum of (x) the product of the Commitments and 0.0025 and (y) $1.25 million, or (B) if the Company has greater than $400 million in Commitments, $2.25 million. Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. Solely by way of example, if Commitments equal $350 million, the Operating Expense Cap will be equal to $2.125 million. For the avoidance of doubt, the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder.

 

35


Table of Contents

Additionally, the Company will not bear the costs of any third-party valuation agent engaged solely for purposes of valuing the net asset value of the Company.

The Adviser or Administrative Coordinator and/or their affiliates has advanced organizational and offering expenses to the Company, which include organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company. The Adviser or Administrative Coordinator (or such affiliate) has been reimbursed by the Company for such advanced costs and expenses in an amount not to exceed $0.5 million. Accordingly, $0.3 million of offering expenses were charged to capital and $0.1 million of organizational costs were expensed in 2019.

Portfolio and Investment Activity

During the three months ended June 30, 2023, we invested $35.8 million across 14 portfolio companies. This compares to investing $30.7 million in 22 portfolio companies for the three months ended June 30, 2022. Investments sold or prepaid during the three months ended June 30, 2023 totaled $41.4 million versus $12.3 million for the three months ended June 30, 2022.

At June 30, 2023, our portfolio consisted of 54 portfolio companies and was invested 98.5% directly in senior secured loans and 1.5% in common equity/equity interests/warrants, in each case, measured at fair value versus 55 portfolio companies invested >99.9% directly in senior secured loans and <0.1% in common equity/equity interests/warrants at June 30, 2022.

At June 30, 2023, 97.1% of our income producing investment portfolio was floating rate and 2.9% was fixed rate, measured at fair value. At June 30, 2022, 97.1% of our income producing investment portfolio was floating rate and 2.9% was fixed rate, measured at fair value.

Critical Accounting Policies

The preparation of consolidated financial statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following items as critical accounting policies. Within the context of these critical accounting policies and disclosed subsequent events herein, we are not currently aware of any other reasonably likely events or circumstances that would result in materially different amounts being reported.

Valuation of Portfolio Investments

In December 2020, the SEC adopted new Rule 2a-5 under the 1940 Act addressing fair valuation of fund investments. The new rule sets forth requirements for good faith determinations of fair value, as well as for the performance of fair value determinations, including related oversight and reporting obligations. The new rule also defines “readily available market quotations” for purposes of the definition of “value” under the 1940 Act, and the SEC noted that this definition will apply in all contexts under the 1940 Act. The Company complies with Rule 2a-5’s valuation requirements.

The Company conducts the valuation of its assets, pursuant to which the Company’s net asset value is determined, at all times consistent with GAAP, and the 1940 Act. The Board will (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule 2a-5 under the 1940 Act; and (6) maintain recordkeeping requirements under Rule 2a-5.

 

36


Table of Contents

It is anticipated that in respect of many of the Company’s assets, readily available market quotations will not be obtainable and that such assets will be valued at fair value. A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation.

For purposes of calculating the NAV, the Company’s assets will generally be valued as described in Note 2(b) to the Company’s Consolidated Financial Statements.

Leverage

The Company is required to comply with the asset coverage requirements of the 1940 Act. The Company expects to employ leverage and otherwise incur indebtedness with respect to the portfolio both on a recourse and non-recourse basis (including and potentially through guarantees, derivatives, forward commitments and reverse repurchase agreements), but will not exceed the maximum amount permitted by the 1940 Act. The Company is generally permitted, under specified conditions, to issue senior securities in amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least equal to 150% immediately after such issuance. In connection with the organization of the Company, the Adviser, as the initial Unitholder, has authorized the Company to adopt the 150% asset coverage ratio as of August 2, 2018. In connection with their subscriptions of the Units, our Unitholders were required to acknowledge our ability to operate with an asset coverage ratio that may be as low as 150%. The Company will be exposed to the risks of leverage, which may be considered a speculative investment technique. The use of leverage magnifies the potential for gain and loss on amounts invested and therefore increases the risks associated with investing in our securities. In addition, the costs associated with our borrowings, including any increase in the management fee payable to the Adviser will be borne by our Unitholders. As of June 30, 2023, the Company had $263.3 million of senior securities, for an asset coverage ratio of 201.5%.

Taxation as a RIC

The Company elected to be treated as a RIC under Subchapter M of the Code and intends to qualify for taxation as a RIC annually. As a RIC, the Company generally will not pay corporate-level U.S. federal income taxes on any ordinary income or capital gains that it timely distributes to Unitholders as dividends. In order to qualify for taxation as a RIC, the Company is required, among other things, to be diversified at each quarter end and to timely distribute to its Unitholders at least 90% of investment company taxable income, as defined by the Code, for each year. There is no guarantee the Company will be able to maintain its status as a RIC. Depending on the level of taxable income earned in a given tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and pay a nondeductible 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company will accrue an estimated excise tax, if any, on estimated excess taxable income.

Recent Accounting Pronouncements

None.

 

37


Table of Contents

Results of Operations

Results are shown for the three and six months ended June 30, 2023 and June 30, 2022:

Investment Income

For the three and six months ended June 30, 2023, gross investment income totaled $15.3 million and $30.1 million, respectively. For the three and six months ended June 30, 2022, gross investment income totaled $9.6 million and $18.3 million, respectively. The comparative increase in gross investment income is due to an increase in the size of the income-producing portfolio as well as the impact of higher interest rates.

Expenses

Expenses totaled $8.7 million and $16.0 million, respectively, for the three and six months ended June 30, 2023, of which $2.8 million and $3.4 million, respectively, were management, incentive and administration fees and $5.7 million and $12.1 million, respectively, were interest and other credit facility expenses. Administrative services, organization and other general and administrative expenses totaled $0.2 million and $0.5 million, respectively, for the three and six months ended June 30, 2023. Expenses totaled $5.2 million and $9.8 million, respectively, for the three and six months ended June 30, 2022, of which $1.7 million and $3.5 million, respectively, were management, incentive and administration fees and $3.2 million and $5.8 million, respectively, were interest and other credit facility expenses. Administrative services, organization and other general and administrative expenses totaled $0.2 million and $0.5 million, respectively, for the three and six months ended June 30, 2022. Expenses generally consist of management fees, administration fees, performance-based incentive fees, insurance, legal expenses, directors’ expenses, audit and tax expenses and other general and administrative expenses. Interest and other credit facility expenses generally consist of interest, unused fees, agency fees and loan origination fees, if any, among others. The comparative increase in expenses is mainly due to higher index rates on our revolving credit facilities.

Net Investment Income

The Company’s net investment income totaled $6.6 million and $14.1 million, or $0.34 and $0.60 per average unit, respectively, for the three and six months ended June 30, 2023. The Company’s net investment income totaled $4.4 million and $8.5 million, or $0.25 and $0.49 per average unit, respectively, for the three and six months ended June 30, 2022.

Net Realized Gain

The Company had investment sales and prepayments totaling approximately $41.4 million and $68.8 million, respectively, for the three and six months ended June 30, 2023. Net realized gain over the same periods totaled $0.1 million and $0, respectively. The Company had investment sales and prepayments totaling approximately $12.3 million and $33.8 million, respectively, for the three and six months ended June 30, 2022. Net realized gain (loss) over the same periods totaled $0 and $0, respectively.

Net Change in Unrealized Gain (Loss)

For the three and six months ended June 30, 2023, net change in unrealized gain (loss) on the Company’s assets totaled $2.4 million and ($8.1) million, respectively. Net unrealized gain for the three months ended June 30, 2023 was primarily due to appreciation on our investments in SLR-AMI Topco Blocker, LLC, World Insurance Associates, LLC and Fertility (ITC) Investment Holdco, LLC, among others, partially offset by depreciation on our investments in Spectrum Pharmaceuticals, Inc., among others. Net unrealized loss for the six months ended June 30, 2023 was primarily due to depreciation on our investments in Amerimark Intermediate Holdings, LLC and TAUC Management, LLC, among others, partially offset by appreciation on our investments in SLR-AMI Topco Blocker, LLC, World Insurance Associates, LLC, and Pinnacle Treatment Centers, Inc., among others. For the three and six months ended June 30, 2022, net change in unrealized gain (loss) on the Company’s assets totaled ($0.3) million and $0.5 million, respectively. Net unrealized loss for the three months ended June 30, 2022 was primarily due to the reversal of previously recognized unrealized appreciation in the value of SOC Telemed, Inc., as well as depreciation on our investments in World Insurance Associates, LLC and Foundation Consumer Brands, LLC, among others, partially offset by appreciation on our investments in ACRES Commercial Mortgage, LLC, High Street Buyer, Inc. and Ivy Fertility Services, LLC, among others. Net unrealized gain for the six months ended June 30, 2022 was primarily due

 

38


Table of Contents

to appreciation on our investments in Apex Service Partners, LLC, ACRES Commercial Mortgage, LLC and Kid Distro Holdings, LLC, among others, partially offset by depreciation on our investments in World Insurance Associates, LLC and Foundation Consumer Brands, LLC, among others, as well as the reversal of previously recognized appreciation in Community Brands ParentCo, LLC.

Net Increase in Unitholders’ Capital Resulting From Operations

For the three and six months ended June 30, 2023, the Company had a net increase in Unitholders’ capital resulting from operations of $9.0 million and $6.0 million, respectively. For the same period, income per average unit was $0.36 and $0.25, respectively. For the three and six months ended June 30, 2022, the Company had a net increase in Unitholders’ capital resulting from operations of $4.2 million and $9.0 million, respectively. For the same period, income per average unit were $0.24 and $0.52, respectively.

Financial Condition, Liquidity and Capital Resources

Our primary uses of cash are for (i) investments in portfolio companies and other investments to comply with certain portfolio diversification requirements, (ii) the cost of operations (including paying the Adviser), (iii) debt service of any borrowings, and (iv) cash distributions to our Unitholders.

Equity

During the period March 12, 2019 (commencement of operations) to June 30, 2023, on a net basis, the Company sold and issued 25,190,253 common units at an average price of $10.38 per unit, for net proceeds of $261.5 million. All of our outstanding units were issued and sold in reliance upon the available exemptions from registration requirements of Section 4(a)(2) of the Securities Act. Unfunded equity capital commitments totaled $64.5 million at June 30, 2023.

Debt

Revolving credit facility due December 2023 (theSPV Facility”)—On February 27, 2019, the Company, through its wholly-owned subsidiary, SCP Private Credit Income BDC SPV LLC (the “SPV”), entered into a $100 million SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. The commitment can also be expanded up to $400 million. The stated interest rate on the SPV Facility is SOFR plus 2.90% with no floor requirement and the current final maturity date is December 31, 2023. The fee on undrawn commitments is generally 0.875%. The SPV Facility is secured by all of the assets held by SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV also includes usual and customary events of default for credit facilities of this nature. On November 18, 2019, the Company amended the SPV Facility, reducing commitments to $75 million. On February 27, 2021, the Company again amended the SPV Facility, increasing commitments to $100 million. On July 16, 2021, the Company entered into an amended and restated SPV Facility, which increased commitments to $125 million, and on August 18, 2021 entered into a second amended and restated SPV Facility which increased commitments to $200 million and extended the final maturity date to December 31, 2023. On November 2, 2021, the Company entered into Amendment No. 1 to the second amended SPV Facility, which increased commitments to $275 million. On August 3, 2022, the Company entered into Amendment No. 2 to the second amended SPV Facility, which increased commitments to $300 million and changed the interest rate to a SOFR-based calculation. As of June 30, 2023, there were $236.5 million of borrowings outstanding under the SPV Facility. Effective with the end of the Investment Period on December 31, 2022, future advances are no longer permitted.

Revolving credit facility due December 2023 (theSubscription Facility”)—During the first quarter of 2019, the Company established the $35.0 million Subscription Facility with East West Bank, and subsequently entered into an amendment on June 24, 2019, which increased commitments from $35.0 million to $50.0 million. On March 5, 2021, the Company entered into a second amendment. Under the second amendment, commitments were increased from $50.0 million to $75.0 million and the maturity date was extended. On October 4, 2021, the Company entered into an amended and restated loan and security agreement, which increased commitments to $100 million and extended the

 

39


Table of Contents

maturity date to December 31, 2022. On December 28, 2022, the Company entered into a first amendment to the amended and restated loan and security agreement, changing the stated interest rate on the Subscription Facility to SOFR plus 2.80%, reducing commitments to $75 million and extending the maturity date to December 31, 2023. Under the terms of the Subscription Facility, the Company has made certain customary representations and warranties, and is required to comply with various covenants, including reporting requirements and other customary requirements for similar credit facilities. The Subscription Facility also includes usual and customary events of default for credit facilities of this nature. As of June 30, 2023, there were $26.8 million of borrowings outstanding under the Subscription Facility.

Cash Equivalents

We deem certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities as cash equivalents. The Company makes purchases that are consistent with its purpose of making investments in securities described in paragraphs 1 through 3 of Section 55(a) of the 1940 Act. From time to time, including at or near the end of each fiscal quarter, we consider using various temporary investment strategies for our business. One strategy includes taking proactive steps by utilizing cash equivalents as temporary assets with the objective of enhancing our investment flexibility pursuant to Section 55 of the 1940 Act. More specifically, from time-to-time we may purchase U.S. Treasury bills or other high-quality, short-term debt securities at or near the end of the quarter and typically close out the position on a net cash basis subsequent to quarter end. We may also utilize repurchase agreements or other balance sheet transactions, including drawing down on our credit facilities, as deemed appropriate. The amount of these transactions or such drawn cash for this purpose is excluded from total assets for purposes of computing the asset base upon which the management fee is determined. We held no cash equivalents at June 30, 2023.

Contractual Obligations

We have entered into certain contracts under which we have material future commitments. We have entered into the Investment Management Agreement with the Adviser in accordance with the 1940 Act. Under the Investment Management Agreement, the Company will pay the Adviser the Management Fee and the Incentive Fee, and the Administrative Coordinator the Administration Fee. Under the Investment Management Agreement, the Administrative Coordinator may engage or delegate certain administrative functions to third parties or affiliates on behalf of the Company. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain on-going, routine, non-investment-related administrative services for the Company, (ii) the coordination of various third party services needed or required by the Company, and (iii) certain Unitholder servicing functions.

A summary of our significant contractual payment obligations is as follows as of June 30, 2023:

 

Payments due by Period as of June 30, 2023
(dollars in millions)

 
     Total      Less than
1 year
     1-3 years      3-5 years      More than
5 years
 

Credit facilities (1)

   $ 263.3      $ 263.3      $ —        $ —        $ —  

 

(1)

At June 30, 2023, we had a total of $48.2 million of unused borrowing capacity under our credit facilities, subject to borrowing base limits.

If any of the contractual obligations discussed above are terminated, our costs under any new agreements that we enter into may increase. In addition, we would likely incur significant time and expense in locating alternative parties to provide the services we expect to receive under the Investment Management Agreement. Any new investment advisory agreement would also be subject to approval by our Unitholders.

 

40


Table of Contents

Off-Balance Sheet Arrangements

From time-to-time and in the normal course of business, the Company may make unfunded capital commitments to current or prospective portfolio companies. Typically, the Company may agree to provide delayed-draw term loans or, to a lesser extent, revolving loan or equity commitments. These unfunded capital commitments always take into account the Company’s liquidity and cash available for investment, portfolio and issuer diversification, and other considerations. Accordingly, the Company had the following unfunded capital commitments at June 30, 2023 and December 31, 2022, respectively:

 

     June 30, 2023      December 31,
2022
 

(in millions)

 

Outset Medical, Inc.

   $ 11.9      $ 11.9  

Human Interest Inc.

     6.8        6.8  

Vessco Midco Holdings, LLC

     3.4        5.0  

Glooko, Inc.

     3.2        3.2  

Arcutis Biotherapeutics, Inc.

     3.1        3.1  

Ardelyx, Inc.

     2.7        2.7  

iCIMS, Inc.

     2.7        3.9  

Cerapedics, Inc.

     2.4        2.4  

High Street Buyer, Inc.

     2.0        2.8  

RxSense Holdings, LLC

     1.6        1.6  

Pediatric Home Respiratory Services, LLC

     1.5        2.4  

Enverus Holdings, Inc.

     1.5        1.2  

Maurices, Incorporated

     1.5        2.7  

RSC Acquisition, Inc.

     1.4        10.3  

Nexus Intermediate III, LLC (Vortex)

     1.3        1.3  

Meditrina, Inc.

     1.2        1.2  

Spectrum Pharmaceuticals, Inc.

     1.2        3.0  

Kid Distro Holdings, LLC

     1.1        1.1  

GSM Acquisition Corp.

     1.1        1.1  

Foundation Consumer Brands, LLC

     1.0        1.0  

Basic Fun, Inc.

     1.0        1.2  

Ultimate Baked Goods Midco LLC

     0.7        0.6  

Orthopedic Care Partners Management, LLC

     0.7        2.2  

Southern Orthodontic Partners Management, LLC

     0.7        2.6  

Kaseya, Inc.

     0.6        1.3  

MRI Software LLC

     0.6        0.6  

ENS Holdings III Corp. & ES Opco USA LLC

     0.6        0.2  

SunMed Group Holdings, LLC

     0.5        0.2  

Transportation Insight, LLC

     0.4        1.8  

World Insurance Associates, LLC

     0.4        0.1  

TAUC Management, LLC

     0.4        0.4  

Amerimark Intermediate Holdings, LLC

     0.2        —    

CC SAG Holdings Corp. (Spectrum Automotive)

     0.2        6.6  

Oral Surgery Partners Holdings, LLC

     —          3.3  

Plastics Management, LLC

     —          3.1  

Erie Construction Mid-west, LLC

     —          1.6  

Tilley Chemical Buyer, Inc.

     —          0.6  

Peter C. Foy & Associates Insurance Services, LLC

     —          0.6  

Pinnacle Treatment Centers, Inc.

     —          0.5  

Ivy Fertility Services, LLC

     —          0.5  

BayMark Health Services, Inc.

     —          0.5  

NAC Holdings Corporation

     —          0.5  

Apex Service Partners, LLC

     —          0.3  

All States Ag Parts, LLC

     —          0.2  
  

 

 

    

 

 

 

Total Commitments

   $ 59.6      $ 98.2  
  

 

 

    

 

 

 

 

41


Table of Contents

The credit agreements of the above loan commitments contain customary lending provisions and/or are subject to the portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of June 30, 2023 and December 31, 2022, the Company had sufficient cash available and/or liquid securities available to fund its commitments.

Distributions

Tax characteristics of all distributions will be reported to unitholders on Form 1099 after the end of the calendar year. Future quarterly distributions, if any, will be determined by our Board. We expect that our distributions to unitholders will generally be from accumulated net investment income, from net realized capital gains or non-taxable return of capital, if any, as applicable.

We have elected to be taxed as a RIC under Subchapter M of the Code. To maintain our RIC tax treatment, we must distribute at least 90% of our ordinary income and realized net short-term capital gains in excess of realized net long-term capital losses, if any, out of the assets legally available for distribution. In addition, although we currently intend to distribute realized net capital gains (i.e., net long-term capital gains in excess of short-term capital losses), if any, at least annually, out of the assets legally available for such distributions, we may in the future decide to retain such capital gains for investment.

We may not be able to achieve operating results that will allow us to make distributions at a specific level or to increase the amount of these distributions from time to time. In addition, due to the asset coverage test applicable to us as a BDC, we may in the future be limited in our ability to make distributions. Also, our revolving credit facility may limit our ability to declare distributions if we default under certain provisions. If we do not distribute a certain percentage of our income annually, we will suffer adverse tax consequences, including possible loss of the tax benefits available to us as a RIC. In addition, in accordance with GAAP and tax regulations, we include in income certain amounts that we have not yet received in cash, such as contractual payment-in-kind income, which represents contractual income added to the loan balance that becomes due at the end of the loan term, or the accrual of original issue or market discount. Since we may recognize income before or without receiving cash representing such income, we may have difficulty meeting the requirement to distribute at least 90% of our investment company taxable income to obtain tax benefits as a RIC.

With respect to the distributions to unitholders, income from origination, structuring, closing and certain other upfront fees associated with investments in portfolio companies are treated as taxable income and accordingly, distributed to unitholders.

Related Parties

We have entered into the Investment Management Agreement with the Adviser. Mr. Gross, our Chairman, Co-Chief Executive Officer and President and Mr. Spohler, our Co-Chief Executive Officer, Chief Operating Officer and board member, are managing members and senior investment professionals of, and have financial and controlling interests in, the Adviser. In addition, Mr. Kajee, our Chief Financial Officer, Treasurer and Secretary serves as the Chief Financial Officer for the Adviser.

The Adviser may also manage other funds in the future that may have investment mandates that are similar, in whole and in part, with ours. For example, the Adviser presently serves as investment adviser to SLR Investment Corp., a publicly traded BDC, which focuses on investing in senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities, SLR HC BDC LLC, an unlisted BDC whose principal focus is to invest directly and indirectly in senior secured loans and other debt instruments typically to middle market companies within the healthcare industry, and SLR Private Credit BDC II LLC, an unlisted BDC whose principal focus is to invest in first

 

42


Table of Contents

lien senior secured floating rate loans primarily to upper middle market leveraged companies with EBITDA between approximately $25 million and $250 million that have significant free cash flow and are in non-cyclical industries in which the Adviser has significant experience. In addition, Michael S. Gross, our Chairman, Co-Chief Executive Officer and President, Bruce Spohler, our Co-Chief Executive Officer and Chief Operating Officer, and Shiraz Y. Kajee, our Chief Financial Officer, serve in similar capacities for SLR Investment Corp., SLR HC BDC LLC and SLR Private Credit BDC II LLC. The Adviser and certain investment advisory affiliates may determine that an investment is appropriate for us and for one or more of those other funds. In such event, depending on the availability of such investment and other appropriate factors, the Adviser or its affiliates may determine that we should invest side-by-side with one or more other funds. Any such investments will be made only to the extent permitted by applicable law and interpretive positions of the SEC and its staff, and consistent with the Adviser’s allocation procedures. On June 13, 2017, the Adviser received an exemptive order that permits the Company to participate in negotiated co-investment transactions with certain affiliates, in a manner consistent with the Company’s investment objective, positions, policies, strategies and restrictions as well as regulatory requirements and other pertinent factors, and pursuant to various conditions (the “Order”). If the Company is unable to rely on the Order for a particular opportunity, such opportunity will be allocated first to the entity whose investment strategy is the most consistent with the opportunity being allocated, and second, if the terms of the opportunity are consistent with more than one entity’s investment strategy, on an alternating basis. Although the Adviser’s investment professionals will endeavor to allocate investment opportunities in a fair and equitable manner, the Company and its Unitholders could be adversely affected to the extent investment opportunities are allocated among us and other investment vehicles managed or sponsored by, or affiliated with, our executive officers, directors and members of the Adviser. In addition, we have adopted a formal code of ethics that governs the conduct of our officers and directors. Our officers and directors also remain subject to the duties imposed by both the 1940 Act and the Delaware Limited Liability Company Act.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are subject to financial market risks, including changes in interest rates. Uncertainty with respect to the rising interest rates, inflationary pressures, risks in respect of a failure to increase the U.S. debt ceiling or a downgrade in the U.S. credit rating, the war between Ukraine and Russia and health epidemics and pandemics introduced significant volatility in the financial markets, and the effects of this volatility has materially impacted and could continue to materially impact our market risks. Because we fund a portion of our investments with borrowings, our net investment income is affected by the difference between the rate at which we invest and the rate at which we borrow. As a result, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In a low interest rate environment, including a reduction of LIBOR or SOFR to zero, the difference between the total interest income earned on interest earning assets and the total interest expense incurred on interest bearing liabilities may be compressed, reducing our net interest income and potentially adversely affecting our operating results. Conversely, in a rising interest rate environment, such as the current economic environment, such difference could potentially increase thereby increasing our net investment income. During the six months ended June 30, 2023, certain investments in our investment portfolio had floating interest rates. These floating rate investments were primarily based on floating LIBOR or SOFR and typically have durations of one to three months after which they reset to current market interest rates. Additionally, some of these investments have floors. The Company also has revolving credit facilities that are generally based on floating LIBOR or SOFR. Assuming no changes to our balance sheet as of June 30, 2023 and no new defaults by portfolio companies, a hypothetical one percent decrease in LIBOR or SOFR on our comprehensive floating rate assets and liabilities would decrease our net investment income by approximately eight cents per average unit over the next twelve months. Assuming no changes to our balance sheet as of June 30, 2023 and no new defaults by portfolio companies, a hypothetical one percent increase in LIBOR or SOFR on our comprehensive floating rate assets and liabilities would increase our net investment income by approximately eight cents per average unit over the next twelve months. However, we may hedge against interest rate fluctuations from time-to-time by using standard hedging instruments such as futures, options, swaps and forward contracts subject to the requirements of the 1940 Act. While hedging activities may insulate us against adverse changes in interest rates, they may also limit our ability to participate in any benefits of certain changes in interest rates with respect to our portfolio of investments. At June 30, 2023, we have no interest rate hedging instruments outstanding on our balance sheet.

 

Increase (Decrease) in LIBOR/SOFR

     (1.00 %)      1.00
  

 

 

   

 

 

 

Increase in Net Investment Income Per Unit Per Year

   $ (0.08   $ 0.08  
  

 

 

   

 

 

 

 

43


Table of Contents

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

As of June 30, 2023 (the end of the period covered by this report), our management, including our Co-Chief Executive Officers and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the 1934 Act). Based on that evaluation, our management, including the Co-Chief Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures were effective and provided reasonable assurance that information required to be disclosed in our periodic SEC filings is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Co-Chief Executive Officers and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. However, in evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of such possible controls and procedures.

(b) Changes in Internal Controls Over Financial Reporting

Management has not identified any change in the Company’s internal control over financial reporting that occurred during the second quarter of 2023 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We and our consolidated subsidiaries are not currently subject to any material pending legal proceedings threatened against us. From time to time, we may be a party to certain legal proceedings incidental to the normal course of our business including the enforcement of our rights under contracts with our portfolio companies. While the outcome of these legal proceedings cannot be predicted with certainty, we do not expect that these proceedings will have a material effect upon our business, financial condition or results of operations beyond what has been disclosed within these financial statements.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in “Risk Factors” in the February 28, 2023 filing of the Annual Report on Form 10-K, which could materially affect our business, financial condition and/or operating results. The risks described in our Annual Report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or operating results. Other than the risk factor set forth below, there have been no material changes during the three months ended June 30, 2023 to the risk factors discussed in “Risk Factors” in the February 28, 2023 filing of our Annual Report on Form 10-K.

Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties could have a material adverse effect on us, the Adviser and our portfolio companies.

Cash not held in custody accounts and held by us, our Adviser and by our portfolio companies in non-interest-bearing and interest-bearing operating accounts could, at times, exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits. If such banking institutions were to fail, we, our Adviser, or our portfolio companies could lose all or a portion of those amounts held in excess of such insurance limits. In addition, actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems, which could adversely affect our, our Adviser’s and our portfolio companies’ business, financial condition, results of operations, or prospects.

 

44


Table of Contents
Although we and our Adviser assess our and our portfolio companies’ banking and financing relationships as we believe necessary or appropriate, our and our portfolio companies’ access to funding sources and other credit arrangements in amounts adequate to finance or capitalize current and projected future business operations could be significantly impaired by factors that affect the financial institutions with which we, our Adviser or our portfolio companies have arrangements directly or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we, our Adviser or our portfolio companies have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.
In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us, our Adviser, or our portfolio companies to acquire financing on acceptable terms or at all.
The alternative reference rates that have replaced LIBOR in our credit arrangements and other financial instruments may not yield the same or similar economic results as LIBOR over the life of such transactions.
The London Interbank Offered Rate (“LIBOR”) is an index rate that historically was widely used in lending transactions and was a common reference rate for setting the floating interest rate on private loans. LIBOR was typically the reference rate used in floating-rate loans extended to our portfolio companies.
The ICE Benchmark Administration (“IBA”) (the entity that is responsible for calculating LIBOR) ceased providing overnight, one, three, six and twelve months USD LIBOR tenors on June 30, 2023. In addition, the United Kingdom’s Financial Conduct Authority (“FCA”), which oversees the IBA, now prohibits entities supervised by the FCA from using LIBORs, including USD LIBOR, except in very limited circumstances.
In the United States, the Secured Overnight Financing Rate (“SOFR”) is the preferred alternative rate for LIBOR. SOFR is a measure of the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. SOFR is published by the Federal Reserve Bank of New York each U.S. Government Securities Business Day, for transactions made on the immediately preceding U.S. Government Securities Business Day. Alternative reference rates that may replace LIBOR, including SOFR for USD transactions, may not yield the same or similar economic results as LIBOR over the lives of such transactions.
As of the filing date of this Quarterly Report on Form 10-Q, many of our loans that referenced LIBOR have been amended to reference the forward-looking term rate published by CME Group Benchmark Administration Limited based on SOFR (“CME Term SOFR”) or CME Term SOFR plus a fixed spread adjustment. CME Term SOFR rates are forward-looking rates that are derived by compounding projected overnight SOFR rates over one, three, and six months taking into account the values of multiple consecutive, executed, one-month and three-month CME Group traded SOFR futures contracts and, in some cases, over-the-counter SOFR Overnight Indexed Swaps as an indicator of CME Term SOFR reference rate values. CME Term SOFR and the inputs on which it is based are derived from SOFR. Since CME Term SOFR is a relatively new market rate, there will likely be no established trading market for credit agreements or other financial instruments when they are issued, and an established market may never develop or may not be liquid. Market terms for instruments referencing CME Term SOFR rates may be lower than those of later-issued CME Term SOFR indexed instruments. Similarly, if CME Term SOFR does not prove to be widely used, the trading price of instruments referencing CME Term SOFR may be lower than those of instruments indexed to indices that are more widely used. Further, the composition and characteristics of SOFR and CME Term SOFR are not the same as those of LIBOR. Even with the application of a fixed spread adjustment, LIBOR and CME Term SOFR will not have the same composition and characteristics, and there can be no assurance that the replacement rate, as so adjusted, will be a direct substitute for LIBOR.
There can be no guarantee that SOFR will not be discontinued or fundamentally altered in a manner that is materially adverse to the interests of investors in loans referencing SOFR. If the manner in which SOFR or CME Term SOFR is calculated is changed, that change may result in a reduction of the amount of interest payable on such loans and the trading prices of the SOFR Loans. In addition, there can be no guarantee that loans referencing SOFR or CME Term SOFR will continue to reference those rates until maturity or that, in the future, our loans will reference benchmark rates other than CME Term SOFR. Should any of these events occur, our loans, and the yield generated thereby, could be affected. Specifically, the anticipated yield on our loans may not be fully realized and our loans may be subject to increased pricing volatility and market risk.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
There were no unregistered sales of equity securities other than those already disclosed in certain Form
8-Ks
filed with the SEC.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosure
Not applicable.
Item 5. Other Information
Rule
10b5-1
Trading Plans
During the fiscal quarter ended June 30, 2023, none
of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)
adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K.
 

45


Table of Contents

Item 6. Exhibits

The following exhibits are filed as part of this report or hereby incorporated by reference to exhibits previously filed with the SEC:

 

3.1    Certificate of Formation(1)
3.2    Second Amended and Restated Limited Liability Company Agreement(2)
4.1    Form of Subscription Agreement(1)
31.1    Certification of Co-Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.*
31.2    Certification of Co-Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.*
31.3    Certification of Chief Financial Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended.*
32.1    Certification of Co-Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.2    Certification of Co-Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.3    Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101.INS    Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded with the Inline XBRL document.
101.SCH    Inline XBRL Taxonomy Extension Schema Document*
101.CAL    Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF    Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB    Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE    Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104    Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

*

Filed herewith.

(1)

Previously filed as an exhibit to Amendment No. 1 to the Registrant’s Registration Statement on Form 10 (File No. 000-55955) filed with the SEC on August 24, 2018.

(2)

Previously filed in connection with the Registrant’s report on Form 10-K filed on February 20, 2020.

 

46


Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on August 8, 2023.

 

SCP PRIVATE CREDIT INCOME BDC LLC
By:  

/s/ MICHAEL S. GROSS

 

Michael S. Gross

Co-Chief Executive Officer

(Principal Executive Officer)

By:  

/s/ BRUCE J. SPOHLER

 

Bruce J. Spohler

Co-Chief Executive Officer

(Principal Executive Officer)

By:  

/s/ SHIRAZ Y. KAJEE

 

Shiraz Y. Kajee

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

47

EX-31.1 2 d530243dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael S. Gross, certify that:

 

  1.

I have reviewed this quarterly report on Form 10-Q of SCP Private Credit Income BDC LLC;

 

  2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

  5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated this 8th day of August, 2023

 

/s/ Michael S. Gross

Michael S. Gross
EX-31.2 3 d530243dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Bruce J. Spohler, certify that:

 

  1.

I have reviewed this quarterly report on Form 10-Q of SCP Private Credit Income BDC LLC;

 

  2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

  5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated this 8th day of August, 2023

 

/s/ Bruce J. Spohler

Bruce J. Spohler
EX-31.3 4 d530243dex313.htm EX-31.3 EX-31.3

Exhibit 31.3

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Shiraz Y. Kajee, certify that:

 

  1.

I have reviewed this quarterly report on Form 10-Q of SCP Private Credit Income BDC LLC;

 

  2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

  a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

  5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated this 8th day of August, 2023

 

/s/ Shiraz Y. Kajee

Shiraz Y. Kajee
EX-32.1 5 d530243dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)

In connection with the Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Report”) of SCP Private Credit Income BDC LLC (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, I, MICHAEL S. GROSS, the Co-Chief Executive Officer of the Registrant, hereby certify, to the best of my knowledge, that:

 

  (1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

 

/s/ Michael S. Gross

Name:   Michael S. Gross
Date:   August 8, 2023
EX-32.2 6 d530243dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)

In connection with the Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Report”) of SCP Private Credit Income BDC LLC (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, I, BRUCE J. SPOHLER, the Co-Chief Executive Officer of the Registrant, hereby certify, to the best of my knowledge, that:

 

  (1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

 

/s/ Bruce J. Spohler

Name:   Bruce J. Spohler
Date:   August 8, 2023
EX-32.3 7 d530243dex323.htm EX-32.3 EX-32.3

Exhibit 32.3

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)

In connection with the Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Report”) of SCP Private Credit Income BDC LLC (the “Registrant”), as filed with the Securities and Exchange Commission on the date hereof, I, SHIRAZ Y. KAJEE, the Chief Financial Officer of the Registrant, hereby certify, to the best of my knowledge, that:

 

  (1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

  (2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

 

/s/ Shiraz Y. Kajee

Name:   Shiraz Y. Kajee
Date:   August 8, 2023
EX-101.SCH 8 ck0001743415-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Consolidated Statements of Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Consolidated Statements of Assets and Liabilities (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Consolidated Statement of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Consolidated Statement of Changes in Unitholders' Capital link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Consolidated Schedule of Investments link:presentationLink link:definitionLink link:calculationLink 1008 - Statement - Consolidated Schedule of Investments 1 link:presentationLink link:definitionLink link:calculationLink 1009 - Statement - Consolidated Schedule of Investments (Parethetical) link:presentationLink link:definitionLink link:calculationLink 999001 - Disclosure - Organization link:presentationLink link:definitionLink link:calculationLink 999002 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 999003 - Disclosure - Agreements and Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 999004 - Disclosure - Fair Value link:presentationLink link:definitionLink link:calculationLink 999005 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 999006 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 999007 - Disclosure - Unitholders' Capital link:presentationLink link:definitionLink link:calculationLink 999008 - Disclosure - Financial Highlights link:presentationLink link:definitionLink link:calculationLink 999009 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 999010 - Disclosure - Fair Value (Tables) link:presentationLink link:definitionLink link:calculationLink 999011 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 999012 - Disclosure - Unitholders' Capital (Tables) link:presentationLink link:definitionLink link:calculationLink 999013 - Disclosure - Financial Highlights (Tables) link:presentationLink link:definitionLink link:calculationLink 999014 - Disclosure - Organization - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999015 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999016 - Disclosure - Agreements and Related Party Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999017 - Disclosure - Fair Value - Summary of Assets Measured At Fair Value On A Recurring Basis (Detail) link:presentationLink link:definitionLink link:calculationLink 999018 - Disclosure - Fair Value - Summary of The Changes In Fair Value Of Level 3 Assets (Detail) link:presentationLink link:definitionLink link:calculationLink 999019 - Disclosure - Fair Value - Summary of Quantitative Information About The Company's Level 3 Asset Fair Value Measurements (Detail) link:presentationLink link:definitionLink link:calculationLink 999020 - Disclosure - Fair Value - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 999021 - Disclosure - Debt - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999022 - Disclosure - Commitments and Contingencies - Summary of Unfunded Commitments (Detail) link:presentationLink link:definitionLink link:calculationLink 999023 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 999024 - Disclosure - Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail) link:presentationLink link:definitionLink link:calculationLink 999025 - Disclosure - Financial Highlights - Summary of Investment Company, Financial Highlights (Detail) link:presentationLink link:definitionLink link:calculationLink 999026 - Disclosure - Financial Highlights - Summary of Investment Company, Financial Highlights (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 999027 - Disclosure - Insider Trading Arrangements link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 ck0001743415-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 ck0001743415-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 ck0001743415-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 12 ck0001743415-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page - shares
6 Months Ended
Jun. 30, 2023
Aug. 04, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Amendment Flag false  
Document Period End Date Jun. 30, 2023  
Entity Registrant Name SCP Private Credit Income BDC LLC  
Entity Central Index Key 0001743415  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   25,190,253
Entity File Number 814-01294  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 500 Park Avenue  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10022  
City Area Code 212  
Local Phone Number 993-1670  
Entity Interactive Data Current Yes  
Entity Tax Identification Number 83-0634992  
Entity Ex Transition Period false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Assets and Liabilities - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Investments at fair value:    
Cash $ 13,060 $ 16,697
Interest receivable 3,625 3,647
Receivable for investments sold 99 0
Prepaid expenses 86 22
Total assets 539,339 553,261
Liabilities    
Distributions payable 0 10,825
Management fee payable (see note 3) 2,136 519
Incentive fee payable (see note 3) 2,039 4,025
Administration fee payable (see note 3) 105 108
Interest payable (see note 5) 4,731 4,041
Other liabilities and accrued expenses 617 940
Total liabilities 272,113 357,007
Commitments and contingencies (see note 6)
Unitholders' Capital    
Common Unitholders' capital (25,190,253 and 18,992,563 units, respectively, issued and outstanding) 261,160 196,160
Accumulated distributable earnings 6,066 94
Total unitholders' capital 267,226 196,254
Total liabilities and unitholders' capital $ 539,339 $ 553,261
Net asset value per unit $ 10.61 $ 10.33
SPV Facility [Member]    
Liabilities    
Revolving credit facility $ 235,800 $ 266,334
Subscription Facility [Member]    
Liabilities    
Revolving credit facility 26,685 70,215
Companies Less Than 5% Owned [Member]    
Investments at fair value:    
Investments at fair value 509,719 532,895
Companies 5% To 25% Owned [Member]    
Investments at fair value:    
Investments at fair value $ 12,750 $ 0
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Assets and Liabilities (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Common unit issued 25,190,253 18,992,563
Common unit outstanding 25,190,253 18,992,563
SPV Facility [Member]    
Debt Instrument face amount $ 236,500 $ 267,726
Net of unamortized debt issuance costs 700 1,392
Subscription Facility [Member]    
Debt Instrument face amount 26,800 70,400
Net of unamortized debt issuance costs 115 185
Companies Less Than 5% Owned [Member]    
Investments at cost 505,230 529,070
Companies 5% To 25% Owned [Member]    
Investments at cost $ 21,595 $ 0
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statement of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Investment Income:        
Total investment income $ 15,311 $ 9,618 $ 30,103 $ 18,265
Expenses:        
Management fees (see note 3) 1,078 889 2,136 1,760
Incentive fees (see note 3) 1,582 736 1,054 1,586
Administration fees (see note 3) 105 93 210 181
Interest and other credit facility expenses (see note 5) 5,694 3,215 12,102 5,804
Other general and administrative expenses 256 246 522 451
Total expenses 8,715 5,179 16,024 9,782
Net investment income 6,596 4,439 14,079 8,483
Realized and unrealized gain (loss) on investments:        
Net realized gain on companies less than 5% owned 74 0 74 0
Net change in unrealized gain (loss) on investments 2,291 (264) (8,181) 507
Net realized and unrealized gain (loss) on investments 2,365 (264) (8,107) 507
Net increase in unitholders' capital resulting from operations $ 8,961 $ 4,175 $ 5,972 $ 8,990
Net Income Per Unit $ 0.36 $ 0.24 $ 0.25 $ 0.52
Companies Less Than 5% Owned [Member]        
Investment Income:        
Interest: $ 15,248 $ 9,573 $ 29,636 $ 18,095
Other income: 63 45 467 170
Realized and unrealized gain (loss) on investments:        
Net realized gain on companies less than 5% owned 74 0 74 0
Net change in unrealized gain (loss) on investments 4,362 (264) (6,110) 507
Companies 5% To 25% Owned [Member]        
Realized and unrealized gain (loss) on investments:        
Net change in unrealized gain (loss) on investments $ (2,071) $ 0 $ (2,071) $ 0
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statement of Changes in Unitholders' Capital - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Increase (decrease) in unitholders' capital resulting from operations:        
Net investment income $ 6,596 $ 4,439 $ 14,079 $ 8,483
Net realized gain 74 0 74 0
Net change in unrealized gain (loss) 2,291 (264) (8,181) 507
Net increase in unitholders' capital resulting from operations 8,961 4,175 5,972 8,990
Distributions to unitholders:        
From net investment income 0 0 0 0
Increase in unitholders' capital resulting from capital activity:        
Contributions 0 20,000 65,000 20,000
Net increase in unitholders' capital resulting from capital activity 0 20,000 65,000 20,000
Total increase in unitholders' capital 8,961 24,175 70,972 28,990
Unitholders' capital, beginning of period 258,265 180,928 196,254 176,113
Unitholders' capital, end of period $ 267,226 $ 205,103 $ 267,226 $ 205,103
Units issued 0 1,855,288 6,197,690 1,855,288
Net increase from capital unit activity 0 1,855,288 6,197,690 1,855,288
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statement of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash Flows from Operating Activities:    
Net increase in unitholders' capital resulting from operations $ 5,972 $ 8,990
Adjustments to reconcile net increase in unitholders' capital resulting from operations to net cash provided by (used in) operating activities:    
Net realized gain on investments (74) 0
Net change in unrealized (gain) loss on investments 8,181 (507)
(Increase) decrease in operating assets:    
Purchase of investments (63,726) (71,185)
Net accretion of discount on investments (1,578) (1,121)
Proceeds from disposition of investments 68,597 33,514
Capitalization of payment-in-kind income (974) (239)
Receivable for investments sold (99) (78)
Interest receivable 22 (376)
Prepaid expenses (64) (74)
Increase (decrease) in operating liabilities:    
Management fee payable 1,617 1,760
Incentive fee payable (1,986) (739)
Administration fee payable (3) 14
Interest payable 690 802
Other liabilities and accrued expenses (323) 264
Deferred financing costs 794 838
Net Cash Provided by (Used in) Operating Activities 17,046 (28,137)
Cash Flows from Financing Activities:    
Contributions from unitholders 65,000 20,000
Cash distributions paid (10,825) (7,277)
Proceeds from borrowings 35,168 72,500
Repayments of borrowings (110,026) (57,200)
Net Cash Provided by (Used in) Financing Activities (20,683) 28,023
NET DECREASE IN CASH (3,637) (114)
CASH AT BEGINNING OF PERIOD 16,697 11,181
CASH AT END OF PERIOD 13,060 11,067
Supplemental disclosure of cash flow information:    
Cash paid for interest $ 11,412 $ 5,002
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Schedule of Investments - USD ($)
$ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Cost $ 520,487  
Fair Value 514,531  
Common Equity/Equity Interests/Warrants — 3.0%    
Summary of Investment Holdings [Line Items]    
Cost 6,338  
Fair Value 7,938  
Total Investments — 195.5%    
Summary of Investment Holdings [Line Items]    
Cost [1] 526,825  
Fair Value [1] 522,469  
Liabilities in Excess of Other Assets — (95.5%)    
Summary of Investment Holdings [Line Items]    
Fair Value (255,243)  
Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Cost   $ 528,920
Fair Value   532,753
Common Equity/Equity Interests/Warrants — 0.0%    
Summary of Investment Holdings [Line Items]    
Cost   150
Fair Value   142
Total Investments — 271.5%    
Summary of Investment Holdings [Line Items]    
Cost [2]   529,070
Fair Value [2]   532,895
Liabilities in Excess of Other Assets — (171.5%)    
Summary of Investment Holdings [Line Items]    
Fair Value   (336,641)
Net Assets — 100.0%    
Summary of Investment Holdings [Line Items]    
Fair Value $ 267,226 $ 196,254
ACRES Commercial Mortgage, LLC | Diversified Financial Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Diversified Financial Services  
Spread above Index [3],[4] S+705  
Floor  [3] 1.00%  
Interest Rate [3],[5] 12.31%  
Acquisition Date [3] Dec. 24, 2021  
Maturity Date [3] Aug. 21, 2028  
Par Amount [3] $ 12,660  
Cost [3] 12,453  
Fair Value [3] $ 12,660  
ACRES Commercial Mortgage, LLC | Diversified Financial Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Diversified Financial Services
Spread above Index [3],[4]   S+705
Floor  [3]   1.00%
Interest Rate [3],[6]   11.38%
Acquisition Date [3]   Dec. 24, 2021
Maturity Date [3]   Aug. 21, 2028
Par Amount [3]   $ 12,660
Cost [3]   12,437
Fair Value [3]   $ 12,660
Alimera Sciences, Inc | Pharmaceuticals | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Pharmaceuticals  
Spread above Index [3],[4] S+515  
Floor  [3] 4.60%  
Interest Rate [3],[5] 10.32%  
Acquisition Date [3] Dec. 31, 2019  
Maturity Date [3] May 01, 2028  
Par Amount [3] $ 5,893  
Cost [3] 5,905  
Fair Value [3] $ 5,893  
Alimera Sciences, Inc | Pharmaceuticals | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Pharmaceuticals
Spread above Index [3],[4]   L+765
Floor  [3]   1.78%
Interest Rate [3],[6]   11.82%
Acquisition Date [3]   Dec. 31, 2019
Maturity Date [3]   Jul. 01, 2024
Par Amount [3]   $ 3,929
Cost [3]   4,059
Fair Value [3]   $ 4,145
All State Ag Parts, LLC | Trading Companies & Distributors | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Trading Companies & Distributors  
Spread above Index [3],[4] S+575  
Floor  [3] 1.00%  
Interest Rate [3],[5] 11.25%  
Acquisition Date [3] Sep. 01, 2021  
Maturity Date [3] Sep. 01, 2026  
Par Amount [3] $ 5,191  
Cost [3] 5,124  
Fair Value [3] $ 5,191  
All State Ag Parts, LLC | Trading Companies & Distributors | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Trading Companies & Distributors
Spread above Index [3],[4]   S+575
Floor  [3]   1.00%
Interest Rate [3],[6]   10.19%
Acquisition Date [3]   Sep. 01, 2021
Maturity Date [3]   Sep. 01, 2026
Par Amount [3]   $ 5,358
Cost [3]   5,279
Fair Value [3]   $ 5,358
AmeriMark Intermediate Holdings, LLC | Internet & Catalog Retail | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[7],[8],[9] Internet & Catalog Retail  
Spread above Index [3],[4],[7],[8],[9] S+800  
Floor  [3],[7],[8],[9] 1.00%  
Interest Rate [3],[5],[7],[8],[9] 0.00%  
Acquisition Date [3],[7],[8],[9] Jul. 28, 2021  
Maturity Date [3],[7],[8],[9] Oct. 15, 2026  
Par Amount [3],[7],[8],[9] $ 16,488  
Cost [3],[7],[8],[9] 15,017  
Fair Value [3],[7],[8],[9] $ 4,516  
AmeriMark Intermediate Holdings, LLC | Internet & Catalog Retail | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[10]   Internet & Catalog Retail
Spread above Index [3],[4],[10]   L+800
Floor  [3],[10]   1.00%
Interest Rate [3],[6],[10]   14.77%
Acquisition Date [3],[10]   Jul. 28, 2021
Maturity Date [3],[10]   Oct. 15, 2026
Par Amount [3],[10]   $ 21,189
Cost [3],[10]   20,858
Fair Value [3],[10]   $ 20,129
AmeriMark Intermediate Holdings, LLC | Internet & Catalog Retail | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [7],[8] Internet & Catalog Retail  
Spread above Index [4],[7],[8] P+475  
Floor  [7],[8] 1.00%  
Interest Rate [5],[7],[8] 13.00%  
Acquisition Date [7],[8] Jun. 16, 2023  
Maturity Date [7],[8] Aug. 04, 2023  
Par Amount [7],[8] $ 408  
Cost [7],[8] 408  
Fair Value [7],[8] $ 408  
Apex Service Partners, LLC | Diversified Consumer Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Diversified Consumer Services  
Spread above Index [3],[4] S+525  
Floor  [3] 1.00%  
Interest Rate [3],[5] 10.55%  
Acquisition Date [3] Nov. 05, 2021  
Maturity Date [3] Jul. 31, 2025  
Par Amount [3] $ 20,699  
Cost [3] 20,449  
Fair Value [3] $ 20,699  
Apex Service Partners, LLC | Diversified Consumer Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Diversified Consumer Services
Spread above Index [3],[4]   S+525
Floor  [3]   1.00%
Interest Rate [3],[6]   9.42%
Acquisition Date [3]   Nov. 05, 2021
Maturity Date [3]   Jul. 31, 2025
Par Amount [3]   $ 21,450
Cost [3]   21,134
Fair Value [3]   $ 21,450
Arcutis Biotherapeutics, Inc. | Pharmaceuticals | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[11] Pharmaceuticals  
Spread above Index [3],[4],[11] L+745  
Floor  [3],[11] 0.10%  
Interest Rate [3],[5],[11] 12.61%  
Acquisition Date [3],[11] Dec. 22, 2021  
Maturity Date [3],[11] Jan. 01, 2027  
Par Amount [3],[11] $ 24,520  
Cost [3],[11] 24,847  
Fair Value [3],[11] $ 24,827  
Arcutis Biotherapeutics, Inc. | Pharmaceuticals | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[12]   Pharmaceuticals
Spread above Index [3],[4],[12]   L+745
Floor  [3],[12]   0.10%
Interest Rate [3],[6],[12]   11.62%
Acquisition Date [3],[12]   Dec. 22, 2021
Maturity Date [3],[12]   Jan. 01, 2027
Par Amount [3],[12]   $ 24,520
Cost [3],[12]   24,654
Fair Value [3],[12]   $ 24,827
Ardelyx, Inc. | Pharmaceuticals | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[11] Pharmaceuticals  
Spread above Index [3],[4],[11] S+795  
Floor  [3],[11] 1.00%  
Interest Rate [3],[5],[11] 13.15%  
Acquisition Date [3],[11] Feb. 23, 2022  
Maturity Date [3],[11] Mar. 01, 2027  
Par Amount [3],[11] $ 3,319  
Cost [3],[11] 3,346  
Fair Value [3],[11] $ 3,352  
Ardelyx, Inc. | Pharmaceuticals | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[12]   Pharmaceuticals
Spread above Index [3],[4],[12]   L+795
Floor  [3],[12]   0.10%
Interest Rate [3],[6],[12]   12.12%
Acquisition Date [3],[12]   Feb. 23, 2022
Maturity Date [3],[12]   Mar. 01, 2027
Par Amount [3],[12]   $ 3,319
Cost [3],[12]   3,328
Fair Value [3],[12]   $ 3,328
Basic Fun, Inc. | Specialty Retail | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Specialty Retail  
Spread above Index [3],[4] S+650  
Floor  [3] 1.00%  
Interest Rate [3],[5] 12.04%  
Acquisition Date [3] Oct. 30, 2020  
Maturity Date [3] Oct. 30, 2023  
Par Amount [3] $ 960  
Cost [3] 959  
Fair Value [3] $ 960  
Basic Fun, Inc. | Specialty Retail | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Specialty Retail
Spread above Index [3],[4]   L+550
Floor  [3]   1.00%
Interest Rate [3],[6]   10.27%
Acquisition Date [3]   Oct. 30, 2020
Maturity Date [3]   Oct. 30, 2023
Par Amount [3]   $ 966
Cost [3]   961
Fair Value [3]   $ 966
BayMark Health Services, Inc. | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Providers & Services  
Spread above Index [3],[4] S+500  
Floor  [3] 1.00%  
Interest Rate [3],[5] 10.50%  
Acquisition Date [3] Jun. 29, 2021  
Maturity Date [3] Jun. 11, 2027  
Par Amount [3] $ 15,782  
Cost [3] 15,666  
Fair Value [3] $ 15,782  
BayMark Health Services, Inc. | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Providers & Services
Spread above Index [3],[4]   L+500
Floor  [3]   1.00%
Interest Rate [3],[6]   9.73%
Acquisition Date [3]   Jun. 29, 2021
Maturity Date [3]   Jun. 11, 2027
Par Amount [3]   $ 15,861
Cost [3]   15,733
Fair Value [3]   $ 15,861
BridgeBio Pharma, Inc. | Biotechnology | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[11] Biotechnology  
Spread above Index [3],[4],[11] 0  
Floor  [3],[11] 0.00%  
Interest Rate [3],[5],[11],[13] 9.00%  
Acquisition Date [3],[11] Nov. 17, 2021  
Maturity Date [3],[11] Nov. 17, 2026  
Par Amount [3],[11] $ 14,581  
Cost [3],[11] 14,523  
Fair Value [3],[11] $ 14,581  
BridgeBio Pharma, Inc. | Biotechnology | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[12]   Biotechnology
Spread above Index [3],[4],[12]   0
Floor  [3],[12]   0.00%
Interest Rate [3],[6],[12],[13]   9.00%
Acquisition Date [3],[12]   Nov. 17, 2021
Maturity Date [3],[12]   Nov. 17, 2026
Par Amount [3],[12]   $ 14,362
Cost [3],[12]   14,257
Fair Value [3],[12]   $ 14,362
CC SAG Holdings Corp. (Spectrum Automotive) | Diversified Consumer Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Diversified Consumer Services  
Spread above Index [3],[4] S+575  
Floor  [3] 0.75%  
Interest Rate [3],[5] 11.25%  
Acquisition Date [3] Jun. 29, 2021  
Maturity Date [3] Jun. 29, 2028  
Par Amount [3] $ 12,609  
Cost [3] 12,441  
Fair Value [3] $ 12,609  
CC SAG Holdings Corp. (Spectrum Automotive) | Diversified Consumer Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Diversified Consumer Services
Spread above Index [3],[4]   L+575
Floor  [3]   0.75%
Interest Rate [3],[6]   10.48%
Acquisition Date [3]   Jun. 29, 2021
Maturity Date [3]   Jun. 29, 2028
Par Amount [3]   $ 6,491
Cost [3]   6,407
Fair Value [3]   $ 6,491
Centrexion Therapeutics, Inc. | Pharmaceuticals | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Pharmaceuticals  
Spread above Index [3],[4] L+725  
Floor  [3] 2.45%  
Interest Rate [3],[5] 12.41%  
Acquisition Date [3] Jun. 28, 2019  
Maturity Date [3] Jan. 01, 2024  
Par Amount [3] $ 1,246  
Cost [3] 1,371  
Fair Value [3] $ 1,401  
Centrexion Therapeutics, Inc. | Pharmaceuticals | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry   Pharmaceuticals
Spread above Index [4]   L+725
Floor    2.45%
Interest Rate [6]   11.42%
Acquisition Date   Jun. 28, 2019
Maturity Date   Jan. 01, 2024
Par Amount   $ 2,314
Cost   2,417
Fair Value   $ 2,453
Cerapedics, Inc. | Biotechnology | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Biotechnology  
Spread above Index [3],[4] S+620  
Floor  [3] 2.75%  
Interest Rate [3],[5] 11.37%  
Acquisition Date [3] Dec. 27, 2022  
Maturity Date [3] Jan. 01, 2028  
Par Amount [3] $ 9,698  
Cost [3] 9,704  
Fair Value [3] $ 9,722  
Cerapedics, Inc. | Biotechnology | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Biotechnology
Spread above Index [3],[4]   S+620
Floor  [3]   2.75%
Interest Rate [3],[6]   10.52%
Acquisition Date [3]   Dec. 27, 2022
Maturity Date [3]   Jan. 01, 2028
Par Amount [3]   $ 9,698
Cost [3]   9,674
Fair Value [3]   $ 9,673
Enhanced Permanent Capital, LLC | Capital Markets | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[11] Capital Markets  
Spread above Index [3],[4],[11] S+700  
Floor  [3],[11] 1.00%  
Interest Rate [3],[5],[11] 11.93%  
Acquisition Date [3],[11] Dec. 29, 2020  
Maturity Date [3],[11] Dec. 29, 2025  
Par Amount [3],[11] $ 9,257  
Cost [3],[11] 9,083  
Fair Value [3],[11] $ 9,257  
Enhanced Permanent Capital, LLC | Capital Markets | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[12]   Capital Markets
Spread above Index [3],[4],[12]   L+700
Floor  [3],[12]   1.00%
Interest Rate [3],[6],[12]   10.13%
Acquisition Date [3],[12]   Dec. 29, 2020
Maturity Date [3],[12]   Dec. 29, 2025
Par Amount [3],[12]   $ 7,503
Cost [3],[12]   7,352
Fair Value [3],[12]   $ 7,503
ENS Holdings III Corp. & ES Opco USA LLC (BlueFin) | Trading Companies & Distributors | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Trading Companies & Distributors  
Spread above Index [3],[4] S+475  
Floor  [3] 1.00%  
Interest Rate [3],[5] 10.09%  
Acquisition Date [3] Dec. 31, 2019  
Maturity Date [3] Dec. 31, 2025  
Par Amount [3] $ 7,143  
Cost [3] 7,079  
Fair Value [3] $ 7,143  
ENS Holdings III Corp. & ES Opco USA LLC (BlueFin) | Trading Companies & Distributors | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Trading Companies & Distributors
Spread above Index [3],[4]   S+475
Floor  [3]   1.00%
Interest Rate [3],[6]   9.43%
Acquisition Date [3]   Dec. 31, 2019
Maturity Date [3]   Dec. 31, 2025
Par Amount [3]   $ 7,570
Cost [3]   7,490
Fair Value [3]   $ 7,570
Enverus Holdings, Inc. (fka Drilling Info Holdings) | IT Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] IT Services  
Spread above Index [3],[4] S+450  
Floor  [3] 0.00%  
Interest Rate [3],[5] 9.70%  
Acquisition Date [3] Jan. 31, 2020  
Maturity Date [3] Jul. 30, 2025  
Par Amount [3] $ 14,096  
Cost [3] 13,936  
Fair Value [3] $ 14,096  
Enverus Holdings, Inc. (fka Drilling Info Holdings) | IT Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   IT Services
Spread above Index [3],[4]   L+450
Floor  [3]   0.00%
Interest Rate [3],[6]   8.88%
Acquisition Date [3]   Jan. 31, 2020
Maturity Date [3]   Jul. 30, 2025
Par Amount [3]   $ 14,454
Cost [3]   14,252
Fair Value [3]   $ 14,454
Erie Construction Mid-west, LLC | Building Products | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Building Products  
Spread above Index [3],[4] S+475  
Floor  [3] 1.00%  
Interest Rate [3],[5] 10.34%  
Acquisition Date [3] Aug. 05, 2021  
Maturity Date [3] Jul. 30, 2027  
Par Amount [3] $ 11,089  
Cost [3] 10,949  
Fair Value [3] $ 11,089  
Erie Construction Mid-west, LLC | Building Products | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Building Products
Spread above Index [3],[4]   S+475
Floor  [3]   1.00%
Interest Rate [3],[6]   9.79%
Acquisition Date [3]   Aug. 05, 2021
Maturity Date [3]   Jul. 30, 2027
Par Amount [3]   $ 11,381
Cost [3]   11,222
Fair Value [3]   $ 11,381
Fertility (ITC) Investment Holdco, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Providers & Services  
Spread above Index [3],[4] S+650  
Floor  [3] 1.00%  
Interest Rate [3],[5] 11.63%  
Acquisition Date [3] Jan. 04, 2023  
Maturity Date [3] Jan. 03, 2029  
Par Amount [3] $ 10,330  
Cost [3] 10,038  
Fair Value [3] $ 10,330  
Foundation Consumer Brands, LLC | Personal Products | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Personal Products  
Spread above Index [3],[4] S+625  
Floor  [3] 1.00%  
Interest Rate [3],[5] 11.47%  
Acquisition Date [3] Feb. 12, 2021  
Maturity Date [3] Feb. 12, 2027  
Par Amount [3] $ 11,876  
Cost [3] 11,680  
Fair Value [3] $ 11,876  
Foundation Consumer Brands, LLC | Personal Products | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Personal Products
Spread above Index [3],[4]   L+550
Floor  [3]   1.00%
Interest Rate [3],[6]   10.15%
Acquisition Date [3]   Feb. 12, 2021
Maturity Date [3]   Feb. 12, 2027
Par Amount [3]   $ 12,288
Cost [3]   12,063
Fair Value [3]   $ 12,288
Glooko, Inc. | Health Care Technology | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Technology  
Spread above Index [3],[4] L+790  
Floor  [3] 0.10%  
Interest Rate [3],[5] 13.06%  
Acquisition Date [3] Sep. 30, 2021  
Maturity Date [3] Oct. 01, 2026  
Par Amount [3] $ 2,831  
Cost [3] 2,850  
Fair Value [3] $ 2,852  
Glooko, Inc. | Health Care Technology | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Technology
Spread above Index [3],[4]   L+790
Floor  [3]   0.10%
Interest Rate [3],[6]   12.07%
Acquisition Date [3]   Sep. 30, 2021
Maturity Date [3]   Oct. 01, 2026
Par Amount [3]   $ 2,831
Cost [3]   2,838
Fair Value [3]   $ 2,838
GSM Acquisition Corp. | Leisure Equipment & Products | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Leisure Equipment & Products  
Spread above Index [3],[4] S+500  
Floor  [3] 1.00%  
Interest Rate [3],[5] 10.50%  
Acquisition Date [3] Apr. 20, 2021  
Maturity Date [3] Nov. 16, 2026  
Par Amount [3] $ 13,998  
Cost [3] 13,904  
Fair Value [3] $ 13,858  
GSM Acquisition Corp. | Leisure Equipment & Products | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Leisure Equipment & Products
Spread above Index [3],[4]   S+500
Floor  [3]   1.00%
Interest Rate [3],[6]   9.03%
Acquisition Date [3]   Apr. 20, 2021
Maturity Date [3]   Nov. 16, 2026
Par Amount [3]   $ 14,069
Cost [3]   13,961
Fair Value [3]   $ 13,928
Higginbotham Insurance Agency, Inc. | Insurance | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Insurance  
Spread above Index [3],[4] S+525  
Floor  [3] 1.00%  
Interest Rate [3],[5] 10.45%  
Acquisition Date [3] Nov. 25, 2020  
Maturity Date [3] Nov. 25, 2026  
Par Amount [3] $ 8,089  
Cost [3] 8,012  
Fair Value [3] $ 8,089  
Higginbotham Insurance Agency, Inc. | Insurance | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Insurance
Spread above Index [3],[4]   L+525
Floor  [3]   0.75%
Interest Rate [3],[6]   9.63%
Acquisition Date [3]   Nov. 25, 2020
Maturity Date [3]   Nov. 25, 2026
Par Amount [3]   $ 8,130
Cost [3]   8,043
Fair Value [3]   $ 8,130
High Street Buyer, Inc. | Insurance | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Insurance  
Spread above Index [3],[4] S+600  
Floor  [3] 0.75%  
Interest Rate [3],[5] 10.79%  
Acquisition Date [3] Apr. 16, 2021  
Maturity Date [3] Apr. 16, 2028  
Par Amount [3] $ 11,886  
Cost [3] 11,698  
Fair Value [3] $ 11,886  
High Street Buyer, Inc. | Insurance | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Insurance
Spread above Index [3],[4]   L+600
Floor  [3]   0.75%
Interest Rate [3],[6]   8.75%
Acquisition Date [3]   Apr. 16, 2021
Maturity Date [3]   Apr. 16, 2028
Par Amount [3]   $ 11,606
Cost [3]   11,408
Fair Value [3]   $ 11,606
Human Interest Inc | Internet Software & Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Internet Software & Services  
Spread above Index [3],[4] S+785  
Floor  [3] 1.00%  
Interest Rate [3],[5] 13.01%  
Acquisition Date [3] Jun. 30, 2022  
Maturity Date [3] Jul. 01, 2027  
Par Amount [3] $ 6,799  
Cost [3] 6,717  
Fair Value [3] $ 6,799  
Human Interest Inc | Internet Software & Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Internet Software & Services
Spread above Index [3],[4]   S+785
Floor  [3]   1.00%
Interest Rate [3],[6]   11.97%
Acquisition Date [3]   Jun. 30, 2022
Maturity Date [3]   Jul. 01, 2027
Par Amount [3]   $ 6,799
Cost [3]   6,690
Fair Value [3]   $ 6,799
iCIMS, Inc. | Software | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Software  
Spread above Index [3],[4] S+725  
Floor  [3] 0.75%  
Interest Rate [3],[5],[14] 12.38%  
Acquisition Date [3] Aug. 18, 2022  
Maturity Date [3] Aug. 18, 2028  
Par Amount [3] $ 13,974  
Cost [3] 13,759  
Fair Value [3] $ 13,974  
iCIMS, Inc. | Software | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Software
Spread above Index [3],[4]   S+725
Floor  [3]   0.75%
Interest Rate [3],[6],[14]   11.52%
Acquisition Date [3]   Aug. 18, 2022
Maturity Date [3]   Aug. 18, 2028
Par Amount [3]   $ 13,757
Cost [3]   13,527
Fair Value [3]   $ 13,517
Ivy Fertility Services, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Providers & Services
Spread above Index [3],[4]   L+625
Floor  [3]   1.00%
Interest Rate [3],[6]   10.39%
Acquisition Date [3]   Dec. 22, 2021
Maturity Date [3]   Feb. 25, 2026
Par Amount [3]   $ 10,515
Cost [3]   10,369
Fair Value [3]   $ 10,620
Kaseya, Inc. | Software | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Software  
Spread above Index [3],[4] S+575  
Floor  [3] 0.75%  
Interest Rate [3],[5],[15] 11.35%  
Acquisition Date [3] Jun. 22, 2022  
Maturity Date [3] Jun. 23, 2029  
Par Amount [3] $ 11,006  
Cost [3] 10,860  
Fair Value [3] $ 11,006  
Kaseya, Inc. | Software | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Software
Spread above Index [3],[4]   S+575
Floor  [3]   0.75%
Interest Rate [3],[6]   10.33%
Acquisition Date [3]   Jun. 22, 2022
Maturity Date [3]   Jun. 23, 2029
Par Amount [3]   $ 10,966
Cost [3]   10,810
Fair Value [3]   $ 10,966
Kid Distro Holdings, LLC (Distro Kid) | Software | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Software  
Spread above Index [3],[4] S+575  
Floor  [3] 1.00%  
Interest Rate [3],[5] 11.14%  
Acquisition Date [3] Sep. 24, 2021  
Maturity Date [3] Oct. 01, 2027  
Par Amount [3] $ 12,394  
Cost [3] 12,207  
Fair Value [3] $ 12,394  
Kid Distro Holdings, LLC (Distro Kid) | Software | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Software
Spread above Index [3],[4]   L+575
Floor  [3]   1.00%
Interest Rate [3],[6]   10.48%
Acquisition Date [3]   Sep. 24, 2021
Maturity Date [3]   Oct. 01, 2027
Par Amount [3]   $ 12,457
Cost [3]   12,251
Fair Value [3]   $ 12,457
KORE Wireless Group, Inc. | Wireless Telecommunication Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Wireless Telecommunication Services  
Spread above Index [3],[4] S+550  
Floor  [3] 0.00%  
Interest Rate [3],[5] 10.84%  
Acquisition Date [3] Mar. 12, 2019  
Maturity Date [3] Dec. 21, 2024  
Par Amount [3] $ 14,030  
Cost [3] 13,945  
Fair Value [3] $ 14,030  
KORE Wireless Group, Inc. | Wireless Telecommunication Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Wireless Telecommunication Services
Spread above Index [3],[4]   S+550
Floor  [3]   0.00%
Interest Rate [3],[6]   10.08%
Acquisition Date [3]   Mar. 12, 2019
Maturity Date [3]   Dec. 21, 2024
Par Amount [3]   $ 14,104
Cost [3]   13,992
Fair Value [3]   $ 14,104
Maurices, Incorporated | Specialty Retail | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Specialty Retail  
Spread above Index [3],[4] S+675  
Floor  [3] 1.00%  
Interest Rate [3],[5] 9.78%  
Acquisition Date [3] Aug. 27, 2021  
Maturity Date [3] Jun. 01, 2024  
Par Amount [3] $ 5,286  
Cost [3] 5,265  
Fair Value [3] $ 5,286  
Maurices, Incorporated | Specialty Retail | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Specialty Retail
Spread above Index [3],[4]   S+675
Floor  [3]   1.00%
Interest Rate [3],[6]   8.74%
Acquisition Date [3]   Aug. 27, 2021
Maturity Date [3]   Jun. 01, 2024
Par Amount [3]   $ 4,947
Cost [3]   4,891
Fair Value [3]   $ 4,947
Meditrina, Inc. | Health Care Equipment & Supplies | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Equipment & Supplies  
Spread above Index [3],[4] S+550  
Floor  [3] 3.45%  
Interest Rate [3],[5] 10.67%  
Acquisition Date [3] Dec. 20, 2022  
Maturity Date [3] Dec. 01, 2027  
Par Amount [3] $ 1,212  
Cost [3] 1,208  
Fair Value [3] $ 1,212  
Meditrina, Inc. | Health Care Equipment & Supplies | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Equipment & Supplies
Spread above Index [3],[4]   S+550
Floor  [3]   3.45%
Interest Rate [3],[6]   9.82%
Acquisition Date [3]   Dec. 20, 2022
Maturity Date [3]   Dec. 01, 2027
Par Amount [3]   $ 1,212
Cost [3]   1,201
Fair Value [3]   $ 1,209
MRI Software LLC | Software | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Software  
Spread above Index [3],[4] S+550  
Floor  [3] 1.00%  
Interest Rate [3],[5] 10.83%  
Acquisition Date [3] Jul. 23, 2019  
Maturity Date [3] Feb. 10, 2026  
Par Amount [3] $ 15,230  
Cost [3] 15,120  
Fair Value [3] $ 15,230  
MRI Software LLC | Software | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Software
Spread above Index [3],[4]   L+550
Floor  [3]   1.00%
Interest Rate [3],[6]   10.23%
Acquisition Date [3]   Jul. 23, 2019
Maturity Date [3]   Feb. 10, 2026
Par Amount [3]   $ 15,308
Cost [3]   15,180
Fair Value [3]   $ 15,308
NAC Holding Corporation (Jaguar) | Insurance | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Insurance
Spread above Index [3],[4]   S+525
Floor  [3]   1.00%
Interest Rate [3],[6]   9.45%
Acquisition Date [3]   Jul. 30, 2021
Maturity Date [3]   Sep. 28, 2024
Par Amount [3]   $ 12,461
Cost [3]   12,355
Fair Value [3]   $ 12,461
Neuronetics, Inc. | Health Care Equipment & Supplies | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Equipment & Supplies  
Spread above Index [3],[4] S+565  
Floor  [3] 3.95%  
Interest Rate [3],[5] 10.82%  
Acquisition Date [3] Mar. 02, 2020  
Maturity Date [3] Mar. 29, 2028  
Par Amount [3] $ 3,274  
Cost [3] 3,272  
Fair Value [3] $ 3,282  
Neuronetics, Inc. | Health Care Equipment & Supplies | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Equipment & Supplies
Spread above Index [3],[4]   L+765
Floor  [3]   1.66%
Interest Rate [3],[6]   11.82%
Acquisition Date [3]   Mar. 02, 2020
Maturity Date [3]   Feb. 28, 2025
Par Amount [3]   $ 3,056
Cost [3]   3,143
Fair Value [3]   $ 3,224
Nexus Intermediate III, LLC (Vortex) | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Professional Services  
Spread above Index [3],[4] L+550  
Floor  [3] 0.75%  
Interest Rate [3],[5] 10.82%  
Acquisition Date [3] Dec. 13, 2021  
Maturity Date [3] Dec. 06, 2027  
Par Amount [3] $ 5,411  
Cost [3] 5,338  
Fair Value [3] $ 5,411  
Nexus Intermediate III, LLC (Vortex) | Professional Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Professional Services
Spread above Index [3],[4]   L+550
Floor  [3]   0.75%
Interest Rate [3],[6]   10.22%
Acquisition Date [3]   Dec. 13, 2021
Maturity Date [3]   Dec. 06, 2027
Par Amount [3]   $ 5,947
Cost [3]   5,858
Fair Value [3]   $ 5,947
Oral Surgery Partners Holdings, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Providers & Services
Spread above Index [3],[4]   S+625
Floor  [3]   1.00%
Interest Rate [3],[6]   10.92%
Acquisition Date [3]   Nov. 29, 2022
Maturity Date [3]   May 10, 2024
Par Amount [3]   $ 2,206
Cost [3]   2,164
Fair Value [3]   $ 2,162
Orthopedic Care Partners Management, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Providers & Services  
Spread above Index [3],[4] S+650  
Floor  [3] 1.00%  
Interest Rate [3],[5] 11.66%  
Acquisition Date [3] Aug. 17, 2022  
Maturity Date [3] May 16, 2024  
Par Amount [3] $ 5,672  
Cost [3] 5,646  
Fair Value [3] $ 5,672  
Orthopedic Care Partners Management, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Providers & Services
Spread above Index [3],[4]   S+650
Floor  [3]   1.00%
Interest Rate [3],[6]   10.91%
Acquisition Date [3]   Aug. 17, 2022
Maturity Date [3]   May 16, 2024
Par Amount [3]   $ 4,226
Cost [3]   4,200
Fair Value [3]   $ 4,226
Outset Medical, Inc. | Health Care Equipment & Supplies | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[11] Health Care Equipment & Supplies  
Spread above Index [3],[4],[11] S+515  
Floor  [3],[11] 2.75%  
Interest Rate [3],[5],[11] 10.32%  
Acquisition Date [3],[11] Nov. 03, 2022  
Maturity Date [3],[11] Nov. 01, 2027  
Par Amount [3],[11] $ 11,865  
Cost [3],[11] 11,859  
Fair Value [3],[11] $ 11,865  
Outset Medical, Inc. | Health Care Equipment & Supplies | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3],[12]   Health Care Equipment & Supplies
Spread above Index [3],[4],[12]   S+515
Floor  [3],[12]   2.75%
Interest Rate [3],[6],[12]   9.33%
Acquisition Date [3],[12]   Nov. 03, 2022
Maturity Date [3],[12]   Nov. 01, 2027
Par Amount [3],[12]   $ 11,865
Cost [3],[12]   11,796
Fair Value [3],[12]   $ 11,775
Pediatric Home Respiratory Services, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Providers & Services  
Spread above Index [3],[4] S+625  
Floor  [3] 1.00%  
Interest Rate [3],[5] 11.45%  
Acquisition Date [3] Aug. 19, 2022  
Maturity Date [3] Dec. 04, 2024  
Par Amount [3] $ 2,685  
Cost [3] 2,653  
Fair Value [3] $ 2,685  
Pediatric Home Respiratory Services, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Providers & Services
Spread above Index [3],[4]   S+625
Floor  [3]   1.00%
Interest Rate [3],[6]   10.67%
Acquisition Date [3]   Aug. 19, 2022
Maturity Date [3]   Dec. 04, 2024
Par Amount [3]   $ 1,802
Cost [3]   1,778
Fair Value [3]   $ 1,784
Peter C. Foy & Associates Insurance Services, LLC | Insurance | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Insurance  
Spread above Index [3],[4] S+600  
Floor  [3] 0.75%  
Interest Rate [3],[5] 11.22%  
Acquisition Date [3] Oct. 29, 2021  
Maturity Date [3] Nov. 01, 2028  
Par Amount [3] $ 15,500  
Cost [3] 15,375  
Fair Value [3] $ 15,500  
Peter C. Foy & Associates Insurance Services, LLC | Insurance | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Insurance
Spread above Index [3],[4]   S+600
Floor  [3]   0.75%
Interest Rate [3],[6]   11.21%
Acquisition Date [3]   Oct. 29, 2021
Maturity Date [3]   Nov. 01, 2028
Par Amount [3]   $ 15,579
Cost [3]   15,444
Fair Value [3]   $ 15,579
Pinnacle Treatment Centers, Inc. | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Providers & Services  
Spread above Index [3],[4] S+675  
Floor  [3] 1.00%  
Interest Rate [3],[5] 12.16%  
Acquisition Date [3] Jan. 22, 2020  
Maturity Date [3] Jan. 02, 2026  
Par Amount [3] $ 8,297  
Cost [3] 8,208  
Fair Value [3] $ 8,297  
Pinnacle Treatment Centers, Inc. | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Providers & Services
Spread above Index [3],[4]   S+650
Floor  [3]   1.00%
Interest Rate [3],[6]   10.57%
Acquisition Date [3]   Jan. 22, 2020
Maturity Date [3]   Jan. 02, 2026
Par Amount [3]   $ 8,339
Cost [3]   8,233
Fair Value [3]   $ 8,152
Plastics Management, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Providers & Services  
Spread above Index [3],[4] S+500  
Floor  [3] 1.00%  
Interest Rate [3],[5] 10.44%  
Acquisition Date [3] Aug. 26, 2021  
Maturity Date [3] Aug. 18, 2027  
Par Amount [3] $ 15,135  
Cost [3] 14,971  
Fair Value [3] $ 15,135  
Plastics Management, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Providers & Services
Spread above Index [3],[4]   S+500
Floor  [3]   1.00%
Interest Rate [3],[6]   9.89%
Acquisition Date [3]   Aug. 26, 2021
Maturity Date [3]   Aug. 18, 2027
Par Amount [3]   $ 12,117
Cost [3]   11,967
Fair Value [3]   $ 12,117
Revlon Consumer Products Corporation | Personal Products | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Personal Products
Spread above Index [3],[4]   P+475
Floor  [3]   2.75%
Interest Rate [3],[6]   12.25%
Acquisition Date [3]   May 07, 2021
Maturity Date [3]   Jun. 17, 2023
Par Amount [3]   $ 13,905
Cost [3]   13,876
Fair Value [3]   $ 13,974
RQM+ Corp. | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Life Sciences Tools & Services  
Spread above Index [3],[4] S+575  
Floor  [3] 1.00%  
Interest Rate [3],[5] 11.51%  
Acquisition Date [3] Aug. 20, 2021  
Maturity Date [3] Aug. 12, 2026  
Par Amount [3] $ 15,601  
Cost [3] 15,443  
Fair Value [3] $ 15,601  
RQM+ Corp. | Life Sciences Tools & Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Life Sciences Tools & Services
Spread above Index [3],[4]   S+575
Floor  [3]   1.00%
Interest Rate [3],[6]   10.59%
Acquisition Date [3]   Aug. 20, 2021
Maturity Date [3]   Aug. 12, 2026
Par Amount [3]   $ 15,680
Cost [3]   15,499
Fair Value [3]   $ 15,680
RSC Acquisition, Inc. | Insurance | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Insurance  
Spread above Index [3],[4] S+550  
Floor  [3] 0.75%  
Interest Rate [3],[5] 10.64%  
Acquisition Date [3] Oct. 05, 2020  
Maturity Date [3] Nov. 01, 2026  
Par Amount [3] $ 18,183  
Cost [3] 17,962  
Fair Value [3] $ 18,183  
RSC Acquisition, Inc. | Insurance | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Insurance
Spread above Index [3],[4]   S+550
Floor  [3]   0.75%
Interest Rate [3],[6]   9.26%
Acquisition Date [3]   Oct. 05, 2020
Maturity Date [3]   Nov. 01, 2026
Par Amount [3]   $ 9,345
Cost [3]   9,191
Fair Value [3]   $ 9,345
RxSense Holdings LLC | Diversified Consumer Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Diversified Consumer Services  
Spread above Index [3],[4] S+500  
Floor  [3] 1.00%  
Interest Rate [3],[5] 10.15%  
Acquisition Date [3] Mar. 17, 2020  
Maturity Date [3] Mar. 13, 2026  
Par Amount [3] $ 14,562  
Cost [3] 14,432  
Fair Value [3] $ 14,562  
RxSense Holdings LLC | Diversified Consumer Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Diversified Consumer Services
Spread above Index [3],[4]   L+500
Floor  [3]   1.00%
Interest Rate [3],[6]   9.41%
Acquisition Date [3]   Mar. 17, 2020
Maturity Date [3]   Mar. 13, 2026
Par Amount [3]   $ 14,674
Cost [3]   14,522
Fair Value [3]   $ 14,674
Southern Orthodontic Partners Management, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Providers & Services  
Spread above Index [3],[4] S+600  
Floor  [3] 1.00%  
Interest Rate [3],[5] 11.50%  
Acquisition Date [3] Jun. 03, 2022  
Maturity Date [3] Jan. 27, 2026  
Par Amount [3] $ 3,791  
Cost [3] 3,758  
Fair Value [3] $ 3,791  
Southern Orthodontic Partners Management, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Providers & Services
Spread above Index [3],[4]   S+600
Floor  [3]   1.00%
Interest Rate [3],[6]   10.84%
Acquisition Date [3]   Jun. 03, 2022
Maturity Date [3]   Jan. 27, 2026
Par Amount [3]   $ 1,901
Cost [3]   1,884
Fair Value [3]   $ 1,901
Spectrum Pharmaceuticals, Inc. | Biotechnology | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Biotechnology  
Spread above Index [3],[4] S+570  
Floor  [3] 2.30%  
Interest Rate [3],[5] 10.87%  
Acquisition Date [3] Sep. 21, 2022  
Maturity Date [3] Sep. 01, 2027  
Par Amount [3] $ 3,559  
Cost [3] 3,776  
Fair Value [3] $ 3,835  
Spectrum Pharmaceuticals, Inc. | Biotechnology | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Biotechnology
Spread above Index [3],[4]   S+570
Floor  [3]   2.30%
Interest Rate [3],[6]   9.88%
Acquisition Date [3]   Sep. 21, 2022
Maturity Date [3]   Sep. 01, 2027
Par Amount [3]   $ 3,559
Cost [3]   3,519
Fair Value [3]   $ 3,524
SunMed Group Holdings, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Spread above Index [3],[4] S+575  
Interest Rate [3],[5] 11.09%  
SunMed Group Holdings, LLC | Health Care Equipment & Supplies | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Equipment & Supplies  
Floor  [3] 0.75%  
Acquisition Date [3] Jun. 16, 2021  
Maturity Date [3] Jun. 16, 2028  
Par Amount [3] $ 7,643  
Cost [3] 7,542  
Fair Value [3] $ 7,643  
SunMed Group Holdings, LLC | Health Care Equipment & Supplies | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Equipment & Supplies
Spread above Index [3],[4]   L+575
Floor  [3]   0.75%
Interest Rate [3],[6]   10.48%
Acquisition Date [3]   Jun. 16, 2021
Maturity Date [3]   Jun. 16, 2028
Par Amount [3]   $ 7,929
Cost [3]   7,815
Fair Value [3]   $ 7,929
TAUC Management, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Providers & Services  
Spread above Index [3],[4] L+525  
Floor  [3] 1.00%  
Interest Rate [3],[5] 10.59%  
Acquisition Date [3] Feb. 12, 2021  
Maturity Date [3] Feb. 12, 2027  
Par Amount [3] $ 9,008  
Cost [3] 8,918  
Fair Value [3] $ 8,557  
TAUC Management, LLC | Health Care Providers & Services | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Providers & Services
Spread above Index [3],[4]   L+525
Floor  [3]   1.00%
Interest Rate [3],[6]   9.98%
Acquisition Date [3]   Feb. 12, 2021
Maturity Date [3]   Feb. 12, 2027
Par Amount [3]   $ 9,013
Cost [3]   8,912
Fair Value [3]   $ 8,968
Tilley Distribution, Inc. | Trading Companies & Distributors | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Trading Companies & Distributors  
Spread above Index [3],[4] S+600  
Floor  [3] 1.00%  
Interest Rate [3],[5] 11.39%  
Acquisition Date [3] Dec. 08, 2021  
Maturity Date [3] Dec. 31, 2026  
Par Amount [3] $ 12,557  
Cost [3] 12,443  
Fair Value [3] $ 12,557  
Tilley Distribution, Inc. | Trading Companies & Distributors | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Trading Companies & Distributors
Spread above Index [3],[4]   S+550
Floor  [3]   1.00%
Interest Rate [3],[6]   10.14%
Acquisition Date [3]   Dec. 08, 2021
Maturity Date [3]   Dec. 31, 2026
Par Amount [3]   $ 12,762
Cost [3]   12,633
Fair Value [3]   $ 12,762
Transportation Insight, LLC | Road & Rail | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Road & Rail  
Spread above Index [3],[4] S+450  
Floor  [3] 1.00%  
Interest Rate [3],[5] 9.64%  
Acquisition Date [3] Oct. 27, 2021  
Maturity Date [3] Dec. 18, 2024  
Par Amount [3] $ 5,581  
Cost [3] 5,528  
Fair Value [3] $ 5,581  
Transportation Insight, LLC | Road & Rail | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Road & Rail
Spread above Index [3],[4]   L+450
Floor  [3]   1.00%
Interest Rate [3],[6]   8.91%
Acquisition Date [3]   Oct. 27, 2021
Maturity Date [3]   Dec. 18, 2024
Par Amount [3]   $ 4,198
Cost [3]   4,150
Fair Value [3]   $ 4,198
Ultimate Baked Goods Midco LLC (Rise Baking) | Packaged Foods & Meats | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Packaged Foods & Meats  
Spread above Index [3],[4] S+625  
Floor  [3] 1.00%  
Interest Rate [3],[5] 11.45%  
Acquisition Date [3] Aug. 12, 2021  
Maturity Date [3] Aug. 13, 2027  
Par Amount [3] $ 7,593  
Cost [3] 7,454  
Fair Value [3] $ 7,593  
Ultimate Baked Goods Midco LLC (Rise Baking) | Packaged Foods & Meats | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Packaged Foods & Meats
Spread above Index [3],[4]   L+650
Floor  [3]   1.00%
Interest Rate [3],[6]   10.88%
Acquisition Date [3]   Aug. 12, 2021
Maturity Date [3]   Aug. 13, 2027
Par Amount [3]   $ 7,877
Cost [3]   7,717
Fair Value [3]   $ 7,877
Vapotherm, Inc. | Health Care Equipment & Supplies | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Health Care Equipment & Supplies  
Spread above Index [3],[4] S+930  
Floor  [3] 1.00%  
Interest Rate [3],[5],[16] 14.57%  
Acquisition Date [3] Feb. 18, 2022  
Maturity Date [3] Feb. 01, 2027  
Par Amount [3] $ 12,608  
Cost [3] 12,709  
Fair Value [3] $ 12,766  
Vapotherm, Inc. | Health Care Equipment & Supplies | Common Equity/Equity Interests/Warrants — 3.0%    
Summary of Investment Holdings [Line Items]    
Industry [17] Health Care Equipment & Supplies  
Acquisition Date [17] Feb. 18, 2022  
Par Amount [17] $ 72,556  
Cost [17] 93  
Fair Value [17] $ 7  
Vapotherm, Inc. | Health Care Equipment & Supplies | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Health Care Equipment & Supplies
Spread above Index [3],[4]   S+830
Floor  [3]   1.00%
Interest Rate [3],[6],[18]   12.58%
Acquisition Date [3]   Feb. 18, 2022
Maturity Date [3]   Feb. 01, 2027
Par Amount [3]   $ 12,070
Cost [3]   12,076
Fair Value [3]   $ 12,131
Vapotherm, Inc. | Health Care Equipment & Supplies | Common Equity/Equity Interests/Warrants — 0.0%    
Summary of Investment Holdings [Line Items]    
Industry [17]   Health Care Equipment & Supplies
Acquisition Date [17]   Feb. 18, 2022
Par Amount [17]   $ 12,960
Cost [17]   75
Fair Value [17]   $ 31
Vessco Midco Holdings, LLC | Water Utilities | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Water Utilities  
Spread above Index [3],[4] S+450  
Floor  [3] 1.00%  
Interest Rate [3],[5] 9.56%  
Acquisition Date [3] Sep. 03, 2021  
Maturity Date [3] Nov. 02, 2026  
Par Amount [3] $ 3,742  
Cost [3] 3,711  
Fair Value [3] $ 3,742  
Vessco Midco Holdings, LLC | Water Utilities | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Water Utilities
Spread above Index [3],[4]   L+450
Floor  [3]   1.00%
Interest Rate [3],[6]   7.87%
Acquisition Date [3]   Sep. 03, 2021
Maturity Date [3]   Nov. 02, 2026
Par Amount [3]   $ 2,207
Cost [3]   2,189
Fair Value [3]   $ 2,206
World Insurance Associates, LLC | Insurance | Bank Debt/Senior Secured Loans — 192.5%    
Summary of Investment Holdings [Line Items]    
Industry [3] Insurance  
Spread above Index [3],[4] S+575  
Floor  [3] 1.00%  
Interest Rate [3],[5] 10.99%  
Acquisition Date [3] Oct. 12, 2020  
Maturity Date [3] Apr. 01, 2026  
Par Amount [3] $ 19,265  
Cost [3] 18,966  
Fair Value [3] $ 19,265  
World Insurance Associates, LLC | Insurance | Bank Debt/Senior Secured Loans — 271.5%    
Summary of Investment Holdings [Line Items]    
Industry [3]   Insurance
Spread above Index [3],[4]   S+575
Floor  [3]   1.00%
Interest Rate [3],[6]   10.07%
Acquisition Date [3]   Oct. 12, 2020
Maturity Date [3]   Apr. 01, 2026
Par Amount [3]   $ 19,614
Cost [3]   19,261
Fair Value [3]   $ 18,829
Centrexion Therapeutics, Inc. Warrants | Pharmaceuticals | Common Equity/Equity Interests/Warrants — 3.0%    
Summary of Investment Holdings [Line Items]    
Industry [17] Pharmaceuticals  
Acquisition Date [17] Jun. 28, 2019  
Par Amount [17] $ 56,483  
Cost [17] 27  
Fair Value [17] $ 10  
Centrexion Therapeutics, Inc. Warrants | Pharmaceuticals | Common Equity/Equity Interests/Warrants — 0.0%    
Summary of Investment Holdings [Line Items]    
Industry [17]   Pharmaceuticals
Acquisition Date [17]   Jun. 28, 2019
Par Amount [17]   $ 56,483
Cost [17]   27
Fair Value [17]   $ 16
Meditrina, Inc. Warrants | Health Care Equipment & Supplies | Common Equity/Equity Interests/Warrants — 3.0%    
Summary of Investment Holdings [Line Items]    
Industry [17] Health Care Equipment & Supplies  
Acquisition Date [17] Dec. 20, 2022  
Par Amount [17] $ 10,572  
Cost [17] 8  
Fair Value [17] $ 7  
Meditrina, Inc. Warrants | Health Care Equipment & Supplies | Common Equity/Equity Interests/Warrants — 0.0%    
Summary of Investment Holdings [Line Items]    
Industry [17]   Health Care Equipment & Supplies
Acquisition Date [17]   Dec. 20, 2022
Par Amount [17]   $ 10,572
Cost [17]   8
Fair Value [17]   $ 8
Senseonics Holdings, Inc. Common Stock | Health Care Equipment & Supplies | Common Equity/Equity Interests/Warrants — 3.0%    
Summary of Investment Holdings [Line Items]    
Industry [11],[17] Health Care Equipment & Supplies  
Acquisition Date [11],[17] Jul. 25, 2019  
Par Amount [11],[17] $ 79,501  
Cost [11],[17] 23  
Fair Value [11],[17] $ 61  
Senseonics Holdings, Inc. Common Stock | Health Care Equipment & Supplies | Common Equity/Equity Interests/Warrants — 0.0%    
Summary of Investment Holdings [Line Items]    
Industry [12],[17]   Health Care Equipment & Supplies
Acquisition Date [12],[17]   Jul. 25, 2019
Par Amount [12],[17]   $ 79,501
Cost [12],[17]   23
Fair Value [12],[17]   $ 82
SLR-AMI Topco Blocker, LLC | Internet & Catalog Retail | Common Equity/Equity Interests/Warrants — 3.0%    
Summary of Investment Holdings [Line Items]    
Industry [8],[17],[19] Internet & Catalog Retail  
Acquisition Date [8],[17],[19] Jun. 16, 2023  
Par Amount [8],[17],[19] $ 0  
Cost [8],[17],[19] 6,170  
Fair Value [8],[17],[19] $ 7,826  
Spectrum Pharmaceuticals, Inc. Warrants | Biotechnology | Common Equity/Equity Interests/Warrants — 3.0%    
Summary of Investment Holdings [Line Items]    
Industry [17] Biotechnology  
Acquisition Date [17] Sep. 21, 2022  
Par Amount [17] $ 53,930  
Cost [17] 17  
Fair Value [17] $ 27  
Spectrum Pharmaceuticals, Inc. Warrants | Biotechnology | Common Equity/Equity Interests/Warrants — 0.0%    
Summary of Investment Holdings [Line Items]    
Industry [17]   Biotechnology
Acquisition Date [17]   Sep. 21, 2022
Par Amount [17]   $ 53,930
Cost [17]   17
Fair Value [17]   $ 5
[1] Aggregate net unrealized depreciation for U.S. federal income tax purposes is $9,108; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $6,687 and $15,795, respectively, based on a tax cost of $531,577. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.
[2] Aggregate net unrealized depreciation for U.S. federal income tax purposes is $927; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $5,202 and $6,129, respectively, based on a tax cost of $533,822. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated.
[3] Indicates an investment that is wholly or partially held by SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”) through its wholly-owned financing subsidiary SCP Private Credit Income BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company.
[4] Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the LIBOR, SOFR or PRIME rate. These instruments are often subject to a LIBOR, SOFR or PRIME rate floor.
[5] Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (PRIME or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment we have provided the current interest rate in effect as of June 30, 2023.
[6] Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (PRIME or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment we have provided the current interest rate in effect as of December 31, 2022.
[7] AmeriMark Interactive, LLC, AmeriMark Direct LLC, AmeriMark Intermediate Sub, Inc., L.T.D. Commodities LLC, Dr. Leonard’s Healthcare Corp. and Amerimark Intermediate Holdings, LLC are each co-Borrowers.
[8] Denotes investments in which we are an “Affiliated Person” but not exercising a controlling influence, as defined in the Investment Company Act of 1940, as amended (the “1940 Act”), due to beneficially owning, either directly or through one or more controlled companies, more than 5% but less than 25% of the outstanding voting securities of the investment.
[9] Investment is on non-accrual status.
[10] AmeriMark Interactive, LLC, AmeriMark Direct LLC, AmeriMark Intermediate Sub, Inc., L.T.D. Commodities LLC, Dr. Leonard’s Healthcare Corp. and Amerimark Intermediate Holdings, LLC are each co-Borrowers. Amerimark may elect to defer up to 8.00% of the coupon as PIK.
[11] Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of June 30, 2023, on a fair value basis, non-qualifying assets in the portfolio represented 11.9% of the total assets of the Company.
[12] Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (“1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2022, on a fair value basis, non-qualifying assets in the portfolio represented 11.2% of the total assets of the Company.
[13] BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK.
[14] iCIMS, Inc. may elect to defer up to 3.875% of the coupon as PIK.
[15] Kaseya, Inc. may elect to defer up to 2.50% of the coupon as PIK.
[16] Vapotherm, Inc. may elect to defer up to 9.00% of the coupon as PIK.
[17] Non-income producing security.
[18] Vapotherm, Inc. may elect to defer up to 8.00% of the coupon as PIK.
[19] Through this entity and other intermediate entities, the Company owns approximately 6.5% of the underlying common units of ASC Holdco, LLC, a joint venture which owns certain assets of the former Amerimark Interactive, LLC.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Schedule of Investments 1
Jun. 30, 2023
Dec. 31, 2022
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 100.00% 100.00%
Insurance    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 14.00% 14.30%
Health Care Providers & Services    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 13.40% 12.40%
Software    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 10.10% 9.80%
Diversified Consumer Services    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 9.20% 8.00%
Health Care Equipment & Supplies    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 7.00% 6.80%
Pharmaceuticals    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 6.80% 6.50%
Biotechnology    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 5.40% 5.20%
Trading Companies & Distributors    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 4.80% 4.80%
Life Sciences Tools & Services    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 3.00% 2.90%
IT Services    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 2.70% 2.70%
Wireless Telecommunication Services    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 2.70% 2.70%
Leisure Equipment & Products    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 2.60% 2.60%
Internet & Catalog Retail    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 2.40% 3.80%
Diversified Financial Services    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 2.40% 2.40%
Personal Products    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 2.30% 4.90%
Building Products    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 2.10% 2.10%
Capital Markets    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 1.80% 1.40%
Packaged Foods & Meats    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 1.50% 1.50%
Internet Software & Services    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 1.30% 1.30%
Specialty Retail    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 1.20% 1.10%
Road & Rail    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 1.10% 0.80%
Professional Services    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 1.00% 1.10%
Water Utilities    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 0.70% 0.40%
Health Care Technology    
Summary of Investment Holdings [Line Items]    
Percentage Of Total Investments At Fair Value 0.50% 0.50%
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Schedule of Investments (Parethetical) - USD ($)
$ in Thousands
1 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Summary of Investment Holdings [Line Items]      
Tax Basis Of Investments Unrealized Appreciation Depreciation Net $ 9,108 $ 9,108 $ 927
Tax Basis Of Investments Gross Unrealized Appreciation 6,687 6,687 5,202
Tax Basis Of Investments Gross Unrealized Depreciation 15,795 15,795 6,129
Tax Basis Of Investments Cost For Income Tax Purposes 531,577 531,577 $ 533,822
Investment, Affiliated Issuer, Noncontrolled [Member]      
Summary of Investment Holdings [Line Items]      
Fair Value at June 16, 2023 14,413    
Gross Additions 408    
Gross Reductions 0    
Realized Gain (Loss) 0    
Change in Unrealized Gain (Loss) (2,071)    
Interest/ Dividend Income 0    
Fair Value at June 30, 2023 $ 12,750 $ 12,750  
iCIMS, Inc.      
Summary of Investment Holdings [Line Items]      
Rate of coupon as PIK   3.875% 3.875%
Vapotherm, Inc.      
Summary of Investment Holdings [Line Items]      
Rate of coupon as PIK   9.00% 8.00%
Kaseya Inc [Member]      
Summary of Investment Holdings [Line Items]      
Rate of coupon as PIK   2.50%  
ASC Holdco, LLC      
Summary of Investment Holdings [Line Items]      
Investment company percentage of ownership 6.50% 6.50%  
BridgeBio Pharma, Inc.      
Summary of Investment Holdings [Line Items]      
Rate of coupon as PIK   3.00% 3.00%
AmeriMark Interactive LLC      
Summary of Investment Holdings [Line Items]      
Rate of coupon as PIK     8.00%
AmeriMark Intermediate Holdings, LLC | Investment, Affiliated Issuer, Noncontrolled [Member]      
Summary of Investment Holdings [Line Items]      
Fair Value at June 16, 2023 $ 8,243    
Gross Additions 0    
Gross Reductions 0    
Realized Gain (Loss) 0    
Change in Unrealized Gain (Loss) (3,727)    
Interest/ Dividend Income 0    
Fair Value at June 30, 2023 4,516 $ 4,516  
AmeriMark Intermediate Holdings, LLC | Investment, Affiliated Issuer, Noncontrolled [Member]      
Summary of Investment Holdings [Line Items]      
Fair Value at June 16, 2023 0    
Gross Additions 408    
Gross Reductions 0    
Realized Gain (Loss) 0    
Change in Unrealized Gain (Loss) 0    
Interest/ Dividend Income 0    
Fair Value at June 30, 2023 408 408  
SLR-AMI Topco Blocker, LLC | Investment, Affiliated Issuer, Noncontrolled [Member]      
Summary of Investment Holdings [Line Items]      
Fair Value at June 16, 2023 6,170    
Gross Additions 0    
Gross Reductions 0    
Realized Gain (Loss) 0    
Change in Unrealized Gain (Loss) 1,656    
Interest/ Dividend Income 0    
Fair Value at June 30, 2023 $ 7,826 $ 7,826  
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Pay vs Performance Disclosure        
Net Income (Loss) $ 8,961 $ 4,175 $ 5,972 $ 8,990
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Insider Trading Arrangements
6 Months Ended
Jun. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Organization
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization
Note 1. Organization
SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”) is a Delaware limited liability company formed on
May 18, 2018
. The Company has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (“the 1940 Act”). Furthermore, as the Company is an investment company, it applies the guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 946. In addition, for U.S. federal income tax purposes, the Company has elected to be treated, and intends to qualify annually, as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). The Company was formed primarily to provide investors with attractive long-term returns through investments made pursuant to the investment strategy of the Company described below (the Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”).
On October 5, 2018 (the “Initial Closing Date”), the Company closed on $326,000 in capital commitments. On March 12, 2019, the sale and issuance of 2,800,000 units, at an aggregate purchase price of $28,000 ($10.00 per unit) occurred and the Company commenced operations. As of June 30, 2023, $261,500 of capital commitments were drawn and $64,500 were unfunded.
The Company has implemented a corporate lending strategy focused on sourcing, underwriting and managing a diverse portfolio of private senior secured loans primarily to upper middle market companies (generally,
 
aggregate
 
loan sizes of $100,000 to $300,000 to companies with earnings before interest, tax, depreciation and amortization (“EBITDA”) between approximately $25,000 and $100,000) across the United States. In addition to senior secured loans to upper middle market companies, the Company intends to invest a portion of its assets in
non-traditional
asset-based loans and first lien loans to rapidly growing healthcare companies. The Company also expects that some of its investments will contain delayed-draw term loan type features and/or other types of unfunded commitments.
The offering period of the Company ended on April 5, 2019 (the “Offering Period”). The investment period of the Company ended on December 31, 2022. The term of the Company will be six years from the end of the Offering Period unless the Company is liquidated earlier as set forth in the Limited Liability Company Agreement of the Company (as amended, restated or otherwise modified from time to time, the “LLC Agreement”), but may be extended by the board of directors for up to two consecutive one year periods upon approval of the Company’s independent directors and the approval of unitholders of the Company (“Unitholders”), which approval will be obtained through a
non-1940
Act vote as described in the LLC Agreement. The Company may be dissolved and its affairs wound up prior to the end of the term under the circumstances set forth in the LLC Agreement. The fiscal year end of the Company is December 31.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 2. Summary of Significant Accounting Policies
The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles (“GAAP”), and include the accounts of the Company and certain wholly-owned subsidiaries. The consolidated financial statements reflect all adjustments and reclassifications which, in the opinion of management, are necessary for the fair presentation of the results of the operations and financial condition for the periods presented. All significant intercompany balances and transactions have been eliminated. Certain prior period amounts may have been reclassified to conform to current period presentation.
 
Interim consolidated financial statements are prepared in accordance with GAAP for interim financial information and pursuant to the requirements for reporting on Form
10-Q
and Regulation
S-X,
as appropriate. Accordingly, they may not include all of the information and notes required by GAAP for annual consolidated financial statements. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported periods. Changes in the economic environment, financial markets and any other parameters used in determining these estimates could cause actual results to differ materially. The current period’s results of operations will not necessarily be indicative of results that ultimately may be achieved for the fiscal year ending on December 31, 2023.
In the opinion of management, all adjustments which are of a normal recurring nature considered necessary for the fair presentation of financial statements, have been included.
The significant accounting policies consistently followed by the Company are:
 
  (a)
Investment transactions are accounted for on the trade date;
 
  (b)
In accordance with GAAP and the 1940 Act, the Company’s assets will generally be valued as follows:
 
  (i)
securities or other instruments (other than as referred to in clauses (ii) and (iii) below) for which market quotes are readily available and deemed to represent fair value under GAAP will be valued based on quotes obtained from a quotation reporting system, market makers or pricing services (when deemed to represent fair value under GAAP). A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation;
 
  (ii)
exchange-traded options, futures and options on futures will be valued at the settlement price determined by the exchange or through the use of a model such as Black-Scholes;
 
  (iii)
short-term investments with maturities of sixty (60) days or less generally will be valued at amortized cost; and
 
  (iv)
securities, loans or other instruments for which market quotes are not readily available or reliable under GAAP will be valued as described below:
 
  a.
the quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals of SLR responsible for the Portfolio Investment; 
 
  b.
preliminary valuation conclusions are then documented and discussed with senior management of the Adviser;
 
  c.
the audit committee of the Board of Directors ( the “Board”) reviews the preliminary valuations of the Adviser and third party valuation specialist, if any, and responds to the valuation recommendations to reflect any comments; and
 
  d.
the Board discusses valuations and determines the fair value of each investment in the Company’s portfolio in good faith based on the input of the Adviser, the audit committee, and third party valuation specialist, if any, which may from time to time be engaged by the Board.
The valuation principles set forth above may be modified from time to time without notice to Unitholders, in whole or in part, as determined by the Board in its sole discretion.
The Board will also (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule
2a-5
under the 1940 Act; and (6) maintain recordkeeping requirements under Rule
2a-5.
When an external event such as a purchase transaction, public offering or subsequent equity sale occurs, the Company will consider the pricing indicated by the external event to corroborate the valuation. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material.
Investments are valued utilizing a market approach, an income approach, or both approaches, as appropriate. However, in accordance with ASC
820-10,
certain investments that qualify as investment companies in accordance with ASC 946, may be valued using net asset value as a practical expedient for fair value. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities (including a business). The income approach uses valuation approaches to convert future amounts (for example, cash flows or earnings) to a single present amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that we may take into account in fair value pricing our investments include, as relevant: available current market data, including relevant and applicable market trading and transaction comparables, applicable market yields and multiples, security covenants, call protection provisions, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, the markets in which the portfolio company does business, comparisons of financial ratios of peer companies that are public, M&A comparables, and enterprise values, among other factors. When available, broker quotations and/or quotations provided by pricing services are considered as an input in the valuation process. For the six months ended June 30, 2023, there has been no change to the Company’s valuation approaches or techniques and the nature of the related inputs considered in the valuation process.
ASC Topic 820 classifies the inputs used to measure these fair values into the following hierarchy:
Level
 1
: Unadjusted quoted prices in active markets for identical assets or liabilities, accessible by the Company at the measurement date.
Level
 2
: Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable inputs other than quoted prices.
Level
 3
: Unobservable inputs for the asset or liability.
In all cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to each investment. The exercise of judgment is based in part on our knowledge of the asset class and our prior experience.
 
  (c)
Gains or losses on investments are calculated by using the specific identification method.
 
  (d)
The Company records dividend income and interest, adjusted for amortization of premium and accretion of discount, on an accrual basis. Loan origination fees, original issue discount, and market discounts are capitalized and we amortize such amounts into income using the effective interest method. Upon the prepayment of a loan, any unamortized loan origination fees are recorded as interest income. We record call premiums on loans repaid as interest income when we receive such amounts. Capital structuring fees, amendment fees, consent fees, and any other
non-recurring
fee income as well as management fee and other fee income for services rendered, if any, are recorded as other income when earned.
 
  (e)
The Company intends to comply with the applicable provisions of the Code pertaining to
RICs
to make distributions of taxable income sufficient to relieve it of substantially all U.S. federal income taxes. The Company, at its discretion, may carry forward taxable income in excess of calendar year distributions and pay a 4% excise tax on this income. The Company will accrue excise tax on such estimated excess taxable income as appropriate.
 
  (f)
Book and tax basis differences relating to Unitholder distributions and other permanent book and tax differences are typically reclassified among the Company’s capital accounts annually. In addition, the character of income and gains to be distributed is determined in accordance with income tax regulations that may differ from GAAP.
 
  (g)
Distributions to Unitholders are recorded as of the record date. The amount to be paid out as a distribution is determined by the Board. Net realized capital gains, if any, are generally distributed or deemed distributed at least annually.
 
  (h)
In accordance with Regulation
S-X
and ASC Topic 810—
Consolidation
, the Company consolidates its interest in controlled investment company subsidiaries, financing subsidiaries and certain wholly-owned holding companies that serve to facilitate investment in portfolio companies. In addition, the Company may also consolidate any controlled operating companies substantially all of whose business consists of providing services to the Company.
 
  (i)
The accounting records of the Company are maintained in U.S. dollars. Any assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rate of exchange of such currencies against the U.S. dollar on the date of valuation. The Company will not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations would be included with the net unrealized gain or loss from investments. The Company’s investments in foreign securities, if any, may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments in terms of U.S. dollars and therefore the earnings of the Company.
 
  (j)
In accordance with ASC
835-30,
the Company reports origination and other expenses related to certain debt issuances, if any, as a direct deduction from the carrying amount of the debt liability. Applicable expenses are deferred and amortized using either the effective interest method or the straight-line method over the stated life. The straight-line method may be used on revolving facilities and/or when it approximates the effective yield method.
 
  (k)
The Company records expenses related to applicable equity offering costs as a charge to capital upon the sale of units, in accordance with ASC
946-20-25.
 
  (l)
Investments that are expected to pay regularly scheduled interest in cash are generally placed on
non-accrual
status when principal or interest cash payments are past due 30 days or more and/or when it is no longer probable that principal or interest cash payments will be collected. Such
non-accrual
investments are restored to accrual status if past due principal and interest are paid in cash, and in management’s judgment, are likely to continue timely payment of their remaining principal and interest obligations. Cash interest payments received on such investments may be recognized as income or applied to principal depending on management’s judgment.
 
  (m)
The Company records expenses directly related to its organization as incurred.
 
  (n)
The Company defines cash equivalents as securities that are readily convertible into known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only securities with a maturity of three months or less would qualify, with limited exceptions. The Company believes that certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities would qualify as cash equivalents.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Agreements and Related Party Transactions
6 Months Ended
Jun. 30, 2023
Agreements And Related Party Transactions [Abstract]  
Agreements and Related Party Transactions
Note 3. Agreements and Related Party Transactions
The Company has entered into an investment management agreement with the Adviser (the “Investment Management Agreement”) pursuant to which it will pay management fees, administrative coordinator fees and incentive fees to the Adviser. The Company will pay the Adviser a fee for investment advisory and management services consisting of two components: a base management fee and an incentive fee. The Company will also pay the Adviser (in its capacity as Administrative Coordinator, defined herein) an administration fee for administrative and coordination services. The cost of the base management fee, the incentive fee, and the administration fee will be borne by the Unitholders.
Management Fees and Administration Fees
The Company will pay the Adviser a management fee (the “Management Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (each such date, the “Management Fee Calculation Date”), in an amount equal to 1.5% per annum of Invested Capital (defined as, as of any date, the sum of (i) capital contributions to the Company plus (ii) the total amount of credit drawn on subscription credit facilities), and payable quarterly in arrears after such Management Fee Calculation Date.
Pursuant to the Investment Management Agreement, the Adviser has also been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Company will pay the Administrative Coordinator, a fee (the “Administration Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (the “Administration Fee Calculation Date”), in an amount equal to 0.08% per annum of the average Cost Basis (defined as the aggregate accreted and amortized cost of all
Portfolio Investments
, including any amounts reinvested in investments and the cost of investments acquired using leverage), as measured on the last day of the preceding quarter and the last day of the current quarter for the period ended and payable quarterly in arrears after such Administration Fee Calculation Date. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain
on-going,
routine,
non-investment-related
administrative services for the Company, (ii) the coordination of various third party services needed or required by the Company and (iii) certain Unitholder servicing functions.
 
Each of the Management Fee and the Administration Fee will be appropriately adjusted for any stub period. Such fees will be paid out of net current income and/or disposition proceeds or, to the extent such amounts are not available, from unfunded capital commitments that will be drawn down, or borrowings of the Company. In the event that the Adviser arranges for the Company to pay any portion of a placement fee to a placement agent, the amount of
Management Fees
otherwise payable shall be reduced by an amount equal to 100% of such payment to the placement agent.
Incentive Fee
The Company will make distributions out of two categories: Current Proceeds and Disposition Proceeds (collectively referred to as “Investment Proceeds”). “Disposition Proceeds” means all amounts received by the Company upon the disposition of an investment, including full or partial repayments or amortization of principal (but excluding Current Proceeds). “Current Proceeds” means all proceeds from investments, including interest income, fee income, warrant gains, prepayment fees and exit fees, other than Disposition Proceeds. The Adviser will apportion each Unitholder’s pro rata share of Investment Proceeds between Disposition Proceeds and Current Proceeds. Amounts of Investment Proceeds apportioned to Unitholders will be divided between and distributed to Unitholders, on the one hand, and the Adviser, on the other hand, in the following amounts and order of priority:
(i) Disposition Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as an
incentive fee
, on the other hand, in the following amounts and order of priority:
(A)
Return of Capital Contributions
. First, 100% to such Unitholder until such Unitholder has received cumulative distributions of Investment Proceeds pursuant to this clause (i)(A) equal to such Unitholder’s total Capital Contributions to the Company (including amounts contributed to pay Management Fees, Administration Fees, Organizational Expenses (as defined below) and other Company expenses);
(B)
Unitholder Preferred Return
. Second, 100% of all remaining Disposition Proceeds to Unitholders until they have each received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (B) and clause (D) below and pursuant to clause (ii)(A) and clause (ii)(C) below equal to 6% per annum, compounded annually, on such Unitholder’s unreturned capital contributions to the Company (including amounts contributed to pay Management Fees, Administration Fees, Organizational Expenses and other Company expenses) (the “
Preferred Return”);
(C)
Adviser Catch Up to 15%
. Third, 80% of all remaining Disposition Proceeds paid to the Adviser as an
incentive fee
until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (C) and clause (ii)(B) equal to 15% of the total amounts distributed to Unitholders and paid to the Adviser pursuant to clause (B) above and this clause (C) and pursuant to clause (ii)(A) and clause (ii)(B); and
 
(D)
85%/15%
 Shares
. Thereafter, 85% to Unitholders and 15% paid to the Adviser as an
incentive fee.
(ii) Current Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as an
incentive fee
, on the other hand, in the following amounts and order of priority:
(A)
Unitholder Preferred Return
. First, 100% of all Current Proceeds to Unitholders until Unitholders have received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (A) and clause (C) below and pursuant to clause (i)(B) and clause (i)(D) equal to the Preferred Return;
(B)
Adviser Catch Up to 15%
. Second, 80% of all remaining Current Proceeds paid to the Adviser as an
incentive fee
until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (B) and clause (i)(C) equal to 15% of the total amounts distributed to Unitholders and paid to the Adviser pursuant to clause (A) above and this clause (B) and pursuant to Section clause (i)(B) and clause (i)(C); and
(C)
85%/15% Units
. Thereafter, 85% to Unitholders and 15% paid to the Adviser as an
incentive fee.
In no event will the Adviser receive amounts attributable to Disposition Proceeds that, as of any distribution or payment date, exceeds 20% of cumulative realized capital gains net of all cumulative realized capital losses and unrealized capital depreciation.
The Adviser has the right with respect to all Unitholders, upon approval of the Company’s independent directors, to waive or reduce the incentive fee to which it is entitled. The Adviser may also elect not to receive all or any portion of the incentive fee that would otherwise be distributed to it, and may cause any or all amounts subsequently available for distribution to the Unitholders to be distributed to the Adviser until it has received the same aggregate amount of incentive fees had it not previously waived receipt of incentive fees.
The Adviser will be entitled to withhold from any distributions, in its discretion, any required tax withholdings. Amounts of taxes paid or withheld from amounts otherwise distributable to a Unitholder will be deemed distributed for purposes of the calculations above.
Upon liquidation of the Company, the Adviser will be required to restore funds to the Company for distribution to the Unitholders if and to the extent that the Adviser has received cumulative incentive fees in excess of the incentive fees that would have been payable to the Adviser on an aggregate basis covering all transactions of the Company; provided, however, that in no event will the Adviser be required to contribute an aggregate amount in excess of 100% of the net amount distributed to the Adviser (net of taxes) on account of its incentive fees. In addition, the Adviser will apply an interim incentive fee adjustment at the end of each fiscal year so that, in the event of any over-distribution of incentive fee to the Adviser (measured with respect to each Unitholder using the fair value of the Company’s portfolio at the end of the applicable fiscal year as if the Company were to liquidate on such date), future distributions that would, absent such interim incentive fee adjustment, otherwise be distributed to the Adviser as an incentive fee, shall be distributed to such Unitholder until such over-distribution (net of taxes payable by the Adviser with respect to such incentive fee) has been eliminated.
For the three and six months ended June 30, 2023, the Company incurred $1,078 and $2,136, respectively, in Management Fees, $105 and $210, respectively, in Administration Fees and $1,582 and $1,054, respectively, in
incentive fees
. For the three and six months ended June 30, 2022, the Company incurred $889 and $1,760, respectively, in Management Fees, $93 and $181, respectively, in Administration Fees and $736 and $1,586, respectively, in
incentive fees.
 
The aggregate amount of certain operating expenses relating to Unitholders investing directly in the Company will not exceed the Operating Expense Cap, calculated as follows: (A) if the Company has less than or equal to $400,000 in capital commitments, an amount equal to the sum of (x) the product of the capital commitments and 0.0025 and (y) $1,250, or (B) if the Company has greater than $400,000 in capital commitments, $2,250. Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. For the avoidance of doubt, the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder.
The Adviser or Administrative Coordinator and/or their affiliates has advanced organizational and offering expenses to the Company, which include organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company (“Organizational Expenses”). The Adviser or Administrative Coordinator (or such affiliate) has been reimbursed by the Company for such advanced costs and expenses in an amount not to exceed $500. $308 of offering expenses were charged to capital and $84 of organizational costs were expensed in 2019.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value
Note 4. Fair Value
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The levels of the fair value hierarchy are as follows:
Level
 1.
 Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the Company has the ability to access.
Level
 2.
 Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following:
 
  a)
Quoted prices for similar assets or liabilities in active markets;
 
  b)
Quoted prices for identical or similar assets or liabilities in
non-active
markets;
 
  c)
Pricing models whose inputs are observable for substantially the full term of the asset or liability; and
 
  d)
Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the asset or liability.
Level
 3.
Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s and, if applicable, an independent third-party valuation firm’s own assumptions about the assumptions a market participant would use in pricing the asset or liability.
When the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3).
 
Gains and losses for assets and liabilities categorized within the Level 3 table below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3).
A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. Such reclassifications involving Level 3 assets and liabilities are reported as transfers in/out of Level 3 as of the end of the quarter in which the reclassifications occur. Within the fair value hierarchy tables below, cash and cash equivalents are excluded but could be classified as Level 1.
The following tables present the balances of assets measured at fair value on a recurring basis, as of June 30, 2023 and December 31, 2022:
Fair Value Measurements
As of June 30, 2023
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $ —      $ —      $ 514,531      $ 514,531  
Common Equity/Equity Interests/Warrants
     61        —          7,877        7,938  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $ 61    $ —        $ 522,408      $ 522,469  
  
 
 
    
 
 
    
 
 
    
 
 
 
While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at June 30, 2023, the fair value of the SPV Facility and the Subscription Facility would be $236,500 and $26,800, respectively.
Fair Value Measurements
As of December 31, 2022
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $ —      $ —      $ 532,753      $ 532,753  
Common Equity/Equity Interests/Warrants
     82        —          60        142  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $ 82    $ —        $ 532,813      $ 532,895  
  
 
 
    
 
 
    
 
 
    
 
 
 
 
While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 31, 2022, the fair value of the SPV Facility and the Subscription Facility would be $267,726 and $70,400, respectively.
The following table provides a summary of the changes in fair value of Level 3 assets for the three and six months ended June 30, 2023, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at June 30, 2023:
 
    
Bank Debt/Senior
Secured Loans
    
Common Equity/Equity
Interests/Warrants
    
Total
 
Fair value, March 31, 2023
   $ 524,025      $ 44      $ 524,069  
Total gains or losses included in earnings:
        
Net realized gain
     6        —          6  
Net change in unrealized gain
     635        1,652        2,287  
Purchase of investment securities
     31,071        6,181        37,252  
Proceeds from dispositions of investment securities
     (41,206      —          (41,206
Transfers into Level 3
     —          —          —    
Transfers out of Level 3
     —          —          —    
  
 
 
    
 
 
    
 
 
 
Fair value, June 30, 2023
   $ 514,531      $ 7,877      $ 522,408  
  
 
 
    
 
 
    
 
 
 
Unrealized gains for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain
   $ 731      $ 1,652      $ 2,383  
  
 
 
    
 
 
    
 
 
 
    
Bank Debt/Senior
Secured Loans
    
Common Equity/Equity
Interests/Warrants
    
Total
 
Fair value, December 31, 2022
   $ 532,753      $ 60      $ 532,813  
Total gains or losses included in earnings:
        
Net realized gain
     6        —          6  
Net change in unrealized gain (loss)
     (9,788      1,629        (8,159
Purchase of investment securities
     60,089        6,188        66,277  
Proceeds from dispositions of investment securities
     (68,529      —          (68,529
Transfers into Level 3
     —          —          —    
Transfers out of Level 3
     —          —          —    
  
 
 
    
 
 
    
 
 
 
Fair value, June 30, 2023
   $ 514,531      $ 7,877      $ 522,408  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ (9,563    $ 1,629      $ (7,934
  
 
 
    
 
 
    
 
 
 
 
The following table provides a summary of the changes in fair value of Level 3 assets for the year ended December 31, 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2022:
 
    
Bank Debt/Senior
Secured Loans
    
Common Equity/Equity
Interests/Warrants
    
Total
 
Fair value, December 31, 2021
   $ 439,661      $ 13      $ 439,674  
Total gains or losses included in earnings:
        
Net realized gain (loss)
     —          —          —    
Net change in unrealized gain (loss)
     340        (53      287  
Purchase of investment securities
     188,107        100        188,207  
Proceeds from dispositions of investment securities
     (95,355      —          (95,355
Transfers into Level 3
     —          —          —    
Transfers out of Level 3
     —          —          —    
  
 
 
    
 
 
    
 
 
 
Fair value, December 31, 2022
   $ 532,753      $ 60      $ 532,813  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ 744      $ (53    $ 691  
  
 
 
    
 
 
    
 
 
 
Quantitative Information about Level 3 Fair Value Measurements
The Company typically determines the fair value of its performing debt investments utilizing a yield analysis. In a yield analysis, a price is ascribed for each investment based upon an assessment of current and expected market yields for similar investments and risk profiles. Additional consideration is given to current contractual interest rates, relative maturities and other key terms and risks associated with an investment. Among other factors, a significant determinant of risk is the amount of leverage used by the portfolio company relative to the total enterprise value of the company, and the rights and remedies of our investment within each portfolio company.
Significant unobservable quantitative inputs typically used in the fair value measurement of the Company’s Level 3 assets and liabilities primarily reflect current market yields, including indices, and readily available quotes from brokers, dealers, and pricing services as indicated by comparable assets and liabilities, as well as enterprise values, returns on equity and earnings before income taxes, depreciation and amortization (“EBITDA”) multiples of similar companies, and comparable market transactions for equity securities.
 
Quantitative information about the Company’s Level 3 asset fair value measurements as of June 30, 2023 is summarized in the table below:
 
    
Asset or
Liability
  
Fair Value at
June 30, 2023
    
Principal Valuation
Technique/Methodology
  
Unobservable
Input
  
Range (Weighted
Average)
Senior Secured Loans
   Asset    $ 510,015      Income Approach    Market Yield    9.9% – 20.8% (12.0%)
      $ 4,516      Recovery Analysis    Recoverable Amount    N/A
Common Equity/Equity Interests/Warrants
   Asset    $ 51      Market Approach    Volatility   
17.3% - 17.3% (17.3%)
      $ 7,826      EBITDA Multiple    Comparable Multiple   
6.25x-7.25x (6.75x)
Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving
bid-ask
spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments.
Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below:
 
    
Asset or
Liability
  
Fair Value at
December 31, 2022
    
Principal Valuation
Technique/Methodology
  
Unobservable
Input
  
Range (Weighted
Average)
Senior Secured Loans
   Asset    $ 532,753      Income Approach    Market Yield    9.4% – 16.2% (11.4%)
Common Equity/Equity Interests/Warrants
   Asset    $ 60      Market Approach    Volatility   
26.0% - 26.0% (26.0%)
Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving
bid-ask
spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Debt
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Debt
Note 5. Debt
SPV Facility
—During the first quarter of 2019, the Company, through its wholly-owned subsidiary, SCP Private Credit Income BDC SPV LLC (the “SPV”), entered into the $100,000 SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. The commitment can also be expanded up to $400,000. The stated interest rate on the SPV Facility is SOFR plus 2.90% with no floor requirement and the current final maturity date is December 31, 2023. The fee on undrawn commitments is generally 0.875%. The SPV Facility is secured by all of the assets held by the SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV also includes usual and customary events of default for credit facilities of this nature. On November 18, 2019, the Company amended the SPV Facility, reducing commitments to $75,000. On February 27, 2021, the Company again amended the SPV Facility, increasing commitments to $100,000. On July 16, 2021, the Company entered into an amended SPV Facility, which increased commitments to $125,000, and on August 18, 2021 entered into a second amended SPV Facility which increased commitments to $200,000 and extended the final maturity date to December 31, 2023. On November 2, 2021, the Company entered into Amendment No. 1 to the second amended SPV Facility, which increased commitments to $275,000. On August 3, 2022, the Company entered into Amendment No. 2 to the second amended SPV Facility, which increased commitments to $300,000 and changed the interest rate to a SOFR-based calculation. There were $236,500 of borrowings outstanding as of June 30, 2023 under the SPV Facility. Effective with the end of the Investment Period on December 31, 2022, future advances are no longer permitted.
Subscription Facility
—During the first quarter of 2019, the Company established the $35,000 Subscription Facility with East West Bank, and subsequently entered into an amendment on June 24, 2019, which increased commitments from $35,000 to $50,000. On March 5, 2021, the Company entered into a second amendment. Under the second amendment, commitments were increased from $50,000 to $75,000 and the maturity date was extended. On October 4, 2021, the Company entered into an amended and restated loan and security agreement, which increased commitments to $100,000 and the maturity date was extended. On December 28, 2022, the Company entered into the first amendment to the amended and restated loan and security agreement, extending the maturity date to December 31, 2023, reducing commitments to $75,000 and the stated interest rate is SOFR plus 2.80%. Under the terms of the Subscription Facility, the Company has made certain customary representations and warranties, and is required to comply with various covenants, including reporting requirements and other customary requirements for similar credit facilities. The Subscription Facility also includes usual and customary events of default for credit facilities of this nature. There were $26,800 of borrowings outstanding as of June 30, 2023 under the Subscription Facility.
The average annualized interest cost for borrowings for the six months ended June 30, 2023 and the year ended December 31, 2022 was 7.93% and 4.67%, respectively. These costs are exclusive of other credit facility expenses such as unused fees and fees paid to the
back-up
servicer, if any. The maximum amount borrowed on the credit facilities during the six months ended June 30, 2023 and the year ended December 31, 2022 was $338,126 and $343,350, respectively.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 6. Commitments and Contingencies
The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of June 30, 2023 and December 31, 2022 is $59,616 and $98,214, respectively, comprised of the following:
 
    
June 30,
2023
    
December 31,
2022
 
Outset Medical, Inc.
   $ 11,865      $ 11,865  
Human Interest Inc.
     6,799        6,799  
Vessco Midco Holdings, LLC
     3,417        4,969  
Glooko, Inc.
     3,185        3,185  
Arcutis Biotherapeutics, Inc.
     3,065        3,065  
Ardelyx, Inc.
     2,716        2,716  
iCIMS, Inc.
     2,665        3,867  
Cerapedics, Inc.
     2,424        2,424  
High Street Buyer, Inc.
     2,040        2,797  
RxSense Holdings, LLC
     1,558        1,558  
Pediatric Home Respiratory Services, LLC
     1,557        2,451  
Enverus Holdings, Inc.
     1,537        1,251  
Maurices, Incorporated
     1,491        2,733  
RSC Acquisition, Inc.
     1,419        10,328  
Nexus Intermediate III, LLC (Vortex)
     1,264        1,264  
Meditrina, Inc.
     1,212        1,212  
Spectrum Pharmaceuticals, Inc.
     1,186        2,966  
Kid Distro Holdings, LLC
     1,121        1,121  
GSM Acquisition Corp.
     1,101        1,101  
Foundation Consumer Brands, LLC
     967        967  
Basic Fun, Inc.
     960        1,195  
Ultimate Baked Goods Midco LLC
     750        578  
Orthopedic Care Partners Management, LLC
     729        2,200  
Southern Orthodontic Partners Management, LLC
     705        2,605  
Kaseya, Inc.
     625        1,315  
MRI Software LLC
     577        577  
ENS Holdings III Corp. & ES Opco USA LLC
     574        179  
SunMed Group Holdings, LLC
     515        268  
Transportation Insight, LLC
     454        1,860  
World Insurance Associates, LLC
     385        135  
TAUC Management, LLC
     385        385  
Amerimark Intermediate Holdings, LLC
     194        —    
CC SAG Holdings Corp. (Spectrum Automotive)
     174        6,568  
Oral Surgery Partners Holdings, LLC
     —          3,277  
Plastics Management, LLC
     —          3,095  
Erie Construction
Mid-west,
LLC
     —          1,593  
Tilley Chemical Buyer, Inc.
     —          670  
Peter C. Foy & Associates Insurance Services, LLC
     —          570  
Pinnacle Treatment Centers, Inc.
     —          520  
Ivy Fertility Services, LLC
     —          499  
BayMark Health Services, Inc.
     —          499  
NAC Holdings Corporation
     —          470  
Apex Service Partners, LLC
     —          345  
All States Ag Parts, LLC
     —          172  
  
 
 
    
 
 
 
Total Commitments
   $ 59,616      $ 98,214  
  
 
 
    
 
 
 
The credit agreements of the above loan commitments contain customary lending provisions and/or are subject to the portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of June 30, 2023 and December 31, 2022, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment.
In the normal course of its business, we invest or trade in various financial instruments and may enter into various investment activities with
off-balance
sheet risk, which may include forward foreign currency contracts. Generally, these financial instruments represent future commitments to purchase or sell other financial instruments at specific terms at future dates. These financial instruments contain varying degrees of
off-balance
sheet risk whereby changes in the market value or our satisfaction of the obligations may exceed the amount recognized in our Consolidated Statements of Assets and Liabilities.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Unitholders' Capital
6 Months Ended
Jun. 30, 2023
Limited Liability Company (LLC) Members' Equity [Abstract]  
Unitholders' Capital
Note 7. Unitholders’ Capital
Transactions in Unitholders’ capital were as follows:
 
    
Three months
ended
June 30, 2023
    
Three months
ended
June 30, 2022
 
Units at beginning of period
     25,190,253        17,137,275  
Units issued
     —          1,855,288  
  
 
 
    
 
 
 
Units issued and outstanding at end of period
     25,190,253        18,992,563  
  
 
 
    
 
 
 
 
    
Six months
ended
June 30, 2023
    
Six months
ended
June 30, 2022
 
Units at beginning of period
     18,992,563        17,137,275  
Units issued
     6,197,690        1,855,288  
  
 
 
    
 
 
 
Units issued and outstanding at end of period
     25,190,253        18,992,563  
  
 
 
    
 
 
 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Highlights
6 Months Ended
Jun. 30, 2023
Investment Company, Financial Highlights [Abstract]  
Financial Highlights
Note 8. Financial Highlights
The following is a schedule of financial highlights for the six months ended June 30, 2023 and June 30, 2022:
 
    
Six months ended
June 30, 2023
   
Six months ended
June 30, 2022
 
Per Share Data: (a)
    
Net asset value per unit, beginning of period
   $ 10.33     $ 10.28  
  
 
 
   
 
 
 
Net investment income
     0.60       0.49  
Net realized and unrealized gain (loss)
     (0.32 )*      0.03  
  
 
 
   
 
 
 
Net increase in Unitholders’ capital resulting from operations
     0.28       0.52  
Distributions to Unitholders:
    
From distributable earnings
     —         —    
  
 
 
   
 
 
 
Net asset value per unit, end of period
   $ 10.61     $ 10.80  
  
 
 
   
 
 
 
Total Return (b)(c)
     2.71     5.06
Unitholders’ capital, end of period
   $ 267,226     $ 205,103  
Units outstanding, end of period
     25,190,253       18,992,563  
  
 
 
   
 
 
 
Ratios to average net assets of Unitholders’ Capital (c):
    
Net investment income
     5.82     4.69
  
 
 
   
 
 
 
Operating expenses
     1.62     2.20
Interest and other credit facility expenses
     5.00     3.21
  
 
 
   
 
 
 
Total expenses
     6.62     5.41
  
 
 
   
 
 
 
Average debt outstanding
   $ 285,613     $ 280,590  
Portfolio turnover ratio
     12.1     7.4
 
(a)
Calculated using the average units outstanding method. Weighted average units outstanding for the six months ended June 30, 2023 and June 30, 2022 were 23,512,651 and 17,342,279, respectively.
(b)
Calculated as the change in NAV per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load.
(c)
Not annualized for periods less than one year.
*
Includes the impact of the different unit amounts used in calculating per unit data as a result of calculating certain per unit data based upon the weighted average units outstanding during the period and certain per unit data based on the units outstanding as of a period end.
 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events
Note 9. Subsequent Events
The Company has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date the consolidated financial statements were issued. There have been no subsequent events that require recognition or disclosure in these consolidated financial statements.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Summary of assets measured at fair value on a recurring basis
The following tables present the balances of assets measured at fair value on a recurring basis, as of June 30, 2023 and December 31, 2022:
Fair Value Measurements
As of June 30, 2023
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $ —      $ —      $ 514,531      $ 514,531  
Common Equity/Equity Interests/Warrants
     61        —          7,877        7,938  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $ 61    $ —        $ 522,408      $ 522,469  
  
 
 
    
 
 
    
 
 
    
 
 
 
While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at June 30, 2023, the fair value of the SPV Facility and the Subscription Facility would be $236,500 and $26,800, respectively.
Fair Value Measurements
As of December 31, 2022
 
    
Level 1
    
Level 2
    
Level 3
    
Total
 
Assets:
           
Bank Debt/Senior Secured Loans
   $ —      $ —      $ 532,753      $ 532,753  
Common Equity/Equity Interests/Warrants
     82        —          60        142  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total Investments
   $ 82    $ —        $ 532,813      $ 532,895  
  
 
 
    
 
 
    
 
 
    
 
 
 
Summary of the changes in fair value of level 3 assets
The following table provides a summary of the changes in fair value of Level 3 assets for the three and six months ended June 30, 2023, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at June 30, 2023:
 
    
Bank Debt/Senior
Secured Loans
    
Common Equity/Equity
Interests/Warrants
    
Total
 
Fair value, March 31, 2023
   $ 524,025      $ 44      $ 524,069  
Total gains or losses included in earnings:
        
Net realized gain
     6        —          6  
Net change in unrealized gain
     635        1,652        2,287  
Purchase of investment securities
     31,071        6,181        37,252  
Proceeds from dispositions of investment securities
     (41,206      —          (41,206
Transfers into Level 3
     —          —          —    
Transfers out of Level 3
     —          —          —    
  
 
 
    
 
 
    
 
 
 
Fair value, June 30, 2023
   $ 514,531      $ 7,877      $ 522,408  
  
 
 
    
 
 
    
 
 
 
Unrealized gains for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain
   $ 731      $ 1,652      $ 2,383  
  
 
 
    
 
 
    
 
 
 
    
Bank Debt/Senior
Secured Loans
    
Common Equity/Equity
Interests/Warrants
    
Total
 
Fair value, December 31, 2022
   $ 532,753      $ 60      $ 532,813  
Total gains or losses included in earnings:
        
Net realized gain
     6        —          6  
Net change in unrealized gain (loss)
     (9,788      1,629        (8,159
Purchase of investment securities
     60,089        6,188        66,277  
Proceeds from dispositions of investment securities
     (68,529      —          (68,529
Transfers into Level 3
     —          —          —    
Transfers out of Level 3
     —          —          —    
  
 
 
    
 
 
    
 
 
 
Fair value, June 30, 2023
   $ 514,531      $ 7,877      $ 522,408  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ (9,563    $ 1,629      $ (7,934
  
 
 
    
 
 
    
 
 
 
 
The following table provides a summary of the changes in fair value of Level 3 assets for the year ended December 31, 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2022:
 
    
Bank Debt/Senior
Secured Loans
    
Common Equity/Equity
Interests/Warrants
    
Total
 
Fair value, December 31, 2021
   $ 439,661      $ 13      $ 439,674  
Total gains or losses included in earnings:
        
Net realized gain (loss)
     —          —          —    
Net change in unrealized gain (loss)
     340        (53      287  
Purchase of investment securities
     188,107        100        188,207  
Proceeds from dispositions of investment securities
     (95,355      —          (95,355
Transfers into Level 3
     —          —          —    
Transfers out of Level 3
     —          —          —    
  
 
 
    
 
 
    
 
 
 
Fair value, December 31, 2022
   $ 532,753      $ 60      $ 532,813  
  
 
 
    
 
 
    
 
 
 
Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:
        
Net change in unrealized gain (loss)
   $ 744      $ (53    $ 691  
  
 
 
    
 
 
    
 
 
 
Summary of quantitative information about the company's level 3 asset fair value measurements
Quantitative information about the Company’s Level 3 asset fair value measurements as of June 30, 2023 is summarized in the table below:
 
    
Asset or
Liability
  
Fair Value at
June 30, 2023
    
Principal Valuation
Technique/Methodology
  
Unobservable
Input
  
Range (Weighted
Average)
Senior Secured Loans
   Asset    $ 510,015      Income Approach    Market Yield    9.9% – 20.8% (12.0%)
      $ 4,516      Recovery Analysis    Recoverable Amount    N/A
Common Equity/Equity Interests/Warrants
   Asset    $ 51      Market Approach    Volatility   
17.3% - 17.3% (17.3%)
      $ 7,826      EBITDA Multiple    Comparable Multiple   
6.25x-7.25x (6.75x)
Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving
bid-ask
spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments.
Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below:
 
    
Asset or
Liability
  
Fair Value at
December 31, 2022
    
Principal Valuation
Technique/Methodology
  
Unobservable
Input
  
Range (Weighted
Average)
Senior Secured Loans
   Asset    $ 532,753      Income Approach    Market Yield    9.4% – 16.2% (11.4%)
Common Equity/Equity Interests/Warrants
   Asset    $ 60      Market Approach    Volatility   
26.0% - 26.0% (26.0%)
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Summary of unfunded commitments
The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of June 30, 2023 and December 31, 2022 is $59,616 and $98,214, respectively, comprised of the following:
 
    
June 30,
2023
    
December 31,
2022
 
Outset Medical, Inc.
   $ 11,865      $ 11,865  
Human Interest Inc.
     6,799        6,799  
Vessco Midco Holdings, LLC
     3,417        4,969  
Glooko, Inc.
     3,185        3,185  
Arcutis Biotherapeutics, Inc.
     3,065        3,065  
Ardelyx, Inc.
     2,716        2,716  
iCIMS, Inc.
     2,665        3,867  
Cerapedics, Inc.
     2,424        2,424  
High Street Buyer, Inc.
     2,040        2,797  
RxSense Holdings, LLC
     1,558        1,558  
Pediatric Home Respiratory Services, LLC
     1,557        2,451  
Enverus Holdings, Inc.
     1,537        1,251  
Maurices, Incorporated
     1,491        2,733  
RSC Acquisition, Inc.
     1,419        10,328  
Nexus Intermediate III, LLC (Vortex)
     1,264        1,264  
Meditrina, Inc.
     1,212        1,212  
Spectrum Pharmaceuticals, Inc.
     1,186        2,966  
Kid Distro Holdings, LLC
     1,121        1,121  
GSM Acquisition Corp.
     1,101        1,101  
Foundation Consumer Brands, LLC
     967        967  
Basic Fun, Inc.
     960        1,195  
Ultimate Baked Goods Midco LLC
     750        578  
Orthopedic Care Partners Management, LLC
     729        2,200  
Southern Orthodontic Partners Management, LLC
     705        2,605  
Kaseya, Inc.
     625        1,315  
MRI Software LLC
     577        577  
ENS Holdings III Corp. & ES Opco USA LLC
     574        179  
SunMed Group Holdings, LLC
     515        268  
Transportation Insight, LLC
     454        1,860  
World Insurance Associates, LLC
     385        135  
TAUC Management, LLC
     385        385  
Amerimark Intermediate Holdings, LLC
     194        —    
CC SAG Holdings Corp. (Spectrum Automotive)
     174        6,568  
Oral Surgery Partners Holdings, LLC
     —          3,277  
Plastics Management, LLC
     —          3,095  
Erie Construction
Mid-west,
LLC
     —          1,593  
Tilley Chemical Buyer, Inc.
     —          670  
Peter C. Foy & Associates Insurance Services, LLC
     —          570  
Pinnacle Treatment Centers, Inc.
     —          520  
Ivy Fertility Services, LLC
     —          499  
BayMark Health Services, Inc.
     —          499  
NAC Holdings Corporation
     —          470  
Apex Service Partners, LLC
     —          345  
All States Ag Parts, LLC
     —          172  
  
 
 
    
 
 
 
Total Commitments
   $ 59,616      $ 98,214  
  
 
 
    
 
 
 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Unitholders' Capital (Tables)
6 Months Ended
Jun. 30, 2023
Limited Liability Company (LLC) Members' Equity [Abstract]  
Summary of limited liability company unit holders capital
Transactions in Unitholders’ capital were as follows:
 
    
Three months
ended
June 30, 2023
    
Three months
ended
June 30, 2022
 
Units at beginning of period
     25,190,253        17,137,275  
Units issued
     —          1,855,288  
  
 
 
    
 
 
 
Units issued and outstanding at end of period
     25,190,253        18,992,563  
  
 
 
    
 
 
 
 
    
Six months
ended
June 30, 2023
    
Six months
ended
June 30, 2022
 
Units at beginning of period
     18,992,563        17,137,275  
Units issued
     6,197,690        1,855,288  
  
 
 
    
 
 
 
Units issued and outstanding at end of period
     25,190,253        18,992,563  
  
 
 
    
 
 
 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Highlights (Tables)
6 Months Ended
Jun. 30, 2023
Investment Company, Financial Highlights [Abstract]  
Summary of investment company, financial highlights
The following is a schedule of financial highlights for the six months ended June 30, 2023 and June 30, 2022:
 
    
Six months ended
June 30, 2023
   
Six months ended
June 30, 2022
 
Per Share Data: (a)
    
Net asset value per unit, beginning of period
   $ 10.33     $ 10.28  
  
 
 
   
 
 
 
Net investment income
     0.60       0.49  
Net realized and unrealized gain (loss)
     (0.32 )*      0.03  
  
 
 
   
 
 
 
Net increase in Unitholders’ capital resulting from operations
     0.28       0.52  
Distributions to Unitholders:
    
From distributable earnings
     —         —    
  
 
 
   
 
 
 
Net asset value per unit, end of period
   $ 10.61     $ 10.80  
  
 
 
   
 
 
 
Total Return (b)(c)
     2.71     5.06
Unitholders’ capital, end of period
   $ 267,226     $ 205,103  
Units outstanding, end of period
     25,190,253       18,992,563  
  
 
 
   
 
 
 
Ratios to average net assets of Unitholders’ Capital (c):
    
Net investment income
     5.82     4.69
  
 
 
   
 
 
 
Operating expenses
     1.62     2.20
Interest and other credit facility expenses
     5.00     3.21
  
 
 
   
 
 
 
Total expenses
     6.62     5.41
  
 
 
   
 
 
 
Average debt outstanding
   $ 285,613     $ 280,590  
Portfolio turnover ratio
     12.1     7.4
 
(a)
Calculated using the average units outstanding method. Weighted average units outstanding for the six months ended June 30, 2023 and June 30, 2022 were 23,512,651 and 17,342,279, respectively.
(b)
Calculated as the change in NAV per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load.
(c)
Not annualized for periods less than one year.
*
Includes the impact of the different unit amounts used in calculating per unit data as a result of calculating certain per unit data based upon the weighted average units outstanding during the period and certain per unit data based on the units outstanding as of a period end.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Organization - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended
Mar. 12, 2019
Oct. 05, 2018
Jun. 30, 2023
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]      
Investment company committed capital   $ 326,000  
Stock issued during period shares new issues 2,800,000    
Stock issued during period value new issues $ 28,000    
Share price $ 10    
Investment company funded capital commitments     $ 261,500
Investment company unfunded capital commitments     64,500
Minimum [Member] | Investments [Member]      
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]      
Investee maximum borrowings     100,000
Earnings before interest tax depreciation and amortization     25,000
Maximum [Member] | Investments [Member]      
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]      
Investee maximum borrowings     300,000
Earnings before interest tax depreciation and amortization     $ 100,000
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Additional Information (Detail)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Percentage of excise tax 4.00%
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Agreements and Related Party Transactions - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Oct. 05, 2018
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Agreements And Related Party Transactions [Line Items]          
Investment company, total return [1],[2]       2.71% 5.06%
Percentage of reimbursement of distributions by adviser upon liquidation   100.00%   100.00%  
Management fee expense   $ 1,078 $ 889 $ 2,136 $ 1,760
Administrative fees expense   105 93 210 181
Incentive fee expense   $ 1,582 736 $ 1,054 1,586
Investment company committed capital $ 326,000        
First, Unitholder Preferred Return [Member]          
Agreements And Related Party Transactions [Line Items]          
percentage of current proceeds to unitholders       100.00%  
Second., Adviser Catch Up [Member]          
Agreements And Related Party Transactions [Line Items]          
Percentage of total amount distributed to unitholders and advisers       15.00%  
Percentage of Current Proceeds to Advisers       80.00%  
Third Order of Priority Return of Capital Contributions [Member]          
Agreements And Related Party Transactions [Line Items]          
Percentage of distribution to unitholders       85.00%  
Percentage of distribution to adviser as an incentive fee       15.00%  
Capital Commitment Condition One [Member]          
Agreements And Related Party Transactions [Line Items]          
Investment company committed capital       $ 400,000  
Multiplier to capital commitment   0.0025   0.0025  
Aggregate operating expenses relating to unitholders   $ 1,250   $ 1,250  
Capital Commitment Condition Two [Member]          
Agreements And Related Party Transactions [Line Items]          
Investment company committed capital       400,000  
Aggregate operating expenses relating to unitholders   2,250   $ 2,250  
First Return Of Capital Contributions [Member]          
Agreements And Related Party Transactions [Line Items]          
Percentage of disposition proceeds to unitholders       100.00%  
Second Unitholder Preferred Return [Member]          
Agreements And Related Party Transactions [Line Items]          
Percentage of disposition proceeds to unitholders       100.00%  
Third Adviser Catch Up [Member]          
Agreements And Related Party Transactions [Line Items]          
Percentage of disposition proceeds to advisers       80.00%  
Percentage of total amount distributed to unitholders and advisers       15.00%  
Fourth Order Of Priority Return Of Capital Contributions [Member]          
Agreements And Related Party Transactions [Line Items]          
Percentage of distribution to unitholders       85.00%  
Percentage of distribution to adviser as an incentive fee       15.00%  
Minimum [Member] | Second Unitholder Preferred Return [Member]          
Agreements And Related Party Transactions [Line Items]          
Investment company, total return       6.00%  
Advisor [Member]          
Agreements And Related Party Transactions [Line Items]          
Management fee expense   1,078 889 $ 2,136 1,760
Administrative fees expense   105 93 210 181
Incentive fee expense   1,582 $ 736 1,054 $ 1,586
Reimbursement of organizational and offering expenses   500   500  
Reimbursement of offering expenses   308   308  
Reimbursement of organizational expenses   $ 84   $ 84  
Management Fee [Member] | Advisor [Member]          
Agreements And Related Party Transactions [Line Items]          
Related party transaction rate       1.50%  
Percentage of payment to placement agent       100.00%  
Administration Fee [Member] | Advisor [Member]          
Agreements And Related Party Transactions [Line Items]          
Related party transaction rate       0.08%  
[1] Calculated as the change in NAV per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load.
[2] Not annualized for periods less than one year.
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value - Summary of Assets Measured At Fair Value On A Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure $ 522,469 $ 532,895
Bank Debt/Senior Secured Loans    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure 514,531 532,753
Common Equity/Equity Interests/Warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure 7,938 142
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure 61 82
Fair Value, Inputs, Level 1 [Member] | Bank Debt/Senior Secured Loans    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 1 [Member] | Common Equity/Equity Interests/Warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure 61 82
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 2 [Member] | Bank Debt/Senior Secured Loans    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 2 [Member] | Common Equity/Equity Interests/Warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure 0 0
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure 522,408 532,813
Fair Value, Inputs, Level 3 [Member] | Bank Debt/Senior Secured Loans    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure 514,531 532,753
Fair Value, Inputs, Level 3 [Member] | Common Equity/Equity Interests/Warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments, Fair Value Disclosure $ 7,877 $ 60
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value - Summary of The Changes In Fair Value Of Level 3 Assets (Detail) - Fair Value, Inputs, Level 3 [Member] - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Opening balance $ 524,069 $ 532,813 $ 439,674
Net realized gain (loss) 6 6 0
Net change in unrealized gain (loss) 2,287 (8,159) 287
Purchase of investment securities 37,252 66,277 188,207
Proceeds from dispositions of investment securities (41,206) (68,529) (95,355)
Transfers into Level 3 0 0 0
Transfers out of Level 3 0 0 0
Closing balance 522,408 522,408 532,813
Net change in unrealized gain (loss) 2,383 (7,934) 691
Bank Debt/Senior Secured Loans      
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Opening balance 524,025 532,753 439,661
Net realized gain (loss) 6 6 0
Net change in unrealized gain (loss) 635 (9,788) 340
Purchase of investment securities 31,071 60,089 188,107
Proceeds from dispositions of investment securities (41,206) (68,529) (95,355)
Transfers into Level 3 0 0 0
Transfers out of Level 3 0 0 0
Closing balance 514,531 514,531 532,753
Net change in unrealized gain (loss) 731 (9,563) 744
Common Equity/Equity Interests/Warrants      
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Opening balance 44 60 13
Net realized gain (loss) 0 0 0
Net change in unrealized gain (loss) 1,652 1,629 (53)
Purchase of investment securities 6,181 6,188 100
Proceeds from dispositions of investment securities 0 0 0
Transfers into Level 3 0 0 0
Transfers out of Level 3 0 0 0
Closing balance 7,877 7,877 60
Net change in unrealized gain (loss) $ 1,652 $ 1,629 $ (53)
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value - Summary of Quantitative Information About The Company's Level 3 Asset Fair Value Measurements (Detail) - Fair Value, Inputs, Level 3 [Member]
$ in Thousands
Jun. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Bank Debt/Senior Secured Loans | Valuation Technique Recovery Analysis Model [Member] | Measurement Input Recoverable Amount [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Investments, Fair Value Disclosure $ 4,516  
Senior Secured Loans [Member] | Valuation, Income Approach [Member] | Measurement Input Market Yield [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Investments, Fair Value Disclosure 510,015 $ 532,753
Common Equity/Equity Interests/Warrants | Valuation, Market Approach [Member] | Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Investments, Fair Value Disclosure 51 $ 60
Common Equity/Equity Interests/Warrants | Measurement Input, EBITDA Multiple [Member] | Measurement Input Comparable Multiple [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Investments, Fair Value Disclosure $ 7,826  
Minimum [Member] | Senior Secured Loans [Member] | Valuation, Income Approach [Member] | Measurement Input Market Yield [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 9.9 9.4
Minimum [Member] | Common Equity/Equity Interests/Warrants | Valuation, Market Approach [Member] | Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 17.3 26
Minimum [Member] | Common Equity/Equity Interests/Warrants | Measurement Input, EBITDA Multiple [Member] | Measurement Input Comparable Multiple [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 6.25  
Maximum [Member] | Senior Secured Loans [Member] | Valuation, Income Approach [Member] | Measurement Input Market Yield [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 20.8 16.2
Maximum [Member] | Common Equity/Equity Interests/Warrants | Valuation, Market Approach [Member] | Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 17.3 26
Maximum [Member] | Common Equity/Equity Interests/Warrants | Measurement Input, EBITDA Multiple [Member] | Measurement Input Comparable Multiple [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 7.25  
Weighted Average [Member] | Senior Secured Loans [Member] | Valuation, Income Approach [Member] | Measurement Input Market Yield [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 12 11.4
Weighted Average [Member] | Common Equity/Equity Interests/Warrants | Valuation, Market Approach [Member] | Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 17.3 26
Weighted Average [Member] | Common Equity/Equity Interests/Warrants | Measurement Input, EBITDA Multiple [Member] | Measurement Input Comparable Multiple [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Alternative Investment, Measurement Input 6.75  
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value - Additional information (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
SPV Facility [Member]    
Line of Credit Facility [Line Items]    
Line of credit facility, Fair value of amount outstanding $ 236,500 $ 267,726
Subscription Facility [Member]    
Line of Credit Facility [Line Items]    
Line of credit facility, Fair value of amount outstanding $ 26,800 $ 70,400
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Debt - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Dec. 28, 2022
Aug. 18, 2021
Mar. 31, 2019
Mar. 31, 2019
Jun. 30, 2023
Dec. 31, 2022
Aug. 03, 2022
Nov. 02, 2021
Oct. 04, 2021
Jul. 16, 2021
Mar. 05, 2021
Feb. 27, 2021
Nov. 18, 2019
Jun. 24, 2019
Line of Credit Facility [Line Items]                            
Line Of Credit Facility Maximum Borrowing Capacity     $ 35,000 $ 35,000                    
Long term debt weighted average interest over a period of time         7.93% 4.67%                
Line of credit facility, average outstanding amount         $ 338,126 $ 343,350                
Subscription Facility [Member]                            
Line of Credit Facility [Line Items]                            
Long-Term Line of Credit         26,685 70,215                
SPV Facility [Member]                            
Line of Credit Facility [Line Items]                            
Line Of Credit Facility Maximum Borrowing Capacity   $ 200,000         $ 300,000 $ 275,000   $ 125,000   $ 100,000 $ 75,000  
Long-Term Line of Credit         235,800 $ 266,334                
Minimum [Member] | SPV Facility [Member]                            
Line of Credit Facility [Line Items]                            
Line Of Credit Facility Maximum Borrowing Capacity     100,000 100,000                    
Maximum [Member] | SPV Facility [Member]                            
Line of Credit Facility [Line Items]                            
Line Of Credit Facility Maximum Borrowing Capacity     400,000 400,000                    
East West Bank [Member] | Subscription Facility [Member]                            
Line of Credit Facility [Line Items]                            
Line Of Credit Facility Maximum Borrowing Capacity $ 75,000   $ 35,000 $ 35,000         $ 100,000   $ 75,000     $ 50,000
Long-Term Line of Credit         26,800                  
Line of credit facility, expiration date Dec. 31, 2023                          
London Interbank Offered Rate (LIBOR) [Member] | SPV Facility [Member]                            
Line of Credit Facility [Line Items]                            
Debt Instrument, Basis Spread on Variable Rate     2.90%                      
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] | East West Bank [Member] | Subscription Facility [Member]                            
Line of Credit Facility [Line Items]                            
Debt Instrument, Basis Spread on Variable Rate 2.80%                          
JPMorgan Chase Bank [Member] | SCP Private Credit Income BDC SPV LLC [Member] | SPV Facility [Member]                            
Line of Credit Facility [Line Items]                            
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage       0.875%                    
Long-Term Line of Credit         $ 236,500                  
Line of credit facility, expiration date   Dec. 31, 2023 Dec. 31, 2023                      
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies - Summary of Unfunded Commitments (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments $ 59,616 $ 98,214
Outset Medical, Inc.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 11,865 11,865
Human Interest Inc    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 6,799 6,799
Vessco Midco Holdings, LLC    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 3,417 4,969
Glooko, Inc.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 3,185 3,185
Arcutis Biotherapeutics, Inc    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 3,065 3,065
Ardelyx, Inc.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 2,716 2,716
iCIMS, Inc.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 2,665 3,867
High Street Buyer, Inc    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 2,040 2,797
RxSense Holdings LLC.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 1,558 1,558
Pediatric Home Respiratory Services, LLC.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 1,557 2,451
Peter C. Foy & Associates Insurance Services, LLC..    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 0 570
RSC Acquisition, Inc.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 1,419 10,328
CC SAG Holdings Corp. (Spectrum Automotive)..    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 174 6,568
Oral Surgery Partners Holdings, LLC.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 0 3,277
Southern Orthodontic Partners Management, LLC.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 705 2,605
Maurices, Incorporated    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 1,491 2,733
Spectrum Pharmaceuticals, Inc.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 1,186 2,966
Plastics Management, LLC.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 0 3,095
Transportation Insight, LLC    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 454 1,860
Cerapedics, Inc.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 2,424 2,424
Orthopedic Care Partners Management, LLC.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 729 2,200
NAC Holdings Corporation    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 0 470
Enverus Holdings, Inc. (fka Drilling Info Holdings)    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 1,537 1,251
Erie Construction Mid-west, LLC    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 0 1,593
Ivy Fertility Services, LLC    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 0 499
Kaseya, Inc.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 625 1,315
Nexus Intermediate III, LLC (Vortex)    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 1,264 1,264
ENS Holdings III Corp. & ES Opco USA LLC (BlueFin)    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 574 179
All States Ag Parts, LLC    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 0 172
Kid Distro Holdings, LLC (Distro Kid)    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 1,121 1,121
Meditrina, Inc.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 1,212 1,212
Basic Fun, Inc. ..    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 960 1,195
Foundation Consumer Brands, LLC    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 967 967
Apex Service Partners, LLC    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 0 345
GSM Acquisition Corp    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 1,101 1,101
BayMark Health Services, Inc    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 0 499
MRI Software LLC.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 577 577
Tilley Chemical Buyer, Inc    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 0 670
AmeriMark Intermediate Holdings, LLC [Member]    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 194 0
TAUC Management, LLC    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 385 385
Ultimate Baked Goods Midco LLC (Rise Baking)    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 750 578
SunMed Group Holdings, LLC    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 515 268
World Insurance Associates, LLC.    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments 385 135
Pinnacle Treatment Centers, Inc. ..    
Schedule Of Unfunded Commitments [Line Items]    
Unfunded commitments $ 0 $ 520
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Unfunded commitments $ 59,616 $ 98,214
Revolving Term Loans [Member]    
Unfunded commitments $ 59,616 $ 98,214
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Schedule Of Members Equity [Line Items]        
Units at beginning of period 25,190,253 17,137,275 18,992,563 17,137,275
Units issued 0 1,855,288 6,197,690 1,855,288
Units issued and outstanding at end of period 25,190,253 18,992,563 25,190,253 18,992,563
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Highlights - Summary of Investment Company, Financial Highlights (Detail) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Per Share Data:    
Net asset value per unit, beginning of period $ 10.33 $ 10.28
Net investment income 0.6 0.49
Net realized and unrealized gain (loss) (0.32) [1] 0.03
Net increase in Unitholders' capital resulting from operations 0.28 0.52
Distributions to Unitholders:    
From distributable earnings 0 0
Net asset value per unit, end of period $ 10.61 $ 10.8
Total Return [2],[3] 2.71% 5.06%
Unitholders' capital, end of period $ 267,226 $ 205,103
Units issued and outstanding at end of period 25,190,253 18,992,563
Ratios to average net assets of Unitholders' Capital:    
Net investment income [3] 5.82% 4.69%
Operating expenses [3] 1.62% 2.20%
Interest and other credit facility expenses [3] 5.00% 3.21%
Total expenses [3] 6.62% 5.41%
Average debt outstanding [3] $ 285,613 $ 280,590
Portfolio turnover ratio [3] 12.10% 7.40%
[1] Includes the impact of the different unit amounts used in calculating per unit data as a result of calculating certain per unit data based upon the weighted average units outstanding during the period and certain per unit data based on the units outstanding as of a period end.
[2] Calculated as the change in NAV per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load.
[3] Not annualized for periods less than one year.
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Financial Highlights - Summary of Investment Company, Financial Highlights (Parenthetical) (Detail) - shares
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Weighted average limited liability company units outstanding 23,512,651 17,342,279
XML 50 d530243d10q_htm.xml IDEA: XBRL DOCUMENT 0001743415 2023-01-01 2023-06-30 0001743415 2023-08-04 0001743415 2022-12-31 0001743415 2023-06-30 0001743415 2022-01-01 2022-06-30 0001743415 2022-04-01 2022-06-30 0001743415 2023-04-01 2023-06-30 0001743415 2018-10-05 2018-10-05 0001743415 2019-03-12 2019-03-12 0001743415 2019-03-12 0001743415 2019-03-31 0001743415 2022-01-01 2022-12-31 0001743415 2021-12-31 0001743415 2022-03-31 0001743415 2023-03-31 0001743415 2022-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2023-06-30 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2023-06-30 0001743415 ck0001743415:SubscriptionFacilityMember 2023-06-30 0001743415 ck0001743415:SpvFacilityMember 2023-06-30 0001743415 ck0001743415:GlookoIncMember 2023-06-30 0001743415 ck0001743415:ArcutisBiotherapeuticsIncMember 2023-06-30 0001743415 ck0001743415:SpectrumPharmaceuticalsInc.Member 2023-06-30 0001743415 ck0001743415:CcSagHoldingsCorpMember 2023-06-30 0001743415 ck0001743415:VesscoMidcoHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:IcimsInc.Member 2023-06-30 0001743415 ck0001743415:OutsetMedicalInc.Member 2023-06-30 0001743415 ck0001743415:RscAcquisitionIncMember 2023-06-30 0001743415 ck0001743415:HumanInterestIncMember 2023-06-30 0001743415 ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:NacHoldingsCorporationMember 2023-06-30 0001743415 ck0001743415:IvyFertilityServicesLlcMember 2023-06-30 0001743415 ck0001743415:BaymarkHealthServicesIncMember 2023-06-30 0001743415 ck0001743415:AllStatesAgPartsLlcMember 2023-06-30 0001743415 ck0001743415:PlasticsManagementLlcMember 2023-06-30 0001743415 ck0001743415:PinnacleTreatmentCentersIncMember 2023-06-30 0001743415 ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember 2023-06-30 0001743415 ck0001743415:WorldInsuranceAssociatesLlcMember 2023-06-30 0001743415 ck0001743415:ApexServicePartnersLlcMember 2023-06-30 0001743415 ck0001743415:TaucManagementLlcMember 2023-06-30 0001743415 ck0001743415:SunmedGroupHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:OralSurgeryPartnersHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:MriSoftwareLlcMember 2023-06-30 0001743415 ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember 2023-06-30 0001743415 ck0001743415:FoundationConsumerBrandsLlcMember 2023-06-30 0001743415 ck0001743415:TilleyChemicalBuyerIncMember 2023-06-30 0001743415 ck0001743415:UltimateBakedGoodsMidcoLlcMember 2023-06-30 0001743415 ck0001743415:KidDistroHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:GsmAcquisitionCorpMember 2023-06-30 0001743415 ck0001743415:TransportationInsightLlcMember 2023-06-30 0001743415 ck0001743415:EnverusHoldingsIncMember 2023-06-30 0001743415 ck0001743415:MeditrinaInc.Member 2023-06-30 0001743415 ck0001743415:BasicFunIncMember 2023-06-30 0001743415 ck0001743415:OrthopedicCarePartnersManagementLlcMember 2023-06-30 0001743415 ck0001743415:KaseyaIncMember 2023-06-30 0001743415 ck0001743415:NexusIntermediateIiiLlcVortexMember 2023-06-30 0001743415 ck0001743415:MauricesIncorporatedMember 2023-06-30 0001743415 ck0001743415:ErieConstructionMidWestLlcMember 2023-06-30 0001743415 ck0001743415:RxsenseHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:PediatricHomeRespiratoryServicesLlcMember 2023-06-30 0001743415 ck0001743415:CerapedicsInc.Member 2023-06-30 0001743415 ck0001743415:SouthernOrthodonticPartnersManagementLlcMember 2023-06-30 0001743415 ck0001743415:HighStreetBuyerIncMember 2023-06-30 0001743415 ck0001743415:ArdelyxIncMember 2023-06-30 0001743415 ck0001743415:CapitalCommitmentConditionOneMember 2023-06-30 0001743415 ck0001743415:CapitalCommitmentConditionTwoMember 2023-06-30 0001743415 ck0001743415:RevolvingTermLoansMember 2023-06-30 0001743415 ck0001743415:SpvFacilityMember ck0001743415:ScpPrivateCreditIncomeBdcSpvLlcMember ck0001743415:JpmorganChaseBankMember 2023-06-30 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:BankDebtSeniorSecuredLoansMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:BankDebtSeniorSecuredLoansMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:BankDebtSeniorSecuredLoansMember 2023-06-30 0001743415 us-gaap:FairValueMeasurementsRecurringMember ck0001743415:BankDebtSeniorSecuredLoansMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:SeniorSecuredLoansMember ck0001743415:MeasurementInputMarketYieldMember us-gaap:IncomeApproachValuationTechniqueMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:BankDebtSeniorSecuredLoansMember ck0001743415:MeasurementInputRecoverableAmountMember ck0001743415:ValuationTechniqueRecoveryAnalysisModelMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember ck0001743415:MeasurementInputComparableMultipleMember us-gaap:MeasurementInputEbitdaMultipleMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2023-06-30 0001743415 srt:MinimumMember us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember ck0001743415:MeasurementInputComparableMultipleMember us-gaap:MeasurementInputEbitdaMultipleMember 2023-06-30 0001743415 srt:MaximumMember us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember ck0001743415:MeasurementInputComparableMultipleMember us-gaap:MeasurementInputEbitdaMultipleMember 2023-06-30 0001743415 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember ck0001743415:MeasurementInputComparableMultipleMember us-gaap:MeasurementInputEbitdaMultipleMember 2023-06-30 0001743415 srt:MinimumMember us-gaap:FairValueInputsLevel3Member ck0001743415:SeniorSecuredLoansMember ck0001743415:MeasurementInputMarketYieldMember us-gaap:IncomeApproachValuationTechniqueMember 2023-06-30 0001743415 srt:MaximumMember us-gaap:FairValueInputsLevel3Member ck0001743415:SeniorSecuredLoansMember ck0001743415:MeasurementInputMarketYieldMember us-gaap:IncomeApproachValuationTechniqueMember 2023-06-30 0001743415 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member ck0001743415:SeniorSecuredLoansMember ck0001743415:MeasurementInputMarketYieldMember us-gaap:IncomeApproachValuationTechniqueMember 2023-06-30 0001743415 srt:MinimumMember us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2023-06-30 0001743415 srt:MaximumMember us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2023-06-30 0001743415 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2023-06-30 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SpectrumPharmaceuticalsIncMember 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SunmedGroupHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:TaucManagementLlcMember 2023-06-30 0001743415 ck0001743415:PackagedFoodsAndMeatsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:UltimateBakedGoodsMidcoLlcMember 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:VapothermIncMember 2023-06-30 0001743415 ck0001743415:RoadAndRailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:TransportationInsightLlcMember 2023-06-30 0001743415 ck0001743415:WaterUtilitiesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:VesscoMidcoHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:WorldInsuranceAssociatesLlcMember 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SouthernOrthodonticPartnersManagementLlcMember 2023-06-30 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:TilleyDistributionIncMember 2023-06-30 0001743415 ck0001743415:ItServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:EnverusHoldingsIncMember 2023-06-30 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:KaseyaIncMember 2023-06-30 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:HighStreetBuyerIncMember 2023-06-30 0001743415 ck0001743415:HealthCareTechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:GlookoIncMember 2023-06-30 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:CerapedicsIncMember 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:AlimeraSciencesIncMember 2023-06-30 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:AllStateAgPartsLlcMember 2023-06-30 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:ApexServicePartnersLlcMember 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:ArcutisBiotherapeuticsIncMember 2023-06-30 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:PediatricHomeRespiratoryServicesLlcMember 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:OrthopedicCarePartnersManagementLlcMember 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:NeuroneticsIncMember 2023-06-30 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:MriSoftwareLlcMember 2023-06-30 0001743415 ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:MauricesIncorporatedMember 2023-06-30 0001743415 ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:BasicFunIncMember 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:BaymarkHealthServicesIncMember 2023-06-30 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:CcSagHoldingsCorpMember 2023-06-30 0001743415 ck0001743415:CapitalMarketsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:EnhancedPermanentCapitalLlcMember 2023-06-30 0001743415 ck0001743415:BuildingProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:ErieConstructionMidWestLlcMember 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:PlasticsManagementLlcMember 2023-06-30 0001743415 ck0001743415:InternetAndCatalogRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:AmeriMarkIntermediateHoldingsLlcOneMember 2023-06-30 0001743415 ck0001743415:DiversifiedFinancialServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:AcresCommercialMortgageLlcMember 2023-06-30 0001743415 ck0001743415:WirelessTelecommunicationServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:KoreWirelessGroupIncMember 2023-06-30 0001743415 ck0001743415:InternetAndCatalogRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:IcimsIncMember 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:OutsetMedicalIncMember 2023-06-30 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:HigginbothamInsuranceAgencyMember 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:ArdelyxIncMember 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:CentrexionTherapeuticsIncMember 2023-06-30 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:FertilityInvestmentHoldcoLlcMember 2023-06-30 0001743415 ck0001743415:PersonalProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:FoundationConsumerBrandsLlcMember 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:PinnacleTreatmentCentersIncMember 2023-06-30 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:BridgebioPharmaIncMember 2023-06-30 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:RscAcquisitionIncMember 2023-06-30 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:RxsenseHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:KidDistroHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:MeditrinaIncMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:NexusIntermediateIiiLlcVortexMember 2023-06-30 0001743415 ck0001743415:LeisureEquipmentAndProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:GsmAcquisitionCorpMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:RqmPlusCorpMember 2023-06-30 0001743415 ck0001743415:InternetSoftwareAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:HumanInterestIncMember 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SunmedGroupHoldingsLlcMember 2023-06-30 0001743415 ck0001743415:InternetAndCatalogRetailMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:SlrAmiTopcoBlockerLlcMember 2023-06-30 0001743415 ck0001743415:BiotechnologyMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:SpectrumPharmaceuticalsInc.WarrantsMember 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:VapothermIncMember 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:SenseonicsHoldingsInc.CommonStockMember 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:MeditrinaInc.WarrantsMember 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:CentrexionTherapeuticsInc.WarrantsMember 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember 2023-06-30 0001743415 ck0001743415:InvestmentsOneHundredAndNinetyFivePointFivePercentageMember 2023-06-30 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember 2023-06-30 0001743415 ck0001743415:LiabilitiesInExcessOfOtherAssetsNinetyFivePointFivePercentageMember 2023-06-30 0001743415 ck0001743415:NetAssetsOneHundredPercentageMember 2023-06-30 0001743415 ck0001743415:SpecialtyRetailMember 2023-06-30 0001743415 ck0001743415:ProfessionalServicesMember 2023-06-30 0001743415 ck0001743415:RoadAndRailMember 2023-06-30 0001743415 ck0001743415:HealthCareTechnologyMember 2023-06-30 0001743415 ck0001743415:WaterUtilitiesMember 2023-06-30 0001743415 ck0001743415:DiversifiedFinancialServicesMember 2023-06-30 0001743415 ck0001743415:LeisureEquipmentAndProductsMember 2023-06-30 0001743415 ck0001743415:InternetAndCatalogRetailMember 2023-06-30 0001743415 ck0001743415:BuildingProductsMember 2023-06-30 0001743415 ck0001743415:CapitalMarketsMember 2023-06-30 0001743415 ck0001743415:PackagedFoodsAndMeatsMember 2023-06-30 0001743415 ck0001743415:InternetSoftwareServicesMember 2023-06-30 0001743415 ck0001743415:BiotechnologyMember 2023-06-30 0001743415 ck0001743415:PersonalProductsMember 2023-06-30 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember 2023-06-30 0001743415 ck0001743415:LifeSciencesToolsAndServicesMember 2023-06-30 0001743415 ck0001743415:ItServicesMember 2023-06-30 0001743415 ck0001743415:WirelessTelecommunicationServicesMember 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember 2023-06-30 0001743415 ck0001743415:InsuranceMember 2023-06-30 0001743415 ck0001743415:SoftwareMember 2023-06-30 0001743415 ck0001743415:DiversifiedConsumerServicesMember 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember 2023-06-30 0001743415 srt:MaximumMember us-gaap:InvestmentsMember 2023-06-30 0001743415 srt:MinimumMember us-gaap:InvestmentsMember 2023-06-30 0001743415 ck0001743415:AdvisorMember 2023-06-30 0001743415 ck0001743415:AscHoldcoLlcMember 2023-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2022-12-31 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2022-12-31 0001743415 ck0001743415:SubscriptionFacilityMember 2022-12-31 0001743415 ck0001743415:SpvFacilityMember 2022-12-31 0001743415 ck0001743415:ArdelyxIncMember 2022-12-31 0001743415 ck0001743415:GlookoIncMember 2022-12-31 0001743415 ck0001743415:ArcutisBiotherapeuticsIncMember 2022-12-31 0001743415 ck0001743415:SpectrumPharmaceuticalsInc.Member 2022-12-31 0001743415 ck0001743415:CcSagHoldingsCorpMember 2022-12-31 0001743415 ck0001743415:VesscoMidcoHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:IcimsInc.Member 2022-12-31 0001743415 ck0001743415:OutsetMedicalInc.Member 2022-12-31 0001743415 ck0001743415:RscAcquisitionIncMember 2022-12-31 0001743415 ck0001743415:HumanInterestIncMember 2022-12-31 0001743415 ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:BaymarkHealthServicesIncMember 2022-12-31 0001743415 ck0001743415:NacHoldingsCorporationMember 2022-12-31 0001743415 ck0001743415:PlasticsManagementLlcMember 2022-12-31 0001743415 ck0001743415:IvyFertilityServicesLlcMember 2022-12-31 0001743415 ck0001743415:AllStatesAgPartsLlcMember 2022-12-31 0001743415 ck0001743415:PinnacleTreatmentCentersIncMember 2022-12-31 0001743415 ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember 2022-12-31 0001743415 ck0001743415:WorldInsuranceAssociatesLlcMember 2022-12-31 0001743415 ck0001743415:ApexServicePartnersLlcMember 2022-12-31 0001743415 ck0001743415:TaucManagementLlcMember 2022-12-31 0001743415 ck0001743415:SunmedGroupHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:OralSurgeryPartnersHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:MriSoftwareLlcMember 2022-12-31 0001743415 ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember 2022-12-31 0001743415 ck0001743415:FoundationConsumerBrandsLlcMember 2022-12-31 0001743415 ck0001743415:TilleyChemicalBuyerIncMember 2022-12-31 0001743415 ck0001743415:UltimateBakedGoodsMidcoLlcMember 2022-12-31 0001743415 ck0001743415:KidDistroHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:GsmAcquisitionCorpMember 2022-12-31 0001743415 ck0001743415:TransportationInsightLlcMember 2022-12-31 0001743415 ck0001743415:EnverusHoldingsIncMember 2022-12-31 0001743415 ck0001743415:MeditrinaInc.Member 2022-12-31 0001743415 ck0001743415:BasicFunIncMember 2022-12-31 0001743415 ck0001743415:OrthopedicCarePartnersManagementLlcMember 2022-12-31 0001743415 ck0001743415:KaseyaIncMember 2022-12-31 0001743415 ck0001743415:NexusIntermediateIiiLlcVortexMember 2022-12-31 0001743415 ck0001743415:MauricesIncorporatedMember 2022-12-31 0001743415 ck0001743415:ErieConstructionMidWestLlcMember 2022-12-31 0001743415 ck0001743415:RxsenseHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:PediatricHomeRespiratoryServicesLlcMember 2022-12-31 0001743415 ck0001743415:CerapedicsInc.Member 2022-12-31 0001743415 ck0001743415:SouthernOrthodonticPartnersManagementLlcMember 2022-12-31 0001743415 ck0001743415:HighStreetBuyerIncMember 2022-12-31 0001743415 ck0001743415:RevolvingTermLoansMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:BankDebtSeniorSecuredLoansMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:BankDebtSeniorSecuredLoansMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:BankDebtSeniorSecuredLoansMember 2022-12-31 0001743415 us-gaap:FairValueMeasurementsRecurringMember ck0001743415:BankDebtSeniorSecuredLoansMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:SeniorSecuredLoansMember ck0001743415:MeasurementInputMarketYieldMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001743415 srt:MinimumMember us-gaap:FairValueInputsLevel3Member ck0001743415:SeniorSecuredLoansMember ck0001743415:MeasurementInputMarketYieldMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001743415 srt:MaximumMember us-gaap:FairValueInputsLevel3Member ck0001743415:SeniorSecuredLoansMember ck0001743415:MeasurementInputMarketYieldMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001743415 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member ck0001743415:SeniorSecuredLoansMember ck0001743415:MeasurementInputMarketYieldMember us-gaap:IncomeApproachValuationTechniqueMember 2022-12-31 0001743415 srt:MinimumMember us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001743415 srt:MaximumMember us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001743415 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:MarketApproachValuationTechniqueMember 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:VapothermIncMember 2022-12-31 0001743415 ck0001743415:WaterUtilitiesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:VesscoMidcoHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:WorldInsuranceAssociatesLlcMember 2022-12-31 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SpectrumPharmaceuticalsIncMember 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SunmedGroupHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:PackagedFoodsAndMeatsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:UltimateBakedGoodsMidcoLlcMember 2022-12-31 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TilleyDistributionIncMember 2022-12-31 0001743415 ck0001743415:RoadAndRailMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TransportationInsightLlcMember 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TaucManagementLlcMember 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PediatricHomeRespiratoryServicesLlcMember 2022-12-31 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BridgebioPharmaIncMember 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:NeuroneticsIncMember 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:OutsetMedicalIncMember 2022-12-31 0001743415 ck0001743415:HealthCareTechnologyMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:GlookoIncMember 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PlasticsManagementLlcMember 2022-12-31 0001743415 ck0001743415:LifeSciencesToolsAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:RqmPlusCorpMember 2022-12-31 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:RxsenseHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:ItServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:EnverusHoldingsIncMember 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:CentrexionTherapeuticsIncMember 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HigginbothamInsuranceAgencyMember 2022-12-31 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:IcimsIncMember 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:MeditrinaIncMember 2022-12-31 0001743415 ck0001743415:InternetAndCatalogRetailMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SouthernOrthodonticPartnersManagementLlcMember 2022-12-31 0001743415 ck0001743415:WirelessTelecommunicationServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:KoreWirelessGroupIncMember 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember 2022-12-31 0001743415 ck0001743415:PersonalProductsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:FoundationConsumerBrandsLlcMember 2022-12-31 0001743415 ck0001743415:LeisureEquipmentAndProductsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:GsmAcquisitionCorpMember 2022-12-31 0001743415 ck0001743415:BuildingProductsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ErieConstructionMidWestLlcMember 2022-12-31 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:RscAcquisitionIncMember 2022-12-31 0001743415 ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:MauricesIncorporatedMember 2022-12-31 0001743415 ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BasicFunIncMember 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BaymarkHealthServicesIncMember 2022-12-31 0001743415 ck0001743415:InternetSoftwareAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HumanInterestIncMember 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:IvyFertilityServicesLlcMember 2022-12-31 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:KaseyaIncMember 2022-12-31 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:KidDistroHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ArdelyxIncMember 2022-12-31 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ApexServicePartnersLlcMember 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ArcutisBiotherapeuticsIncMember 2022-12-31 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:CcSagHoldingsCorpMember 2022-12-31 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:CerapedicsIncMember 2022-12-31 0001743415 ck0001743415:CapitalMarketsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:EnhancedPermanentCapitalLlcMember 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:OrthopedicCarePartnersManagementLlcMember 2022-12-31 0001743415 ck0001743415:ProfessionalServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:NexusIntermediateIiiLlcVortexMember 2022-12-31 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:AllStateAgPartsLlcMember 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PinnacleTreatmentCentersIncMember 2022-12-31 0001743415 ck0001743415:PersonalProductsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:RevlonConsumerProductsCorporationMember 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:OralSurgeryPartnersHoldingsLlcMember 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:NACHoldingCorporationJaguarMember 2022-12-31 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:MriSoftwareLlcMember 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HighStreetBuyerIncMember 2022-12-31 0001743415 ck0001743415:DiversifiedFinancialServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:AcresCommercialMortgageLlcMember 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:AlimeraSciencesIncMember 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:CentrexionTherapeuticsInc.WarrantsMember 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:VapothermIncMember 2022-12-31 0001743415 ck0001743415:BiotechnologyMember ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:SpectrumPharmaceuticalsInc.WarrantsMember 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:SenseonicsHoldingsInc.CommonStockMember 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:MeditrinaInc.WarrantsMember 2022-12-31 0001743415 ck0001743415:CommonEquityEquityInterestsWarrantsMember 2022-12-31 0001743415 ck0001743415:InvestmentsTwoHundredSeventyOnePointFivePercentageMember 2022-12-31 0001743415 ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember 2022-12-31 0001743415 ck0001743415:LiabilitiesInExcessOfOtherAssetsOneHundredSeventyOnePointFivePercentageMember 2022-12-31 0001743415 ck0001743415:NetAssetsOneHundredPercentageMember 2022-12-31 0001743415 ck0001743415:InsuranceMember 2022-12-31 0001743415 ck0001743415:BiotechnologyMember 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember 2022-12-31 0001743415 ck0001743415:DiversifiedConsumerServicesMember 2022-12-31 0001743415 ck0001743415:SoftwareMember 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember 2022-12-31 0001743415 ck0001743415:WirelessTelecommunicationServicesMember 2022-12-31 0001743415 ck0001743415:ItServicesMember 2022-12-31 0001743415 ck0001743415:LifeSciencesToolsAndServicesMember 2022-12-31 0001743415 ck0001743415:InternetAndCatalogRetailMember 2022-12-31 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember 2022-12-31 0001743415 ck0001743415:PersonalProductsMember 2022-12-31 0001743415 ck0001743415:InternetSoftwareServicesMember 2022-12-31 0001743415 ck0001743415:CapitalMarketsMember 2022-12-31 0001743415 ck0001743415:PackagedFoodsAndMeatsMember 2022-12-31 0001743415 ck0001743415:BuildingProductsMember 2022-12-31 0001743415 ck0001743415:DiversifiedFinancialServicesMember 2022-12-31 0001743415 ck0001743415:LeisureEquipmentAndProductsMember 2022-12-31 0001743415 ck0001743415:WaterUtilitiesMember 2022-12-31 0001743415 ck0001743415:HealthCareTechnologyMember 2022-12-31 0001743415 ck0001743415:RoadAndRailMember 2022-12-31 0001743415 ck0001743415:SpecialtyRetailMember 2022-12-31 0001743415 ck0001743415:ProfessionalServicesMember 2022-12-31 0001743415 ck0001743415:AdvisorMember 2022-01-01 2022-06-30 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2022-01-01 2022-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2022-01-01 2022-06-30 0001743415 ck0001743415:KaseyaIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BridgebioPharmaIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:IcimsIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:VapothermIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AdministrationFeeMember ck0001743415:AdvisorMember 2023-01-01 2023-06-30 0001743415 ck0001743415:ManagementFeeMember ck0001743415:AdvisorMember 2023-01-01 2023-06-30 0001743415 ck0001743415:SecondUnitholderPreferredReturnMember 2023-01-01 2023-06-30 0001743415 ck0001743415:FirstReturnOfCapitalContributionsMember 2023-01-01 2023-06-30 0001743415 srt:MinimumMember ck0001743415:SecondUnitholderPreferredReturnMember 2023-01-01 2023-06-30 0001743415 ck0001743415:ThirdAdviserCatchUpMember 2023-01-01 2023-06-30 0001743415 ck0001743415:Second.AdviserCatchUpMember 2023-01-01 2023-06-30 0001743415 ck0001743415:FirstUnitholderPreferredReturnMember 2023-01-01 2023-06-30 0001743415 ck0001743415:FourthOrderOfPriorityReturnOfCapitalContributionsMember 2023-01-01 2023-06-30 0001743415 ck0001743415:ThirdOrderOfPriorityReturnOfCapitalContributionsMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AdvisorMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CapitalCommitmentConditionOneMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CapitalCommitmentConditionTwoMember 2023-01-01 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:BankDebtSeniorSecuredLoansMember 2023-01-01 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-01-01 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:CerapedicsIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CapitalMarketsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:EnhancedPermanentCapitalLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:ItServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:EnverusHoldingsIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BuildingProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:ErieConstructionMidWestLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:PersonalProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:FoundationConsumerBrandsLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:PinnacleTreatmentCentersIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:PlasticsManagementLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:RqmPlusCorpMember 2023-01-01 2023-06-30 0001743415 ck0001743415:InternetSoftwareAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:HumanInterestIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:MeditrinaIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:NeuroneticsIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:OrthopedicCarePartnersManagementLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:OutsetMedicalIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:PediatricHomeRespiratoryServicesLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:BaymarkHealthServicesIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:FertilityInvestmentHoldcoLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:LeisureEquipmentAndProductsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:GsmAcquisitionCorpMember 2023-01-01 2023-06-30 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:AllStateAgPartsLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:InternetAndCatalogRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:InternetAndCatalogRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:AmeriMarkIntermediateHoldingsLlcOneMember 2023-01-01 2023-06-30 0001743415 ck0001743415:DiversifiedFinancialServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:AcresCommercialMortgageLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:AlimeraSciencesIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:ApexServicePartnersLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:ArcutisBiotherapeuticsIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:ArdelyxIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:BasicFunIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:IcimsIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:HighStreetBuyerIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:HigginbothamInsuranceAgencyMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareTechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:GlookoIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:RscAcquisitionIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:RxsenseHoldingsLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:NexusIntermediateIiiLlcVortexMember 2023-01-01 2023-06-30 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:MriSoftwareLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:MauricesIncorporatedMember 2023-01-01 2023-06-30 0001743415 ck0001743415:WirelessTelecommunicationServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:KoreWirelessGroupIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:KidDistroHoldingsLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:KaseyaIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SpectrumPharmaceuticalsIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:CentrexionTherapeuticsInc.WarrantsMember 2023-01-01 2023-06-30 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:WorldInsuranceAssociatesLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:WaterUtilitiesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:VesscoMidcoHoldingsLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BiotechnologyMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:SpectrumPharmaceuticalsInc.WarrantsMember 2023-01-01 2023-06-30 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:BridgebioPharmaIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:CcSagHoldingsCorpMember 2023-01-01 2023-06-30 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:CentrexionTherapeuticsIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:InternetAndCatalogRetailMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:SlrAmiTopcoBlockerLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:VapothermIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:PackagedFoodsAndMeatsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:UltimateBakedGoodsMidcoLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:VapothermIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:MeditrinaInc.WarrantsMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember ck0001743415:SenseonicsHoldingsInc.CommonStockMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SunmedGroupHoldingsLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:TaucManagementLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:TilleyDistributionIncMember 2023-01-01 2023-06-30 0001743415 ck0001743415:RoadAndRailMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:TransportationInsightLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SouthernOrthodonticPartnersManagementLlcMember 2023-01-01 2023-06-30 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember ck0001743415:SunmedGroupHoldingsLlcMember 2023-01-01 2023-06-30 0001743415 srt:MaximumMember us-gaap:InvestmentsMember 2023-01-01 2023-06-30 0001743415 srt:MinimumMember us-gaap:InvestmentsMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2023-01-01 2023-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2023-01-01 2023-06-30 0001743415 ck0001743415:AdvisorMember 2023-04-01 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:BankDebtSeniorSecuredLoansMember 2023-04-01 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-04-01 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member 2023-04-01 2023-06-30 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2023-04-01 2023-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2023-04-01 2023-06-30 0001743415 ck0001743415:AdvisorMember 2022-04-01 2022-06-30 0001743415 ck0001743415:CompaniesLessThanFivePercentageOwnedMember 2022-04-01 2022-06-30 0001743415 ck0001743415:CompaniesFivePercentageToTwentyFivePercentageOwnedMember 2022-04-01 2022-06-30 0001743415 ck0001743415:AmerimarkInteractiveLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BridgebioPharmaIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:IcimsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:VapothermIncMember 2022-01-01 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2022-01-01 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:BankDebtSeniorSecuredLoansMember 2022-01-01 2022-12-31 0001743415 ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:MauricesIncorporatedMember 2022-01-01 2022-12-31 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:MriSoftwareLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:NACHoldingCorporationJaguarMember 2022-01-01 2022-12-31 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:RxsenseHoldingsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:KaseyaIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareTechnologyMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:GlookoIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:PersonalProductsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:FoundationConsumerBrandsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:ItServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:EnverusHoldingsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HigginbothamInsuranceAgencyMember 2022-01-01 2022-12-31 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:IcimsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HighStreetBuyerIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PeterCFoyandAssociatesInsuranceServicesLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ApexServicePartnersLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:ProfessionalServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:NexusIntermediateIiiLlcVortexMember 2022-01-01 2022-12-31 0001743415 ck0001743415:WirelessTelecommunicationServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:KoreWirelessGroupIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:AlimeraSciencesIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ArdelyxIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BridgebioPharmaIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:DiversifiedConsumerServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:CcSagHoldingsCorpMember 2022-01-01 2022-12-31 0001743415 ck0001743415:CapitalMarketsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:EnhancedPermanentCapitalLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:CerapedicsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TilleyDistributionIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:RoadAndRailMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TransportationInsightLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:PackagedFoodsAndMeatsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:UltimateBakedGoodsMidcoLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:VapothermIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:MeditrinaInc.WarrantsMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:SenseonicsHoldingsInc.CommonStockMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PinnacleTreatmentCentersIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PlasticsManagementLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:LifeSciencesToolsAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:RqmPlusCorpMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SouthernOrthodonticPartnersManagementLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SunmedGroupHoldingsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:TaucManagementLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:MeditrinaIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:NeuroneticsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:OralSurgeryPartnersHoldingsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:OrthopedicCarePartnersManagementLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:OutsetMedicalIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:PediatricHomeRespiratoryServicesLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:InternetAndCatalogRetailMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BaymarkHealthServicesIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:LeisureEquipmentAndProductsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:GsmAcquisitionCorpMember 2022-01-01 2022-12-31 0001743415 ck0001743415:InternetSoftwareAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:HumanInterestIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareProvidersAndServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:IvyFertilityServicesLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:HealthCareEquipmentAndSuppliesMember ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:VapothermIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:TradingCompaniesAndDistributorsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:AllStateAgPartsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:CentrexionTherapeuticsInc.WarrantsMember 2022-01-01 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:WorldInsuranceAssociatesLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:WaterUtilitiesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:VesscoMidcoHoldingsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:SpecialtyRetailMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:BasicFunIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BiotechnologyMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:SpectrumPharmaceuticalsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BiotechnologyMember ck0001743415:CommonEquityEquityInterestsWarrantsMember ck0001743415:SpectrumPharmaceuticalsInc.WarrantsMember 2022-01-01 2022-12-31 0001743415 ck0001743415:DiversifiedFinancialServicesMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:AcresCommercialMortgageLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ArcutisBiotherapeuticsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:SoftwareMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:KidDistroHoldingsLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:PersonalProductsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:RevlonConsumerProductsCorporationMember 2022-01-01 2022-12-31 0001743415 ck0001743415:BuildingProductsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:ErieConstructionMidWestLlcMember 2022-01-01 2022-12-31 0001743415 ck0001743415:InsuranceMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:RscAcquisitionIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:PharmaceuticalsMember ck0001743415:BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember ck0001743415:CentrexionTherapeuticsIncMember 2022-01-01 2022-12-31 0001743415 ck0001743415:SpvFacilityMember ck0001743415:ScpPrivateCreditIncomeBdcSpvLlcMember ck0001743415:JpmorganChaseBankMember 2019-01-01 2019-03-31 0001743415 ck0001743415:SpvFacilityMember ck0001743415:LondonInterbankOfferedRateMember 2019-03-31 2019-03-31 0001743415 ck0001743415:SpvFacilityMember ck0001743415:ScpPrivateCreditIncomeBdcSpvLlcMember ck0001743415:JpmorganChaseBankMember 2019-03-31 2019-03-31 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2019-03-31 0001743415 srt:MinimumMember ck0001743415:SpvFacilityMember 2019-03-31 0001743415 srt:MaximumMember ck0001743415:SpvFacilityMember 2019-03-31 0001743415 ck0001743415:SpvFacilityMember 2019-11-18 0001743415 ck0001743415:SpvFacilityMember 2021-02-27 0001743415 ck0001743415:SpvFacilityMember 2021-07-16 0001743415 ck0001743415:SpvFacilityMember 2021-08-18 0001743415 ck0001743415:SpvFacilityMember 2021-11-02 0001743415 ck0001743415:SpvFacilityMember 2022-08-03 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2019-06-24 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2021-03-05 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2021-10-04 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-12-28 2022-12-28 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2022-12-28 2022-12-28 0001743415 ck0001743415:SubscriptionFacilityMember ck0001743415:EastWestBankMember 2022-12-28 0001743415 ck0001743415:SpvFacilityMember ck0001743415:ScpPrivateCreditIncomeBdcSpvLlcMember ck0001743415:JpmorganChaseBankMember 2021-08-18 2021-08-18 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2023-06-16 2023-06-30 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember ck0001743415:SlrAmiTopcoBlockerLlcMember 2023-06-16 2023-06-30 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember ck0001743415:AmeriMarkIntermediateHoldingsLlcOneMember 2023-06-16 2023-06-30 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-16 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:BankDebtSeniorSecuredLoansMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:BankDebtSeniorSecuredLoansMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2023-03-31 0001743415 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:BankDebtSeniorSecuredLoansMember 2023-03-31 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:BankDebtSeniorSecuredLoansMember 2021-12-31 0001743415 us-gaap:FairValueInputsLevel3Member ck0001743415:CommonEquityAndEquityInterestsAndWarrantsMember 2021-12-31 0001743415 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember ck0001743415:AmeriMarkIntermediateHoldingsLlcOneMember 2023-06-15 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember ck0001743415:SlrAmiTopcoBlockerLlcMember 2023-06-15 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-15 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2023-06-15 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember 2023-06-30 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember ck0001743415:SlrAmiTopcoBlockerLlcMember 2023-06-30 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember ck0001743415:AmeriMarkIntermediateHoldingsLlcOneMember 2023-06-30 0001743415 us-gaap:InvestmentAffiliatedIssuerNoncontrolledMember ck0001743415:AmerimarkIntermediateHoldingsLlcMember 2023-06-30 pure shares iso4217:USD iso4217:USD shares false 0001743415 Q2 --12-31 NY 10-Q true 2023-06-30 2023 false 814-01294 SCP Private Credit Income BDC LLC DE 83-0634992 500 Park Avenue New York 10022 212 993-1670 Yes Yes Non-accelerated Filer false true false false 25190253 505230000 529070000 509719000 532895000 21595000 0 12750000 0 13060000 16697000 3625000 3647000 99000 0 86000 22000 539339000 553261000 236500000 267726000 700000 1392000 235800000 266334000 26800000 70400000 115000 185000 26685000 70215000 0 10825000 2136000 519000 2039000 4025000 105000 108000 4731000 4041000 617000 940000 272113000 357007000 25190253 25190253 18992563 18992563 261160000 196160000 6066000 94000 267226000 196254000 539339000 553261000 10.61 10.33 15248000 9573000 29636000 18095000 63000 45000 467000 170000 15311000 9618000 30103000 18265000 1078000 889000 2136000 1760000 1582000 736000 1054000 1586000 105000 93000 210000 181000 5694000 3215000 12102000 5804000 256000 246000 522000 451000 8715000 5179000 16024000 9782000 6596000 4439000 14079000 8483000 74000 0 74000 0 4362000 -264000 -6110000 507000 -2071000 0 -2071000 0 2291000 -264000 -8181000 507000 2365000 -264000 -8107000 507000 8961000 4175000 5972000 8990000 0.36 0.24 0.25 0.52 6596000 4439000 14079000 8483000 74000 0 74000 0 2291000 -264000 -8181000 507000 8961000 4175000 5972000 8990000 0 0 0 0 0 20000000 65000000 20000000 0 20000000 65000000 20000000 8961000 24175000 70972000 28990000 258265000 180928000 196254000 176113000 267226000 205103000 267226000 205103000 0 1855288 6197690 1855288 0 1855288 6197690 1855288 5972000 8990000 74000 0 -8181000 507000 -63726000 -71185000 -1578000 -1121000 68597000 33514000 974000 239000 99000 78000 -22000 376000 64000 74000 1617000 1760000 -1986000 -739000 -3000 14000 690000 802000 -323000 264000 -794000 -838000 17046000 -28137000 65000000 20000000 10825000 7277000 35168000 72500000 110026000 57200000 -20683000 28023000 -3637000 -114000 16697000 11181000 13060000 11067000 11412000 5002000 Diversified Financial Services S+705 0.01 0.1231 2021-12-24 2028-08-21 12660000 12453000 12660000 Pharmaceuticals S+515 0.046 0.1032 2019-12-31 2028-05-01 5893000 5905000 5893000 Trading Companies & Distributors S+575 0.01 0.1125 2021-09-01 2026-09-01 5191000 5124000 5191000 Internet & Catalog Retail S+800 0.01 0 2021-07-28 2026-10-15 16488000 15017000 4516000 Internet & Catalog Retail P+475 0.01 0.13 2023-06-16 2023-08-04 408000 408000 408000 Diversified Consumer Services S+525 0.01 0.1055 2021-11-05 2025-07-31 20699000 20449000 20699000 Pharmaceuticals L+745 0.001 0.1261 2021-12-22 2027-01-01 24520000 24847000 24827000 Pharmaceuticals S+795 0.01 0.1315 2022-02-23 2027-03-01 3319000 3346000 3352000 Specialty Retail S+650 0.01 0.1204 2020-10-30 2023-10-30 960000 959000 960000 Health Care Providers & Services S+500 0.01 0.105 2021-06-29 2027-06-11 15782000 15666000 15782000 Biotechnology 0 0 0.09 2021-11-17 2026-11-17 14581000 14523000 14581000 Diversified Consumer Services S+575 0.0075 0.1125 2021-06-29 2028-06-29 12609000 12441000 12609000 Pharmaceuticals L+725 0.0245 0.1241 2019-06-28 2024-01-01 1246000 1371000 1401000 Biotechnology S+620 0.0275 0.1137 2022-12-27 2028-01-01 9698000 9704000 9722000 Capital Markets S+700 0.01 0.1193 2020-12-29 2025-12-29 9257000 9083000 9257000 Trading Companies & Distributors S+475 0.01 0.1009 2019-12-31 2025-12-31 7143000 7079000 7143000 IT Services S+450 0 0.097 2020-01-31 2025-07-30 14096000 13936000 14096000 Building Products S+475 0.01 0.1034 2021-08-05 2027-07-30 11089000 10949000 11089000 Health Care Providers & Services S+650 0.01 0.1163 2023-01-04 2029-01-03 10330000 10038000 10330000 Personal Products S+625 0.01 0.1147 2021-02-12 2027-02-12 11876000 11680000 11876000 Health Care Technology L+790 0.001 0.1306 2021-09-30 2026-10-01 2831000 2850000 2852000 Leisure Equipment & Products S+500 0.01 0.105 2021-04-20 2026-11-16 13998000 13904000 13858000 Insurance S+525 0.01 0.1045 2020-11-25 2026-11-25 8089000 8012000 8089000 Insurance S+600 0.0075 0.1079 2021-04-16 2028-04-16 11886000 11698000 11886000 Internet Software & Services S+785 0.01 0.1301 2022-06-30 2027-07-01 6799000 6717000 6799000 Software S+725 0.0075 0.1238 2022-08-18 2028-08-18 13974000 13759000 13974000 Software S+575 0.0075 0.1135 2022-06-22 2029-06-23 11006000 10860000 11006000 Software S+575 0.01 0.1114 2021-09-24 2027-10-01 12394000 12207000 12394000 Wireless Telecommunication Services S+550 0 0.1084 2019-03-12 2024-12-21 14030000 13945000 14030000 Specialty Retail S+675 0.01 0.0978 2021-08-27 2024-06-01 5286000 5265000 5286000 Health Care Equipment & Supplies S+550 0.0345 0.1067 2022-12-20 2027-12-01 1212000 1208000 1212000 Software S+550 0.01 0.1083 2019-07-23 2026-02-10 15230000 15120000 15230000 Health Care Equipment & Supplies S+565 0.0395 0.1082 2020-03-02 2028-03-29 3274000 3272000 3282000 Professional Services L+550 0.0075 0.1082 2021-12-13 2027-12-06 5411000 5338000 5411000 Health Care Providers & Services S+650 0.01 0.1166 2022-08-17 2024-05-16 5672000 5646000 5672000 Health Care Equipment & Supplies S+515 0.0275 0.1032 2022-11-03 2027-11-01 11865000 11859000 11865000 Health Care Providers & Services S+625 0.01 0.1145 2022-08-19 2024-12-04 2685000 2653000 2685000 Insurance S+600 0.0075 0.1122 2021-10-29 2028-11-01 15500000 15375000 15500000 Health Care Providers & Services S+675 0.01 0.1216 2020-01-22 2026-01-02 8297000 8208000 8297000 Health Care Providers & Services S+500 0.01 0.1044 2021-08-26 2027-08-18 15135000 14971000 15135000 Life Sciences Tools & Services S+575 0.01 0.1151 2021-08-20 2026-08-12 15601000 15443000 15601000 Insurance S+550 0.0075 0.1064 2020-10-05 2026-11-01 18183000 17962000 18183000 Diversified Consumer Services S+500 0.01 0.1015 2020-03-17 2026-03-13 14562000 14432000 14562000 Health Care Providers & Services S+600 0.01 0.115 2022-06-03 2026-01-27 3791000 3758000 3791000 Biotechnology S+570 0.023 0.1087 2022-09-21 2027-09-01 3559000 3776000 3835000 Health Care Equipment & Supplies S+575 0.0075 0.1109 2021-06-16 2028-06-16 7643000 7542000 7643000 Health Care Providers & Services L+525 0.01 0.1059 2021-02-12 2027-02-12 9008000 8918000 8557000 Trading Companies & Distributors S+600 0.01 0.1139 2021-12-08 2026-12-31 12557000 12443000 12557000 Road & Rail S+450 0.01 0.0964 2021-10-27 2024-12-18 5581000 5528000 5581000 Packaged Foods & Meats S+625 0.01 0.1145 2021-08-12 2027-08-13 7593000 7454000 7593000 Health Care Equipment & Supplies S+930 0.01 0.1457 2022-02-18 2027-02-01 12608000 12709000 12766000 Water Utilities S+450 0.01 0.0956 2021-09-03 2026-11-02 3742000 3711000 3742000 Insurance S+575 0.01 0.1099 2020-10-12 2026-04-01 19265000 18966000 19265000 520487000 514531000 Pharmaceuticals 2019-06-28 56483000 27000 10000 Health Care Equipment & Supplies 2022-12-20 10572000 8000 7000 Health Care Equipment & Supplies 2019-07-25 79501000 23000 61000 Internet & Catalog Retail 2023-06-16 0 6170000 7826000 Biotechnology 2022-09-21 53930000 17000 27000 Health Care Equipment & Supplies 2022-02-18 72556000 93000 7000 6338000 7938000 526825000 522469000 -255243000 267226000 0.03 0.03875 0.09 9108000 6687000 15795000 531577000 0.065 8243000 0 0 0 -3727000 0 4516000 0 408000 0 0 0 0 408000 6170000 0 0 0 1656000 0 7826000 14413000 408000 0 0 -2071000 0 12750000 0.025 0.14 0.134 0.101 0.092 0.07 0.068 0.054 0.048 0.03 0.027 0.027 0.026 0.024 0.024 0.023 0.021 0.018 0.015 0.013 0.012 0.011 0.01 0.007 0.005 1 Diversified Financial Services S+705 0.01 0.1138 2021-12-24 2028-08-21 12660000 12437000 12660000 Pharmaceuticals L+765 0.0178 0.1182 2019-12-31 2024-07-01 3929000 4059000 4145000 Trading Companies & Distributors S+575 0.01 0.1019 2021-09-01 2026-09-01 5358000 5279000 5358000 Internet & Catalog Retail L+800 0.01 0.1477 2021-07-28 2026-10-15 21189000 20858000 20129000 Diversified Consumer Services S+525 0.01 0.0942 2021-11-05 2025-07-31 21450000 21134000 21450000 Pharmaceuticals L+745 0.001 0.1162 2021-12-22 2027-01-01 24520000 24654000 24827000 Pharmaceuticals L+795 0.001 0.1212 2022-02-23 2027-03-01 3319000 3328000 3328000 Specialty Retail L+550 0.01 0.1027 2020-10-30 2023-10-30 966000 961000 966000 Health Care Providers & Services L+500 0.01 0.0973 2021-06-29 2027-06-11 15861000 15733000 15861000 Biotechnology 0 0 0.09 2021-11-17 2026-11-17 14362000 14257000 14362000 Diversified Consumer Services L+575 0.0075 0.1048 2021-06-29 2028-06-29 6491000 6407000 6491000 Pharmaceuticals L+725 0.0245 0.1142 2019-06-28 2024-01-01 2314000 2417000 2453000 Biotechnology S+620 0.0275 0.1052 2022-12-27 2028-01-01 9698000 9674000 9673000 Capital Markets L+700 0.01 0.1013 2020-12-29 2025-12-29 7503000 7352000 7503000 Trading Companies & Distributors S+475 0.01 0.0943 2019-12-31 2025-12-31 7570000 7490000 7570000 IT Services L+450 0 0.0888 2020-01-31 2025-07-30 14454000 14252000 14454000 Building Products S+475 0.01 0.0979 2021-08-05 2027-07-30 11381000 11222000 11381000 Personal Products L+550 0.01 0.1015 2021-02-12 2027-02-12 12288000 12063000 12288000 Health Care Technology L+790 0.001 0.1207 2021-09-30 2026-10-01 2831000 2838000 2838000 Leisure Equipment & Products S+500 0.01 0.0903 2021-04-20 2026-11-16 14069000 13961000 13928000 Insurance L+525 0.0075 0.0963 2020-11-25 2026-11-25 8130000 8043000 8130000 Insurance L+600 0.0075 0.0875 2021-04-16 2028-04-16 11606000 11408000 11606000 Internet Software & Services S+785 0.01 0.1197 2022-06-30 2027-07-01 6799000 6690000 6799000 Software S+725 0.0075 0.1152 2022-08-18 2028-08-18 13757000 13527000 13517000 Health Care Providers & Services L+625 0.01 0.1039 2021-12-22 2026-02-25 10515000 10369000 10620000 Software S+575 0.0075 0.1033 2022-06-22 2029-06-23 10966000 10810000 10966000 Software L+575 0.01 0.1048 2021-09-24 2027-10-01 12457000 12251000 12457000 Wireless Telecommunication Services S+550 0 0.1008 2019-03-12 2024-12-21 14104000 13992000 14104000 Specialty Retail S+675 0.01 0.0874 2021-08-27 2024-06-01 4947000 4891000 4947000 Health Care Equipment & Supplies S+550 0.0345 0.0982 2022-12-20 2027-12-01 1212000 1201000 1209000 Software L+550 0.01 0.1023 2019-07-23 2026-02-10 15308000 15180000 15308000 Insurance S+525 0.01 0.0945 2021-07-30 2024-09-28 12461000 12355000 12461000 Health Care Equipment & Supplies L+765 0.0166 0.1182 2020-03-02 2025-02-28 3056000 3143000 3224000 Professional Services L+550 0.0075 0.1022 2021-12-13 2027-12-06 5947000 5858000 5947000 Health Care Providers & Services S+625 0.01 0.1092 2022-11-29 2024-05-10 2206000 2164000 2162000 Health Care Providers & Services S+650 0.01 0.1091 2022-08-17 2024-05-16 4226000 4200000 4226000 Health Care Equipment & Supplies S+515 0.0275 0.0933 2022-11-03 2027-11-01 11865000 11796000 11775000 Health Care Providers & Services S+625 0.01 0.1067 2022-08-19 2024-12-04 1802000 1778000 1784000 Insurance S+600 0.0075 0.1121 2021-10-29 2028-11-01 15579000 15444000 15579000 Health Care Providers & Services S+650 0.01 0.1057 2020-01-22 2026-01-02 8339000 8233000 8152000 Health Care Providers & Services S+500 0.01 0.0989 2021-08-26 2027-08-18 12117000 11967000 12117000 Personal Products P+475 0.0275 0.1225 2021-05-07 2023-06-17 13905000 13876000 13974000 Life Sciences Tools & Services S+575 0.01 0.1059 2021-08-20 2026-08-12 15680000 15499000 15680000 Insurance S+550 0.0075 0.0926 2020-10-05 2026-11-01 9345000 9191000 9345000 Diversified Consumer Services L+500 0.01 0.0941 2020-03-17 2026-03-13 14674000 14522000 14674000 Health Care Providers & Services S+600 0.01 0.1084 2022-06-03 2026-01-27 1901000 1884000 1901000 Biotechnology S+570 0.023 0.0988 2022-09-21 2027-09-01 3559000 3519000 3524000 Health Care Equipment & Supplies L+575 0.0075 0.1048 2021-06-16 2028-06-16 7929000 7815000 7929000 Health Care Providers & Services L+525 0.01 0.0998 2021-02-12 2027-02-12 9013000 8912000 8968000 Trading Companies & Distributors S+550 0.01 0.1014 2021-12-08 2026-12-31 12762000 12633000 12762000 Road & Rail L+450 0.01 0.0891 2021-10-27 2024-12-18 4198000 4150000 4198000 Packaged Foods & Meats L+650 0.01 0.1088 2021-08-12 2027-08-13 7877000 7717000 7877000 Health Care Equipment & Supplies S+830 0.01 0.1258 2022-02-18 2027-02-01 12070000 12076000 12131000 Water Utilities L+450 0.01 0.0787 2021-09-03 2026-11-02 2207000 2189000 2206000 Insurance S+575 0.01 0.1007 2020-10-12 2026-04-01 19614000 19261000 18829000 528920000 532753000 Pharmaceuticals 2019-06-28 56483000 27000 16000 Health Care Equipment & Supplies 2022-12-20 10572000 8000 8000 Health Care Equipment & Supplies 2019-07-25 79501000 23000 82000 Biotechnology 2022-09-21 53930000 17000 5000 Health Care Equipment & Supplies 2022-02-18 12960000 75000 31000 150000 142000 529070000 532895000 -336641000 196254000 0.08 0.03 0.03875 0.08 927000 5202000 6129000 533822000 0.143 0.124 0.098 0.08 0.068 0.065 0.052 0.049 0.048 0.038 0.029 0.027 0.027 0.026 0.024 0.021 0.015 0.014 0.013 0.011 0.011 0.008 0.005 0.004 1 <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Note 1. Organization </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”) is a Delaware limited liability company formed on <div style="letter-spacing: 0px; top: 0px;;display:inline;">May 18, 2018</div>. The Company has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (“the 1940 Act”). Furthermore, as the Company is an investment company, it applies the guidance in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 946. In addition, for U.S. federal income tax purposes, the Company has elected to be treated, and intends to qualify annually, as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). The Company was formed primarily to provide investors with attractive long-term returns through investments made pursuant to the investment strategy of the Company described below (the Company’s investments in portfolio companies are referred to herein as “Portfolio Investments”). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 5, 2018 (the “Initial Closing Date”), the Company closed on $326,000 in capital commitments. On March 12, 2019, the sale and issuance of 2,800,000 units, at an aggregate purchase price of $28,000 ($10.00 per unit) occurred and the Company commenced operations. As of June 30, 2023, $261,500 of capital commitments were drawn and $64,500 were unfunded. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has implemented a corporate lending strategy focused on sourcing, underwriting and managing a diverse portfolio of private senior secured loans primarily to upper middle market companies (generally,<div style="display:inline;"> </div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">aggregate<div style="display:inline;"> </div></div></div>loan sizes of $100,000 to $300,000 to companies with earnings before interest, tax, depreciation and amortization (“EBITDA”) between approximately $25,000 and $100,000) across the United States. In addition to senior secured loans to upper middle market companies, the Company intends to invest a portion of its assets in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-traditional</div> asset-based loans and first lien loans to rapidly growing healthcare companies. The Company also expects that some of its investments will contain delayed-draw term loan type features and/or other types of unfunded commitments. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering period of the Company ended on April 5, 2019 (the “Offering Period”). The investment period of the Company ended on December 31, 2022. The term of the Company will be six years from the end of the Offering Period unless the Company is liquidated earlier as set forth in the Limited Liability Company Agreement of the Company (as amended, restated or otherwise modified from time to time, the “LLC Agreement”), but may be extended by the board of directors for up to two consecutive one year periods upon approval of the Company’s independent directors and the approval of unitholders of the Company (“Unitholders”), which approval will be obtained through a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-1940</div> Act vote as described in the LLC Agreement. The Company may be dissolved and its affairs wound up prior to the end of the term under the circumstances set forth in the LLC Agreement. The fiscal year end of the Company is December 31.</div> 326000000 2800000 28000000 10 261500000 64500000 100000000 300000000 25000000 100000000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Note 2. Summary of Significant Accounting Policies </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in conformity with U.S. generally accepted accounting principles (“GAAP”), and include the accounts of the Company and certain wholly-owned subsidiaries. The consolidated financial statements reflect all adjustments and reclassifications which, in the opinion of management, are necessary for the fair presentation of the results of the operations and financial condition for the periods presented. All significant intercompany balances and transactions have been eliminated. Certain prior period amounts may have been reclassified to conform to current period presentation. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interim consolidated financial statements are prepared in accordance with GAAP for interim financial information and pursuant to the requirements for reporting on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X,</div> as appropriate. Accordingly, they may not include all of the information and notes required by GAAP for annual consolidated financial statements. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported periods. Changes in the economic environment, financial markets and any other parameters used in determining these estimates could cause actual results to differ materially. The current period’s results of operations will not necessarily be indicative of results that ultimately may be achieved for the fiscal year ending on December 31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the opinion of management, all adjustments which are of a normal recurring nature considered necessary for the fair presentation of financial statements, have been included. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant accounting policies consistently followed by the Company are: </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(a)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Investment transactions are accounted for on the trade date; </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(b)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In accordance with GAAP and the 1940 Act, the Company’s assets will generally be valued as follows: </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:13%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(i)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">securities or other instruments (other than as referred to in clauses (ii) and (iii) below) for which market quotes are readily available and deemed to represent fair value under GAAP will be valued based on quotes obtained from a quotation reporting system, market makers or pricing services (when deemed to represent fair value under GAAP). A market quotation is readily available for a security only when that quotation is a quoted price (unadjusted) in active markets for identical investments that the Company can access at the measurement date, provided that a quotation will not be readily available if it is not reliable. If the Company anticipates using a market quotation for a security, it will also monitor for circumstances that may necessitate the use of fair value, such as significant events that may cause concern over the reliability of a market quotation; </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:13%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(ii)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">exchange-traded options, futures and options on futures will be valued at the settlement price determined by the exchange or through the use of a model such as Black-Scholes; </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:13%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(iii)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">short-term investments with maturities of sixty (60) days or less generally will be valued at amortized cost; and </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:13%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(iv)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">securities, loans or other instruments for which market quotes are not readily available or reliable under GAAP will be valued as described below: </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:18%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">a.</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;;text-indent: 0px;">the quarterly valuation process begins with each portfolio company or investment being initially valued by the investment professionals of SLR responsible for the Portfolio Investment;  </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:18%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">b.</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">preliminary valuation conclusions are then documented and discussed with senior management of the Adviser; </div></td></tr></table><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:18%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">c.</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the audit committee of the Board of Directors ( the “Board”) reviews the preliminary valuations of the Adviser and third party valuation specialist, if any, and responds to the valuation recommendations to reflect any comments; and </div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:18%"> </td> <td style="width:4%;vertical-align:top;text-align:left;">d.</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the Board discusses valuations and determines the fair value of each investment in the Company’s portfolio in good faith based on the input of the Adviser, the audit committee, and third party valuation specialist, if any, which may from time to time be engaged by the Board. </div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The valuation principles set forth above may be modified from time to time without notice to Unitholders, in whole or in part, as determined by the Board in its sole discretion. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Board will also (1) periodically assess and manage valuation risks; (2) establish and apply fair value methodologies; (3) test fair value methodologies; (4) oversee and evaluate third-party pricing services, as applicable; (5) oversee the reporting required by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-5</div> under the 1940 Act; and (6) maintain recordkeeping requirements under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-5.</div> </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">When an external event such as a purchase transaction, public offering or subsequent equity sale occurs, the Company will consider the pricing indicated by the external event to corroborate the valuation. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Investments are valued utilizing a market approach, an income approach, or both approaches, as appropriate. However, in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">820-10,</div> certain investments that qualify as investment companies in accordance with ASC 946, may be valued using net asset value as a practical expedient for fair value. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities (including a business). The income approach uses valuation approaches to convert future amounts (for example, cash flows or earnings) to a single present amount (discounted). The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that we may take into account in fair value pricing our investments include, as relevant: available current market data, including relevant and applicable market trading and transaction comparables, applicable market yields and multiples, security covenants, call protection provisions, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, the markets in which the portfolio company does business, comparisons of financial ratios of peer companies that are public, M&amp;A comparables, and enterprise values, among other factors. When available, broker quotations and/or quotations provided by pricing services are considered as an input in the valuation process. For the six months ended June 30, 2023, there has been no change to the Company’s valuation approaches or techniques and the nature of the related inputs considered in the valuation process. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">ASC Topic 820 classifies the inputs used to measure these fair values into the following hierarchy: </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Level</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> 1</div>: Unadjusted quoted prices in active markets for identical assets or liabilities, accessible by the Company at the measurement date. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Level</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> 2</div>: Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other observable inputs other than quoted prices. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Level</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"> 3</div>: Unobservable inputs for the asset or liability. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">In all cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls is determined based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to each investment. The exercise of judgment is based in part on our knowledge of the asset class and our prior experience. </div><div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(c)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Gains or losses on investments are calculated by using the specific identification method. </div></td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(d)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Company records dividend income and interest, adjusted for amortization of premium and accretion of discount, on an accrual basis. Loan origination fees, original issue discount, and market discounts are capitalized and we amortize such amounts into income using the effective interest method. Upon the prepayment of a loan, any unamortized loan origination fees are recorded as interest income. We record call premiums on loans repaid as interest income when we receive such amounts. Capital structuring fees, amendment fees, consent fees, and any other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-recurring</div> fee income as well as management fee and other fee income for services rendered, if any, are recorded as other income when earned. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(e)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Company intends to comply with the applicable provisions of the Code pertaining to <div style="null;text-indent: 0px;;display:inline;">RICs</div> to make distributions of taxable income sufficient to relieve it of substantially all U.S. federal income taxes. The Company, at its discretion, may carry forward taxable income in excess of calendar year distributions and pay a 4% excise tax on this income. The Company will accrue excise tax on such estimated excess taxable income as appropriate. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(f)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Book and tax basis differences relating to Unitholder distributions and other permanent book and tax differences are typically reclassified among the Company’s capital accounts annually. In addition, the character of income and gains to be distributed is determined in accordance with income tax regulations that may differ from GAAP. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(g)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Distributions to Unitholders are recorded as of the record date. The amount to be paid out as a distribution is determined by the Board. Net realized capital gains, if any, are generally distributed or deemed distributed at least annually. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(h)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In accordance with Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> and ASC Topic 810—<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consolidation</div></div>, the Company consolidates its interest in controlled investment company subsidiaries, financing subsidiaries and certain wholly-owned holding companies that serve to facilitate investment in portfolio companies. In addition, the Company may also consolidate any controlled operating companies substantially all of whose business consists of providing services to the Company. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(i)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The accounting records of the Company are maintained in U.S. dollars. Any assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the rate of exchange of such currencies against the U.S. dollar on the date of valuation. The Company will not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. Such fluctuations would be included with the net unrealized gain or loss from investments. The Company’s investments in foreign securities, if any, may involve certain risks, including without limitation: foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments in terms of U.S. dollars and therefore the earnings of the Company. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(j)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">In accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">835-30,</div> the Company reports origination and other expenses related to certain debt issuances, if any, as a direct deduction from the carrying amount of the debt liability. Applicable expenses are deferred and amortized using either the effective interest method or the straight-line method over the stated life. The straight-line method may be used on revolving facilities and/or when it approximates the effective yield method. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(k)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Company records expenses related to applicable equity offering costs as a charge to capital upon the sale of units, in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">946-20-25.</div></div> </div> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(l)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Investments that are expected to pay regularly scheduled interest in cash are generally placed on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accrual</div> status when principal or interest cash payments are past due 30 days or more and/or when it is no longer probable that principal or interest cash payments will be collected. Such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accrual</div> investments are restored to accrual status if past due principal and interest are paid in cash, and in management’s judgment, are likely to continue timely payment of their remaining principal and interest obligations. Cash interest payments received on such investments may be recognized as income or applied to principal depending on management’s judgment. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(m)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Company records expenses directly related to its organization as incurred. </div> </td> </tr> </table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">(n)</td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Company defines cash equivalents as securities that are readily convertible into known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only securities with a maturity of three months or less would qualify, with limited exceptions. The Company believes that certain U.S. Treasury bills, repurchase agreements and other high-quality, short-term debt securities would qualify as cash equivalents. </div> </td> </tr> </table> 0.04 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 3. Agreements and Related Party Transactions </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into an investment management agreement with the Adviser (the “Investment Management Agreement”) pursuant to which it will pay management fees, administrative coordinator fees and incentive fees to the Adviser. The Company will pay the Adviser a fee for investment advisory and management services consisting of two components: a base management fee and an incentive fee. The Company will also pay the Adviser (in its capacity as Administrative Coordinator, defined herein) an administration fee for administrative and coordination services. The cost of the base management fee, the incentive fee, and the administration fee will be borne by the Unitholders. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Management Fees and Administration Fees </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will pay the Adviser a management fee (the “Management Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (each such date, the “Management Fee Calculation Date”), in an amount equal to 1.5% per annum of Invested Capital (defined as, as of any date, the sum of (i) capital contributions to the Company plus (ii) the total amount of credit drawn on subscription credit facilities), and payable quarterly in arrears after such Management Fee Calculation Date. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Investment Management Agreement, the Adviser has also been appointed to provide administrative and coordination services to the Company (in such capacity, the “Administrative Coordinator”). The Company will pay the Administrative Coordinator, a fee (the “Administration Fee”), calculated as of the close of business in New York, New York on the last day of each calendar quarter (the “Administration Fee Calculation Date”), in an amount equal to 0.08% per annum of the average Cost Basis (defined as the aggregate accreted and amortized cost of all <div style="null;text-indent: 0px;;display:inline;">Portfolio Investments</div>, including any amounts reinvested in investments and the cost of investments acquired using leverage), as measured on the last day of the preceding quarter and the last day of the current quarter for the period ended and payable quarterly in arrears after such Administration Fee Calculation Date. The Administrative Coordinator will be responsible for all expenses of its own staff responsible for (i) certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">on-going,</div> routine, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-investment-related</div> administrative services for the Company, (ii) the coordination of various third party services needed or required by the Company and (iii) certain Unitholder servicing functions. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Management Fee and the Administration Fee will be appropriately adjusted for any stub period. Such fees will be paid out of net current income and/or disposition proceeds or, to the extent such amounts are not available, from unfunded capital commitments that will be drawn down, or borrowings of the Company. In the event that the Adviser arranges for the Company to pay any portion of a placement fee to a placement agent, the amount of <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Management Fees</div> otherwise payable shall be reduced by an amount equal to 100% of such payment to the placement agent. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentive Fee </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will make distributions out of two categories: Current Proceeds and Disposition Proceeds (collectively referred to as “Investment Proceeds”). “Disposition Proceeds” means all amounts received by the Company upon the disposition of an investment, including full or partial repayments or amortization of principal (but excluding Current Proceeds). “Current Proceeds” means all proceeds from investments, including interest income, fee income, warrant gains, prepayment fees and exit fees, other than Disposition Proceeds. The Adviser will apportion each Unitholder’s pro rata share of Investment Proceeds between Disposition Proceeds and Current Proceeds. Amounts of Investment Proceeds apportioned to Unitholders will be divided between and distributed to Unitholders, on the one hand, and the Adviser, on the other hand, in the following amounts and order of priority: </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Disposition Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as an <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">incentive fee</div>, on the other hand, in the following amounts and order of priority: </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Return of Capital Contributions</div>. First, 100% to such Unitholder until such Unitholder has received cumulative distributions of Investment Proceeds pursuant to this clause (i)(A) equal to such Unitholder’s total Capital Contributions to the Company (including amounts contributed to pay Management Fees, Administration Fees, Organizational Expenses (as defined below) and other Company expenses); </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Unitholder Preferred Return</div>. Second, 100% of all remaining Disposition Proceeds to Unitholders until they have each received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (B) and clause (D) below and pursuant to clause (ii)(A) and clause (ii)(C) below equal to 6% per annum, compounded annually, on such Unitholder’s unreturned capital contributions to the Company (including amounts contributed to pay Management Fees, Administration Fees, Organizational Expenses and other Company expenses) (the “<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Preferred Return”);</div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Adviser Catch Up to 15%</div>. Third, 80% of all remaining Disposition Proceeds paid to the Adviser as an <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">incentive fee</div> until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (C) and clause (ii)(B) equal to 15% of the total amounts distributed to Unitholders and paid to the Adviser pursuant to clause (B) above and this clause (C) and pursuant to clause (ii)(A) and clause (ii)(B); and </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">85%/15%</div><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> Shares</div>. Thereafter, 85% to Unitholders and 15% paid to the Adviser as an <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">incentive fee.</div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Current Proceeds apportioned to Unitholders shall be divided between and distributed to Unitholders, on the one hand, and paid to the Adviser as an <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">incentive fee</div>, on the other hand, in the following amounts and order of priority: </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Unitholder Preferred Return</div>. First, 100% of all Current Proceeds to Unitholders until Unitholders have received cumulative distributions of Investment Proceeds, without duplication, pursuant to this clause (A) and clause (C) below and pursuant to clause (i)(B) and clause (i)(D) equal to the Preferred Return; </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Adviser Catch Up to 15%</div>. Second, 80% of all remaining Current Proceeds paid to the Adviser as an <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">incentive fee</div> until the Adviser has received payments of Investment Proceeds with respect to Unitholders pursuant to this clause (B) and clause (i)(C) equal to 15% of the total amounts distributed to Unitholders and paid to the Adviser pursuant to clause (A) above and this clause (B) and pursuant to Section clause (i)(B) and clause (i)(C); and </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">85%/15% Units</div>. Thereafter, 85% to Unitholders and 15% paid to the Adviser as an <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">incentive fee.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no event will the Adviser receive amounts attributable to Disposition Proceeds that, as of any distribution or payment date, exceeds 20% of cumulative realized capital gains net of all cumulative realized capital losses and unrealized capital depreciation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adviser has the right with respect to all Unitholders, upon approval of the Company’s independent directors, to waive or reduce the incentive fee to which it is entitled. The Adviser may also elect not to receive all or any portion of the incentive fee that would otherwise be distributed to it, and may cause any or all amounts subsequently available for distribution to the Unitholders to be distributed to the Adviser until it has received the same aggregate amount of incentive fees had it not previously waived receipt of incentive fees. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adviser will be entitled to withhold from any distributions, in its discretion, any required tax withholdings. Amounts of taxes paid or withheld from amounts otherwise distributable to a Unitholder will be deemed distributed for purposes of the calculations above. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon liquidation of the Company, the Adviser will be required to restore funds to the Company for distribution to the Unitholders if and to the extent that the Adviser has received cumulative incentive fees in excess of the incentive fees that would have been payable to the Adviser on an aggregate basis covering all transactions of the Company; provided, however, that in no event will the Adviser be required to contribute an aggregate amount in excess of 100% of the net amount distributed to the Adviser (net of taxes) on account of its incentive fees. In addition, the Adviser will apply an interim incentive fee adjustment at the end of each fiscal year so that, in the event of any over-distribution of incentive fee to the Adviser (measured with respect to each Unitholder using the fair value of the Company’s portfolio at the end of the applicable fiscal year as if the Company were to liquidate on such date), future distributions that would, absent such interim incentive fee adjustment, otherwise be distributed to the Adviser as an incentive fee, shall be distributed to such Unitholder until such over-distribution (net of taxes payable by the Adviser with respect to such incentive fee) has been eliminated. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three and six months ended June 30, 2023, the Company incurred $1,078 and $2,136, respectively, in Management Fees, $105 and $210, respectively, in Administration Fees and $1,582 and $1,054, respectively, in <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">incentive fees</div>. For the three and six months ended June 30, 2022, the Company incurred $889 and $1,760, respectively, in Management Fees, $93 and $181, respectively, in Administration Fees and $736 and $1,586, respectively, in <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">incentive fees.</div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate amount of certain operating expenses relating to Unitholders investing directly in the Company will not exceed the Operating Expense Cap, calculated as follows: (A) if the Company has less than or equal to $400,000 in capital commitments, an amount equal to the sum of (x) the product of the capital commitments and 0.0025 and (y) $1,250, or (B) if the Company has greater than $400,000 in capital commitments, $2,250. Any amount in excess of the Operating Expense Cap for any fiscal year will be paid by the Adviser. For the avoidance of doubt, the Operating Expense Cap will not apply to any fees, costs, expenses and liabilities allocable to persons investing indirectly in the Company through any Unitholder. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adviser or Administrative Coordinator and/or their affiliates has advanced organizational and offering expenses to the Company, which include organizational fees, costs, expenses and liabilities of the Company, including legal expenses, incurred in connection with the initial offering of Units and the formation and establishment of the Company (“Organizational Expenses”). The Adviser or Administrative Coordinator (or such affiliate) has been reimbursed by the Company for such advanced costs and expenses in an amount not to exceed $500. $308 of offering expenses were charged to capital and $84 of organizational costs were expensed in 2019. </div> 0.015 0.0008 1 1 1 0.06 0.80 0.15 0.85 0.15 0.85 0.15 1 0.15 0.80 0.15 0.85 0.15 0.85 0.15 1 1078000 2136000 105000 210000 1582000 1054000 889000 1760000 93000 181000 736000 1586000 400000000 0.0025 1250000 400000000 2250000 500000 308000 84000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 4. Fair Value </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a framework for measuring fair value that includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement. The levels of the fair value hierarchy are as follows: </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 1.</div></div> Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the Company has the ability to access. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2.</div></div> Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">a)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Quoted prices for similar assets or liabilities in active markets; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">b)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Quoted prices for identical or similar assets or liabilities in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-active</div> markets; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">c)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Pricing models whose inputs are observable for substantially the full term of the asset or liability; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%"> </td> <td style="width:5%;vertical-align:top;text-align:left;">d)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the asset or liability. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 3. </div></div>Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s and, if applicable, an independent third-party valuation firm’s own assumptions about the assumptions a market participant would use in pricing the asset or liability. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement in its entirety. For example, a Level 3 fair value measurement may include inputs that are observable (Levels 1 and 2) and unobservable (Level 3). </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gains and losses for assets and liabilities categorized within the Level 3 table below may include changes in fair value that are attributable to both observable inputs (Levels 1 and 2) and unobservable inputs (Level 3). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. Such reclassifications involving Level 3 assets and liabilities are reported as transfers in/out of Level 3 as of the end of the quarter in which the reclassifications occur. Within the fair value hierarchy tables below, cash and cash equivalents are excluded but could be classified as Level 1. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the balances of assets measured at fair value on a recurring basis, as of June 30, 2023 and December 31, 2022: </div><div style="margin-top: 24pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">As of June 30, 2023 </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:70%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt/Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">514,531</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">514,531</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common Equity/Equity Interests/Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">61</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">7,877</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">7,938</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Investments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">522,408</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">522,469</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at June 30, 2023, the fair value of the SPV Facility and the Subscription Facility would be $236,500 and $26,800, respectively. </div><div style="margin-top: 24pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2022 </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:70%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt/Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common Equity/Equity Interests/Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">82</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">142</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Investments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,895</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at December 31, 2022, the fair value of the SPV Facility and the Subscription Facility would be $267,726 and $70,400, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in fair value of Level 3 assets for the three and six months ended June 30, 2023, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at June 30, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:55%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bank Debt/Senior<br/> Secured Loans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Equity/Equity<br/> Interests/Warrants</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, March 31, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">524,025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">524,069</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total gains or losses included in earnings:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">635</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,652</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,287</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,071</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,181</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,252</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from dispositions of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41,206</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41,206</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers into Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers out of Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, June 30, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">514,531</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,877</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">522,408</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains for the period relating to those Level 3 assets that were still held by the Company at the end of the period:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">731</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,652</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-size:1pt"> <td style="height:12pt"></td> <td colspan="4" style="height:12pt"></td> <td colspan="4" style="height:12pt"></td> <td colspan="4" style="height:12pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bank Debt/Senior<br/> Secured Loans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Equity/Equity<br/> Interests/Warrants</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2022</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total gains or losses included in earnings:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,788</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,629</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,159</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,089</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,188</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66,277</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from dispositions of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(68,529</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(68,529</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers into Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers out of Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, June 30, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">514,531</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,877</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">522,408</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,563</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,629</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,934</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in fair value of Level 3 assets for the year ended December 31, 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:55%"></td> <td style="vertical-align:bottom;width:10%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bank Debt/Senior<br/> Secured Loans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Equity/Equity<br/> Interests/Warrants</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2021</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">439,661</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">439,674</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total gains or losses included in earnings:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">340</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">287</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">188,107</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">188,207</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from dispositions of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(95,355</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(95,355</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers into Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers out of Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2022</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">744</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">691</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top: 24pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Quantitative Information about Level 3 Fair Value Measurements </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company typically determines the fair value of its performing debt investments utilizing a yield analysis. In a yield analysis, a price is ascribed for each investment based upon an assessment of current and expected market yields for similar investments and risk profiles. Additional consideration is given to current contractual interest rates, relative maturities and other key terms and risks associated with an investment. Among other factors, a significant determinant of risk is the amount of leverage used by the portfolio company relative to the total enterprise value of the company, and the rights and remedies of our investment within each portfolio company. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant unobservable quantitative inputs typically used in the fair value measurement of the Company’s Level 3 assets and liabilities primarily reflect current market yields, including indices, and readily available quotes from brokers, dealers, and pricing services as indicated by comparable assets and liabilities, as well as enterprise values, returns on equity and earnings before income taxes, depreciation and amortization (“EBITDA”) multiples of similar companies, and comparable market transactions for equity securities. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;background-color:white;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quantitative information about the Company’s Level 3 asset fair value measurements as of June 30, 2023 is summarized in the table below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:42%"></td> <td style="vertical-align:bottom;width:3%"></td> <td style="width:5%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td style="width:15%"></td> <td style="vertical-align:bottom;width:3%"></td> <td style="width:16%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Asset or<br/> Liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value at<br/> June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Principal Valuation<br/> Technique/Methodology</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Unobservable<br/> Input</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range (Weighted<br/> Average)</div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Asset</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">510,015</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Income Approach</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Market Yield</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">9.9% – 20.8% (12.0%)</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,516</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Recovery Analysis</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Recoverable Amount</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">N/A</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common Equity/Equity Interests/Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Asset</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Market Approach</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Volatility</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">17.3% - 17.3% (17.3%)</div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,826</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">EBITDA Multiple</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Comparable Multiple</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">6.25x-7.25x (6.75x)</div></div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bid-ask</div> spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:43%"></td> <td style="vertical-align:bottom;width:4%"></td> <td style="width:5%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td style="width:15%"></td> <td style="vertical-align:bottom;width:4%"></td> <td style="width:10%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Asset or<br/> Liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value at<br/> December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Principal Valuation<br/> Technique/Methodology</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Unobservable<br/> Input</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range (Weighted<br/> Average)</div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Asset</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Income Approach</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Market Yield</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">9.4% – 16.2% (11.4%)</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common Equity/Equity Interests/Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Asset</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Market Approach</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Volatility</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">26.0% - 26.0% (26.0%)</div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bid-ask</div> spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the balances of assets measured at fair value on a recurring basis, as of June 30, 2023 and December 31, 2022: </div><div style="margin-top: 24pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">As of June 30, 2023 </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:70%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt/Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">514,531</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">514,531</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common Equity/Equity Interests/Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">61</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">7,877</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">7,938</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Investments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61</td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">522,408</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">522,469</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Company has not made an election to apply the fair value option of accounting to any of its debt obligations, if the Company’s debt obligations were carried at fair value at June 30, 2023, the fair value of the SPV Facility and the Subscription Facility would be $236,500 and $26,800, respectively. </div><div style="margin-top: 24pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">As of December 31, 2022 </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:70%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bank Debt/Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common Equity/Equity Interests/Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">82</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom;text-align:right;">142</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Investments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td> <td style="white-space:nowrap;vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,895</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 0 0 514531000 514531000 61000 0 7877000 7938000 61000 0 522408000 522469000 236500000 26800000 0 0 532753000 532753000 82000 0 60000 142000 82000 0 532813000 532895000 267726000 70400000 <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in fair value of Level 3 assets for the three and six months ended June 30, 2023, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at June 30, 2023: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:55%"></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:8%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bank Debt/Senior<br/> Secured Loans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Equity/Equity<br/> Interests/Warrants</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, March 31, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">524,025</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">524,069</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total gains or losses included in earnings:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">635</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,652</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,287</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,071</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,181</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,252</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from dispositions of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41,206</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(41,206</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers into Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers out of Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, June 30, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">514,531</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,877</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">522,408</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains for the period relating to those Level 3 assets that were still held by the Company at the end of the period:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">731</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,652</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,383</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-size:1pt"> <td style="height:12pt"></td> <td colspan="4" style="height:12pt"></td> <td colspan="4" style="height:12pt"></td> <td colspan="4" style="height:12pt"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bank Debt/Senior<br/> Secured Loans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Equity/Equity<br/> Interests/Warrants</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2022</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total gains or losses included in earnings:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized gain</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,788</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,629</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,159</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,089</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,188</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66,277</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from dispositions of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(68,529</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(68,529</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers into Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers out of Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, June 30, 2023</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">514,531</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,877</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">522,408</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,563</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,629</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,934</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the changes in fair value of Level 3 assets for the year ended December 31, 2022, as well as the portion of gains or losses included in income attributable to unrealized gains or losses related to those assets still held at December 31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:55%"></td> <td style="vertical-align:bottom;width:10%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bank Debt/Senior<br/> Secured Loans</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Equity/Equity<br/> Interests/Warrants</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2021</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">439,661</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">439,674</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total gains or losses included in earnings:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">340</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">287</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">188,107</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">188,207</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from dispositions of investment securities</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(95,355</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(95,355</td> <td style="white-space:nowrap;vertical-align:bottom">) </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers into Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers out of Level 3</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair value, December 31, 2022</div></div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,813</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized gains (losses) for the period relating to those Level 3 assets that were still held by the Company at the end of the period:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net change in unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">744</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">691</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 524025000 44000 524069000 6000 0 6000 635000 1652000 2287000 31071000 6181000 37252000 -41206000 0 -41206000 0 0 0 0 0 0 514531000 7877000 522408000 731000 1652000 2383000 532753000 60000 532813000 6000 0 6000 -9788000 1629000 -8159000 60089000 6188000 66277000 -68529000 0 -68529000 0 0 0 0 0 0 514531000 7877000 522408000 -9563000 1629000 -7934000 439661000 13000 439674000 0 0 0 340000 -53000 287000 188107000 100000 188207000 -95355000 0 -95355000 0 0 0 0 0 0 532753000 60000 532813000 744000 -53000 691000 <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quantitative information about the Company’s Level 3 asset fair value measurements as of June 30, 2023 is summarized in the table below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:42%"></td> <td style="vertical-align:bottom;width:3%"></td> <td style="width:5%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td style="width:15%"></td> <td style="vertical-align:bottom;width:3%"></td> <td style="width:16%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Asset or<br/> Liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value at<br/> June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Principal Valuation<br/> Technique/Methodology</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Unobservable<br/> Input</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range (Weighted<br/> Average)</div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Asset</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">510,015</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Income Approach</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Market Yield</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">9.9% – 20.8% (12.0%)</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,516</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Recovery Analysis</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Recoverable Amount</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">N/A</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common Equity/Equity Interests/Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Asset</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Market Approach</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Volatility</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">17.3% - 17.3% (17.3%)</div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,826</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">EBITDA Multiple</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Comparable Multiple</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">6.25x-7.25x (6.75x)</div></div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant increases or decreases in any of the above unobservable inputs in isolation, including unobservable inputs used in deriving <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bid-ask</div> spreads, if applicable, would result in a significantly lower or higher fair value measurement for such assets. Generally, an increase in market yields may result in a decrease in the fair value of certain of the Company’s investments. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quantitative information about the Company’s Level 3 asset fair value measurements as of December 31, 2022 is summarized in the table below: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:43%"></td> <td style="vertical-align:bottom;width:4%"></td> <td style="width:5%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:4%"></td> <td style="width:15%"></td> <td style="vertical-align:bottom;width:4%"></td> <td style="width:10%"></td> <td style="vertical-align:bottom;width:4%"></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Asset or<br/> Liability</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value at<br/> December 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Principal Valuation<br/> Technique/Methodology</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Unobservable<br/> Input</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range (Weighted<br/> Average)</div></div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Senior Secured Loans</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Asset</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">532,753</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Income Approach</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Market Yield</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">9.4% – 16.2% (11.4%)</td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common Equity/Equity Interests/Warrants</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Asset</td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Market Approach</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Volatility</td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">26.0% - 26.0% (26.0%)</div></td></tr></table> 510015000 9.9 20.8 12 4516000 51000 17.3 17.3 17.3 7826000 6.25 7.25 6.75 532753000 9.4 16.2 11.4 60000 26 26 26 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 5. Debt </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SPV Facility</div></div>—During the first quarter of 2019, the Company, through its wholly-owned subsidiary, SCP Private Credit Income BDC SPV LLC (the “SPV”), entered into the $100,000 SPV Facility with JPMorgan Chase Bank, N.A. acting as administrative agent. The commitment can also be expanded up to $400,000. The stated interest rate on the SPV Facility is SOFR plus 2.90% with no floor requirement and the current final maturity date is December 31, 2023. The fee on undrawn commitments is generally 0.875%. The SPV Facility is secured by all of the assets held by the SPV. Under the terms of the SPV Facility, the Company and SPV, as applicable, have made certain customary representations and warranties, and are required to comply with various covenants, including leverage restrictions, reporting requirements and other customary requirements for similar credit facilities. The SPV also includes usual and customary events of default for credit facilities of this nature. On November 18, 2019, the Company amended the SPV Facility, reducing commitments to $75,000. On February 27, 2021, the Company again amended the SPV Facility, increasing commitments to $100,000. On July 16, 2021, the Company entered into an amended SPV Facility, which increased commitments to $125,000, and on August 18, 2021 entered into a second amended SPV Facility which increased commitments to $200,000 and extended the final maturity date to December 31, 2023. On November 2, 2021, the Company entered into Amendment No. 1 to the second amended SPV Facility, which increased commitments to $275,000. On August 3, 2022, the Company entered into Amendment No. 2 to the second amended SPV Facility, which increased commitments to $300,000 and changed the interest rate to a SOFR-based calculation. There were $236,500 of borrowings outstanding as of June 30, 2023 under the SPV Facility. Effective with the end of the Investment Period on December 31, 2022, future advances are no longer permitted. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subscription Facility</div></div>—During the first quarter of 2019, the Company established the $35,000 Subscription Facility with East West Bank, and subsequently entered into an amendment on June 24, 2019, which increased commitments from $35,000 to $50,000. On March 5, 2021, the Company entered into a second amendment. Under the second amendment, commitments were increased from $50,000 to $75,000 and the maturity date was extended. On October 4, 2021, the Company entered into an amended and restated loan and security agreement, which increased commitments to $100,000 and the maturity date was extended. On December 28, 2022, the Company entered into the first amendment to the amended and restated loan and security agreement, extending the maturity date to December 31, 2023, reducing commitments to $75,000 and the stated interest rate is SOFR plus 2.80%. Under the terms of the Subscription Facility, the Company has made certain customary representations and warranties, and is required to comply with various covenants, including reporting requirements and other customary requirements for similar credit facilities. The Subscription Facility also includes usual and customary events of default for credit facilities of this nature. There were $26,800 of borrowings outstanding as of June 30, 2023 under the Subscription Facility. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The average annualized interest cost for borrowings for the six months ended June 30, 2023 and the year ended December 31, 2022 was 7.93% and 4.67%, respectively. These costs are exclusive of other credit facility expenses such as unused fees and fees paid to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">back-up</div> servicer, if any. The maximum amount borrowed on the credit facilities during the six months ended June 30, 2023 and the year ended December 31, 2022 was $338,126 and $343,350, respectively. </div> 100000000 400000000 0.029 2023-12-31 0.00875 75000000 100000000 125000000 200000000 2023-12-31 275000000 300000000 236500000 35000000 35000000 50000000 50000000 75000000 100000000 2023-12-31 75000000 0.028 26800000 0.0793 0.0467 338126000 343350000 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 6. Commitments and Contingencies</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of June 30, 2023 and December 31, 2022 is $59,616 and $98,214, respectively, comprised of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outset Medical, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,865</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,865</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Human Interest Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,799</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,799</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vessco Midco Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,417</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,969</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Glooko, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,185</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,185</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Arcutis Biotherapeutics, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,065</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,065</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ardelyx, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,716</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,716</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">iCIMS, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,665</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,867</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cerapedics, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,424</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,424</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">High Street Buyer, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,040</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,797</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RxSense Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,558</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,558</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pediatric Home Respiratory Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,557</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,451</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Enverus Holdings, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,537</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,251</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Maurices, Incorporated</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,491</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,733</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSC Acquisition, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,419</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,328</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Nexus Intermediate III, LLC (Vortex)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,264</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,264</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Meditrina, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,212</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,212</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Spectrum Pharmaceuticals, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,186</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,966</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Kid Distro Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,121</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,121</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">GSM Acquisition Corp.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,101</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,101</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foundation Consumer Brands, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">967</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">967</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic Fun, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">960</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,195</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ultimate Baked Goods Midco LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">750</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">578</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Orthopedic Care Partners Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">729</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,200</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Southern Orthodontic Partners Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">705</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,605</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Kaseya, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">625</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,315</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">MRI Software LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">577</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">577</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ENS Holdings III Corp. &amp; ES Opco USA LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">574</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">SunMed Group Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">515</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transportation Insight, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">454</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,860</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">World Insurance Associates, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">385</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">135</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TAUC Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">385</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">385</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amerimark Intermediate Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">194</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CC SAG Holdings Corp. (Spectrum Automotive)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">174</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,568</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oral Surgery Partners Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,277</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plastics Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,095</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Erie Construction <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Mid-west,</div> LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,593</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tilley Chemical Buyer, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">670</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Peter C. Foy &amp; Associates Insurance Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">570</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pinnacle Treatment Centers, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">520</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ivy Fertility Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">499</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">BayMark Health Services, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">499</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">NAC Holdings Corporation</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">470</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Apex Service Partners, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">345</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All States Ag Parts, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">172</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Commitments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,616</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98,214</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The credit agreements of the above loan commitments contain customary lending provisions and/or are subject to the portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of June 30, 2023 and December 31, 2022, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of its business, we invest or trade in various financial instruments and may enter into various investment activities with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet risk, which may include forward foreign currency contracts. Generally, these financial instruments represent future commitments to purchase or sell other financial instruments at specific terms at future dates. These financial instruments contain varying degrees of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet risk whereby changes in the market value or our satisfaction of the obligations may exceed the amount recognized in our Consolidated Statements of Assets and Liabilities. </div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of June 30, 2023 and December 31, 2022 is $59,616 and $98,214, respectively, comprised of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:76%"></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:6%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June 30,<br/> 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outset Medical, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,865</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,865</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Human Interest Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,799</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,799</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vessco Midco Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,417</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,969</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Glooko, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,185</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,185</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Arcutis Biotherapeutics, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,065</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,065</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ardelyx, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,716</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,716</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">iCIMS, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,665</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,867</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cerapedics, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,424</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,424</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">High Street Buyer, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,040</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,797</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RxSense Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,558</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,558</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pediatric Home Respiratory Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,557</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,451</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Enverus Holdings, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,537</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,251</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Maurices, Incorporated</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,491</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,733</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSC Acquisition, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,419</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,328</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Nexus Intermediate III, LLC (Vortex)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,264</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,264</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Meditrina, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,212</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,212</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Spectrum Pharmaceuticals, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,186</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,966</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Kid Distro Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,121</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,121</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">GSM Acquisition Corp.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,101</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,101</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foundation Consumer Brands, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">967</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">967</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic Fun, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">960</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,195</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ultimate Baked Goods Midco LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">750</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">578</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Orthopedic Care Partners Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">729</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,200</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Southern Orthodontic Partners Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">705</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,605</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Kaseya, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">625</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,315</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">MRI Software LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">577</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">577</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">ENS Holdings III Corp. &amp; ES Opco USA LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">574</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">SunMed Group Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">515</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">268</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transportation Insight, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">454</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,860</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">World Insurance Associates, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">385</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">135</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">TAUC Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">385</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">385</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amerimark Intermediate Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">194</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CC SAG Holdings Corp. (Spectrum Automotive)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">174</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,568</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Oral Surgery Partners Holdings, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,277</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plastics Management, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,095</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Erie Construction <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Mid-west,</div> LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,593</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tilley Chemical Buyer, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">670</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Peter C. Foy &amp; Associates Insurance Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">570</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pinnacle Treatment Centers, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">520</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ivy Fertility Services, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">499</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">BayMark Health Services, Inc.</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">499</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">NAC Holdings Corporation</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">470</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Apex Service Partners, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">345</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All States Ag Parts, LLC</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">172</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Commitments</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,616</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">98,214</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 59616000 98214000 11865000 11865000 6799000 6799000 3417000 4969000 3185000 3185000 3065000 3065000 2716000 2716000 2665000 3867000 2424000 2424000 2040000 2797000 1558000 1558000 1557000 2451000 1537000 1251000 1491000 2733000 1419000 10328000 1264000 1264000 1212000 1212000 1186000 2966000 1121000 1121000 1101000 1101000 967000 967000 960000 1195000 750000 578000 729000 2200000 705000 2605000 625000 1315000 577000 577000 574000 179000 515000 268000 454000 1860000 385000 135000 385000 385000 194000 0 174000 6568000 0 3277000 0 3095000 0 1593000 0 670000 0 570000 0 520000 0 499000 0 499000 0 470000 0 345000 0 172000 59616000 98214000 <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 7. Unitholders’ Capital </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transactions in Unitholders’ capital were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:72%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months<br/> ended<br/> June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months<br/> ended<br/> June 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units at beginning of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,190,253</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,137,275</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,855,288</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued and outstanding at end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,190,253</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,992,563</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:74%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months<br/> ended<br/> June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months<br/> ended<br/> June 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units at beginning of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,992,563</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,137,275</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,197,690</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,855,288</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued and outstanding at end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,190,253</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,992,563</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transactions in Unitholders’ capital were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:72%"></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:3%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months<br/> ended<br/> June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months<br/> ended<br/> June 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units at beginning of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,190,253</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,137,275</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,855,288</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued and outstanding at end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,190,253</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,992,563</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:74%"></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:2%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months<br/> ended<br/> June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months<br/> ended<br/> June 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units at beginning of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,992,563</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,137,275</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,197,690</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,855,288</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units issued and outstanding at end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,190,253</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,992,563</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 25190253 17137275 0 1855288 25190253 18992563 18992563 17137275 6197690 1855288 25190253 18992563 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 8. Financial Highlights </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a schedule of financial highlights for the six months ended June 30, 2023 and June 30, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:67%"></td> <td style="vertical-align:bottom;width:10%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended<br/> June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended<br/> June 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Per Share Data: (a)</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net asset value per unit, beginning of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.33</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.28</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net investment income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized and unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.32</td> <td style="white-space:nowrap;vertical-align:bottom">)* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.03</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net increase in Unitholders’ capital resulting from operations</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.28</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distributions to Unitholders:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">From distributable earnings</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net asset value per unit, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.61</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.80</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Return (b)(c)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.71</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.06</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unitholders’ capital, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">267,226</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">205,103</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units outstanding, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,190,253</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,992,563</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ratios to average net assets of Unitholders’ Capital (c):</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net investment income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.82</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.69</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.62</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.20</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest and other credit facility expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.00</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.21</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.62</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.41</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Average debt outstanding</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">285,613</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280,590</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Portfolio turnover ratio</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.1</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.4</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(a)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Calculated using the average units outstanding method. Weighted average units outstanding for the six months ended June 30, 2023 and June 30, 2022 were 23,512,651 and 17,342,279, respectively. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(b)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Calculated as the change in NAV per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(c)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Not annualized for periods less than one year. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Includes the impact of the different unit amounts used in calculating per unit data as a result of calculating certain per unit data based upon the weighted average units outstanding during the period and certain per unit data based on the units outstanding as of a period end.</div> </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a schedule of financial highlights for the six months ended June 30, 2023 and June 30, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"> <tr style="font-size: 0px;"> <td style="width:67%"></td> <td style="vertical-align:bottom;width:10%"></td> <td></td> <td></td> <td></td> <td style="vertical-align:bottom;width:9%"></td> <td></td> <td></td> <td></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended<br/> June 30, 2023</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six months ended<br/> June 30, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Per Share Data: (a)</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net asset value per unit, beginning of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.33</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.28</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net investment income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.49</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net realized and unrealized gain (loss)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.32</td> <td style="white-space:nowrap;vertical-align:bottom">)* </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.03</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net increase in Unitholders’ capital resulting from operations</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.28</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distributions to Unitholders:</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">From distributable earnings</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">—  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net asset value per unit, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.61</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.80</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Return (b)(c)</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.71</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.06</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unitholders’ capital, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">267,226</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">205,103</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Units outstanding, end of period</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,190,253</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,992,563</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ratios to average net assets of Unitholders’ Capital (c):</div></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom"></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net investment income</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.82</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.69</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.62</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.20</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest and other credit facility expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.00</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.21</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total expenses</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.62</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.41</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"></td> <td style="vertical-align:bottom">  </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Average debt outstanding</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">285,613</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280,590</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Portfolio turnover ratio</div></td> <td style="vertical-align:bottom">  </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.1</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.4</td> <td style="white-space:nowrap;vertical-align:bottom">% </td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(a)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Calculated using the average units outstanding method. Weighted average units outstanding for the six months ended June 30, 2023 and June 30, 2022 were 23,512,651 and 17,342,279, respectively. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(b)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Calculated as the change in NAV per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">(c)</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Not annualized for periods less than one year. </div></td></tr></table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;">*</td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Includes the impact of the different unit amounts used in calculating per unit data as a result of calculating certain per unit data based upon the weighted average units outstanding during the period and certain per unit data based on the units outstanding as of a period end.</div> </div></td></tr></table> 10.33 10.28 0.6 0.49 -0.32 0.03 0.28 0.52 0 0 10.61 10.8 0.0271 0.0506 267226000 205103000 25190253 18992563 0.0582 0.0469 0.0162 0.022 0.05 0.0321 0.0662 0.0541 285613000 280590000 0.121 0.074 23512651 17342279 <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 9. Subsequent Events </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the need for disclosures and/or adjustments resulting from subsequent events through the date the consolidated financial statements were issued. There have been no subsequent events that require recognition or disclosure in these consolidated financial statements. </div> false false false false Includes the impact of the different unit amounts used in calculating per unit data as a result of calculating certain per unit data based upon the weighted average units outstanding during the period and certain per unit data based on the units outstanding as of a period end. Not annualized for periods less than one year. Calculated as the change in NAV per unit during the period plus distributions declared per unit, divided by the beginning NAV per unit. Total return does not include a sales load. Indicates an investment that is wholly or partially held by SCP Private Credit Income BDC LLC (the “Company”, “we”, “us” or “our”) through its wholly-owned financing subsidiary SCP Private Credit Income BDC SPV LLC (the “SPV”). Such investments are pledged as collateral under the SPV Facility (see Note 5 to the consolidated financial statements) and are not generally available to creditors, if any, of the Company. Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of June 30, 2023, on a fair value basis, non-qualifying assets in the portfolio represented 11.9% of the total assets of the Company. Non-income producing security. Indicates assets that the Company believes may not represent “qualifying assets” under Section 55(a) of the Investment Company Act of 1940, as amended (“1940 Act”). If we fail to invest a sufficient portion of our assets in qualifying assets, we could be prevented from making follow-on investments in existing portfolio companies or could be required to dispose of investments at inappropriate times in order to comply with the 1940 Act. As of December 31, 2022, on a fair value basis, non-qualifying assets in the portfolio represented 11.2% of the total assets of the Company. Floating rate instruments accrue interest at a predetermined spread relative to an index, typically the LIBOR, SOFR or PRIME rate. These instruments are often subject to a LIBOR, SOFR or PRIME rate floor. Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (PRIME or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment we have provided the current interest rate in effect as of December 31, 2022. Floating rate debt investments typically bear interest at a rate determined by reference to either the London Interbank Offered Rate (“LIBOR” or “L”) index rate, the Secured Overnight Financing Rate (“SOFR” or “S”) or the prime index rate (PRIME or “P”), and which typically reset monthly, quarterly or semi-annually. For each debt investment we have provided the current interest rate in effect as of June 30, 2023. Vapotherm, Inc. may elect to defer up to 9.00% of the coupon as PIK. Investment is on non-accrual status. Denotes investments in which we are an “Affiliated Person” but not exercising a controlling influence, as defined in the Investment Company Act of 1940, as amended (the “1940 Act”), due to beneficially owning, either directly or through one or more controlled companies, more than 5% but less than 25% of the outstanding voting securities of the investment. AmeriMark Interactive, LLC, AmeriMark Direct LLC, AmeriMark Intermediate Sub, Inc., L.T.D. Commodities LLC, Dr. Leonard’s Healthcare Corp. and Amerimark Intermediate Holdings, LLC are each co-Borrowers. BridgeBio Pharma, Inc. may elect to defer up to 3.00% of the coupon as PIK. iCIMS, Inc. may elect to defer up to 3.875% of the coupon as PIK. Kaseya, Inc. may elect to defer up to 2.50% of the coupon as PIK. AmeriMark Interactive, LLC, AmeriMark Direct LLC, AmeriMark Intermediate Sub, Inc., L.T.D. Commodities LLC, Dr. Leonard’s Healthcare Corp. and Amerimark Intermediate Holdings, LLC are each co-Borrowers. Amerimark may elect to defer up to 8.00% of the coupon as PIK. Through this entity and other intermediate entities, the Company owns approximately 6.5% of the underlying common units of ASC Holdco, LLC, a joint venture which owns certain assets of the former Amerimark Interactive, LLC. Vapotherm, Inc. may elect to defer up to 8.00% of the coupon as PIK. Aggregate net unrealized depreciation for U.S. federal income tax purposes is $9,108; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $6,687 and $15,795, respectively, based on a tax cost of $531,577. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated. Aggregate net unrealized depreciation for U.S. federal income tax purposes is $927; aggregate gross unrealized appreciation and depreciation for U.S. federal tax purposes is $5,202 and $6,129, respectively, based on a tax cost of $533,822. The Company generally acquires its investments in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). These investments are generally subject to certain limitations on resale, and may be deemed to be “restricted securities” under the Securities Act. All investments are Level 3 unless otherwise indicated. EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

XKP/*'5"6Z#JR+*T;+/&@Q]D*\-1:H:4' M&3>9M\J&)FD9AY*K?ZGRDX./F'+P&4<+ GX#PW4M 9N"2R&(%.">8+'@9 (N M)2B9_I. 2_!(Q@O.:?($KK"@ KR_(1+3Z(,"TJ9G);.O]R0>$?Y-&7P:WH#W M[SZ =X FX-\96PB<3$3/ERJE-#!_G(=_M0X?[@C_KT5R#E!P!F 487[M=W] MAHR5>YBY0]/=5T06;,*"39CAH5?9/'MA4.4%[B@>T8A*2DJ,JA[6U*16?[.$ M;U#Z]4Y= -Q*$HMO5>2LHVE41Y/> 2[$'(])WU,C+@A?$F_PZR]A*_B]BBI' M8 9QJ" .V= 'M\F2"*EN#U*I6 MRQ&8D7JS2+UY4FW>=$F<(S"#N%9!7.L(;;[&;);[-VPT4;C1YA5F"+:;J+K- MVT7(;6O(URR.50W_^+Z@\J>__@*WB22*'2G\+YASK-*IBML*7+=LCL ,#CH% M!YV3ZO>.2^(<@1G$=0OBND?H]^Y6([>[J+/1[=M&80-6MWH8:#$46.,M%_HV MF2_2L._(DD0@+-1+I4BQPM:MF"LTDX22(@Q/JMOS<%R1YPC-)$\+P- JDP[L M^!RTW,VMS=M[A4UG5\-KV17:==<^#0_^ _6UCOVZM8OJ",UD22N]L'%:$^%4 M*;I",\G36C&T*JI#)Z*YU>W!YD#83,Q@M3X+[0)MSWEX@RBR!U"[MH[03+JT M-@S;IS483B6E*S23/"TJ0ZOT.G0P.GL\*K9M=CXJM)0+[5IN]VA NS:RPM:N MF2,TRTA6:29Z6E="^YGC@8+1?'PR;B1FL MEG'0+N-V#P:RZB([;.V*'6.9#VIQ"+NGU>Y.1:4K-'/K2XM*9%]U/'#S*]A> M[X>P$6PNE%;9(=@)=^P+("WGD%W.[=/X!RDD^W7K%M<5FLF2UI'HM+:$D5-Y MZ0K-)*^T*WR4;6&TWX99E9UEQPQI88?LPF[/R7B#5K('4+O*QU@A1%I:HM/: M3D9.A:8K-),\+331,;:4<]#R.Q'M3KN].2#;5JU-O>27WCU*7_RZQ_R))@)$ M9*J<@O.VHH>OWZ5:GT@VSUY'&C$I69P=S@B>$)X:J/^GC,F7D_0-I^*-ML'_ M4$L#!!0 ( %2!"%=^')D&2P8 (XB 9 >&PO=V]R:W-H965T\:U*DYQ="R"W64;%SPN6\KOS$1S=?_ ^6:U5\8$W/=O0%;MAZN/F6N@C MK\ZR2#*6RX3G0+#E^>@E?$%P4 24BD\)NY-[[T%A9<;YM^+@S>)\Y!Z8_=1.P%Z#SV M +0+0$,#\"X =P.B P'!+J"<:J^R4LX#H8I.SP2_ Z)0ZVS%FW(RRVAM/\F+ M=;]10G^;Z#@U?4T3 3[1=,O *;BI%A_P)?BP9N!R3?,5D^!-#O9D[Y;@+;ME M*<#@I91,2?"4,$63])G.T.A.=-AFJ^1)K?YRQ;(9$U^U[.,- 4^?/ -/0)+K M4_&MI/E"GGE*.RK&Y[ M/R46&48QQ&T9,64!GD3CH):U;(2UC=!IXV_=!W5S2Y-_]/Y9Z:8&GJ9IX M,E51A,8=Y\14P3A&_@%;<6TK=ML2?,[80H*EX!E8)'+#95(4(?D@H[&Y+ %$ M?G5Z*UI-'150CIJ-'"M;>S(;1H'! M+P:+T$E-#UZ,8V8CQ\K67HR&M* ;M080(S3QJ$!&%':O4(L.HW'894:+KH#& MZ-!5VD 7[*>NP47'Y*-NI^Z7$(OD4$MH( NZ*>O19=3"4-A8(U-T.AG'1H^P M4%MPR%G#6; 'M![#C] D(0S],>P:,V61[\==K++(-$+"0P@)&["";K(Z$D1" M$Y>L%&G3V3#2IG-P)&H8# UEL$$DB?H)K%]"G)*VD8; D)O '@R3R.0GPTJO MA#@E;2L-@"$W@ V 263B40B#$'?=\FZJ=7O6BL44RW=R6]SU3H M':FLU<&=^:$<<]1LY%C9VK/:< P*?S&H1$ZP>O!B'#,;.5:V]F(T((;<(#8 M*I%)3D'0O4PM &;445-SZ#]9U" 8ZD>PP07'1"6C'?1*B%/2=M'@%G+CUJ-+ MJ(61(N..G55E\(=%=7JP.32PA7I@ZS$@B4P4BF!LM :KJLO'%A7T#RP8;I@* MNYGJ2 R)^UFK7T*O!T(A-3C*L M]$J(4]*VLO?+G1NT!D CMG!0W+TY?SE(12RJZ)"'!JFP&ZD>6^FP^?.5I=)9 M54:ELZC,2N?M_8"?,;$J'X208,ZWN:I^RZ\_K1^V>%D^8N U\NI)C2LJ5HFN M#"E;ZE#_^5A/J:@>?J@.%-^4CP/,N%(\*]^N&5TP40CT]TO.U?U!<8+Z$93I MOU!+ P04 " !4@0A7 .M91Q0& N+P &0 'AL+W=O/NEB4;)F+8SK*E_A&'O$]XC$?,QP\LNB>SRD5X$?@A_S4 MF@NQ.+%M[LYI0/@Q6]!0?G++HH (^3*ZL_DBHF26=@I\&SE.QPZ(%UK#0?K> M930.I!:W5&U^\N[E(WK"'@P6YHU=4?%M<1O*5 M7:C,O("&W&,AB.CMJ36")^^GRC)<3SDHE9QS:1C^?E*_5-:O"QF2C@]9_Z--Q/S4ZMG@1F] M);$OOK#'/VE>4#O14 M=T#/[8#S#C@M-!M96M:8"#(<1.P11$EKJ98\2;U)>\MJO#"YC5!*Z)'U/P.[C*[B5@M^#OF(3"$R0Q&5R$V7Q)?!]-Y60 7^<4G+-@0<*G MWSCX3)?4!QB,.)<3KR0YH83'$96W77#P?DP%\?P/\D*JR9$47\2"'Q4BWR*&\$(LY"6=\8 M9;C)HV\U+.\M*0UM*^RL.CP%VC@!R$ ;?KL;@ M_;L/-3+G>IDQ=:4,3&50O8PM32^<1X7S*-5M;=$](^$]&-.IL*]HZ+$(7%%7 M>C4#GQD).?B9^I-Y_I6Z\]![D(9^H2Y;4GF+1B'QG[C'P83-I&V%:3_+GF?> MKCJ1J4_!*&"Q_OLY5[;"3KY43OB N/;7D]P:GT9):PU]_@1WGCSIO#8E5 M',:%PSA5Q_\_MS=,X4!.JCJ+.?C^6>J "T$#7NL/-NF/(;&*/ZW"GY9V!EZ$ M2\I%&LZC/RP(9BL4B8L2=ZV,T(=&]_'K[QZ/^3!L@[?!VG2"&Q"I.=@HG M.TT$J&/2'T-B%7^ZA3_= P0HTVR7 M2&C@/;:Q'J;N2LC5&WC8MFE2'WBB'W MM$.6BW8@[];'A]@33W;V(&^HH-(=P>T;$D4D6:PK,?R.NRHAWMKG/!D%C%V'YA;+^)K/1-^F-(K.(/=!1I.@=(2RY:C\\]PY! M#!<.PW4B^C$*N*;6J1PISH982AR-??JN'J[V. M5=:.-@VK=2+3AJB4L_YQ?SUFM:U:6Q8I!:!03Z U\7EKA*>O8.>98DBMZK>B M9]AK)$U&,=B46M4C!<)0RY%[IJF_F1/8/<;K<>IO4&%I9:ONQRE 17I W2M, MKPV!^EIVWJ8SI%9U7K$V@DW$"AD%95-J58]*V\7Z_>*]8I5K0US^B72,UO<< M]$-X:8F**3:E5_VVK0!P[ MC?SCUB@RFU*K>J20&>NWI_>*5:Y=P<'N)@[JA_#2$A7Q8CWQWJ1G<"3UC9+3 M"W?T37&A?NP[3Z:#G),H'91HYJ2$V:,2AV!GK-@9ZW>J]PM<:V.!@F@];:V: MM0YNVR/$"FBQ'FAU,7IK=*@O9><9:)BVUTB!768CW6FDG5:V.BOJB=Y\XA-IJQ G3NO;9KV%W'1/T0=BW1+AUF3DZ2R]7FSI-PY]-;*>_(RUL@ MR@YG9R\$6Z3GFZ=,"!:D3^>4S&B4-)"?WS(F5B^2(]/%$?GA?U!+ P04 M" !4@0A7HV!2"JL" #S" &0 'AL+W=OO*= 4%EA>\!*9' M+T!RC=C M9^!L/SR0Y4J9#VX2EW@)]9;^UVK66 M!98PX?0'R=1J[%PZ*(,<5U0]\,T7:/2,#%_*J;1/M*EC(\]!:245+QJPGD%! M6/W&+XT/'Z8C'^12=GIRA M$QV OJ]X)3'+9.PJ/15#Z*9-VILZK;\G[=>*7:# .T>^YP<]\,EA^!12#1]8 MN+\+=[4!K0M^ZX)O^89[^.:S)W2+4T*)>D4_[Z%8@/C5I^H@C=EQ5[+$*8P= MO:4DB#4XR< 86O \."2;PU(:P/RQH!S9'?$VNX(/8P+7C&%]/]/*EWJA"W[ M7*E3A3:5^6^N$S\(1YX7N^NNWIZP,(K\L W;43)JE8P.%V^UD*D@I=VK[ZKB M@WQ_NXA'(MN1'K;2PW]2Q>$Q#3@2V8X!46M ]/^J..HIS\LW1?PV*O*&G:A: MA]LYDLQUX!Z+)6$24<@USKN(=-F(^HBM.XJ7]I1:<*7//-M?KM($W$7+J;YU^3)%.LGM!S@.)EFR_]+ M3^ME>QUIO,CR9+8N+D8PB^+5O^'W]89X45 XS07*ND YM*"_+N@?6G"R+C@Y MM&"P+A@<6C!<%PRW"X9["D[7!:?;!2=["L[6!6>'%IRO"\X/+9![SWNN=W#) M9F?O[.V])<^[6][9WWM+GG>XO+/']Y8\[W)Y9Y_O+7G>Z:L7?'?UBE\>+FJ8 MAY<7:?(DI>7RA5?>6!YSR_KB*(GB,AYN\K1X-"KJ\DM5W.;2K]*7R20J#]=P M*EGQ*G3*@_>=*O(PFKXOEOC]1I7>_?)>^D6*8NFWAV21A?$DN^CFQ2!*JCM> MKU!;K5#9L\*^Y"5Q_I!)6CP1DX9ZO;U^^%J]T5XO*RU M]AZFTVH/&_"*Z55 M5,7XHZ2E'J2^7Y?)YT^[XN7*] MO=Q>Q$5Y;SGX?M/..K=;>N.G, S9=K[^WW&HO]Y/'HES9N^7M]O)@G!?E M)WO+G=X!.ZXWV%ONM9?KXK9XT9[N+?-4E'DF*2'XV@:Y7])_UX^8.5BEOVG8917 M*_6D62W/S#YE\W L/G>*4Z],I(^B<_G/?\C#WK^:#G,24TE,(S&=Q P2,TG, M(C&;Q!P2LZCHTJ$E-7V'")E;/1Q\O^H-?K770?7V;004OIY, ,$C-)S"(Q MF\0<$G-)S",QG\0""*N%RV 3+H/V<$F*W,A%.I,FY4SN:7DY1$RD\%&DX;TH M)FO%@R++I:3X@Q1*G#W9.G_IFL M#+?RI6&QDWYQFK65+^30+!*S2;+*\_5)1Q/S&Y%VGCYIM4[-DI(3"4QC<1T$C-(S"0QB\1L$G-(S"4QC\1\ M$@L@K!9+9YM8.GN3:\MG9#B1F$IB&HGI)&:0F$EB%HG9).:0F$MB'HGY)!9 M6"VU@-+JH5)U!+[A(_Y,.OQ!#]B^.4$U%-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+ M**T>6%6GL3QXFPLQ:$F!53R&S=OT!J>#KM4][ 7GH2OU42UH> J#VG:K']%5N[3" MM4NW4T>?[I=&5FJAFH9J-:@ZJN:CFH9J/:@&EU9.G MZJE66EL@]W]%H?@^C]+5;UI,PKSQ>T]?H3<_5;#OIPY&[<#1X4-J&JKIJ&:@ MFHEJ%JK9J.:@FHMJ'JKYJ!906CVCJC9JY=5O;)X4,6257\Q\6UY?#N[N1)%7 MTM9U6CM3)\FVO-:&LUJJFHIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH! MI=7#JFK35MK;M)>_=FC%69XN9B+./TA7819ETLV\_&55J3@K^R-,H_!V*I8G M8XVQA39KHYJZUK9^7T(YW[X:CFHUI :?4\ MJKJPE=;&RAI6 M;=[*^=M,)='&;E1344U#-1W5#%0S4 M;V\2__FIY'H%V].ULZV6I?9Q')M'J*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J M :75\ZCJ^>ZWMFE>VM=>DMZ'L31Z"#.Q.P4<74O7:?18SAG7YU=6/$YFQ9+J M:/D6H^N.?NA=Q_9Q'7OVA6HJJFFHIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:0&GU MM%.JM%/>9*K81[]9&]545--034U@-+J857U MP_=?Z8=O#JL/TN_Q(A.3S>=:/DBC9#:+\G(^*>E"2-WP_OF^2/:.H]J M*JII:ZW\(9J74^7>V?(3%YO_Y*T/U*"#,%#-1#4+U6Q4 M=]_\54K%7?DM=9^^*)UN45DM?GDQ+V9G7IC>1W$F3<5=4=K[>%H,-"W;M9[O MY,F\)*7;),^3V?+F@P@G(BT7*!Z_2Y+\^4ZY@JP &0 'AL+W=O2LKC MWU]*=DQ2HJ@(&'Y)8F=X,AQ.Y*,YY.CTL:"_R@TA%7K*TKP\FVVJ:OONY*1< M;4@6E\?%EN3L-W<%S>**O:3W)^66DGC=#LK2$]NR_),L3O+9^6G[W@T]/RWJ M*DURY*O$E*B/]!RM[ZHN$/?\[LZ7Y/&AH\Y M>D^J.$G?,-/OR_?HZ+4Y.C;IJA+!EB>GE3,S>:/G:SV+EWL7+('7/IO MG1\CQWJ+;,MV%,,7^N'OR8H-Q^UP6QY^PH)SB)!]B)#=XCD#>$OVK[.N4X*^ M#H3@G\]L!+JJ2%;^3S7;';RKAF_^3]^5VWA%SF;L'[$D](',SG__#_:M/U5S M!P*3(N$<(N'HT,\/LU_QV:LFO$/Q6Y3F.O)P[D4^]D]/'L29]*VBT,;NP4IR MT3VXZ&I=_%I7);OX79-ULHK3M^@J7QVK7-2B3%T3(#!IPMYAPI[9[/0@(P$$ M)D7"/T3"!\G.'8HGY!W&H>]ULG/,2G(Q.+@8:%W\5&=QSG*R(FSZ59.<*@>U M&%-7! A,FFYXF&YH-C=#R$@ @4F1B Z1B$!R,^IEG1]$428"E M=?$'*/BH).L"BLW\H>RE3,1K* M$2 T>;*$O5R5;X<^\_5PDU<("$V>/&+QVSDIWD_ 3K"H.P'"DV.!F<_MKZD\^KT=/N)Y_>NGPHK)_2#@?3DI,36DY)/ MR?T&L3>:ROM%_4SHX">]'FCRVIBHN-B6=5V=J MT,]4R[6ZF:JP"J*A3.5TQ-;3D=NG)EIR0]9)7-%DQ5(U M(^B6E-N$QE5!G]&21219D5UY2IF\>NRIRP6%)D>"$:_Q]GV3S0ORV+%,IJ4 MC!J4-8WS%>EDLCJ508LW4&AR7#A/<@S+50XH?8)"DZ/!Z9,#(UDY?36JRQ84 M)EY@#:0Q9S2.GM'<+A=HOOJW3LJDV70Q?/^EQYF\+"8J-@ZG2(YAW78 VS!Y93&U5.:Q0(MYQ\YJUT4='N,CI9; MLJIHG:%Y7159T6P9>J.^S.KQ)V\),%'2<3EW<@TK6BXH?X)"DZ/!^9,+HVBY M?:T*!VXG@15&ONU7RE<8J6-;TGC-_>Q+3*"2UE'5:=MJ"E'B@T M.0C"YAW#0I<+NZ_'!%=R.5=R880NMR]A==F!PL2Q@X%:@LOYBZOG+\NB;M2M M''VEU:98-UL'5SQYK^,\OB>-VYKT!:W_0*')X>!LR36L>[F@+ H*38X&9U$N MC.[E]A6MP.J6;15&MF\-R%XNYS:NGMM'A-E'8_3(L^P*N:! MLB(H-#D:G!5Y,*J8U]>[NC168>)8T0 +\#A3\?1,Y1N-\Y)]]E=Q>[+H*B^; MLS^#>U_U:)-7QT1UQ^,,R#,LC'F@Q @*33Y!P(F1#R.,^7W)R_6ZE0*%$;OX M#M1D?4Y7?#U=6;3;"=NS)RV6BB.-S%N0;%KQ\ M4&8$A29'0SBB!71&JZ]F!7972E 8V;8U='WE?,77\Y4O\X4L(S1% <8+E'Z" M%FR@T.2).= >+A*H!\^>35,E&Y"3H="PYI6"$J$ MH-#D:' B%,)H6F%?K?+MKOBJ,,(.'BB[AIR>A'IZ\H4\U>6N&T;6[O5FJW-U MU5Y)T=&/@E;D255CSMUF:#0Y"AP MMA095L$B4-H$A29'@].F"$8%BQ2'P+#=W;,U9B4[R=E,I&@T.1H<#X4P6A=D:+5H(WM;HJ.6,E. Z$Q>:%UJFNQ=:L.T+H> Z$1$:&%I '0RM MOHR%V<=$+V5'S#J."DT,+3V9N8B?KV/Z"WTB<5IM!'%VJ.NF'F_Z2IFHY&"Q MAS,V+()AX,;.ACH[BZV=882P%QSMM59A,RC38K'C\DC+Y>O;*[0L[JK'9J_L MT+;8$9#I2V.B@H/%%L[8L/2%@;L\FVGS+/9YUK=.GI"L?67+"WJ$=L2JXZ; M7T8Z,']+TI0\H\6&9,T9Q)&&AR-HTU?)1%D'BZV=L6&A"P-W>S;3[EGL]ZQO MH3PA;\?/>*EL_*'=LEALPSS2AWF>$9JT]$#:<*S#Q1*5]25;5560XDLM&O&(_V:O\V_ M+[H':=1.PM9[H. Z$Q=HDFU8 L.P;:+!X#H1$2B4OO?RA'SM*UQ._UD((U8= M-P5>,];".:V2K+G87L2_F+,?BV)=[I\TT^JXMTG9_HY=AY5"[@C^]'4S4@$2 MND5CV[!2AF';2(/!=2(BD"I];^8)F:PX&N;U2(3"R@L&FG1AH<,S'FGQO*SS MZR:#:5%O7_&4)#W:]%4R4@D2>D=CV[!VAF&[2H/!=2(B<"A]J^8)>=O7QCS< MOP+WK>RAYG)8:/B,1SH^_UW0="WTG>7-:(?/X8Y@3EXK*+A.$ 3BY)A6T&#; M2H/!=2(B,"I]K^;79Z^C>-A7GS\HK+ SQ!\<\6%?>IISD^1YO&(+]XV2N/42 M+4AS$U=JMRV,P$Y?+B/U(:&I-'9,2VFPS:3!X#H1$8B4OD/SA 3>X8B/F^V1 M!H6-9W=OV$Z$9RTW3[J^CNE]DIX7W^?U!+ P04 " !4@0A7MFTB'5 " M #%!0 &0 'AL+W=O].-5 ^Z C#HD3.A)[@RIKX, IU7P(D^E34(>U-*Q8FQ6[4.=*V %![$ M61"'X3C@A JWN2DF.'2" M@$%N' .QKQ:FP)@CLC+^])QX^*0#;J^?V+]X[];+BFB82O:3%J::X'.,"BA) MP\Q<;KY"[^?,\>62:?]$FSXVQ"AOM)&\!UL%G(KN31[[/&P!HN0 (.X!\6L! MHQXP\D8[9=[6C!B2I4IND'+1ELTM?&X\VKJAPE5Q892]I19GLJGDG!I;%J,1 M$06:2F&H6(/(*6CT$5T5!77Y)@S=B.ZG<=D_GH$AE)W8B.5BAHZ/3M 1H@+= M5[+1ED>G@;'JW#>"O%=RW2F)#RCYUHA3- H_H#B,1WO@TY?A,\@M//+P>!<> MV)P,B8F'Q,2>+SG MQ1E(PHH4/X_0_M,=2QCS^):ILW.+L;1. W:;>W/HR[. MXR@9HG8DC@:)HQ@./HNB=#HURWP%:C?^[2^2.?FQ:6N20X3 M; >"!M4"SMZ_B\;AYWWE>".R'>?)X#QYD^(DKRK.\ZA]Q0FVFLP-N%NBUM0F MG$%I<>'IIS.,5#^[E32VB_VRLG,6E NP]Z64YFGC6GF8W-D_4$L# M!!0 ( %2!"%?LKBER$0, D* 9 >&PO=V]R:W-H965T49-6+X@IM+B(YFO=FXS*##1 M =-_EERD6.FE6-DR$X#C I12VW.A6)8XIRJ.[ZYA"J>P/ M.)7%%VTJ7<="BUPJGE9@ M[4%*6#GBIRH/.P#-TPSP*H!W".B\ / K@-_60J<"=-I:""I $;I=QEXD;H(5 MC@:";Y PVIK-3(KL%VB=+\+,/IDIH?\2C5/1/2,JX30&(=^A,(YH40]HS%/,\R>D<&BRQ)<8]]/0&%"/V@2F6 !Q M9B\JGT:E3]X+/OGHAC.52#1E,<0-^,EI?'@";^O\U$GRMDD:>2<)O^;L#/G. M1^0YGM_@S[@]W&L*Y_^L3__9^EXR_'K'^ 6?_P+?3%]5<4X!?5NB&TCGIOC3 MQ]QLC)_76A==*4CEKZ:RE\2=9F)S(Y[+#"]@:.DK3X)8@Q6]?>.&SN>FG+\F MV>0UR::O1+97G4Y=GVZ?M?K!ON*DP;%7K_O!>$!X[0%XUX*@CH%08L4$"GS MQLMC%!S9=0YB/=9P>T'@]7H'H1[KA6Z_&_8/^*9_Y]L+-*P##5L'BC"+D>X# MI-(34W6]!<"(3A4_;%O\8\7FFD[:,DY;,)8YL7?>MA3$JF@J)%KPG*GRTJJE M==]R43S7!_*1>SYV&^03W>>4;>LJ]T59>-1+A3/ MBI=USI5^IXMIHGLU$$9!_U]RKK8+8Z#N_J+?4$L#!!0 ( %2!"%=6);$4 M%08 'H6 9 >&PO=V]R:W-H965T.$HI%X/YF1V[R^9G,M<)%^PN0RI/4YH]7;)$/IX/ M\& _<,_7&VT&1O.S+5VS!Z:_;.\RN!M546*>,J&X%"ACJ_/!!3Z])L0X6(NO MG#VJQC4R5)92_C WM_'YP#.(6,(B;4)0^-FQ!4L2$PEP_%T&'53O-([-ZWWT M&TL>R"RI8@N9_,5CO3D?3 /GY@):' Q(MDHNQ_]%C:>@,4Y4K+ MM'0&!"D7Q2_]62:BX8#]#@=2.I"V0]#AX)<._DO?,"X=QFV'<8=#4#I8ZJ." MNTW<%=5T?I;)1Y09:XAF+FSVK3?DBPNS4!YT!D\Y^.GY#1=41)PFZ .D-#%I M5>@]>BC6#9(K="MV3&E8&QHM9+JEXND$.;W>7C%->?(.W+\\7*&W;]ZA-VB$ MU(9F3"$NT!?!M3J!0;C^O)&YHB)69R,-- R8451"7A2020?D$'V40F\4NA8Q MBP_]1T"_R@'9YV!!>@/^D8LA\KT31#SB._!'%Q$,F4NC$483!JO]X9A"V)IY!\8C6=N MB&$%,7P6(I2/A/_#8@2[#7);W:ZABJ"WB53JG0MT>(SG/626',*^ZG__-_S= MM>(DY.]S39'+$S&D7>&$'-5)3([W87/O])1-21 T;>$@X(:2MSRX[+\!= MJH7K:H]["ZS%#>V14GFIT=#.*PT71J6H?@$#_VB%DP#//!*TRZ##$D]G,Q*$ M72SJ.H['O8)U;V34*A7=@::N&1+[3:(,_(/9612SXQ0RW-LP_%ZUHAUFI M.P3\.BW"Y3-QNO9=Z?=..SH+G#=7N#^^OYG43]AH;*?<'15S*71 ME\\$Z2(7ND#C\(B!>TM[61YZ:?4'Z*(U=0$.0SQK_K59 M.IV"<1?+NL/ _2W&1:E0,5OJIMHZ^?:'ZN([.RX6TR#$1X+LLO."64>'0NH. MA?1W*'9-Q!T#0RAR-U M_2?]]1_.&K"@M97"OOC1?JHR MI;U<=;FM]\TB'^>9^3'6196WDM,7O8Q]'(K:8DOW<:!W&$+/MBA!&Q1%V.^XS&,+)^L;WUV;T8?HD)> M,MM]HEC"1 EIJZ*9-4"M: )CB:2 VO_^21KM%7EY7EW)K 0%)DP9'E1 )AAZ M@@/"T%6O1XWO8BG+UO:#I$*1F?OBG%^-5A\]+^VGOM;X I]>8]3/L5@#/&TZ@;&?%A\[B1LNM_9*WE%K+U%YN M&(6>RAC \Y64>G]C7E!];I[_"U!+ P04 " !4@0A7([E0[TH" .!0 M&0 'AL+W=OW>2VL?!'9CLM_?>[=M+0L8+VDOC:]QR?<^WK?&OLBZL! M/'E54KMI4GO?7%'JRAH4=^>F 8TK*V,5]QC:-76-!5Y%D)*4I>D%55SHI,CC MW,(6N6F]%!H6EKA6*6YW,Y!F.TU&R7[B4:QK'R9HD3=\#4_@?S8+BQ$=6"JA M0#MA-+&PFB;7HZMY%O)CPB\!6W_;;Z!V]++F#N9'/HO+U-/F:D I6O)7^T6SOH/X*A#GBUNAN2X%E^0.#G"=SHQJN=Z?D*.IDP2UFU>!%R>47;0YK^)H\MLS-CEMR&Q,T0/KI8" MNXX=YU!5JWU7]F%V:.KK>)??S<^PV;O>?*/I7HH';M=".R)AA93I^27*LEWW M=8$W3;S 2^.Q'>*PQ@<+;$C ]94Q?A^$#88GL/@#4$L#!!0 ( %2!"%&PO!ETJB'V/S[G']DUC M&-1Z)=CMG#$=+ LAZR&9:UU]"L-Z.F<%K2_*BDF#Y*4JJ#9=-0OK2C&:U4 J M1-CM=)*PH%R2T4 NBNM"U\&T7$@])/TV%+C;UVQ(HN0C"9SA5[1W@.A%!]L>V"0"]$:[!(7& TJJC53\MIT[& ;? (%3?MN51F' M,T574;='-@1[,TDFI MUHRF862G3(A;>/Y_YCO:RWQK3VTIR+9I##5-)^,ZH+^MYK2W97LOT@TJ_E#J M+PLS'6G[4"OL1K&<+VU_F;<&,/4(5Z=5)5:?!9_)@KG)'YQP-*!K7C O%7\T MV:!4IB; % D>F-)\NAWYK6AUQY9Z74[+'/?"0;-K?6<871=J.NH&%:$9MVM]@>E'2'OM-+BXSMF39 MN.FJV<0V ],P69L+"/O(M;W\",9QF!\!#,N#.< XCH7E^9_FTT?GXS#,6]^+ M]%%.'^4XE@\9VP^6Q\])S>6?:9K&<9)@*SH>>QV,L75+$OCQJV'>@('E@4Q_ MM];X;N,5\GP=8'OZ7(5@,\4K$9LIOM: ^-<-&&GJWVTL#S"P7<.>8!Q)4PR!6O37:)(@JY/ Q[\_V%,2QVGJ1P#S.XAC#(&G$4

7BKL

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 551 188 1 true 148 0 false 4 false false R1.htm 1001 - Document - Cover Page Sheet http://www.scppcibl.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Consolidated Statements of Assets and Liabilities Sheet http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities Consolidated Statements of Assets and Liabilities Statements 2 false false R3.htm 1003 - Statement - Consolidated Statements of Assets and Liabilities (Parenthetical) Sheet http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical Consolidated Statements of Assets and Liabilities (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Consolidated Statement of Operations Sheet http://www.scppcibl.com/role/ConsolidatedStatementOfOperations Consolidated Statement of Operations Statements 4 false false R5.htm 1005 - Statement - Consolidated Statement of Changes in Unitholders' Capital Sheet http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital Consolidated Statement of Changes in Unitholders' Capital Statements 5 false false R6.htm 1006 - Statement - Consolidated Statement of Cash Flows Sheet http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows Consolidated Statement of Cash Flows Statements 6 false false R7.htm 1007 - Statement - Consolidated Schedule of Investments Sheet http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments Consolidated Schedule of Investments Statements 7 false false R8.htm 1008 - Statement - Consolidated Schedule of Investments 1 Sheet http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1 Consolidated Schedule of Investments 1 Statements 8 false false R9.htm 1009 - Statement - Consolidated Schedule of Investments (Parethetical) Sheet http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical Consolidated Schedule of Investments (Parethetical) Statements 9 false false R10.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 10 false false R11.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 11 false false R12.htm 999001 - Disclosure - Organization Sheet http://www.scppcibl.com/role/Organization Organization Notes 12 false false R13.htm 999002 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.scppcibl.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 13 false false R14.htm 999003 - Disclosure - Agreements and Related Party Transactions Sheet http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactions Agreements and Related Party Transactions Notes 14 false false R15.htm 999004 - Disclosure - Fair Value Sheet http://www.scppcibl.com/role/FairValue Fair Value Notes 15 false false R16.htm 999005 - Disclosure - Debt Sheet http://www.scppcibl.com/role/Debt Debt Notes 16 false false R17.htm 999006 - Disclosure - Commitments and Contingencies Sheet http://www.scppcibl.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 999007 - Disclosure - Unitholders' Capital Sheet http://www.scppcibl.com/role/UnitholdersCapital Unitholders' Capital Notes 18 false false R19.htm 999008 - Disclosure - Financial Highlights Sheet http://www.scppcibl.com/role/FinancialHighlights Financial Highlights Notes 19 false false R20.htm 999009 - Disclosure - Subsequent Events Sheet http://www.scppcibl.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 999010 - Disclosure - Fair Value (Tables) Sheet http://www.scppcibl.com/role/FairValueTables Fair Value (Tables) Tables http://www.scppcibl.com/role/FairValue 21 false false R22.htm 999011 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.scppcibl.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.scppcibl.com/role/CommitmentsAndContingencies 22 false false R23.htm 999012 - Disclosure - Unitholders' Capital (Tables) Sheet http://www.scppcibl.com/role/UnitholdersCapitalTables Unitholders' Capital (Tables) Tables http://www.scppcibl.com/role/UnitholdersCapital 23 false false R24.htm 999013 - Disclosure - Financial Highlights (Tables) Sheet http://www.scppcibl.com/role/FinancialHighlightsTables Financial Highlights (Tables) Tables http://www.scppcibl.com/role/FinancialHighlights 24 false false R25.htm 999014 - Disclosure - Organization - Additional Information (Detail) Sheet http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail Organization - Additional Information (Detail) Details 25 false false R26.htm 999015 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.scppcibl.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 26 false false R27.htm 999016 - Disclosure - Agreements and Related Party Transactions - Additional Information (Detail) Sheet http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail Agreements and Related Party Transactions - Additional Information (Detail) Details 27 false false R28.htm 999017 - Disclosure - Fair Value - Summary of Assets Measured At Fair Value On A Recurring Basis (Detail) Sheet http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail Fair Value - Summary of Assets Measured At Fair Value On A Recurring Basis (Detail) Details 28 false false R29.htm 999018 - Disclosure - Fair Value - Summary of The Changes In Fair Value Of Level 3 Assets (Detail) Sheet http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail Fair Value - Summary of The Changes In Fair Value Of Level 3 Assets (Detail) Details 29 false false R30.htm 999019 - Disclosure - Fair Value - Summary of Quantitative Information About The Company's Level 3 Asset Fair Value Measurements (Detail) Sheet http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail Fair Value - Summary of Quantitative Information About The Company's Level 3 Asset Fair Value Measurements (Detail) Details 30 false false R31.htm 999020 - Disclosure - Fair Value - Additional information (Detail) Sheet http://www.scppcibl.com/role/FairValueAdditionalInformationDetail Fair Value - Additional information (Detail) Details 31 false false R32.htm 999021 - Disclosure - Debt - Additional Information (Detail) Sheet http://www.scppcibl.com/role/DebtAdditionalInformationDetail Debt - Additional Information (Detail) Details 32 false false R33.htm 999022 - Disclosure - Commitments and Contingencies - Summary of Unfunded Commitments (Detail) Sheet http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail Commitments and Contingencies - Summary of Unfunded Commitments (Detail) Details 33 false false R34.htm 999023 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.scppcibl.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 34 false false R35.htm 999024 - Disclosure - Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail) Sheet http://www.scppcibl.com/role/UnitholdersCapitalSummaryOfLimitedLiabilityCompanyUnitHoldersCapitalDetail Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail) Details 35 false false R36.htm 999025 - Disclosure - Financial Highlights - Summary of Investment Company, Financial Highlights (Detail) Sheet http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail Financial Highlights - Summary of Investment Company, Financial Highlights (Detail) Details 36 false false R37.htm 999026 - Disclosure - Financial Highlights - Summary of Investment Company, Financial Highlights (Parenthetical) (Detail) Sheet http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsParentheticalDetail Financial Highlights - Summary of Investment Company, Financial Highlights (Parenthetical) (Detail) Details 37 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince - d530243d10q.htm 9 d530243d10q.htm ck0001743415-20230630.xsd ck0001743415-20230630_cal.xml ck0001743415-20230630_def.xml ck0001743415-20230630_lab.xml ck0001743415-20230630_pre.xml d530243dex311.htm d530243dex312.htm d530243dex313.htm d530243dex321.htm d530243dex322.htm d530243dex323.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d530243d10q.htm": { "axisCustom": 5, "axisStandard": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1140, "http://xbrl.sec.gov/dei/2023": 27, "http://xbrl.sec.gov/ecd/2023": 4 }, "contextCount": 551, "dts": { "calculationLink": { "local": [ "ck0001743415-20230630_cal.xml" ] }, "definitionLink": { "local": [ "ck0001743415-20230630_def.xml" ] }, "inline": { "local": [ "d530243d10q.htm" ] }, "labelLink": { "local": [ "ck0001743415-20230630_lab.xml" ] }, "presentationLink": { "local": [ "ck0001743415-20230630_pre.xml" ] }, "schema": { "local": [ "ck0001743415-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 525, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 5, "total": 5 }, "keyCustom": 49, "keyStandard": 139, "memberCustom": 134, "memberStandard": 14, "nsprefix": "ck0001743415", "nsuri": "http://www.scppcibl.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.scppcibl.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "menuCat": "Notes", "order": "10", "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "shortName": "Pay vs Performance Disclosure", "subGroupType": "", "uniqueAnchor": null }, "R11": { "firstAnchor": { "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrTrmntdFlag", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:Rule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995445 - Disclosure - Insider Trading Arrangements", "menuCat": "Notes", "order": "11", "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "shortName": "Insider Trading Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrTrmntdFlag", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:Rule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999001 - Disclosure - Organization", "menuCat": "Notes", "order": "12", "role": "http://www.scppcibl.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999002 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "13", "role": "http://www.scppcibl.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ck0001743415:DisclosureOfAgreementsAndRelatedPartyTransactionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999003 - Disclosure - Agreements and Related Party Transactions", "menuCat": "Notes", "order": "14", "role": "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactions", "shortName": "Agreements and Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ck0001743415:DisclosureOfAgreementsAndRelatedPartyTransactionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999004 - Disclosure - Fair Value", "menuCat": "Notes", "order": "15", "role": "http://www.scppcibl.com/role/FairValue", "shortName": "Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999005 - Disclosure - Debt", "menuCat": "Notes", "order": "16", "role": "http://www.scppcibl.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999006 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "17", "role": "http://www.scppcibl.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MembersEquityNotesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999007 - Disclosure - Unitholders' Capital", "menuCat": "Notes", "order": "18", "role": "http://www.scppcibl.com/role/UnitholdersCapital", "shortName": "Unitholders' Capital", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MembersEquityNotesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999008 - Disclosure - Financial Highlights", "menuCat": "Notes", "order": "19", "role": "http://www.scppcibl.com/role/FinancialHighlights", "shortName": "Financial Highlights", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Consolidated Statements of Assets and Liabilities", "menuCat": "Statements", "order": "2", "role": "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "shortName": "Consolidated Statements of Assets and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999009 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "20", "role": "http://www.scppcibl.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999010 - Disclosure - Fair Value (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.scppcibl.com/role/FairValueTables", "shortName": "Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ck0001743415:ScheduleOfUnfundedCommitmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999011 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.scppcibl.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ck0001743415:ScheduleOfUnfundedCommitmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:MembersEquityNotesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ck0001743415:ScheduleOfMembersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999012 - Disclosure - Unitholders' Capital (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.scppcibl.com/role/UnitholdersCapitalTables", "shortName": "Unitholders' Capital (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:MembersEquityNotesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "ck0001743415:ScheduleOfMembersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999013 - Disclosure - Financial Highlights (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.scppcibl.com/role/FinancialHighlightsTables", "shortName": "Financial Highlights (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P10_05_2018To10_05_2018", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentCompanyCommittedCapital", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999014 - Disclosure - Organization - Additional Information (Detail)", "menuCat": "Details", "order": "25", "role": "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail", "shortName": "Organization - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P03_12_2019To03_12_2019", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "2", "first": true, "lang": null, "name": "ck0001743415:PercentageOfExciseTax", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999015 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "menuCat": "Details", "order": "26", "role": "http://www.scppcibl.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "2", "first": true, "lang": null, "name": "ck0001743415:PercentageOfExciseTax", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:InvestmentCompanyTotalReturn", "reportCount": 1, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999016 - Disclosure - Agreements and Related Party Transactions - Additional Information (Detail)", "menuCat": "Details", "order": "27", "role": "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Agreements and Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023_FirstUnitholderPreferredReturnMemberck0001743415OrderOfPriorityAxis", "decimals": "2", "lang": null, "name": "ck0001743415:PercentageOfCurrentProceedsToUnitholders", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999017 - Disclosure - Fair Value - Summary of Assets Measured At Fair Value On A Recurring Basis (Detail)", "menuCat": "Details", "order": "28", "role": "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "shortName": "Fair Value - Summary of Assets Measured At Fair Value On A Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999018 - Disclosure - Fair Value - Summary of The Changes In Fair Value Of Level 3 Assets (Detail)", "menuCat": "Details", "order": "29", "role": "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail", "shortName": "Fair Value - Summary of The Changes In Fair Value Of Level 3 Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn03_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonUnitOutstanding", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonUnitIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Consolidated Statements of Assets and Liabilities (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "shortName": "Consolidated Statements of Assets and Liabilities (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonUnitOutstanding", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonUnitIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023_BankDebtSeniorSecuredLoansMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRecoverableAmountMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueRecoveryAnalysisModelMemberusgaapValuationTechniqueAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999019 - Disclosure - Fair Value - Summary of Quantitative Information About The Company's Level 3 Asset Fair Value Measurements (Detail)", "menuCat": "Details", "order": "30", "role": "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "shortName": "Fair Value - Summary of Quantitative Information About The Company's Level 3 Asset Fair Value Measurements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023_BankDebtSeniorSecuredLoansMemberusgaapInvestmentTypeAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRecoverableAmountMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueRecoveryAnalysisModelMemberusgaapValuationTechniqueAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023_SpvFacilityMemberusgaapCreditFacilityAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999020 - Disclosure - Fair Value - Additional information (Detail)", "menuCat": "Details", "order": "31", "role": "http://www.scppcibl.com/role/FairValueAdditionalInformationDetail", "shortName": "Fair Value - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023_SpvFacilityMemberusgaapCreditFacilityAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn03_31_2019", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999021 - Disclosure - Debt - Additional Information (Detail)", "menuCat": "Details", "order": "32", "role": "http://www.scppcibl.com/role/DebtAdditionalInformationDetail", "shortName": "Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "4", "lang": null, "name": "us-gaap:LongTermDebtWeightedAverageInterestRateOverTime", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ck0001743415:ScheduleOfUnfundedCommitmentsTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "ck0001743415:UnfundedCommitments", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999022 - Disclosure - Commitments and Contingencies - Summary of Unfunded Commitments (Detail)", "menuCat": "Details", "order": "33", "role": "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "shortName": "Commitments and Contingencies - Summary of Unfunded Commitments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ck0001743415:ScheduleOfUnfundedCommitmentsTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023_OutsetMedicalInc.MemberdeiLegalEntityAxis", "decimals": "-3", "lang": null, "name": "ck0001743415:UnfundedCommitments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ck0001743415:ScheduleOfUnfundedCommitmentsTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "ck0001743415:UnfundedCommitments", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999023 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "menuCat": "Details", "order": "34", "role": "http://www.scppcibl.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ck0001743415:ScheduleOfUnfundedCommitmentsTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023_RevolvingTermLoansMemberusgaapDebtInstrumentAxis", "decimals": "-3", "lang": null, "name": "ck0001743415:UnfundedCommitments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ck0001743415:ScheduleOfMembersEquityTableTextBlock", "us-gaap:MembersEquityNotesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonUnitOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999024 - Disclosure - Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail)", "menuCat": "Details", "order": "35", "role": "http://www.scppcibl.com/role/UnitholdersCapitalSummaryOfLimitedLiabilityCompanyUnitHoldersCapitalDetail", "shortName": "Unitholders' Capital - Summary of Limited Liability Company Unit Holders Capital (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ck0001743415:ScheduleOfMembersEquityTableTextBlock", "us-gaap:MembersEquityNotesDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn03_31_2023", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonUnitOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn12_31_2022", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:NetAssetValuePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999025 - Disclosure - Financial Highlights - Summary of Investment Company, Financial Highlights (Detail)", "menuCat": "Details", "order": "36", "role": "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail", "shortName": "Financial Highlights - Summary of Investment Company, Financial Highlights (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn12_31_2021", "decimals": "2", "lang": null, "name": "us-gaap:NetAssetValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "0", "first": true, "lang": null, "name": "ck0001743415:WeightedAverageLimitedLiabilityCompanyUnitsOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "999026 - Disclosure - Financial Highlights - Summary of Investment Company, Financial Highlights (Parenthetical) (Detail)", "menuCat": "Details", "order": "37", "role": "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsParentheticalDetail", "shortName": "Financial Highlights - Summary of Investment Company, Financial Highlights (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:InvestmentCompanyFinancialHighlightsTableTextBlock", "us-gaap:InvestmentCompanyFinancialHighlightsTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "0", "first": true, "lang": null, "name": "ck0001743415:WeightedAverageLimitedLiabilityCompanyUnitsOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "ck0001743415:GrossInvestmentIncome", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Consolidated Statement of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations", "shortName": "Consolidated Statement of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "ck0001743415:GrossInvestmentIncome", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeNet", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Consolidated Statement of Changes in Unitholders' Capital", "menuCat": "Statements", "order": "5", "role": "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital", "shortName": "Consolidated Statement of Changes in Unitholders' Capital", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P04_01_2023To06_30_2023", "decimals": "-3", "lang": null, "name": "us-gaap:InvestmentCompanyDistributionOrdinaryIncome", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Consolidated Statement of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows", "shortName": "Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "P01_01_2023To06_30_2023", "decimals": "-3", "lang": null, "name": "ck0001743415:IncreaseDecreaseInPurchaseOfInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023_BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMemberusgaapInvestmentTypeAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - Consolidated Schedule of Investments", "menuCat": "Statements", "order": "7", "role": "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "shortName": "Consolidated Schedule of Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023_BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMemberusgaapInvestmentTypeAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedAtCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "3", "first": true, "lang": null, "name": "ck0001743415:PercentageOfTotalInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1008 - Statement - Consolidated Schedule of Investments 1", "menuCat": "Statements", "order": "8", "role": "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1", "shortName": "Consolidated Schedule of Investments 1", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "3", "first": true, "lang": null, "name": "ck0001743415:PercentageOfTotalInvestmentsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn06_30_2023", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:TaxBasisOfInvestmentsUnrealizedAppreciationDepreciationNet", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1009 - Statement - Consolidated Schedule of Investments (Parethetical)", "menuCat": "Statements", "order": "9", "role": "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical", "shortName": "Consolidated Schedule of Investments (Parethetical)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d530243d10q.htm", "contextRef": "PAsOn12_31_2022", "decimals": "-3", "lang": null, "name": "us-gaap:TaxBasisOfInvestmentsUnrealizedAppreciationDepreciationNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } } }, "segmentCount": 148, "tag": { "ck0001743415_AcresCommercialMortgageLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acres commercial mortgage, llc.", "label": "ACRES Commercial Mortgage, LLC [Member]", "terseLabel": "ACRES Commercial Mortgage, LLC" } } }, "localname": "AcresCommercialMortgageLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_AdministrationFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Administration fee.", "label": "Administration Fee [Member]" } } }, "localname": "AdministrationFeeMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_AdministrationFeePayable": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 10.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Administration fee payable.", "label": "Administration Fee Payable", "terseLabel": "Administration fee payable (see note 3)" } } }, "localname": "AdministrationFeePayable", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "ck0001743415_AdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advisor.", "label": "Advisor [Member]" } } }, "localname": "AdvisorMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_AggregateOperatingExpensesRelatingToUnitholders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate operating expenses relating to unitholders.", "label": "Aggregate Operating Expenses Relating To Unitholders", "terseLabel": "Aggregate operating expenses relating to unitholders" } } }, "localname": "AggregateOperatingExpensesRelatingToUnitholders", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ck0001743415_AggregateReimbursementOfOfferingExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate reimbursement of offering expenses.", "label": "Aggregate Reimbursement Of Offering Expenses", "terseLabel": "Reimbursement of offering expenses" } } }, "localname": "AggregateReimbursementOfOfferingExpenses", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ck0001743415_AggregateReimbursementOfOrganizationalAndOfferingExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate reimbursement of organizational and offering expenses.", "label": "Aggregate Reimbursement Of Organizational And Offering Expenses", "terseLabel": "Reimbursement of organizational and offering expenses" } } }, "localname": "AggregateReimbursementOfOrganizationalAndOfferingExpenses", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ck0001743415_AggregateReimbursementOfOrganizationalExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate reimbursement of organizational expenses.", "label": "Aggregate Reimbursement Of Organizational Expenses", "terseLabel": "Reimbursement of organizational expenses" } } }, "localname": "AggregateReimbursementOfOrganizationalExpenses", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ck0001743415_AgreementsAndRelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreements and related party transactions.", "label": "Agreements And Related Party Transactions [Abstract]" } } }, "localname": "AgreementsAndRelatedPartyTransactionsAbstract", "nsuri": "http://www.scppcibl.com/20230630", "xbrltype": "stringItemType" }, "ck0001743415_AgreementsAndRelatedPartyTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreements and related party transactions.", "label": "Agreements And Related Party Transactions [Line Items]" } } }, "localname": "AgreementsAndRelatedPartyTransactionsLineItems", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_AgreementsAndRelatedPartyTransactionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreements and related party transactions.", "label": "Agreements And Related Party Transactions [Table]" } } }, "localname": "AgreementsAndRelatedPartyTransactionsTable", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_AlimeraSciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alimera sciences, inc.", "label": "Alimera Sciences, Inc [Member]", "terseLabel": "Alimera Sciences, Inc" } } }, "localname": "AlimeraSciencesIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_AllStateAgPartsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All state ag parts, lllc.", "label": "All State Ag Parts, LLC [Member]", "terseLabel": "All State Ag Parts, LLC" } } }, "localname": "AllStateAgPartsLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_AllStatesAgPartsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All states ag parts LLC.", "label": "All States Ag Parts LLC [Member]", "terseLabel": "All States Ag Parts, LLC" } } }, "localname": "AllStatesAgPartsLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_AmeriMarkIntermediateHoldingsLlcOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AmeriMark intermediate holdings, LLC one.", "label": "Ameri Mark Intermediate Holdings, LLC One [Member]", "terseLabel": "AmeriMark Intermediate Holdings, LLC" } } }, "localname": "AmeriMarkIntermediateHoldingsLlcOneMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "ck0001743415_AmerimarkInteractiveLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AmeriMark interactive llc.", "label": "AmeriMark Interactive LLC [Member]", "terseLabel": "AmeriMark Interactive LLC" } } }, "localname": "AmerimarkInteractiveLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "ck0001743415_AmerimarkIntermediateHoldingsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amerimark intermediate holdings, llc.", "label": "AmeriMark Intermediate Holdings, LLC [Member]", "terseLabel": "AmeriMark Intermediate Holdings, LLC" } } }, "localname": "AmerimarkIntermediateHoldingsLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "ck0001743415_ApexServicePartnersLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Apex service partners LLC.", "label": "Apex Service Partners LLC [Member]", "terseLabel": "Apex Service Partners, LLC" } } }, "localname": "ApexServicePartnersLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_ArcutisBiotherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arcutis biotherapeutics inc.", "label": "Arcutis Biotherapeutics Inc [Member]", "terseLabel": "Arcutis Biotherapeutics, Inc.", "verboseLabel": "Arcutis Biotherapeutics, Inc" } } }, "localname": "ArcutisBiotherapeuticsIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_ArdelyxIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ardelyx inc.", "label": "Ardelyx Inc [Member]", "terseLabel": "Ardelyx, Inc." } } }, "localname": "ArdelyxIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_AscHoldcoLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASC Holdco, LLC [Member]", "terseLabel": "ASC Holdco, LLC" } } }, "localname": "AscHoldcoLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "ck0001743415_BankDebtSeniorSecuredLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bank debt senior secured loans.", "label": "Bank Debt Senior Secured Loans [Member]", "terseLabel": "Bank Debt/Senior Secured Loans" } } }, "localname": "BankDebtSeniorSecuredLoansMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bank debt senior secured loans one hundred and ninety two point five percentage.", "label": "Bank Debt Senior Secured Loans \u2014 192.5%", "terseLabel": "Bank Debt/Senior Secured Loans \u2014 192.5%" } } }, "localname": "BankDebtSeniorSecuredLoansOneHundredAndNinetyTwoPointFivePercentageMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bank debt senior secured loans two hundred and seventy one point five percentage.", "label": "Bank Debt Senior Secured Loans Two Hundred and Seventy One Point Five Percentage [Member]", "terseLabel": "Bank Debt/Senior Secured Loans \u2014 271.5%" } } }, "localname": "BankDebtSeniorSecuredLoansTwoHundredAndSeventyOnePointFivePercentageMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_BasicFunIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basic fun inc.", "label": "Basic Fun Inc [Member]", "terseLabel": "Basic Fun, Inc.", "verboseLabel": "Basic Fun, Inc. .." } } }, "localname": "BasicFunIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_BaymarkHealthServicesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BayMark health services inc.", "label": "BayMark Health Services Inc [Member]", "terseLabel": "BayMark Health Services, Inc.", "verboseLabel": "BayMark Health Services, Inc" } } }, "localname": "BaymarkHealthServicesIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_BiotechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biotechnology.", "label": "Biotechnology [Member]", "terseLabel": "Biotechnology" } } }, "localname": "BiotechnologyMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_BridgebioPharmaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BridgeBio pharma inc.", "label": "BridgeBio Pharma Inc [Member]", "terseLabel": "BridgeBio Pharma, Inc." } } }, "localname": "BridgebioPharmaIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "ck0001743415_BuildingProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Building products.", "label": "Building Products [Member]", "terseLabel": "Building Products" } } }, "localname": "BuildingProductsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_CapitalCommitmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital commitment.", "label": "Capital Commitment [Axis]" } } }, "localname": "CapitalCommitmentAxis", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_CapitalCommitmentConditionOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital commitment condition one.", "label": "Capital Commitment Condition One [Member]" } } }, "localname": "CapitalCommitmentConditionOneMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_CapitalCommitmentConditionTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital commitment condition two.", "label": "Capital Commitment Condition Two [Member]" } } }, "localname": "CapitalCommitmentConditionTwoMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_CapitalCommitmentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital commitment.", "label": "Capital Commitment [Domain]" } } }, "localname": "CapitalCommitmentDomain", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_CapitalMarketsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital markets.", "label": "Capital Markets [Member]", "terseLabel": "Capital Markets" } } }, "localname": "CapitalMarketsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_CcSagHoldingsCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CC SAG holdings corp.", "label": "CC SAG Holdings Corp [Member]", "terseLabel": "CC SAG Holdings Corp. (Spectrum Automotive)", "verboseLabel": "CC SAG Holdings Corp. (Spectrum Automotive).." } } }, "localname": "CcSagHoldingsCorpMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_CentrexionTherapeuticsInc.WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Centrexion therapeutics, inc. warrants.", "label": "Centrexion Therapeutics, Inc. Warrants [Member]", "terseLabel": "Centrexion Therapeutics, Inc. Warrants" } } }, "localname": "CentrexionTherapeuticsInc.WarrantsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_CentrexionTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Centrexion therapeutics, inc.", "label": "Centrexion Therapeutics, Inc [Member]", "terseLabel": "Centrexion Therapeutics, Inc." } } }, "localname": "CentrexionTherapeuticsIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_CerapedicsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cerapedics, inc.", "label": "Cerapedics, Inc. [Member]", "terseLabel": "Cerapedics, Inc." } } }, "localname": "CerapedicsInc.Member", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_CerapedicsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cerapedics, inc.", "label": "Cerapedics, Inc [Member]", "terseLabel": "Cerapedics, Inc." } } }, "localname": "CerapedicsIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_CollateralAgentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "collateral agent.", "label": "Collateral Agent [Axis]" } } }, "localname": "CollateralAgentAxis", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_CollateralAgentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "collateral agent.", "label": "Collateral Agent [Domain]" } } }, "localname": "CollateralAgentDomain", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_CommonEquityAndEquityInterestsAndWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common equity and equity interests and warrants.", "label": "Common Equity And Equity Interests And Warrants [Member]", "terseLabel": "Common Equity/Equity Interests/Warrants" } } }, "localname": "CommonEquityAndEquityInterestsAndWarrantsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_CommonEquityEquityInterestsWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common equity equity interests warrants.", "label": "Common Equity Equity Interests Warrants [Member]", "terseLabel": "Common Equity/Equity Interests/Warrants \u2014 0.0%" } } }, "localname": "CommonEquityEquityInterestsWarrantsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common equity equity interests warrants three point zero percentage.", "label": "Common Equity Equity Interests Warrants Three Point Zero Percentage [Member]", "terseLabel": "Common Equity/Equity Interests/Warrants \u2014 3.0%" } } }, "localname": "CommonEquityEquityInterestsWarrantsThreePointZeroPercentageMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_CompaniesFivePercentageToTwentyFivePercentageOwnedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Companies five percentage to twenty five percentage owned.", "label": "Companies Five Percentage To Twenty Five Percentage Owned [Member]", "terseLabel": "Companies 5% To 25% Owned [Member]" } } }, "localname": "CompaniesFivePercentageToTwentyFivePercentageOwnedMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "xbrltype": "domainItemType" }, "ck0001743415_CompaniesLessThanFivePercentageOwnedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Companies less than five percentage owned.", "label": "Companies Less Than Five Percentage Owned [Member]", "terseLabel": "Companies Less Than 5% Owned [Member]" } } }, "localname": "CompaniesLessThanFivePercentageOwnedMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "xbrltype": "domainItemType" }, "ck0001743415_DisclosureOfAgreementsAndRelatedPartyTransactionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of agreements and related party transactions.", "label": "Disclosure Of Agreements And Related Party Transactions [Text Block]", "terseLabel": "Agreements and Related Party Transactions" } } }, "localname": "DisclosureOfAgreementsAndRelatedPartyTransactionsTextBlock", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "ck0001743415_DiversifiedConsumerServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diversified consumer services.", "label": "Diversified Consumer Services [Member]", "terseLabel": "Diversified Consumer Services" } } }, "localname": "DiversifiedConsumerServicesMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_DiversifiedFinancialServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diversified financial services.", "label": "Diversified Financial Services [Member]", "terseLabel": "Diversified Financial Services" } } }, "localname": "DiversifiedFinancialServicesMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_EarningsBeforeInterestTaxDepreciationAndAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Earnings before interest tax depreciation and amortization.", "label": "Earnings Before Interest Tax Depreciation And Amortization", "terseLabel": "Earnings before interest tax depreciation and amortization" } } }, "localname": "EarningsBeforeInterestTaxDepreciationAndAmortization", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ck0001743415_EastWestBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "east west bank.", "label": "East West Bank [Member]" } } }, "localname": "EastWestBankMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_EnhancedPermanentCapitalLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Enhanced permanent capital, llc.", "label": "Enhanced Permanent Capital, LLC [Member]", "terseLabel": "Enhanced Permanent Capital, LLC" } } }, "localname": "EnhancedPermanentCapitalLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ENS holdings III corp and ES opco USA LLC.", "label": "ENS Holdings III Corp And ES Opco USA LLC [Member]", "terseLabel": "ENS Holdings III Corp. & ES Opco USA LLC (BlueFin)" } } }, "localname": "EnsHoldingsIiiCorpAndEsOpcoUsaLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_EnverusHoldingsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Enverus holdings inc.", "label": "Enverus Holdings Inc [Member]", "terseLabel": "Enverus Holdings, Inc. (fka Drilling Info Holdings)" } } }, "localname": "EnverusHoldingsIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_ErieConstructionMidWestLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Erie construction\u00a0mid-west\u00a0LLC.", "label": "Erie Construction Mid west LLC [Member]", "terseLabel": "Erie Construction Mid-west, LLC" } } }, "localname": "ErieConstructionMidWestLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetNetChangeInUnrealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis asset net change in unrealized gain loss.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Net Change In Unrealized Gain Loss", "terseLabel": "Net change in unrealized gain (loss)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetNetChangeInUnrealizedGainLoss", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "monetaryItemType" }, "ck0001743415_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetNetChangeInUnrealizedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis asset net change in unrealized loss.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Net Change In Unrealized Loss", "terseLabel": "Net change in unrealized gain (loss)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetNetChangeInUnrealizedLoss", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "monetaryItemType" }, "ck0001743415_FertilityInvestmentHoldcoLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fertility investment holdco, llc.", "label": "Fertility Investment Holdco, LLC [Member]", "terseLabel": "Fertility (ITC) Investment Holdco, LLC" } } }, "localname": "FertilityInvestmentHoldcoLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_FirstReturnOfCapitalContributionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First return of capital contributions.", "label": "First Return Of Capital Contributions [Member]" } } }, "localname": "FirstReturnOfCapitalContributionsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_FirstUnitholderPreferredReturnMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First, unitholder preferred return.", "label": "First, Unitholder Preferred Return [Member]", "terseLabel": "First, Unitholder Preferred Return [Member]" } } }, "localname": "FirstUnitholderPreferredReturnMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_FoundationConsumerBrandsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foundation consumer brands LLC.", "label": "Foundation Consumer Brands LLC [Member]", "terseLabel": "Foundation Consumer Brands, LLC" } } }, "localname": "FoundationConsumerBrandsLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_FourthOrderOfPriorityReturnOfCapitalContributionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fourth order of priority return of capital contributions.", "label": "Fourth Order Of Priority Return Of Capital Contributions [Member]" } } }, "localname": "FourthOrderOfPriorityReturnOfCapitalContributionsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_GlookoIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glooko inc.", "label": "Glooko Inc [Member]", "terseLabel": "Glooko, Inc." } } }, "localname": "GlookoIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_GrossInvestmentIncome": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 8.0, "parentTag": "us-gaap_InvestmentIncomeNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross investment income.", "label": "Gross Investment Income", "totalLabel": "Total investment income" } } }, "localname": "GrossInvestmentIncome", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "ck0001743415_GsmAcquisitionCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GSM acquisition corp.", "label": "GSM Acquisition Corp [Member]", "terseLabel": "GSM Acquisition Corp.", "verboseLabel": "GSM Acquisition Corp" } } }, "localname": "GsmAcquisitionCorpMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_HealthCareEquipmentAndSuppliesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health care equipment and supplies.", "label": "Health Care Equipment and Supplies [Member]", "terseLabel": "Health Care Equipment\u00a0& Supplies" } } }, "localname": "HealthCareEquipmentAndSuppliesMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_HealthCareProvidersAndServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health care providers and services.", "label": "Health Care Providers and Services [Member]", "terseLabel": "Health Care Providers\u00a0& Services" } } }, "localname": "HealthCareProvidersAndServicesMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_HealthCareTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health care technology.", "label": "Health Care Technology [Member]", "terseLabel": "Health Care Technology" } } }, "localname": "HealthCareTechnologyMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_HigginbothamInsuranceAgencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Higginbotham insurance agency.", "label": "Higginbotham Insurance Agency [Member]", "terseLabel": "Higginbotham Insurance Agency, Inc." } } }, "localname": "HigginbothamInsuranceAgencyMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_HighStreetBuyerIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "High street buyer inc.", "label": "High Street Buyer Inc [Member]", "terseLabel": "High Street Buyer, Inc.", "verboseLabel": "High Street Buyer, Inc" } } }, "localname": "HighStreetBuyerIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_HumanInterestIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Human interest inc.", "label": "Human Interest Inc [Member]", "terseLabel": "Human Interest Inc" } } }, "localname": "HumanInterestIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_IcimsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "iCIMS, inc.", "label": "iCIMS Inc. [Member]", "terseLabel": "iCIMS, Inc." } } }, "localname": "IcimsInc.Member", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_IcimsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "iCIMS, inc.", "label": "iCIMS, Inc [Member]", "terseLabel": "iCIMS, Inc." } } }, "localname": "IcimsIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "ck0001743415_IncentiveFeeExpenses": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 4.0, "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Incentive fee expenses.", "label": "Incentive Fee Expenses", "terseLabel": "Incentive fees (see note 3)", "verboseLabel": "Incentive fee expense" } } }, "localname": "IncentiveFeeExpenses", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "ck0001743415_IncreaseDecreaseInAdministrationFeePayable": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in administration fee payable.", "label": "Increase Decrease In Administration Fee Payable", "terseLabel": "Administration fee payable" } } }, "localname": "IncreaseDecreaseInAdministrationFeePayable", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ck0001743415_IncreaseDecreaseInCapitalizationOfPaymentInKindIncome": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in capitalization of\u00a0payment-in-kind\u00a0income.", "label": "Increase Decrease In Capitalization Of Payment In Kind Income", "negatedLabel": "Capitalization of\u00a0payment-in-kind\u00a0income" } } }, "localname": "IncreaseDecreaseInCapitalizationOfPaymentInKindIncome", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ck0001743415_IncreaseDecreaseInDeferredFinancingCosts": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in deferred financing costs.", "label": "Increase Decrease In Deferred Financing Costs", "negatedLabel": "Deferred financing costs" } } }, "localname": "IncreaseDecreaseInDeferredFinancingCosts", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ck0001743415_IncreaseDecreaseInNetAccretionOfDiscountOnInvestments": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in net accretion of discount on investments.", "label": "Increase Decrease In Net Accretion Of Discount On Investments", "terseLabel": "Net accretion of discount on investments" } } }, "localname": "IncreaseDecreaseInNetAccretionOfDiscountOnInvestments", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ck0001743415_IncreaseDecreaseInProceedsFromDispositionOfInvestments": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in proceeds from disposition of investments.", "label": "Increase Decrease In Proceeds From Disposition Of Investments", "terseLabel": "Proceeds from disposition of investments" } } }, "localname": "IncreaseDecreaseInProceedsFromDispositionOfInvestments", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ck0001743415_IncreaseDecreaseInPurchaseOfInvestments": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in purchase of investments.", "label": "Increase Decrease In Purchase Of Investments", "terseLabel": "Purchase of investments" } } }, "localname": "IncreaseDecreaseInPurchaseOfInvestments", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ck0001743415_IncreaseDecreaseInReceivableForInvestmentsSold": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in receivable for investments sold.", "label": "Increase Decrease In Receivable For Investments Sold", "negatedLabel": "Receivable for investments sold" } } }, "localname": "IncreaseDecreaseInReceivableForInvestmentsSold", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ck0001743415_InsuranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance.", "label": "Insurance [Member]", "terseLabel": "Insurance" } } }, "localname": "InsuranceMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_InternetAndCatalogRetailMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internet and catalog retail.", "label": "Internet and Catalog Retail [Member]", "terseLabel": "Internet\u00a0& Catalog Retail" } } }, "localname": "InternetAndCatalogRetailMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_InternetSoftwareAndServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internet software\u00a0and services.", "label": "Internet Software and Services [Member]", "terseLabel": "Internet Software & Services" } } }, "localname": "InternetSoftwareAndServicesMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_InternetSoftwareServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internet Software & Services [Member]", "label": "Internet Software Services [Member]", "terseLabel": "Internet Software & Services" } } }, "localname": "InternetSoftwareServicesMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_InvesteeMaximumBorrowings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investee maximum borrowings.", "label": "Investee Maximum Borrowings", "terseLabel": "Investee maximum borrowings" } } }, "localname": "InvesteeMaximumBorrowings", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ck0001743415_InvestmentCompanyFundedCapitalCommitments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment company funded capital commitments.", "label": "Investment Company Funded Capital Commitments", "terseLabel": "Investment company funded capital commitments" } } }, "localname": "InvestmentCompanyFundedCapitalCommitments", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ck0001743415_InvestmentCompanyIndustryType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment company, industry type.", "label": "Investment Company, Industry Type", "terseLabel": "Industry" } } }, "localname": "InvestmentCompanyIndustryType", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "stringItemType" }, "ck0001743415_InvestmentCompanyInterestAndOtherCreditFacilityExpensesRatioAfterIncentiveAllocation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment company interest and other credit facility expenses ratio after incentive allocation.", "label": "Investment Company Interest And Other Credit Facility Expenses Ratio After Incentive Allocation", "terseLabel": "Interest and other credit facility expenses" } } }, "localname": "InvestmentCompanyInterestAndOtherCreditFacilityExpensesRatioAfterIncentiveAllocation", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_InvestmentCompanyOperatingExpensesRatioAfterIncentiveAllocation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment company operating expenses ratio after incentive allocation.", "label": "Investment Company Operating Expenses Ratio After Incentive Allocation", "terseLabel": "Operating expenses" } } }, "localname": "InvestmentCompanyOperatingExpensesRatioAfterIncentiveAllocation", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_InvestmentCompanyPercentageOfOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment company percentage of ownership.", "label": "Investment Company Percentage Of Ownership", "terseLabel": "Investment company percentage of ownership" } } }, "localname": "InvestmentCompanyPercentageOfOwnership", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "percentItemType" }, "ck0001743415_InvestmentCompanyUnfundedCapitalCommitments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment company unfunded capital commitments.", "label": "Investment Company Unfunded Capital Commitments", "terseLabel": "Investment company unfunded capital commitments" } } }, "localname": "InvestmentCompanyUnfundedCapitalCommitments", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "ck0001743415_InvestmentFloorRateOfInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment floor rate of interest.", "label": "Investment Floor Rate Of Interest", "terseLabel": "Floor" } } }, "localname": "InvestmentFloorRateOfInterest", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "percentItemType" }, "ck0001743415_InvestmentOtherIncome": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 9.0, "parentTag": "ck0001743415_GrossInvestmentIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment other income.", "label": "Investment Other Income", "terseLabel": "Other income:" } } }, "localname": "InvestmentOtherIncome", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "ck0001743415_InvestmentSpreadAboveIndexRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment spread above index rate.", "label": "Investment Spread Above Index Rate", "terseLabel": "Spread above Index" } } }, "localname": "InvestmentSpreadAboveIndexRate", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "stringItemType" }, "ck0001743415_InvestmentsOneHundredAndNinetyFivePointFivePercentageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments one hundred and ninety five point five percentage.", "label": "Investments One Hundred and Ninety Five Point Five Percentage [Member]", "terseLabel": "Total Investments \u2014 195.5%" } } }, "localname": "InvestmentsOneHundredAndNinetyFivePointFivePercentageMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_InvestmentsTwoHundredSeventyOnePointFivePercentageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments two hundred seventy one point five percentage.", "label": "Investments Two Hundred Seventy One Point Five Percentage [Member]", "terseLabel": "Total Investments \u2014 271.5%" } } }, "localname": "InvestmentsTwoHundredSeventyOnePointFivePercentageMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_ItServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It services.", "label": "IT Services [Member]", "terseLabel": "IT Services" } } }, "localname": "ItServicesMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_IvyFertilityServicesLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ivy fertility services LLC.", "label": "Ivy Fertility Services LLC [Member]", "terseLabel": "Ivy Fertility Services, LLC" } } }, "localname": "IvyFertilityServicesLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_JpmorganChaseBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "jpmorgan chase bank.", "label": "JPMorgan Chase Bank [Member]" } } }, "localname": "JpmorganChaseBankMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_KaseyaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kaseya inc.", "label": "Kaseya Inc [Member]", "terseLabel": "Kaseya, Inc." } } }, "localname": "KaseyaIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "ck0001743415_KidDistroHoldingsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kid distro holdings LLC.", "label": "Kid Distro Holdings LLC [Member]", "terseLabel": "Kid Distro Holdings, LLC (Distro Kid)" } } }, "localname": "KidDistroHoldingsLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_KoreWirelessGroupIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KORE wireless group, inc.", "label": "KORE Wireless Group, Inc [Member]", "terseLabel": "KORE Wireless Group, Inc." } } }, "localname": "KoreWirelessGroupIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_LeisureEquipmentAndProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leisure equipment\u00a0and products.", "label": "Leisure Equipment and Products [Member]", "terseLabel": "Leisure Equipment\u00a0& Products" } } }, "localname": "LeisureEquipmentAndProductsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_LiabilitiesInExcessOfOtherAssetsNinetyFivePointFivePercentageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liabilities in excess of other assets ninety five point five percentage.", "label": "Liabilities In Excess of Other Assets Ninety Five Point Five Percentage [Member]", "terseLabel": "Liabilities in Excess of Other Assets \u2014 (95.5%)" } } }, "localname": "LiabilitiesInExcessOfOtherAssetsNinetyFivePointFivePercentageMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_LiabilitiesInExcessOfOtherAssetsOneHundredSeventyOnePointFivePercentageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liabilities in excess of other assets one hundred seventy one point five percentage.", "label": "Liabilities In Excess of Other Assets One Hundred Seventy One Point Five Percentage [Member]", "terseLabel": "Liabilities in Excess of Other Assets \u2014 (171.5%)" } } }, "localname": "LiabilitiesInExcessOfOtherAssetsOneHundredSeventyOnePointFivePercentageMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_LifeSciencesToolsAndServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life sciences tools\u00a0and services.", "label": "Life Sciences Tools and Services [Member]", "terseLabel": "Life Sciences Tools\u00a0& Services" } } }, "localname": "LifeSciencesToolsAndServicesMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_LondonInterbankOfferedRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_ManagementFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management fee.", "label": "Management Fee [Member]" } } }, "localname": "ManagementFeeMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_MauricesIncorporatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maurices incorporated.", "label": "Maurices Incorporated [Member]", "terseLabel": "Maurices, Incorporated" } } }, "localname": "MauricesIncorporatedMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_MeasurementInputComparableMultipleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Comparable Multiple.", "label": "Measurement Input Comparable Multiple [Member]" } } }, "localname": "MeasurementInputComparableMultipleMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_MeasurementInputMarketYieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input market yield.", "label": "Measurement Input Market Yield [Member]" } } }, "localname": "MeasurementInputMarketYieldMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_MeasurementInputRecoverableAmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input recoverable amount.", "label": "Measurement Input Recoverable Amount [Member]", "terseLabel": "Measurement Input Recoverable Amount [Member]" } } }, "localname": "MeasurementInputRecoverableAmountMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_MeditrinaInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Meditrina, inc.", "label": "Meditrina, Inc. [Member]", "terseLabel": "Meditrina, Inc." } } }, "localname": "MeditrinaInc.Member", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_MeditrinaInc.WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Meditrina, inc. warrants.", "label": "Meditrina, Inc. Warrants [Member]", "terseLabel": "Meditrina, Inc. Warrants" } } }, "localname": "MeditrinaInc.WarrantsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_MeditrinaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Meditrina Inc.", "label": "Meditrina Inc [Member]", "terseLabel": "Meditrina, Inc." } } }, "localname": "MeditrinaIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_MriSoftwareLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MRI software LLC.", "label": "MRI Software LLC [Member]", "terseLabel": "MRI Software LLC", "verboseLabel": "MRI Software LLC." } } }, "localname": "MriSoftwareLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_MultiplierToCapitalCommitment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multiplier to capital commitment.", "label": "Multiplier To Capital Commitment", "terseLabel": "Multiplier to capital commitment" } } }, "localname": "MultiplierToCapitalCommitment", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "ck0001743415_NACHoldingCorporationJaguarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NAC holding corporation jaguar", "label": "NAC Holding Corporation Jaguar [Member]", "terseLabel": "NAC Holding Corporation (Jaguar)" } } }, "localname": "NACHoldingCorporationJaguarMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_NacHoldingsCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NAC holdings corporation.", "label": "NAC Holdings Corporation [Member]", "terseLabel": "NAC Holdings Corporation" } } }, "localname": "NacHoldingsCorporationMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_NetAssetsOneHundredPercentageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net assets one hundered percentage.", "label": "Net Assets One Hundred Percentage [Member]", "terseLabel": "Net Assets \u2014 100.0%" } } }, "localname": "NetAssetsOneHundredPercentageMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_NetIncreaseInUnitholdersCapitalResultingFromCapitalActivity": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital": { "order": 2.0, "parentTag": "us-gaap_PartnersCapitalAccountPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net increase in unitholders' capital resulting from capital activity.", "label": "Net Increase In Unitholders Capital Resulting From Capital Activity", "totalLabel": "Net increase in unitholders' capital resulting from capital activity" } } }, "localname": "NetIncreaseInUnitholdersCapitalResultingFromCapitalActivity", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital" ], "xbrltype": "monetaryItemType" }, "ck0001743415_NeuroneticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Neuronetics inc.", "label": "Neuronetics Inc [Member]", "terseLabel": "Neuronetics, Inc." } } }, "localname": "NeuroneticsIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_NexusIntermediateIiiLlcVortexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nexus intermediate III LLC vortex.", "label": "Nexus Intermediate III LLC Vortex [Member]", "terseLabel": "Nexus Intermediate III, LLC (Vortex)" } } }, "localname": "NexusIntermediateIiiLlcVortexMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_OralSurgeryPartnersHoldingsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oral surgery partners holdings, LLC.", "label": "Oral Surgery Partners Holdings, LLC [Member]", "terseLabel": "Oral Surgery Partners Holdings, LLC", "verboseLabel": "Oral Surgery Partners Holdings, LLC." } } }, "localname": "OralSurgeryPartnersHoldingsLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_OrderOfPriorityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Order of priority.", "label": "Order of Priority [Axis]" } } }, "localname": "OrderOfPriorityAxis", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_OrderOfPriorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Order of Priority Domain.", "label": "Order of Priority [Domain]" } } }, "localname": "OrderOfPriorityDomain", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_OrderOfPriorityReturnOfCapitalContributionsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Order of priority return of capital contributions.", "label": "Order Of Priority Return Of Capital Contributions [Axis]" } } }, "localname": "OrderOfPriorityReturnOfCapitalContributionsAxis", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_OrderOfPriorityReturnOfCapitalContributionsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Order of priority return of capital contributions.", "label": "Order Of Priority Return Of Capital Contributions [Domain]" } } }, "localname": "OrderOfPriorityReturnOfCapitalContributionsDomain", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_OrthopedicCarePartnersManagementLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Orthopedic care partners management, LLC.", "label": "Orthopedic Care Partners Management LLC [Member]", "terseLabel": "Orthopedic Care Partners Management, LLC", "verboseLabel": "Orthopedic Care Partners Management, LLC." } } }, "localname": "OrthopedicCarePartnersManagementLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_OutsetMedicalInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outset medical, inc.", "label": "Outset Medical, Inc. [Member]", "terseLabel": "Outset Medical, Inc." } } }, "localname": "OutsetMedicalInc.Member", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_OutsetMedicalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outset medical, inc.", "label": "Outset Medical, Inc [Member]", "terseLabel": "Outset Medical, Inc." } } }, "localname": "OutsetMedicalIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_OwnershipPercentageInAffiliatesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership percentage in affiliates.", "label": "Ownership Percentage In Affiliates [Axis]", "terseLabel": "Ownership Percentage in Affiliates [Axis]" } } }, "localname": "OwnershipPercentageInAffiliatesAxis", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "xbrltype": "stringItemType" }, "ck0001743415_OwnershipPercentageInAffiliatesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ownership percentage in affiliates.", "label": "Ownership Percentage In Affiliates [Domain]", "terseLabel": "Ownership Percentage in Affiliates [Domain]" } } }, "localname": "OwnershipPercentageInAffiliatesDomain", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "xbrltype": "domainItemType" }, "ck0001743415_PackagedFoodsAndMeatsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Packaged foods\u00a0and meats .", "label": "Packaged Foods and Meats [Member]", "terseLabel": "Packaged Foods\u00a0& Meats" } } }, "localname": "PackagedFoodsAndMeatsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_PaymentOfCashDistributions": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of cash distributions.", "label": "Payment Of Cash Distributions", "negatedLabel": "Cash distributions paid" } } }, "localname": "PaymentOfCashDistributions", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ck0001743415_PediatricHomeRespiratoryServicesLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pediatric home respiratory services, LLC.", "label": "Pediatric Home Respiratory Services, LLC [Member]", "terseLabel": "Pediatric Home Respiratory Services, LLC", "verboseLabel": "Pediatric Home Respiratory Services, LLC." } } }, "localname": "PediatricHomeRespiratoryServicesLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_PercentageOfCurrentProceedsToAdvisers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of current proceeds to advisers.", "label": "Percentage Of Current Proceeds To Advisers", "terseLabel": "Percentage of Current Proceeds to Advisers" } } }, "localname": "PercentageOfCurrentProceedsToAdvisers", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_PercentageOfCurrentProceedsToUnitholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of current proceeds to unitholders.", "label": "Percentage Of Current Proceeds To Unitholders", "terseLabel": "percentage of current proceeds to unitholders" } } }, "localname": "PercentageOfCurrentProceedsToUnitholders", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_PercentageOfDispositionProceedsToAdvisers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of disposition proceeds to advisers.", "label": "Percentage Of Disposition Proceeds To Advisers", "terseLabel": "Percentage of disposition proceeds to advisers" } } }, "localname": "PercentageOfDispositionProceedsToAdvisers", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_PercentageOfDispositionProceedsToUnitholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of disposition proceeds to unitholders.", "label": "Percentage Of Disposition Proceeds To Unitholders", "terseLabel": "Percentage of disposition proceeds to unitholders" } } }, "localname": "PercentageOfDispositionProceedsToUnitholders", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_PercentageOfDistributionToAdviserAsAnIncentiveFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of distribution to adviser as an incentive fee.", "label": "Percentage Of Distribution To Adviser As An Incentive Fee", "terseLabel": "Percentage of distribution to adviser as an incentive fee" } } }, "localname": "PercentageOfDistributionToAdviserAsAnIncentiveFee", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_PercentageOfDistributionToUnitHolders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of distribution to unit holders.", "label": "Percentage Of Distribution to Unit Holders", "terseLabel": "Percentage of distribution to unitholders" } } }, "localname": "PercentageOfDistributionToUnitHolders", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_PercentageOfExciseTax": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of excise tax.", "label": "Percentage Of Excise Tax", "terseLabel": "Percentage of excise tax" } } }, "localname": "PercentageOfExciseTax", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_PercentageOfPaymentToPlacementAgent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of payment to placement agent.", "label": "Percentage Of Payment To Placement Agent", "terseLabel": "Percentage of payment to placement agent" } } }, "localname": "PercentageOfPaymentToPlacementAgent", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_PercentageOfReimbursementOfDistributionsByAdviserUponLiquidation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of reimbursement of distributions by adviser upon liquidation.", "label": "Percentage Of Reimbursement Of Distributions By Adviser Upon Liquidation", "terseLabel": "Percentage of reimbursement of distributions by adviser upon liquidation" } } }, "localname": "PercentageOfReimbursementOfDistributionsByAdviserUponLiquidation", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_PercentageOfTotalAmountDistributedToUnitholdersAndAdvisers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of total amount distributed to unitholders and advisers.", "label": "Percentage Of Total Amount Distributed To Unitholders And Advisers", "terseLabel": "Percentage of total amount distributed to unitholders and advisers" } } }, "localname": "PercentageOfTotalAmountDistributedToUnitholdersAndAdvisers", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_PercentageOfTotalInvestmentsAtFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of total investments at fair value.", "label": "Percentage Of Total Investments At Fair Value", "terseLabel": "Percentage Of Total Investments At Fair Value" } } }, "localname": "PercentageOfTotalInvestmentsAtFairValue", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "percentItemType" }, "ck0001743415_PersonalProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Personal products.", "label": "Personal Products [Member]", "terseLabel": "Personal Products" } } }, "localname": "PersonalProductsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_PeterCFoyandAssociatesInsuranceServicesLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Peter C foy\u00a0and associates insurance services LLC.", "label": "Peter C FoyAnd Associates Insurance Services LLC [Member]", "terseLabel": "Peter C. Foy & Associates Insurance Services, LLC", "verboseLabel": "Peter C. Foy & Associates Insurance Services, LLC.." } } }, "localname": "PeterCFoyandAssociatesInsuranceServicesLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_PharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceuticals.", "label": "Pharmaceuticals [Member]", "terseLabel": "Pharmaceuticals" } } }, "localname": "PharmaceuticalsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_PinnacleTreatmentCentersIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pinnacle treatment centers inc.", "label": "Pinnacle Treatment Centers Inc [Member]", "terseLabel": "Pinnacle Treatment Centers, Inc.", "verboseLabel": "Pinnacle Treatment Centers, Inc. .." } } }, "localname": "PinnacleTreatmentCentersIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_PlasticsManagementLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plastics management LLC.", "label": "Plastics Management LLC [Member]", "terseLabel": "Plastics Management, LLC", "verboseLabel": "Plastics Management, LLC." } } }, "localname": "PlasticsManagementLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_PortfolioTurnoverRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portfolio turnover ratio.", "label": "Portfolio Turnover Ratio", "terseLabel": "Portfolio turnover ratio" } } }, "localname": "PortfolioTurnoverRatio", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "percentItemType" }, "ck0001743415_ProfessionalServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Professional services.", "label": "Professional Services [Member]", "terseLabel": "Professional Services" } } }, "localname": "ProfessionalServicesMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_RateOfCouponAsPik": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rate of coupon as pik.", "label": "Rate Of Coupon As PIK", "terseLabel": "Rate of coupon as PIK" } } }, "localname": "RateOfCouponAsPik", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "percentItemType" }, "ck0001743415_ReceivableForInvestmentsSold": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 16.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivable for investments sold.", "label": "Receivable For Investments Sold", "terseLabel": "Receivable for investments sold" } } }, "localname": "ReceivableForInvestmentsSold", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "ck0001743415_RevlonConsumerProductsCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revlon consumer products corporation.", "label": "Revlon Consumer Products Corporation [Member]", "terseLabel": "Revlon Consumer Products Corporation" } } }, "localname": "RevlonConsumerProductsCorporationMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_RevolvingTermLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving term loans.", "label": "Revolving Term Loans [Member]" } } }, "localname": "RevolvingTermLoansMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_RoadAndRailMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Road\u00a0and rail.", "label": "Road and Rail [Member]", "terseLabel": "Road\u00a0& Rail" } } }, "localname": "RoadAndRailMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_RqmPlusCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RQM plus corp.", "label": "RQM Plus Corp [Member]", "terseLabel": "RQM+ Corp." } } }, "localname": "RqmPlusCorpMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_RscAcquisitionIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RSC acquisition inc.", "label": "RSC Acquisition Inc [Member]", "terseLabel": "RSC Acquisition, Inc." } } }, "localname": "RscAcquisitionIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_RxsenseHoldingsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RxSense holdings LLC.", "label": "RxSense Holdings LLC [Member]", "terseLabel": "RxSense Holdings LLC", "verboseLabel": "RxSense Holdings LLC." } } }, "localname": "RxsenseHoldingsLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_ScheduleOfMembersEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of members equity.", "label": "Schedule Of Members Equity [Line Items]" } } }, "localname": "ScheduleOfMembersEquityLineItems", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/UnitholdersCapitalSummaryOfLimitedLiabilityCompanyUnitHoldersCapitalDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_ScheduleOfMembersEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of members equity.", "label": "Schedule Of Members Equity [Table]" } } }, "localname": "ScheduleOfMembersEquityTable", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/UnitholdersCapitalSummaryOfLimitedLiabilityCompanyUnitHoldersCapitalDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_ScheduleOfMembersEquityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of members equity.", "label": "Schedule Of Members Equity [Table Text Block]", "terseLabel": "Summary of limited liability company unit holders capital" } } }, "localname": "ScheduleOfMembersEquityTableTextBlock", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/UnitholdersCapitalTables" ], "xbrltype": "textBlockItemType" }, "ck0001743415_ScheduleOfUnfundedCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of unfunded commitments.", "label": "Schedule Of Unfunded Commitments [Line Items]" } } }, "localname": "ScheduleOfUnfundedCommitmentsLineItems", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_ScheduleOfUnfundedCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of unfunded commitments.", "label": "Schedule Of Unfunded Commitments [Table]" } } }, "localname": "ScheduleOfUnfundedCommitmentsTable", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "xbrltype": "stringItemType" }, "ck0001743415_ScheduleOfUnfundedCommitmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of unfunded commitments.", "label": "Schedule Of Unfunded Commitments [Table Text Block]", "terseLabel": "Summary of unfunded commitments" } } }, "localname": "ScheduleOfUnfundedCommitmentsTableTextBlock", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "ck0001743415_ScpPrivateCreditIncomeBdcSpvLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "scp private credit income bdc spv llc.", "label": "SCP Private Credit Income BDC SPV LLC [Member]" } } }, "localname": "ScpPrivateCreditIncomeBdcSpvLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_Second.AdviserCatchUpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second., Adviser Catch Up member.", "label": "Second., Adviser Catch Up [Member]", "terseLabel": "Second., Adviser Catch Up [Member]" } } }, "localname": "Second.AdviserCatchUpMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_SecondUnitholderPreferredReturnMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second unitholder preferred return.", "label": "Second Unitholder Preferred Return [Member]" } } }, "localname": "SecondUnitholderPreferredReturnMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_SeniorSecuredLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior secured loans.", "label": "Senior Secured Loans [Member]" } } }, "localname": "SeniorSecuredLoansMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_SenseonicsHoldingsInc.CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senseonics holdings, inc. common stock.", "label": "Senseonics Holdings, Inc. Common Stock [Member]", "terseLabel": "Senseonics Holdings, Inc. Common Stock" } } }, "localname": "SenseonicsHoldingsInc.CommonStockMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_SlrAmiTopcoBlockerLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SLR-AMI topco blocker, LLC.", "label": "SLR AMI Topco Blocker, LLC [Member]", "terseLabel": "SLR-AMI Topco Blocker, LLC" } } }, "localname": "SlrAmiTopcoBlockerLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "ck0001743415_SoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Software", "label": "Software [Member]", "terseLabel": "Software" } } }, "localname": "SoftwareMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_SouthernOrthodonticPartnersManagementLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Southern orthodontic partners management LLC.", "label": "Southern Orthodontic Partners Management LLC [Member]", "terseLabel": "Southern Orthodontic Partners Management, LLC", "verboseLabel": "Southern Orthodontic Partners Management, LLC." } } }, "localname": "SouthernOrthodonticPartnersManagementLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_SpecialtyRetailMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specialty retail.", "label": "Specialty Retail [Member]", "terseLabel": "Specialty Retail" } } }, "localname": "SpecialtyRetailMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_SpectrumPharmaceuticalsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spectrum pharmaceuticals, inc.", "label": "Spectrum Pharmaceuticals, Inc. [Member]", "terseLabel": "Spectrum Pharmaceuticals, Inc." } } }, "localname": "SpectrumPharmaceuticalsInc.Member", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_SpectrumPharmaceuticalsInc.WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spectrum pharmaceuticals, inc. warrants.", "label": "Spectrum Pharmaceuticals, Inc. Warrants [Member]", "terseLabel": "Spectrum Pharmaceuticals, Inc. Warrants" } } }, "localname": "SpectrumPharmaceuticalsInc.WarrantsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_SpectrumPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spectrum pharmaceuticals inc.", "label": "Spectrum Pharmaceuticals Inc [Member]", "terseLabel": "Spectrum Pharmaceuticals, Inc." } } }, "localname": "SpectrumPharmaceuticalsIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_SpvFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPV facility.", "label": "SPV Facility [Member]", "terseLabel": "SPV Facility [Member]" } } }, "localname": "SpvFacilityMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.scppcibl.com/role/DebtAdditionalInformationDetail", "http://www.scppcibl.com/role/FairValueAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_SubscriptionFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription facility.", "label": "Subscription Facility [Member]", "terseLabel": "Subscription Facility [Member]" } } }, "localname": "SubscriptionFacilityMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.scppcibl.com/role/DebtAdditionalInformationDetail", "http://www.scppcibl.com/role/FairValueAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_SunmedGroupHoldingsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SunMed group holdings LLC.", "label": "SunMed Group Holdings LLC [Member]", "terseLabel": "SunMed Group Holdings, LLC" } } }, "localname": "SunmedGroupHoldingsLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_TaucManagementLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TAUC management LLC.", "label": "TAUC Management LLC [Member]", "terseLabel": "TAUC Management, LLC" } } }, "localname": "TaucManagementLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_ThirdAdviserCatchUpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third adviser catch up.", "label": "Third Adviser Catch Up [Member]" } } }, "localname": "ThirdAdviserCatchUpMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_ThirdOrderOfPriorityReturnOfCapitalContributionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Order of Priority Return of Capital Contributions Member.", "label": "Third Order of Priority Return of Capital Contributions [Member]", "terseLabel": "Third Order of Priority Return of Capital Contributions [Member]" } } }, "localname": "ThirdOrderOfPriorityReturnOfCapitalContributionsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_TilleyChemicalBuyerIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tilley chemical buyer inc.", "label": "Tilley Chemical Buyer Inc [Member]", "terseLabel": "Tilley Chemical Buyer, Inc" } } }, "localname": "TilleyChemicalBuyerIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_TilleyDistributionIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tilley distribution, inc.", "label": "Tilley Distribution, Inc [Member]", "terseLabel": "Tilley Distribution, Inc." } } }, "localname": "TilleyDistributionIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_TradingCompaniesAndDistributorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading companies and distributors.", "label": "Trading Companies and Distributors [Member]", "terseLabel": "Trading Companies\u00a0& Distributors" } } }, "localname": "TradingCompaniesAndDistributorsMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_TransportationInsightLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transportation insight LLC.", "label": "Transportation Insight LLC [Member]", "terseLabel": "Transportation Insight, LLC" } } }, "localname": "TransportationInsightLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_UltimateBakedGoodsMidcoLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ultimate baked goods midco LLC.", "label": "Ultimate Baked Goods Midco LLC [Member]", "terseLabel": "Ultimate Baked Goods Midco LLC (Rise Baking)" } } }, "localname": "UltimateBakedGoodsMidcoLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_UnfundedCommitments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unfunded commitments.", "label": "Unfunded Commitments", "terseLabel": "Unfunded commitments" } } }, "localname": "UnfundedCommitments", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail" ], "xbrltype": "monetaryItemType" }, "ck0001743415_ValuationTechniqueRecoveryAnalysisModelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Valuation technique recovery analysis model.", "label": "Valuation Technique Recovery Analysis Model [Member]", "terseLabel": "Valuation Technique Recovery Analysis Model [Member]" } } }, "localname": "ValuationTechniqueRecoveryAnalysisModelMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "ck0001743415_VapothermIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vapotherm inc.", "label": "Vapotherm Inc [Member]", "terseLabel": "Vapotherm, Inc." } } }, "localname": "VapothermIncMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "ck0001743415_VesscoMidcoHoldingsLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vessco midco holdings LLC.", "label": "Vessco Midco Holdings LLC [Member]", "terseLabel": "Vessco Midco Holdings, LLC" } } }, "localname": "VesscoMidcoHoldingsLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "ck0001743415_WaterUtilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Water utilities.", "label": "Water Utilities [Member]", "terseLabel": "Water Utilities" } } }, "localname": "WaterUtilitiesMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_WeightedAverageLimitedLiabilityCompanyUnitsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average limited liability company units outstanding.", "label": "Weighted Average Limited Liability Company Units Outstanding", "terseLabel": "Weighted average limited liability company units outstanding" } } }, "localname": "WeightedAverageLimitedLiabilityCompanyUnitsOutstanding", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsParentheticalDetail" ], "xbrltype": "sharesItemType" }, "ck0001743415_WirelessTelecommunicationServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wireless telecommunication services.", "label": "Wireless Telecommunication Services [Member]", "terseLabel": "Wireless Telecommunication Services" } } }, "localname": "WirelessTelecommunicationServicesMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "ck0001743415_WorldInsuranceAssociatesLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "World insurance associates LLC.", "label": "World Insurance Associates LLC [Member]", "terseLabel": "World Insurance Associates, LLC", "verboseLabel": "World Insurance Associates, LLC." } } }, "localname": "WorldInsuranceAssociatesLlcMember", "nsuri": "http://www.scppcibl.com/20230630", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesSummaryOfUnfundedCommitmentsDetail", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.scppcibl.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "ecd_Additional402vDisclosureTextBlock": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "localname": "Additional402vDisclosureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToCompAmt": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "localname": "AdjToCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AdjToCompAxis": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "localname": "AdjToCompAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "localname": "AdjToNonPeoNeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToPeoCompFnTextBlock": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "localname": "AdjToPeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AggtErrCompAmt": { "auth_ref": [ "r421", "r432", "r442", "r467" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "localname": "AggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "auth_ref": [ "r424", "r435", "r445", "r470" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "localname": "AggtErrCompNotYetDeterminedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AllAdjToCompMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "localname": "AllAdjToCompMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllExecutiveCategoriesMember": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "localname": "AllExecutiveCategoriesMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllIndividualsMember": { "auth_ref": [ "r428", "r436", "r446", "r463", "r471", "r475", "r483" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "localname": "AllIndividualsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllTradingArrangementsMember": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "localname": "AllTradingArrangementsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "ecd_AwardExrcPrice": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "localname": "AwardExrcPrice", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "perShareItemType" }, "ecd_AwardGrantDateFairValue": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "localname": "AwardGrantDateFairValue", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AwardTmgDiscLineItems": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "localname": "AwardTmgDiscLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMethodTextBlock": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "localname": "AwardTmgMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMnpiCnsdrdFlag": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "localname": "AwardTmgMnpiCnsdrdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardTmgMnpiDiscTextBlock": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "localname": "AwardTmgMnpiDiscTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgPredtrmndFlag": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "localname": "AwardTmgPredtrmndFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardUndrlygSecuritiesAmt": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "localname": "AwardUndrlygSecuritiesAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_AwardsCloseToMnpiDiscIndName": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "localname": "AwardsCloseToMnpiDiscIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTable": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "localname": "AwardsCloseToMnpiDiscTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "localname": "AwardsCloseToMnpiDiscTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ChangedPeerGroupFnTextBlock": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "localname": "ChangedPeerGroupFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CoSelectedMeasureAmt": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "localname": "CoSelectedMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_CoSelectedMeasureName": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "localname": "CoSelectedMeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "localname": "CompActuallyPaidVsNetIncomeTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompAnalysisTextBlock": { "auth_ref": [ "r421", "r432", "r442", "r467" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "localname": "ErrCompAnalysisTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompRecoveryTable": { "auth_ref": [ "r418", "r429", "r439", "r464" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "localname": "ErrCompRecoveryTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ExecutiveCategoryAxis": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "localname": "ExecutiveCategoryAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "auth_ref": [ "r425", "r436", "r446", "r471" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "auth_ref": [ "r425", "r436", "r446", "r471" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "auth_ref": [ "r425", "r436", "r446", "r471" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "auth_ref": [ "r425", "r436", "r446", "r471" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ForgoneRecoveryIndName": { "auth_ref": [ "r425", "r436", "r446", "r471" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "ForgoneRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_IndividualAxis": { "auth_ref": [ "r428", "r436", "r446", "r463", "r471", "r475", "r483" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "localname": "IndividualAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_InsiderTradingArrLineItems": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "localname": "InsiderTradingArrLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTradingPoliciesProcLineItems": { "auth_ref": [ "r417", "r487" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "localname": "InsiderTradingPoliciesProcLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "auth_ref": [ "r417", "r487" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "localname": "InsiderTrdPoliciesProcAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "booleanItemType" }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "auth_ref": [ "r417", "r487" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "textBlockItemType" }, "ecd_MeasureAxis": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "localname": "MeasureAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_MeasureName": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "localname": "MeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_MnpiDiscTimedForCompValFlag": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "localname": "MnpiDiscTimedForCompValFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_MtrlTermsOfTrdArrTextBlock": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "localname": "MtrlTermsOfTrdArrTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "textBlockItemType" }, "ecd_NamedExecutiveOfficersFnTextBlock": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "localname": "NamedExecutiveOfficersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonGaapMeasureDescriptionTextBlock": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "localname": "NonGaapMeasureDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonNeosMember": { "auth_ref": [ "r425", "r436", "r446", "r463", "r471" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "localname": "NonNeosMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoAvgTotalCompAmt": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "localname": "NonPeoNeoAvgTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoMember": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "localname": "NonPeoNeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonRule10b51ArrAdoptedFlag": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "localname": "NonRule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_NonRule10b51ArrTrmntdFlag": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "localname": "NonRule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_OtherPerfMeasureAmt": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "localname": "OtherPerfMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_OutstandingAggtErrCompAmt": { "auth_ref": [ "r423", "r434", "r444", "r469" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "localname": "OutstandingAggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryCompAmt": { "auth_ref": [ "r426", "r437", "r447", "r472" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "localname": "OutstandingRecoveryCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryIndName": { "auth_ref": [ "r426", "r437", "r447", "r472" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "OutstandingRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PayVsPerformanceDisclosureLineItems": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "localname": "PayVsPerformanceDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_PeerGroupIssuersFnTextBlock": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "localname": "PeerGroupIssuersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_PeerGroupTotalShareholderRtnAmt": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "localname": "PeerGroupTotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoActuallyPaidCompAmt": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "localname": "PeoActuallyPaidCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoMember": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "localname": "PeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_PeoName": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "localname": "PeoName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_PeoTotalCompAmt": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "localname": "PeoTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PvpTable": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "localname": "PvpTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PvpTableTextBlock": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "localname": "PvpTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "auth_ref": [ "r418", "r429", "r439", "r464" ], "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "localname": "RecoveryOfErrCompDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_RestatementDateAxis": { "auth_ref": [ "r419", "r430", "r440", "r465" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "localname": "RestatementDateAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_RestatementDeterminationDate": { "auth_ref": [ "r420", "r431", "r441", "r466" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "localname": "RestatementDeterminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "dateItemType" }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "auth_ref": [ "r427", "r438", "r448", "r473" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "localname": "RestatementDoesNotRequireRecoveryTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_Rule10b51ArrAdoptedFlag": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "localname": "Rule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_Rule10b51ArrTrmntdFlag": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "localname": "Rule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "auth_ref": [ "r422", "r433", "r443", "r468" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "localname": "StkPrcOrTsrEstimationMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TabularListTableTextBlock": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "localname": "TabularListTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TotalShareholderRtnAmt": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "localname": "TotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TradingArrAxis": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "localname": "TradingArrAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TradingArrByIndTable": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "localname": "TradingArrByIndTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrAdoptionDate": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "localname": "TrdArrAdoptionDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrDuration": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "localname": "TrdArrDuration", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "durationItemType" }, "ecd_TrdArrIndName": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "localname": "TrdArrIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrIndTitle": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "localname": "TrdArrIndTitle", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrSecuritiesAggAvailAmt": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "localname": "TrdArrSecuritiesAggAvailAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "sharesItemType" }, "ecd_TrdArrTerminationDate": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "localname": "TrdArrTerminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_UndrlygSecurityMktPriceChngPct": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "localname": "UndrlygSecurityMktPriceChngPct", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "pureItemType" }, "srt_MaximumMember": { "auth_ref": [ "r107", "r108", "r109", "r110", "r155", "r208", "r230", "r276", "r277", "r337", "r347", "r351", "r352", "r368", "r391", "r392", "r395", "r402", "r406", "r408", "r508", "r515", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r107", "r108", "r109", "r110", "r155", "r208", "r230", "r276", "r277", "r337", "r347", "r351", "r352", "r368", "r391", "r392", "r395", "r402", "r406", "r408", "r508", "r515", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.scppcibl.com/role/DebtAdditionalInformationDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r107", "r108", "r109", "r110", "r147", "r155", "r178", "r179", "r180", "r207", "r208", "r230", "r276", "r277", "r337", "r347", "r351", "r352", "r368", "r391", "r392", "r395", "r402", "r406", "r408", "r409", "r504", "r508", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.scppcibl.com/role/DebtAdditionalInformationDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r107", "r108", "r109", "r110", "r147", "r155", "r178", "r179", "r180", "r207", "r208", "r230", "r276", "r277", "r337", "r347", "r351", "r352", "r368", "r391", "r392", "r395", "r402", "r406", "r408", "r409", "r504", "r508", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.scppcibl.com/role/DebtAdditionalInformationDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r391", "r392", "r515", "r517", "r520" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Other liabilities and accrued expenses" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net increase in unitholders' capital resulting from operations to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdministrativeFeesExpense": { "auth_ref": [ "r26", "r311", "r531" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 5.0, "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost.", "label": "Administrative Fees Expense", "terseLabel": "Administration fees (see note 3)", "verboseLabel": "Administrative fees expense" } } }, "localname": "AdministrativeFeesExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestmentMeasurementInput": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure alternative investment.", "label": "Alternative Investment, Measurement Input", "verboseLabel": "Alternative Investment, Measurement Input" } } }, "localname": "AlternativeInvestmentMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "decimalItemType" }, "us-gaap_Assets": { "auth_ref": [ "r55", "r65", "r77", "r97", "r100", "r102", "r104", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r182", "r184", "r198", "r222", "r304", "r407", "r414", "r506", "r507", "r513" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r61", "r224", "r262", "r298", "r407", "r414", "r490" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 14.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r16", "r44", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH AT END OF PERIOD", "periodStartLabel": "CASH AT BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r2", "r44" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET DECREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r14", "r29", "r223", "r289" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r48", "r105", "r106", "r390", "r505" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r35", "r225", "r407" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 3.0, "parentTag": "us-gaap_MembersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common Unitholders' capital (25,190,253 and 18,992,563 units, respectively, issued and outstanding)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitIssued": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Number of common units issued of limited liability company (LLC).", "label": "Common Unit, Issued", "terseLabel": "Common unit issued" } } }, "localname": "CommonUnitIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonUnitOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC).", "label": "Common Unit, Outstanding", "periodEndLabel": "Units issued and outstanding at end of period", "periodStartLabel": "Units at beginning of period", "terseLabel": "Common unit outstanding" } } }, "localname": "CommonUnitOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail", "http://www.scppcibl.com/role/UnitholdersCapitalSummaryOfLimitedLiabilityCompanyUnitHoldersCapitalDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.scppcibl.com/role/DebtAdditionalInformationDetail", "http://www.scppcibl.com/role/FairValueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.scppcibl.com/role/DebtAdditionalInformationDetail", "http://www.scppcibl.com/role/FairValueAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": { "auth_ref": [ "r320", "r321", "r370", "r371", "r372", "r492", "r493" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt and equity securities.", "label": "Debt and Equity Securities, Realized Gain (Loss)", "terseLabel": "Realized Gain (Loss)" } } }, "localname": "DebtAndEquitySecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": { "auth_ref": [ "r326", "r327", "r373", "r374", "r375", "r492", "r493" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities.", "label": "Debt and Equity Securities, Unrealized Gain (Loss)", "terseLabel": "Change in Unrealized Gain (Loss)" } } }, "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r49", "r76", "r120", "r126", "r127", "r128", "r129", "r130", "r131", "r136", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r10", "r31", "r32", "r56", "r58", "r78", "r121", "r122", "r123", "r124", "r125", "r127", "r132", "r133", "r134", "r135", "r137", "r138", "r139", "r140", "r141", "r142", "r199", "r397", "r398", "r399", "r400", "r401", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r23", "r25", "r121", "r199", "r398", "r399" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt Instrument face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r13", "r78", "r121", "r122", "r123", "r124", "r125", "r127", "r132", "r133", "r134", "r135", "r137", "r138", "r139", "r140", "r141", "r142", "r199", "r397", "r398", "r399", "r400", "r401", "r497" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r24", "r132", "r146", "r398", "r399" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Net of unamortized debt issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DistributionsMadeToMembersOrLimitedPartnersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Distributions Made to Members or Limited Partners [Abstract]", "terseLabel": "Distributions to Unitholders:" } } }, "localname": "DistributionsMadeToMembersOrLimitedPartnersAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r32", "r33", "r57", "r411", "r522" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Distributions payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesByIndustryAxis": { "auth_ref": [ "r266", "r270", "r273", "r339", "r349", "r358", "r380", "r396", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Axis]" } } }, "localname": "EquitySecuritiesByIndustryAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesIndustryMember": { "auth_ref": [ "r266", "r270", "r273", "r339", "r349", "r358", "r380", "r409" ], "lang": { "en-us": { "role": { "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Domain]" } } }, "localname": "EquitySecuritiesIndustryMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r188", "r189", "r195" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r188", "r189", "r195" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of quantitative information about the company's level 3 asset fair value measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r20", "r54" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of assets measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r8", "r22" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r8", "r22" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of the changes in fair value of level 3 assets" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r134", "r148", "r149", "r150", "r151", "r152", "r153", "r189", "r204", "r205", "r206", "r398", "r399", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r188", "r189", "r191", "r192", "r196" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r134", "r148", "r153", "r189", "r204", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r134", "r148", "r153", "r189", "r205", "r398", "r399", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r134", "r148", "r149", "r150", "r151", "r152", "r153", "r189", "r206", "r398", "r399", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsQuantitativeInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]" } } }, "localname": "FairValueInputsQuantitativeInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r193" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "terseLabel": "Net realized gain (loss)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "auth_ref": [ "r21" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "terseLabel": "Purchase of investment securities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": { "auth_ref": [ "r21" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales", "terseLabel": "Proceeds from dispositions of investment securities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Transfers into Level\u00a03" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "terseLabel": "Transfers out of Level\u00a03" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Closing balance", "periodStartLabel": "Opening balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r134", "r148", "r149", "r150", "r151", "r152", "r153", "r204", "r205", "r206", "r398", "r399", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r187", "r196" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncentiveFeePayable": { "auth_ref": [ "r528" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 9.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of fee payable for management of operations based on performance under arrangement, including, but not limited to, investment.", "label": "Incentive Fee Payable", "terseLabel": "Incentive fee payable (see note 3)" } } }, "localname": "IncentiveFeePayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeApproachValuationTechniqueMember": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach converting future amounts to single current discounted amount.", "label": "Valuation, Income Approach [Member]" } } }, "localname": "IncomeApproachValuationTechniqueMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r3" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "Interest receivable" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r496" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Other liabilities and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncentiveFeePayable": { "auth_ref": [ "r533" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in fee payable for management of operations based on performance under arrangement, including, but not limited to, investment.", "label": "Increase (Decrease) in Incentive Fee Payable", "terseLabel": "Incentive fee payable" } } }, "localname": "IncreaseDecreaseInIncentiveFeePayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r3" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Interest payable" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInManagementFeePayable": { "auth_ref": [ "r533" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in fee payable for management of fund or trust.", "label": "Increase (Decrease) in Management Fee Payable", "terseLabel": "Management fee payable" } } }, "localname": "IncreaseDecreaseInManagementFeePayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "(Increase) decrease in operating assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Liabilities [Abstract]", "terseLabel": "Increase (decrease) in operating liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r3" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDebtExpense": { "auth_ref": [ "r5" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 6.0, "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.", "label": "Interest and Debt Expense", "terseLabel": "Interest and other credit facility expenses (see note 5)" } } }, "localname": "InterestAndDebtExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDividendIncomeSecurities": { "auth_ref": [ "r530", "r535" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating dividend and interest income, including amortization and accretion of premiums and discounts, on securities.", "label": "Interest and Dividend Income, Securities, Operating", "terseLabel": "Interest/ Dividend Income" } } }, "localname": "InterestAndDividendIncomeSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r70", "r72", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r28", "r522" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 11.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable", "terseLabel": "Interest payable (see note 5)" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r491", "r534" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 15.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable", "terseLabel": "Interest receivable" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentAcquisitionDate": { "auth_ref": [ "r341", "r345", "r355", "r379" ], "lang": { "en-us": { "role": { "documentation": "Date when investment is acquired, in YYYY-MM-DD format.", "label": "Investment, Acquisition Date", "terseLabel": "Acquisition Date" } } }, "localname": "InvestmentAcquisitionDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "dateItemType" }, "us-gaap_InvestmentAffiliatedIssuerNoncontrolledMember": { "auth_ref": [ "r235", "r245", "r285", "r287", "r294", "r309", "r315", "r316", "r363", "r370", "r371", "r373", "r374", "r376", "r377", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Noncontrolled affiliated issuer of investment.", "label": "Investment, Affiliated Issuer, Noncontrolled [Member]", "terseLabel": "Investment, Affiliated Issuer, Noncontrolled [Member]" } } }, "localname": "InvestmentAffiliatedIssuerNoncontrolledMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Company, Capital Share Transaction, Increase (Decrease) [Abstract]", "terseLabel": "Increase in unitholders' capital resulting from capital activity:" } } }, "localname": "InvestmentCompanyCapitalShareTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyCommittedCapital": { "auth_ref": [ "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of funds committed to investment company from investors.", "label": "Investment Company, Committed Capital", "terseLabel": "Investment company committed capital" } } }, "localname": "InvestmentCompanyCommittedCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyDistributionOrdinaryIncome": { "auth_ref": [ "r244", "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of dividend distribution by investment company from ordinary income.", "label": "Investment Company, Distribution, Ordinary Income", "verboseLabel": "From net investment income" } } }, "localname": "InvestmentCompanyDistributionOrdinaryIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyDistributionToShareholdersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Company, Distribution to Shareholders [Abstract]", "terseLabel": "Distributions to unitholders:" } } }, "localname": "InvestmentCompanyDistributionToShareholdersAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyDistributionToShareholdersPerShare": { "auth_ref": [ "r244", "r258" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit amount of distribution to shareholders. Includes, but is not limited to, dividend and capital gain. Excludes distribution for tax return of capital.", "label": "Investment Company, Distribution to Shareholders, Per Share", "negatedLabel": "From distributable earnings" } } }, "localname": "InvestmentCompanyDistributionToShareholdersPerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_InvestmentCompanyExpenseRatioAfterIncentiveAllocation": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Percentage of expense, after incentive allocation, to average net assets.", "label": "Investment Company, Expense Ratio after Incentive Allocation", "verboseLabel": "Total expenses" } } }, "localname": "InvestmentCompanyExpenseRatioAfterIncentiveAllocation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_InvestmentCompanyFinancialHighlightsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Company, Financial Highlights [Abstract]" } } }, "localname": "InvestmentCompanyFinancialHighlightsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyFinancialHighlightsLineItems": { "auth_ref": [ "r249", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Investment Company, Financial Highlights [Line Items]" } } }, "localname": "InvestmentCompanyFinancialHighlightsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyFinancialHighlightsTable": { "auth_ref": [ "r249", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about financial highlights. Includes, but is not limited to, per share information, income and expense ratios, total return, capital commitment and fee waiver.", "label": "Investment Company, Financial Highlights [Table]" } } }, "localname": "InvestmentCompanyFinancialHighlightsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyFinancialHighlightsTableTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial highlights. Includes, but is not limited to, per share information, income and expense ratios, total return, capital commitment and fee waiver.", "label": "Investment Company, Financial Highlights [Table Text Block]", "terseLabel": "Summary of investment company, financial highlights" } } }, "localname": "InvestmentCompanyFinancialHighlightsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentCompanyFinancialHighlightsTextBlock": { "auth_ref": [ "r243", "r247", "r250", "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of financial highlights reported by investment company.", "label": "Investment Company, Financial Highlights [Text Block]", "terseLabel": "Financial Highlights" } } }, "localname": "InvestmentCompanyFinancialHighlightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlights" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentCompanyFinancialRatiosAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Company, Financial Ratios [Abstract]", "terseLabel": "Ratios to average net assets of Unitholders' Capital:" } } }, "localname": "InvestmentCompanyFinancialRatiosAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyGainLossOnInvestmentPerShare": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit amount of realized and unrealized gain (loss) on investment.", "label": "Investment Company, Gain (Loss) on Investment, Per Share", "terseLabel": "Net realized and unrealized gain (loss)" } } }, "localname": "InvestmentCompanyGainLossOnInvestmentPerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_InvestmentCompanyInvestmentIncomeLossFromOperationsPerShare": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit amount of investment income (loss) and realized and unrealized gain (loss) on investment.", "label": "Investment Company, Investment Income (Loss) from Operations, Per Share", "terseLabel": "Net Income Per Unit" } } }, "localname": "InvestmentCompanyInvestmentIncomeLossFromOperationsPerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_InvestmentCompanyInvestmentIncomeLossFromOperationsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Company, Investment Income (Loss) from Operations, Per Share [Abstract]", "terseLabel": "Per Share Data:" } } }, "localname": "InvestmentCompanyInvestmentIncomeLossFromOperationsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyInvestmentIncomeLossPerShare": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit amount, after investment expense, of dividend and interest investment income (loss).", "label": "Investment Company, Investment Income (Loss), Per Share", "terseLabel": "Net investment income" } } }, "localname": "InvestmentCompanyInvestmentIncomeLossPerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_InvestmentCompanyInvestmentIncomeLossRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of investment income (loss) to average net assets.", "label": "Investment Company, Investment Income (Loss) Ratio", "terseLabel": "Net investment income" } } }, "localname": "InvestmentCompanyInvestmentIncomeLossRatio", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_InvestmentCompanyNetAssetValuePerSharePeriodIncreaseDecrease": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit amount of increase (decrease) in net asset value.", "label": "Investment Company, Net Asset Value Per Share, Period Increase (Decrease)", "terseLabel": "Net increase in Unitholders' capital resulting from operations" } } }, "localname": "InvestmentCompanyNetAssetValuePerSharePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_InvestmentCompanyNetAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Investment Company, Net Assets [Roll Forward]" } } }, "localname": "InvestmentCompanyNetAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrency": { "auth_ref": [ "r312", "r389", "r412", "r532" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 11.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of realized and unrealized gain (loss) on investment and derivative, classified as operating, and foreign currency transaction. Investment includes, but is not limited to, debt and equity securities, security sold short, real estate, and commodity.", "label": "Investment Company, Realized and Unrealized Gain (Loss) on Investment and Foreign Currency", "totalLabel": "Net realized and unrealized gain (loss) on investments" } } }, "localname": "InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrency", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrencyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Company, Realized and Unrealized Gain (Loss) on Investment and Foreign Currency [Abstract]", "verboseLabel": "Realized and unrealized gain (loss) on investments:" } } }, "localname": "InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrencyAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentCompanyTotalReturn": { "auth_ref": [ "r242", "r248", "r252" ], "lang": { "en-us": { "role": { "documentation": "Percentage increase (decrease) in fund net asset value, assuming reinvestment of dividends and capital gain distributions.", "label": "Investment Company, Total Return", "terseLabel": "Investment company, total return", "verboseLabel": "Total Return" } } }, "localname": "InvestmentCompanyTotalReturn", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r41", "r98" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 10.0, "parentTag": "ck0001743415_GrossInvestmentIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest:" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInvestmentExpense": { "auth_ref": [ "r43", "r412", "r524" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_InvestmentIncomeNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the generation of investment income.", "label": "Investment Income, Investment Expense", "totalLabel": "Total expenses" } } }, "localname": "InvestmentIncomeInvestmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r40", "r42" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "terseLabel": "Net investment income", "totalLabel": "Net investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital", "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Income, Net [Abstract]", "terseLabel": "Investment Income:" } } }, "localname": "InvestmentIncomeNetAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentInterestRate": { "auth_ref": [ "r337", "r338", "r347", "r348", "r350", "r351", "r368", "r369", "r409", "r499", "r501" ], "lang": { "en-us": { "role": { "documentation": "Rate of interest on investment.", "label": "Investment Interest Rate", "terseLabel": "Interest Rate" } } }, "localname": "InvestmentInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "percentItemType" }, "us-gaap_InvestmentIssuerAffiliationAxis": { "auth_ref": [ "r235", "r245", "r269", "r280", "r293", "r294", "r315", "r316", "r317", "r318", "r320", "r321", "r326", "r327", "r339", "r340", "r343", "r357", "r358", "r359", "r370", "r371", "r373", "r374", "r376", "r377", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by affiliation of issuer of investment.", "label": "Investment, Issuer Affiliation [Axis]" } } }, "localname": "InvestmentIssuerAffiliationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentIssuerAffiliationDomain": { "auth_ref": [ "r235", "r245", "r269", "r280", "r293", "r294", "r315", "r316", "r317", "r318", "r320", "r321", "r326", "r327", "r339", "r340", "r343", "r357", "r358", "r359", "r370", "r371", "r373", "r374", "r376", "r377", "r378", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "Affiliation of issuer of investment.", "label": "Investment, Issuer Affiliation [Domain]" } } }, "localname": "InvestmentIssuerAffiliationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentMaturityDate": { "auth_ref": [ "r337", "r338", "r347", "r348", "r350", "r351", "r368", "r369", "r409", "r500", "r502" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of investment, in YYYY-MM-DD format.", "label": "Investment Maturity Date", "terseLabel": "Maturity Date" } } }, "localname": "InvestmentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "dateItemType" }, "us-gaap_InvestmentOwnedAtCost": { "auth_ref": [ "r235", "r271", "r272", "r342", "r346", "r356", "r379", "r409", "r414", "r527" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of the investment.", "label": "Investment Owned, at Cost", "terseLabel": "Investments at cost", "verboseLabel": "Cost" } } }, "localname": "InvestmentOwnedAtCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedAtFairValue": { "auth_ref": [ "r235", "r264", "r265", "r266", "r268", "r270", "r271", "r272", "r275", "r280", "r281", "r293", "r294", "r336", "r339", "r340", "r344", "r353", "r354", "r358", "r359", "r360", "r364", "r367", "r378", "r380", "r381", "r409", "r414", "r527" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in security owned.", "label": "Investment Owned, at Fair Value", "periodEndLabel": "Fair Value at June 30, 2023", "periodStartLabel": "Fair Value at June 16, 2023", "terseLabel": "Fair Value" } } }, "localname": "InvestmentOwnedAtFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue": { "auth_ref": [ "r18", "r19" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Nominal or face amount on the investment owned.", "label": "Investment Owned, Face Amount", "terseLabel": "Par Amount" } } }, "localname": "InvestmentOwnedUnderlyingFaceAmountAtMarketValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r265", "r267", "r268", "r271", "r275", "r336", "r339", "r349", "r354", "r358", "r361", "r362", "r380", "r382", "r383", "r384", "r385", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail", "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r265", "r267", "r268", "r271", "r275", "r336", "r339", "r349", "r354", "r358", "r361", "r362", "r380", "r382", "r383", "r384", "r385", "r409" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail", "http://www.scppcibl.com/role/FairValueSummaryOfTheChangesInFairValueOfLevel3AssetsDetail", "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r188" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 13.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments at fair value", "verboseLabel": "Investments, Fair Value Disclosure" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/FairValueSummaryOfAssetsMeasuredAtFairValueOnARecurringBasisDetail", "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure [Abstract]", "terseLabel": "Investments at fair value:" } } }, "localname": "InvestmentsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossAdditions": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross additions to the investment in and advance to the affiliate.", "label": "Investments in and Advances to Affiliates, at Fair Value, Gross Additions", "terseLabel": "Gross Additions" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossAdditions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross reductions to the investment in and advance to the affiliate.", "label": "Investments in and Advances to Affiliates, at Fair Value, Gross Reductions", "terseLabel": "Gross Reductions" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets held for their financial return, rather than for the entity's operations.", "label": "Investments [Member]" } } }, "localname": "InvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r12", "r77", "r104", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r183", "r184", "r185", "r198", "r288", "r393", "r414", "r506", "r513", "r514" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r37", "r59", "r227", "r407", "r498", "r503", "r511" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and unitholders' capital" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_LimitedLiabilityCompanyLLCMembersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Limited Liability Company (LLC) Members' Equity [Abstract]" } } }, "localname": "LimitedLiabilityCompanyLLCMembersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r10", "r58", "r523" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "terseLabel": "Revolving credit facility", "verboseLabel": "Long-Term Line of Credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAverageOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Average amount borrowed under the credit facility during the period.", "label": "Line of Credit Facility, Average Outstanding Amount", "terseLabel": "Line of credit facility, average outstanding amount" } } }, "localname": "LineOfCreditFacilityAverageOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r11", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.", "label": "Line of Credit Facility, Expiration Date", "terseLabel": "Line of credit facility, expiration date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r197" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Line of credit facility, Fair value of amount outstanding" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r11", "r497" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail", "http://www.scppcibl.com/role/FairValueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r11" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line Of Credit Facility Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r11", "r497" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail", "http://www.scppcibl.com/role/FairValueAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermDebtAverageAmountOutstanding": { "auth_ref": [ "r62", "r63", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Average amount outstanding of long-term debt.", "label": "Long-Term Debt, Average Amount Outstanding", "terseLabel": "Average debt outstanding" } } }, "localname": "LongTermDebtAverageAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.", "label": "Long-Term Debt, Weighted Average Interest Rate, over Time", "terseLabel": "Long term debt weighted average interest over a period of time" } } }, "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r13", "r17" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "domainItemType" }, "us-gaap_ManagementFeeExpense": { "auth_ref": [ "r26", "r316", "r412", "r529" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 3.0, "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment.", "label": "Management Fee Expense", "terseLabel": "Management fees (see note 3)", "verboseLabel": "Management fee expense" } } }, "localname": "ManagementFeeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManagementFeePayable": { "auth_ref": [ "r282" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 8.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of fee payable for management of fund or trust.", "label": "Management Fee Payable", "terseLabel": "Management fee payable (see note 3)" } } }, "localname": "ManagementFeePayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketApproachValuationTechniqueMember": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach using price and other relevant information generated by market transaction involving identical or comparable asset, liability, or group of assets and liabilities.", "label": "Valuation, Market Approach [Member]" } } }, "localname": "MarketApproachValuationTechniqueMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputEbitdaMultipleMember": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using earnings before interest, tax, depreciation and amortization (EBITDA) multiple.", "label": "Measurement Input, EBITDA Multiple [Member]" } } }, "localname": "MeasurementInputEbitdaMultipleMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MembersCapital": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of member capital in limited liability company (LLC).", "label": "Members' Capital", "periodEndLabel": "Unitholders' capital, end of period", "periodStartLabel": "Unitholders' capital, beginning of period" } } }, "localname": "MembersCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital", "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MembersEquity": { "auth_ref": [ "r51", "r92", "r93", "r94", "r96" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of ownership interest in limited liability company (LLC), attributable to the parent entity.", "label": "Members' Equity", "totalLabel": "Total unitholders' capital" } } }, "localname": "MembersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_MembersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Members' Equity [Abstract]", "terseLabel": "Unitholders' Capital" } } }, "localname": "MembersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "stringItemType" }, "us-gaap_MembersEquityNotesDisclosureTextBlock": { "auth_ref": [ "r90", "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the formation, structure, control and ownership of a limited liability company (LLC).", "label": "Members' Equity Notes Disclosure [Text Block]", "terseLabel": "Unitholders' Capital" } } }, "localname": "MembersEquityNotesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/UnitholdersCapital" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetAssetValuePerShare": { "auth_ref": [ "r0", "r1", "r9", "r254", "r261", "r263", "r292", "r310", "r386", "r414" ], "lang": { "en-us": { "role": { "documentation": "Net asset value per share or per unit of investments in certain entities that calculate net asset value per share. Includes, but is not limited to, by unit, membership interest, or other ownership interest. Investment includes, but is not limited to, investment in certain hedge funds, venture capital funds, private equity funds, real estate partnerships or funds. Excludes fair value disclosure.", "label": "Net Asset Value Per Share", "periodEndLabel": "Net asset value per unit, end of period", "periodStartLabel": "Net asset value per unit, beginning of period", "terseLabel": "Net asset value per unit" } } }, "localname": "NetAssetValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by (Used in) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r44", "r45", "r46" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by (Used in) Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r38", "r46", "r60", "r64", "r67", "r68", "r69", "r77", "r82", "r83", "r84", "r85", "r86", "r87", "r88", "r89", "r97", "r99", "r101", "r103", "r104", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r119", "r186", "r198", "r228", "r313", "r332", "r333", "r394", "r412", "r506" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital": { "order": 4.0, "parentTag": "us-gaap_PartnersCapitalAccountPeriodIncreaseDecrease", "weight": 1.0 }, "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net increase in unitholders' capital resulting from operations", "verboseLabel": "Net increase in unitholders' capital resulting from operations" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows", "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital", "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToReportingEntityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Increase (decrease) in unitholders' capital resulting from operations:" } } }, "localname": "NetIncomeLossAttributableToReportingEntityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r30", "r53", "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r39", "r531" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 7.0, "parentTag": "us-gaap_InvestmentIncomeInvestmentExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "Other General and Administrative Expense", "terseLabel": "Other general and administrative expenses" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnersCapitalAccountContributions": { "auth_ref": [ "r50", "r51" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital": { "order": 3.0, "parentTag": "ck0001743415_NetIncreaseInUnitholdersCapitalResultingFromCapitalActivity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total contributions made by each class of partners (i.e., general, limited and preferred partners).", "label": "Partners' Capital Account, Contributions", "terseLabel": "Contributions" } } }, "localname": "PartnersCapitalAccountContributions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnersCapitalAccountPeriodIncreaseDecrease": { "auth_ref": [ "r51", "r52" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Changes in the ownership interest during the period of each class of partners. Partners include general, limited and preferred partners.", "label": "Increase (Decrease) in Partners' Capital", "totalLabel": "Total increase in unitholders' capital" } } }, "localname": "PartnersCapitalAccountPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnersCapitalAccountUnitsPeriodIncreaseDecrease": { "auth_ref": [ "r51", "r52" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Total net change in the units of each class of partners' capital accounts during the year. Units represent shares of ownership of the general, limited, and preferred partners.", "label": "Partners' Capital Account, Units, Period Increase (Decrease)", "totalLabel": "Net increase from capital unit activity" } } }, "localname": "PartnersCapitalAccountUnitsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital" ], "xbrltype": "sharesItemType" }, "us-gaap_PartnersCapitalAccountUnitsSaleOfUnits": { "auth_ref": [ "r51" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital": { "order": 1.0, "parentTag": "us-gaap_PartnersCapitalAccountUnitsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Total units issued during the year due to the sale of units. All partners include general, limited and preferred partners.", "label": "Partners' Capital Account, Units, Sale of Units", "terseLabel": "Units issued" } } }, "localname": "PartnersCapitalAccountUnitsSaleOfUnits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital", "http://www.scppcibl.com/role/UnitholdersCapitalSummaryOfLimitedLiabilityCompanyUnitHoldersCapitalDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "auth_ref": [ "r27", "r66", "r303", "r521" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 17.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.", "label": "Prepaid Expense", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromContributionsFromParent": { "auth_ref": [ "r15" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from parent as a source of financing that is recorded as additional paid in capital.", "label": "Proceeds from Contributions from Parent", "terseLabel": "Contributions from unitholders" } } }, "localname": "ProceedsFromContributionsFromParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r494" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from borrowings" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r229" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 12.0, "parentTag": "us-gaap_InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Net realized gain on companies less than 5% owned", "documentation": "Amount of realized gain (loss) on investment.", "label": "Realized Investment Gains (Losses)", "negatedTerseLabel": "Net realized gain on investments", "verboseLabel": "Net realized gain" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows", "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital", "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r154", "r200", "r201", "r283", "r284", "r285", "r286", "r287", "r309", "r311", "r335" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r200", "r201", "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Related Party Transaction, Rate", "terseLabel": "Related party transaction rate" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r154", "r200", "r201", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r283", "r284", "r285", "r286", "r287", "r309", "r311", "r335", "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/AgreementsAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r495" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.", "label": "Repayments of Debt", "negatedLabel": "Repayments of borrowings" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r36", "r51", "r226", "r231", "r232", "r241", "r291", "r407" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_MembersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated distributable earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Abstract]" } } }, "localname": "ScheduleOfInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "All Award Types", "terseLabel": "All Award Types" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r47", "r75" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r79", "r80", "r81", "r91", "r209", "r235", "r263", "r280", "r283", "r284", "r285", "r286", "r287", "r290", "r293", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r305", "r306", "r307", "r308", "r309", "r311", "r315", "r316", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r334", "r410" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r79", "r80", "r81", "r91", "r209", "r235", "r263", "r280", "r283", "r284", "r285", "r286", "r287", "r290", "r293", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r305", "r306", "r307", "r308", "r309", "r311", "r315", "r316", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r334", "r410" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilities", "http://www.scppcibl.com/role/ConsolidatedStatementsOfAssetsAndLiabilitiesParenthetical", "http://www.scppcibl.com/role/FinancialHighlightsSummaryOfInvestmentCompanyFinancialHighlightsParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r6", "r34", "r35", "r51", "r240", "r334", "r387" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued during period shares new issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r6", "r34", "r35", "r51", "r246", "r334", "r387", "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Stock issued during period value new issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r202", "r203" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfInvestmentHoldingsLineItems": { "auth_ref": [ "r245", "r264", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r278", "r279", "r314", "r409" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Summary of Investment Holdings [Line Items]" } } }, "localname": "SummaryOfInvestmentHoldingsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfInvestmentHoldingsTable": { "auth_ref": [ "r245", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r278", "r279", "r314", "r409" ], "lang": { "en-us": { "role": { "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded 1 percent of net asset value of the registrant as of the close of the period.", "label": "Summary of Investment Holdings [Table]" } } }, "localname": "SummaryOfInvestmentHoldingsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestments1", "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxBasisOfInvestmentsCostForIncomeTaxPurposes": { "auth_ref": [ "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost of investment for federal income tax purpose.", "label": "Tax Basis of Investments, Cost for Income Tax Purposes", "terseLabel": "Tax Basis Of Investments Cost For Income Tax Purposes" } } }, "localname": "TaxBasisOfInvestmentsCostForIncomeTaxPurposes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxBasisOfInvestmentsGrossUnrealizedAppreciation": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase in investment from unrealized gain when value exceeds cost for federal income tax purpose.", "label": "Tax Basis of Investments, Gross, Unrealized Appreciation", "terseLabel": "Tax Basis Of Investments Gross Unrealized Appreciation" } } }, "localname": "TaxBasisOfInvestmentsGrossUnrealizedAppreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxBasisOfInvestmentsGrossUnrealizedDepreciation": { "auth_ref": [ "r237" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative decrease in investment from unrealized loss when cost for federal income tax purpose exceeds value.", "label": "Tax Basis of Investments, Gross, Unrealized Depreciation", "terseLabel": "Tax Basis Of Investments Gross Unrealized Depreciation" } } }, "localname": "TaxBasisOfInvestmentsGrossUnrealizedDepreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxBasisOfInvestmentsUnrealizedAppreciationDepreciationNet": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase (decrease) in investment from unrealized gain (loss) when value exceeds (is less than) cost for federal income tax purpose.", "label": "Tax Basis of Investments, Unrealized Appreciation (Depreciation), Net", "terseLabel": "Tax Basis Of Investments Unrealized Appreciation Depreciation Net" } } }, "localname": "TaxBasisOfInvestmentsUnrealizedAppreciationDepreciationNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedScheduleOfInvestmentsParethetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r4" ], "calculation": { "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital": { "order": 7.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations": { "order": 13.0, "parentTag": "us-gaap_InvestmentCompanyRealizedAndUnrealizedGainLossOnInvestmentAndForeignCurrency", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Net change in unrealized gain (loss) on investments", "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedTerseLabel": "Net change in unrealized (gain) loss on investments", "verboseLabel": "Net change in unrealized gain (loss)" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/ConsolidatedStatementOfCashFlows", "http://www.scppcibl.com/role/ConsolidatedStatementOfChangesInUnitholdersCapital", "http://www.scppcibl.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/FairValueSummaryOfQuantitativeInformationAboutTheCompanySLevel3AssetFairValueMeasurementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.scppcibl.com/role/DebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-54B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "59", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482134/820-10-35-59", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "10", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480679/815-10-10-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "10", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480769/815-20-10-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(2)(iii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(2)(iv))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(g)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(g)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(11))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(7)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 6)(f))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "36", "Publisher": "FASB", "Section": "45", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-36", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r415": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r416": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r417": { "Name": "Form 20-F", "Paragraph": "a", "Publisher": "SEC", "Section": "16", "Subsection": "J", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r418": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r419": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "A", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r421": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "B", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r422": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "C", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r423": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "D", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r424": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "E", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r425": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r426": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "iii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r427": { "Name": "Form 20-F", "Paragraph": "2", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r428": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r429": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r431": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r432": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r433": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r434": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r435": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r436": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r437": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r438": { "Name": "Form 40-F", "Paragraph": "b", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r439": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r441": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r442": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r443": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r444": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r445": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r446": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r447": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r448": { "Name": "Form N-CSR", "Paragraph": "b", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r449": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r451": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r452": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r453": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r454": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r455": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "vi", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r456": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "3", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r457": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "4", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r458": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r459": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r461": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r462": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r463": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r464": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r465": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r466": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r467": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "B", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r468": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r469": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r47": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r471": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r472": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r473": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r474": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r475": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r476": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r477": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r478": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r479": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "F", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r481": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r482": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r483": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "A", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r484": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "B", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r485": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "C", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r486": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "D", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r487": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r488": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r489": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(c))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480369/946-230-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "272", "URI": "https://asc.fasb.org//272/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 58 0001193125-23-206204-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-206204-xbrl.zip M4$L#!!0 ( %2!"%<^K]58"Q< "D' 0 9 8VLP,# Q-S0S-#$U+3(P M,C,P-C,P+GAS9.U=7W/C.')_3U6^ ^.7VU3%_\:[L^.IG;V2[?&.[^RU8\N[ MFZ125Q )2:@A 0U RM:E\MW3#9(2*1$4"5&&+O:#79((=/^Z&V@ 3:#QTY^? MH]";4JF8X)_VC@^.]CS*?1$P/OJTE\3#_0][?_[YG__IIW_9W_^%I=R'\)*(\]O:]<1Q//AX>/CT]'01#QI4(DQ@8 MJ -?1(?P_+>4H7=_];0D(V9#38\T '7'WTOQX='1W_^/W)]\<_-"&J:Y4*/IT< M"#F"(D?'AW_<7#]HO#GYD/&OI=+/ QGFY4\.\?& *)H7?UXIGU$_/CT]/=1/ MYT6!$*LAS3(+%?$C40!?-'FC% MS54M$A[+61F"HO[!2$P/LX?E"HF4T"Y--;*GI2H!9=6EX4&I('WVQ]4E\4FI M*"?,5]5E]:-28<7\ZJ+PH%00-!3/)E15ZDX_*=.-)]) &)XLZ6 BJ8]]UFC& MTT,B?2E""ES]>)\^3T+"22SD[!*^SWG*>!4=_%@&)F.3(/-'97BQ7*I00@>/ M#_$QUCG:/SK>?W>\AWZ <"YB@@Y%?YM,&!\*_(B=XB/*TH=:'GYXO+\R=V4M M];D [W='1M [&&AI\75.,*#@PIAF=PP]&_Q5P=/I\AY6^.EPN71.(%$TN.4_ MZ\]@#P4U-7KL/EFMK$A5C07!9N5]$OI):&9P6-*2O=K0J[, V]8#B*/]J[H= M]I2BL>KQX)J1 0L!-U6Y9EO4,"C_'6A\7E=K?T%S\4!Y8NBE9#W" Z] ^,U( M)I7?$7"A\9C&#+"UMUBYNL%\)YN:S_NNQ.=?W\P9WPYO)S@MP^E5C=E*Q0SF M^;Z1>= Z"UIO%@#5GH\)'U%UQ1\!\EB$ 4QOS\F$Q;4]J;Z>P48_-+911MQC MW"N0_Y.7,7@S'!J J/%E*)[J>\ZBE,$H[YL;!4AYFM8KUC\LBX(DI+?#*SZE M*M8^O\( E<4,%OBQU@(9)31 @=:;!4JJ/6YH@F.3#3Y8V, [?K-"2;LXOZF9 MA:VM8K#-J8UMOBM2?F5SK5LY(IS]7;-)[5#ZI4K-IZ>GV?*0*3\4*I$4OA2K MO2X5/B111.3L=OC 1IP-H1'QN.?KZ [CHSMH?OY\<=BPK%'M[Y;5GA'$)ET@ MZ2UH>CG1UV64WDC2=)4%Z[=[&J(#@&X>S_J2<$7\PCJB65&C24Z63;*@IY=U M&45/D_2*-%^712X)D[^1,,D"4(NO1LU^OZQ9K./I2J]+=1=T$*=:TY^,"OMA M66%8_'6IZEQ$$8OSW@S#/_I ROU">,YVUM4?UV*?4@&BGY+ M0)3/T\6*?.57HTI/5Z=@>54OK?NZ]#D?R/MD$.9>=OE'DS:/C\QCO/==6OF5 MKU6.YJ]4C.L#E]%[1N?&I6^LG*K&N)>J:XKAK22,S$^ M-FI[95%6->Z]4FT7(S6](-#X2'C%AT)&^L<+&A,6KD:#Z@H;+;&RB"M2Q-7R MG*A7H.I]E])]9:9I%AY::[3-R1C-N;+$;!Z >C.V18AJK:TWIF(T] MZN79CI6+BT5ON=?SYIP]S?K-ZIFU^F,ZWPJQL-3PFDYI>)+JM=['-P*E]_CV!L8^A9%-:<'N]@4ABM)V( M)H3/'@KVFM/(^I-VK_6-H%LFQH:R$NU@[ZC4J:+/NN+N92&KG9JQ^Y\07*6FNL*V0TQ$H@!BF]39X:Q\/F+O&1 M#Q,>T*!0MFB@S4@8S;<2TJF/HY6<9LZN5.?-P$O66=OU+.L:3;H2-UIGTK>N M6ALSG7>O:P9JI/.=]+-L1H UOI1J%*W;(3VCQ5?B4Y5QV5+?S7C/-^S/\OF- MKNME_!10DO'2P#5Z14:LLXK(,\?FG SI%VH8J=R<)5U#FD8J_P7W2@;"UN=R*$60E65 M_(LE\W).B&;&$Q5=&OOP^_VC=_OO?FS=HM$G;-JB-8UE@;/<7YK_I[U[ZE,V MQ>V-ET(6#KL^B! JI%-TG4_K8R3 9Q(YNXIIA&O+/8\,5"S!:WW:&Y)09^K2 M!6&VS$30UU7322IX0\["$+E\VHME?K2K.,W_6ST0:"DJ9K'.FO:+%,DD1\4 M38NIC("+">)6(*>Q5"8-$9N=_UXI8P7^-;%5"0 U?LHG6 MDE-I:H"T%^OVB5.IQFQR1Z6/\9$1O>*]X1#(PHQ(]9Z9*C='D(3QT99D:X3& M(&00?PP82(:Y"Z\LQ;W0AGMA@S;$U-ZV:2R7475-E>J/";]D4[I@@GP#)TVX M#; -Q"Y3[8O^$WR:[9P26L-LKQ(HI=1B'+OBOHBZ&&9:B&N T-D@LR!]&X^I M="&B 4*'(F)K@'8!HS0LSL#54?72$E8AZ&H^]"O%9B$I4;0JZ]8]54F(^Q@N MI8BRWWH^H($!\&75L!'0+IN#AG!!RJ;V462'-37N"XQP9IBOV7U4,=CBW,NR]#(>0] M+%E1K3&5\//JDFJ2+FFV/P6O1--^Y;2R/>N*!PD@GJ7HFT5&NI6L$L@FDCU, MH)L$O8' HSD!?4:MN1&M&DE[V7 HU8>\;CG]DO FN]B+>UDM=\(D56L [S( MYV\)+"W2_WEC5[\3W#&&YRS=!#>:XFHO]!GA7_'0R0/E3,@'/+=)@VM!>$&Y M/1[\RL"]SOI/XDXP\ >E>(H3I72(>Y/N7L5-<]D1-6V$M+UB"AGLK_CG9Y\J M=3O4 9RTP^Z>@CI!O!5?TQ]+FC+]3RJ%8S5U@+?[UK1HT0\4\V[-X(=_E';5 M$OM&/@K<8)I MK+H.?2;3C3 LE@[^ QGE(]VYD!,W"P(3"@N!X*.DSU"^OP,N8BT:&P&13N!4 MJ H$[07YS,<8P\9H6T0XAD_3]R6NO$4#/.V%O"&)9.E(#LU:Z(N G4A7!\1" M+,D>Q#!^(M+9++ :@L4.K%"(K\)57UKA;K/$F.'2Y0LE83S.ACMGOF$=F/;B M_55(^CN3\*-2NH8KT>J 6(C% OWB3[A>^]8!L1"+*#IS-C-:X=Y>@"\)./\\ M'.E*#A,("W'8:/P 4Q :GR4SO?/1C4!&&%8BC1@?P**+1%=< 0@8M7N80\G- MMO\&>"Q&)17U_&\)2[=#.)N8FV'8S/=4[F*N&$-:/1Y\5K<37SPJXF[6UQ"5 MA<"24;PQ$#CK1,8W+/@=^K,S2=?":2_BI4AX0-*V 4T_HO(,FG_@;#!K@,?B M@!'NIA8,Y4<50./0,T.!O0L;TV=$F MC0:(V@MZ1X'B^:6801OI*25\?:YG[L3S^:NKUMP>GH4*&.?$#VE?4I)N8J*H M9F<+B 9XV@O9)XE_0SA)LS2Y,J<117N![I5?&)==V1JTY4!?:B!*K^A8P2(MVXU?5X;'PL)K^6(RIGN2-S/>UJ!LEB MED*GX2(<<"=%D/BQ*NC2S=RE*2J+=W-X(D@R[BP*7P7 HHDFL:(QTO(QY[ZC M1FD 8;$$Q0O-,*,32==*"O,V.UN)K@'37KS',&81C)5GY"L-?A$B4'H!Y4K M]7 L+ A,Z:QX6L]5JZQ%8A'$S=KG9'0O3%;X+))=,8C\&98UO5DK1Z*A6@BP1@(UVOL M "_%\7=GX=\6G,4<]5GAVQS75C7#Z+*'[EC'W& 9[+/(F4#+S"TL%,I>Q/IB MXHNS4/A?J736P>J06!XQNC&?YKGE;@Y>M+ I*IOSE= B.(WQUCD2DU",[O7]/6Y@.U?M$DQ13OFU+Z3*[#AM8,DH6M8J=BK;*WF^Q"MXMG#KVV 8/% M8D00//]][TJ0"OX6TR'B?X6567")L3^@=D.)HY! +1*K.'+Z+BC+40P4YX% M(=V(V!"3S5MQJ? RW/S]B*-7X-4@-G'J?>J/N8"9E:,MZS5 +#*K4(97(V(F MEPG^#.9W:K &>#::]^5O[79EVF?"8Y,C9TCSW -](4+G=M-\^J>0U'!>^J.?7WQ1+\5"#I([EML$?-K M>5ZZ639%M6E6-()74KA+KU6/Q4(XY;O=3U(%P$*,D:0T=4$\N*S"5B+ MP)\_ID$2 J]'/DQX@(NQ*&)9"DH$ZE(7K=!M(GS:J52:RW6'Q*[%9;-K>D1X M=IT#+KI%R-+#QCK"0!4.!?CU=KAX$X.I[[2^%PVSOWKSSU8=1+>PS9?\C6K5E!5XSKGF\Z 6(G4.W.$I"),>] F=T*"3-\X/TR?,%G4B,_F=X>I&0 M<8;U92^VL$.XA2LOL@G:9>KUTAA%P?EUH)4-IHUF5-O3Q'P$V#%=U.'J6!N4 MWI!G%B71F9!2/&$[=2![)8K.)"VN2#X_^TR!VWY^\36@ <66YMPO/9ZV ;7) M:-D+IDP)-Z?.EGC;S)4"*F^'=\!=,OU2.I$<+SS*NCE?W'GTTE<9MT5FMF&# M:XV;,W-SQ7%[?%99@F0\;L'*S:D36Y06"F%2Q;NG@*:H;%(H^8('BPM98<:< M7K>9LG.S8:89)HLM&F,F ^U J3PGL3]^=),?HP:'32+;_*3#)76SJZX2@<64 M8OG*6T?CJP'%QB.MV]&T\Q%S%T;%#48^=*F[Y?::0;)U\0<[X/=JD5BZ\UV? MO-B"M-YSLEBHO[##,?#?Q.6LD'3B=(PH.K 1V#[02=KZ3\+E-J%Z1%T*ZNJ0 M5R-$6PJ$N(B+MP6VV1Z5PA71^8*'=)76-7ROE/]%XIFML6TERGE/631(I-+/M1$6H]S9+)L$/$X$OV;?DNR= MCI@)ULO$@F,H3D/&I0:([Z#2E7M5@=MH6ZF MF/,$9OH\WCW760^L8Z%WPO UJ#88)9:<2_&E-30S'MP.8;%7<-1NQHOV*#L; M.8P8=E(QV]/#31+&##(< LKIIT8 =<@ ML[D(S72QM9O#1&OA6,0[]/4>Z7Y&O*=&?\BW6>%,T6TJN[;H+ +J^=F/&TIP M/QT^^AVFBH]<#*#=3!'?%9\D,:Q!?<%]%J9[SNY1_3B6XH78JJ<4C7^E\?F8 M\!&4?^22DI#]'>VCNA@6VL3C7T2B=J-)0 >&P63;:'^!UOG_SP8+J;J;P"V0 M:F0(;$HE(DV7DX[2/#9$99/+LDPZ/7'Z'XR&P4Z(6H%GV-8-A=PA(G&H5,1L&\)S1H-#"$DG$&_NA$!=9.*I"4VJZO%=F&JTNT4)<27 M !)6\B,';P>KN&_T;K!,T,V;P6H,[6WSETDD<+D)(Y2B.#]UTMJ,*"P25@@> MB/2FU $0T@$3&N 15#?I*M;"L3EE-;F3; HTSO5L "_PCNA9X#],ILX2=C;# M9'/"1<5X*:6SMED%8!O' E_0)38!L\DV]30;_?F81ICUT^DUP_50+.Z"(7Z> MG]7UA2'U4#:_7N/ B51&%/;9F-T(LL+=YGX"S/X?9,G_W01P*B%L>.^ HQ5+ M!8).[QG8L33F&PC9"].CJJHWPIT[SM+/U^#H> AVL5&J*2"+NW=6Z;WHFZU* M_IT%NN[I5(13W$Q$9>1NB6R&T6WB!"+]FI#Q4(1, M]!/),1QTCVA>_F6: 48'Z9;RES:X&0/O/DF7>9?$U],-:S[/2- M)?APX7>XQZY5,JUM"-&!,E>W1^ZVWMKBM;@/@.*% *1!5VU**+4*K5/682SW+H=S#%Z2C;$/UX,5S M234!TT3$0P5N-R(__Q]02P,$% @ 5($(5UW9;+*A" 070 !T !C M:S P,#$W-#,T,34M,C R,S V,S!?8V%L+GAM;.U=;8_:.!#^?M+]AQSWF86% M;;N[ZK:BL%3HMF7%:JM*IU,5D@E8#39G)_O2T_WWLP,L!)S$"2%QN'YH2\!C MS\SCL9:SP 98C@J]KI2;-F +:(C?#DJN9[3OV\]O[=K[^\_:U> M_P@8J.F!;8R?C5Y_\-GX^F%T8PPP\TQL@=$CEC\#[!EU8^IY\\M&X_'Q\<1V M$&;$]3W> #NQR*S!?_^R:- 8M4^:_)%_:I[7._[$9UZ]U6RUC3^;YY?M\\NS MB[^,?VX__5NO"QUU7VM/'UT\V=-86964=+0UZD1#4RN=.+BXM&\"LORM E"^1OB&5Z@1<3 M]3(B2XBG^JI877Q5/VW5VZM[DUOWYJQ]=OHJ<&GS=;LI:OF]2P0>R!9(WGG\;X$9&SH=QL!C'6S? M('.,7.0A8#5#M'<_&H2,8M9\;J&Q&Z I"C32U=DXH"%#9S@7O53TMKVT#U=T M6)6[4Q-/@ WP/4;>E+@V#X^N.4>>Z>YI0VS-!S;*9-.^2Q[WA6&CGD!ARW0M MWPV N>'JA12')P^P#?9*=5'OWN '0P^Q0@VY(M@)#;M(M,-X0T%(.R8;!W'M ML_K$-.<-X;,&N!Y;?1-X,?#@\HMOG\$;\,%W!C>$L57=KCD&-VCQ6T2Y1G$: M#O #,$^X:*$ UR1&3VGI;1 [-*RX2:U5E?SC#H+A\7)9HL'\V2RHK8XX@BMY MAY)9K.>6[1(%M7W&]2!ST8:('4)Y*/$)LV8\ II,O>!CB4"LGZ^?YH 9I(!% M(ELJ2#&=+ DJB2ERX%IKX.K%(O?)Q.8D&&7Z ,E@R8MKA4]DW]M&2VZ+'*!V MQLB*GJFXT!3EAPT M,3+5@DO!(#E]/=@K#0;R06J"524-7*47I>%TM"; ETLZ%VN M:KA[)6.F)EY-!-5LD^/YYK"3UD?*L]9MPY)FK0@AK<"19'@J-LA!.#]TYK!2 M(^@I:B!$")4"@GJ7BD@:I*;(L;C09WVT&)=3+8M6(A6!*=F0B$5LLWR4NF0V M-_'S"$P7_0";#[SWF"X?/IH(B_7Z$*_+\P)]0KG2N.M3"MAZ5D(VCV:JM(&1 MA[T1G::TK8^5,6NMA25,F")=PRG*:3(AYA<(V[TBP?X(F%MEP1QO=AS0B9)' M#W6B!R+ EFRZ-+;VVXO;@H\[NRBN&]Z:U,/KECN617SL"978+5!$>#A9W-D, M>K#X-Z9C9JBKP("+T>[.=&'H!!^SF1>JH-3PRXSG=HRI6JM\7A(D$+:I?Y,U]4]- #\F09;'Y5:QAT:O&6GPL23X** M37#D3N$AZE$T]I?$@Y3=?$NZ_(5K#N&@-O!N69[OH5*I)_M5#-H(>S0[6OK) M9M#DT.@8E_1*X&1:DY=V:G2L2W(EJ#*NJ25'0B4F^B]++WC:Q_T4M_)0D2Y[/$\9#CMK#!4;\UU/*NXOW)K/Z[&\ M)X@),8M%9E7I..L1X3!U$,<65[\Z5$YK"YMZWZB@>UU#AIMT]%O*(8 MIS,R7YKE 8#M6!;U8?.2*1_W G;BBR]"%U!3@)ZVZJ/K$&D=D"\/-/, WP,' M* 7[);GI$B;=HIS@*YD> 7[F';?,Z(_ O0@9I@^H1O]\XZX=GK8XVL[3KSC;8X ^K5& M.?=R;;C:,UC;DW9K);ZBBJ*?U=P(X-]H!/PMA;F);)7+_4FB1P?NMH$1<)X7 M/F!OGK'QS&).&%K,,_MEXTJU5A3E7&R/Z "E78T^4K+EGH&>A>V03,JZ @\/DB"?6U2S*.6\:6) M/Q/N!;L'#K)0/+\I6;A4S*3];'?F3[9"LZN#73*;$1STP2^FZ\>MP':+ZH_( MKLZ:7><3"J)%.L'' D$0YAT'L!7/+HB5JN38%FN19KQ--0:(/F2.K)@HL#%* MN^?'4S,8.ET*=NR\$BZF"PK1#M_45K,K>STDTG-LL^5I\.+-,>)5,I\)MA8/ M,4BHB>N.D)H5FO$74W(>-&0X*""3AK!0)N$P';5(,R*1 @XI>$$'IO)E969K MRL..\;VB^OJ]LS'$$$XYH2A)ZXI8*B-T8]5%$WG5,F-%>=VQ4S1#G3/W_]V- M7#0?UV66!4IYI0OKFX@&VP>"1N42YE.U_Q1%+EAJOPY[.OH-+W+5^["_328$U$\_>&DTNAO_\F\O\_#-,R9)$$>_ MOSU\?_#V#8Z\V ^BZ>]OLW3R;OCVW_[UO_Z7?_EO[]Y]QA$F*,7^FZ?EFT]7 MUU_?_.?YP\V;ZRA)4>3A-Y]B+YOC*'WS[LTL31>_??CPZ]>O]_XDB)(XS%+Z M \E[+YY_H/_^O?C!-P^#]P?TK_1/!\-WHVR:)>F[HX.CP9O_=3#\;3#\[?CL M?[_Y/_>W__?=.R9#&$0_GU""WU"9H^3WMQN_\O)$PO7)-CZ^M=@]>WAA_^\O1E[,SQ'[P(.9-V*=5/5[O#L[.Q#_J_TTR3X+2G,M*N5Z(_R"_>W=ZK-W[#^].SQZ-SA\_Y+X:[GH-WZZ_IG-#DX^%/_X MEJF+Q"%^P),WN:2_I!AT(;J'9^P";$N\G=@LU9-O<: M0=GNR(;(= [Y68CO)M?1,T[27'^U1*[NJ"V1#XW)?-B>T&Q$-AKQZDX-0;DC M4Q0%?^<#<>3[ ?O_*+R.)C&9Y__Q$TY1 8![LZ0^*,IP<720)>$!QPRY5$] MI?G\,H"K^>\8 GR% O(=A1D>9_,Y(LO5BGB+49(1[(_2]1=WT>@! M>QDAU/0X1TF0Z$$V\4O60#_.\,4,15.<7$>E&),;_(S#02%G4[0:/V$-YG]D M*$H#NF<$SWAC3(V>XBQE\L7S!8J6XPV9UGUPFO(QVU05AL4PK2X#\QO6ER'! M/^&GU(#,RFZ,[7;S>9"N%C^Z3:5TFM,S#;6\UB/D6S3)(A_[&]_J@6GX(_:A M&B"L;N^&P'V+@G06ASX]*EZ@!9W.X5JS-P$5#*]MZB6?T:S%EZT6>H!-_J*I M12.(Z)$T0.&78#H+Z?^EY?@J;2TN3<7'FLN*H5_K"/BM@U:[FJC\Z5PMB'@K MS? _;DJS/LP'4?K!#^8?^#068/^$DUVS>6Q-QZ)]QQ%PX M[WP\05F8&A2NHF]#HL9S%$1V).5=-Q(T[^/=',^?,#$IY7:_342<46F(ESWA M=VOH!@6M[+V)N%&T*ZV?@2_I)AM_:N?8=*8](OE MWM#8V_K-D/D?8[*/+%FI:(*2IQQ;EKR;(K3XP%;;#SA,D]5_R=??'"G_#S_6 MHE",^)K^,5G]0(B><)C_[ _QQS\./QX-#SZ><96U+/,C>BJIELF;?UC(>GRT M1^^(;$M-A]>J4S[2M-;O"8GG<+WQ'XYADA<#]C>/&FMT#%Z&^3=TT.,I^T/Y M[V&<8/_WMRG)J'ZRA *(%X5!]_9-3*@]\_O;PU8YNZ!'](">P[S"?*?TB1#V)+CL+/%6&<% M *N:GH\6Z+G[%6&2S(+%/=U7Z5:)IO@Z&DTF5"RZ>2:"W5^WBQ]'A\>GQ\.C MPY-!7\R"1A"K^3MMGS_A1J3?20G0TKQ3V@^-**G/;@7\:GZ'KX5?UQ9(5XA6 MV2Q:9VD@X84C,\#)#4Z2QQF*KH)G7,K+(/BP_1/>4PGYT,66VG R2@BOJ0+! M*?S )MW;DCW&C[_HGY;-R=?LM]2#$YNWA:'01"&"@=&N?X:[(9^2E" OK1@( MU1\R0^?T\..)2Z-9W[LFPB!@HEV7S$:(U3H,X%.0,)=>1C" (5@''/692^9$ M/%2SIHM+P&:[+IP"HG(^%5(/3UVRH:M?V=PJ\0A8T/+,6)Y3M>=2@?+4SO&S M5=:@. 5LVO#Q/& /!\_L-'T5DPWYQG'HJPP565L^-'M,6@VH MZTG#\&9F&* M"96O%%DZ\W8_YJ/0Z8YE:K:)L0F8TG+S-+]X0,E,=M% _YE+_+'_;&RC$>A? MRPW36/_W!"]0X%^^+'"4X(N,L&BC4>1_C2.O^(N$'75COBXXM=K-<*>#5O]8@HQJ"@(1V?0^?@N? QY&?\#&B:4= FG/$3BV)&J3I01.0 MV:X+8RMM&K+_\'W4J8%>:SY5(! PH.5V:.[*\SR2X[M(9)C!N0.TY M9J?>B1JL:6(3\&DC%F7DSZD&&8H\-D9F*H#:Y2".SOHRK30Q"8AIU_MP';$; ML^ 9@PR[BJ\Y'JQ]Y-GKA9B UT054T+ MI$=.%T<%!6J7A!R8@,*6,U[B^3R.UZ);[B-+^>SF6[QV0\0]+;W\KO^3!SNNC5(D>!1L!0NRZ++6#0[8@#=WHQ M6(L1 0H!$^WZ&QY84GN$_4M$HB":)O2$E\VSO-+0)ZI@3^K74S?F:)T:>K4X MTX$F('+EMOBPG6'L-N=XNVI=SQ*0A^U:9ZS4#2N+2?)ZF%?(PZ-YG,F=J8(F M7'Y+V9/-3&BF58'_5(FF"SG'VU)^B] \)FGP-YVH0>(Q<>\)G@?9G$Z$_-,D MR5A]T(LX21.Z68+9U.Z9JZF34;-0TAN [D3BP[)J>&ASZ,"2A<2G\O@D#QH?I2R000*T]SXGD/JI'="S(X"BH$\9X-SA\UQ M7!6-*?J4 ^EDM IDQNRB,)#R[+8GZ\%]U'O3QL+=YT(:)_L?E01\[R>YJ M.!DEA-=4P?_/@Z;_ZR1\I(6AT$0AG. TAJ<^+0!8BGQE-S>G6X]D]>>&=&UCN?+A7T=4KYB%G^@4+]EK14?' MV>%9Y_SYF^I5N?0EF Q"VP:53;BTCN- 6DZC13 MNG!MN?>NRR[F&[H27%'-E+L\($:T0:^%>LZZ%CZ@LZ$UP-R%JU,N7S3E!20@ M*?["-GRT.\T,JT4G )&!.U,+V^#J[UQNK?UPIRT?ETZ-2P /T&U1B,[ Y6GS M1-J--,0\V2U1$RALPW7C=!&M31P E8';4!M'.;TC'!]_3LU.8[-K"X^!NTNS ME5#44ZGJ? M7C[CB&(,J:#;"[2:-DASCMBI\[8VB7H 35P=@H_C9?+\"I3Z-+[?ABO :82J M-CL:J#IQ75@W9'5]EK'C*]&-6E4?K23RFWS*S\;E8?G 5$QQ,HZ*"E0>I#&7CY_@)LFM9\35NQHPJHQ,%L4U";&E8<0UV MY'4=&R/#_F@L==B)ZM]?\<95LV08;7W',3CU[;@8!P(E=*)2N!RSC%I%2XZS M(P^4M$7FSW^)0U81);F!A%L#FK.H]K.34[LQB%=A'),'JE$F MBC \%-Z8"^W49-)3KO1&!(2T"S6K-H,-^"-A5%I@M$79@(-R6V>E 7U0= ;" ML[6GVCKFT<_HLKQ\I%W#IUI%8X[&[6'7_%23(GU51:;.3MP&U)N=:)7@NA6_ M?8O2C+"D,^C2N-F @W(:0V.6L6IT!N*KM9?&\8(:MO[H*7[&=-[C%\'>I=&: M:\%MJ43SBZ,<:K>BK?,%X1N5DH1+BKFL]CFB(X_\Y 6EX0NGLBL^AMV^F&=^ M3=7 W84H[;T=8?U,I\X>N6[$P?76RM%!V(68;0E69="5HBE7D9U<"7D,E@$" MX>@,1FBYN@%D5K>BB,W^QWP@V]ES]0*RX%PI)NL^MH[$A6\*>$&M@&E,@K_S MG#GA13Z\,4=KR0<.+GDCHP%"G!Q:)^+&6R+2=>A5&XPJPZILN'=6CZ,D=Q'^ MDD4^P7X9[@$+J0%TD4/\>-B1]'OUU)*<9;30F@@ZAP=,S>.H>-.C^-^5YS#Y M$Q&"HC0!1TC!.BI@6HI?;I?4&IA;C$@_1]%/ECDTQE$0DS'V,CKH;F(4;8Q! M]N8>M033Y>.O^#ZFVMP.W()1;^R'RN"PCA1W:#0Z[*BEQ7#XC2O&"HES2>L. MF09=E]IPFGUN:)"84D2+0?0;KR!=1YZ%;L< :&AX&?*+7CU#%F M:)B85DB[$?BJ3?*1=E@(_C\QB74'2^,?6&G&\>,G[1DE&NIH,79?-<;+]7&, MGUF0.?T/UE88K1_[<7K8D6!9JXM,#9V8B/#7MU:H,65NI-3MERJ@(\&4I@R4 M&O!-A. W/NZ4U3048@CS<'<_X;):\A8H M'?92[>TKNEIRXW'EUK3LVIMN0-TJ9_F1#4?<:(Y)0*?GS]P0GV.?Y5NN+V)# M#[;KP'HI@ Z*TH@ C9L>$]&89BG8(^F]XBD&MN*H!T' MX>0(6Y,-%1 !&S:<$51)61HDYT',W"=H@>G?/(TI(F_.%V4G,=GUN('B$20Z MV/ 7C&C?X?)%@Y/M[[G03FX7:I(@ B#0NHW7-$8+_#+&Y#GP,)NFK"()?*F2 MM.6SW$E403TV0& $S-@(Z3DG@3_%3T%\/T-DCN!&KZ ='U[]V<[50 1L6(G+ M\<9HNCH&7<1D ;P+JV[&(?1G,U?B$%!AX_A^@:.4X!?Z2X]U]G)%Y(+X>+7M-N.A.LH!K4B'!(%"_C?/Z931#] 3$(AKG*&+)K&@1 MI"@$[^S*#CBL_FSO&H@$1-DXLM^BC 3%496NJ3%A)25@#(E;%D ^]F=O@4 1 M<&+CX'Y+@G$\27\A G=P5;7APO=G]9*#$#!@X[#^.8SCGS%XY]CYO!#YI#_C M7RB_(&O=SF7]DOG\OV 4IC-^#(+OW?+6?&5U$D)1KH(A MX,'&F?M+,)V-4X)Q>IXM\R=,@4P(VG$[I#]'/#40 1LVCN!4F&D0/<7I#,VO MHR0C[/0YFK)RB&!:Y!UP6/TY7V@@$A!EXPC^.9F/O+^R(,EU!_?LBMIQ$/WQ M'ZJ!"-BP1?)G<++_Z6( W_%:@;#K$_VXTV+@%U-D[M MER3 K#1J2C(OCU<._#_II@CG3-&>@^J/<08')*AU9N.@?Q5GD8^*F4[7X#DF MYW0=]N%G%V4''%9_CC :B 1$V3CQC]G#=W$4>.6,C[SW13+9.(V]GS"Z@-T4 M$-V\6%&+-&U< NKL%.-XR9+-\%FZ5M/!]#TF*7Z!T0;HHH!VVI]X%RU, KIL M^ SN,17IXBI>TDD_2I+8RY_?65NH*P<@>(74[8^#[L_&5A^@@%4;;HG[((J0 M%^)'@E%1T!>SH0=W:BL[X+#ZLV9J(!(09<-O\8@RKWP"&SS+!,T*"+9*AED@ M18E#0(4-I\5#XFTQM.@J\X(W&$M>)? MJ]KP@=,?_K/$J6)2D",?++A<;BEMBDU32-XG.]^BQ^GA_WA0R2^ M0.N. ^Q,Y M6A>>@$\;#HJ'EX2E!&C/,E$[#J(_C@HU$ $;-MP5XH6YZ:ZU]G_U:.T#@1&P M8\-9<>T%XX47G]-^?F("WU#$ M3=>V3(]J>4+A",BQX73('SJX%3]T_OI1_H;:^?(Z\K,D):(7A6 -<[6=6/+$MO+(D"Y. 9M:/@GC;*Y$%,8D"28!]J^""$7LZ2Z] ME5'= ]>(TS?N#7"F U3 H!6'"J]/#77*;W[-%W G1V^#S(A "5BPX3E99YI MMZ&MSPN1#_IN-@A1"8BP4F0RKU"=9]:1^#F@/Y3DSSKK+&F0/KA"G 2?&:1, M#ZJ 1QN1&->I'F>[W_/!UW=#00Q+P(6MP NZV:5+'4N[LA''["2LUN2&(\ 4\6?#A7$33/#8"W!$Y7B,XU#?@:'N@3O) M^NZ^T $JHM"&]X*](J^YS54TX8R6GIE1W8HCZ/M)2P5.0,^A#:?&ZCYY=<^BO1\I.^"K M=-\/7!HX1?S9<'/0,33!29+_E!YQXI8<2=\]N1" (JIL>#'*L^#FJ6*<+18A M.&X"TD>.[JSW$TX/JHA(+7]'XV#/,C)YH[+Z)Y1B29RGL V/9W9JQTMBKF^" M"%^G>,Z#.UF9D6TV-0"*V%N-X0\E>/JS/[?5P?[+EC[P2XHC'_LK@;8T\NO7 MK_>)MUAXP5/XWHOG'W)UL#-B' 8^>XQ][,VPGX5X$W1R^+:]4011NF1 @3D; M'MIP4=QCXM&?1%.JP, M9L&\:77-4Z5EU!NI94;'<+T9FR47A:$=2O71,1G]]#=/VJ+I]8 M$JM)$ZN@]&[?#_S#XZY?^*AXU(,JJ&K4QZRDH9OGTPU2!P4IR-MLP:_=S*F] MXSY<5R'LNH\-RAL IR#PM4\N[:&;QTL-\@4!*+K'[HI:VF0$@DN 1UV[WX,AT@.W52(M6+VB0$*F+(1S&HTFWGH]O;& #MR M: )>K#QP;CH&?'C2]> KI36@ "=@QTJ.K(F4ON%)W^TS,2P!%S;<#A;SE(9N MWDPU.6<@" 5DV7 N&(U;')YV/6Y118\^&HA29@!0; M?HG6:D0-/W8]G%A%F0Y0 8,V_!7&\RN&'_ONLU"!$[!CPVMAH';4<-#W74F( M2D"$#0=%J[6CAFXJGEMQRD*@"GBTX=QH7!)O..C[\B8")6#!AM>BI33TX7'? M[3P-G +Z;#@W#->T'A[W_0Y*@4U S6HA<9^=3>YB+,%':[)??!3>46^VV =(#-T>DNNIT?)-) #[$*RR2-Z.4=)D&R- M_L\D3I)O$:$V2_ W]C_A!6%A&.E&9'_%Z-/MJM#@1Z?>VB9,-\?=A8R32NDO MXB2]BLEU1%=,3+^XS\@B3K!L[='J)U?!X;'3N@/6J%>#[D)RRH; UQ$]BHS\ M9U1<.(PFDR!DSS1MILCEXWGD^SE+LG'0J-_U\F@KNZ6]H6%.#UU(@:F#Y@$S M9Y&%X5)V7.JIM_:"!4482*UI/& ^X2=V[[5[E'C@^^%GJM8;BD R,H ]E,C[ MD+(L'0)U$!M(OK'%=6G]U&=[OX\2O5-7AD6^%9@-Y.D8V Y23"CL/#.,>3,C MOS!W2A32-5_9ND3<^^.!+EH#*3T&M_N[7Q'VY54FU(W6^-S64#2[34M!&DCN ML7.R*Q>7T:(\DFX>3[_B5$)R_4X+S9[T?@28T(")E*)67#^;:!JZ?C:[XBX0 MIX%>;;E^JG&WF+E4BE9D="\WJ^*P58PDLV"AODF']+):! ^&O;7&FZ(VD035 M\1I"3&]V#MPF:@A)9RPJ(CYZ25A;7"78>S^-GS_X."AHHG\HV:%_^7&#IRB\C-(@%95$J_CJ MQZFE]S-:6*(B\-GO%-"*1!VKB,K.D')7 P+:84?4>+.)W131\\-?9;4 O!B5]'FP&1 MZ"UF"UU[P3P!ZWK[ZW*,. FCT5:W1/H6LWNVI]T<^^QB?>U%J+<2B7HIKW7Z MP5 -5"UF_N32W8JENXN .0S@CDJD_5C0Z@%K,6=H')+1/'B,%UY\3OOYB0EX MQDF:EA=O3C(BM6F"0FDQ"6B4>&R<>#%\!=QK43K!G01FZ,\6.8(6DW_^0 E> MPD\C.Y^74O=CEY&);R)EQV#PPW629)BLXN^8/N6>=$7+OPHLUL!5A!+'N[H0QM<>O:X>:&9)6O;M!NRM+& M\U>KR&B_ /$UCMAU+=5FB'WA9EJKGU(=3@,;].:FBGI=W +Z5YX1ZVF;=V2* MHN#O8ISS7 GVIM,D)G,><,6J!,,3-H$&VN;OEJFC3 A6V0DG+""$_?5N4A8R MH?\ECQA(/@4)BQ'("+Z1I'!:_3V6>#ND)+8;@I+2LTT^KOQ/&6'50^CI-/;' M,T01?,6_\G^29K.".N#8G)PY6B*M>AKKJJ<+V:9[X53T_\V#E"Y O$XA:+D6 MM.50G9R"G(X$#-4,'#S(.H&Z\)V>P[9R6;=Q65!I)TNI*+F2]8]"3QI M6.+Z(RZ\DPQ1M]16J,! @7-,S2V\RFIY1"^;4>XL<7$>DY1K M167HU.FSP'[VSZ'?H,;:>W1M;T^ZRIBQSS>D8H/*%:&\](1VQ!Q6Q\=N"ARY M'QNVU[PGV+)J:&@[BK NF)DP3"#@X(B*+:? ..B8?Q+7H)YMG\/"8D M_L46-M@ J&C(43BY ^P*W5*UM/=6G"$-B#)5K/T6U[2=V_[*U!;W \>._@PF MS[BZ)0)DSNQ_G&O@;&AG$0+=[[5!KL(+L:^,3N2[;@MX06%.8\*5HW%9(&K, MT5K*;ZYQ_[=/ X0X.303::M](;)[EWWF&56&X;?K&MS(HM8@,MG$=.:TN+?. M7%)QMP?+7G)I0M(->NC?2FKH7WX\H&@JV@NW_KV0U=*KH]W<_@3X[2680K@2 M3IZ=+[B\KE*T!+H3*'A79'N)HC94['HW::)KBPF?4)W?4FW1Q)[&/O)8_R-Z=D728DGJ-Z>NAD&,ICG*+P :<9 M@46*[C?+WS8XX^@>%DVY,$D.D?Y=:QG6["Z_!SGI0$"0A96X MMBJZ4%I\Y,\I$TG*!'_&=(@FZMDK;,/'M?L80+-3&("WO=".S7W_ 0?SIXPD M.=3<#$A)\)3EZ,Z7(_\Y2##YMF#&\E\9=[[HV%=U^B_V)3F)DO+UK9* >U%E:1NQO;3[% MTP9L:&IQKM=SL2Q^?"W;@'&MM!<* E( *- #WA-78XL52NT;>/K8>QN"(<)W MOMS\%T5H!KR38E80NQ$X$9!@BS/4569O,F0V\@&[&S!"(";#"R^;''*C35]EDTT"V=U;C M,!%, 0Z'I7W?3>Y)$),@71;>T[O).A [*L]M@EVM27?%F>#8CE?3Q?YF1ADF M C3,\R]5PLF MBL!#*V-B+X[\TFUW3QMC0K!?R NLD0GII( WM&,.NB=94P[> M%J=:SJV]=ARCZPJ1(!:T"-R%9Z*"?KGH9.%$@?I9+<)_:HIXS*):8#UD0E?RV7V/LZ'A-)T[5F MSKI0**X!=5",)NKSZWBXC-]BU.MUI8/C@Y[S; "^B:K]P"&P5UP.8HA6-BJ< M?)82ZIS;H0K(BD+[5AF#V3F"9AQ")P(-%#K686<7G( ?&\X0._QTR@RU1I3R MX1(;GI(]F>CR7.3O/_Z*85L>H(LBA\^-=TMOKNC0)\,IH-"&,T4L%_B124 7 M7$7N"UG;H; "IX!"^]5C] I8#8_L3"L75H< G8 )^_5E]&LG#=?W1N[+4^6Z M$RAX5V2!B@V\96A#Q:X-@B:Z5F[S!O*7K)2G&AXY.9P*A^R^M@4R"^H&V' J M;*8[7F2$T#\WKMHCZV?M[OKH?F.VG#T*5H. ;AL.!*E\=1*'A9VL'3"GEDKV M=ICH2AT(6+;A=+B.F&Q%*8M5J1(5J55M>/D+]RX^"P3*\0K(LEJW9Z?@Q&9U M5112W'>3"28;Q6>4P0%U.RY.% /W@8\V:_G45XI@;%@)"Q%):VHH5(.TY%_L M*/-"'0B(MN$2N:7V=; ( TP>X[TSOS(Z2]:81_.ZOTFU0"D0N(!'&U$GL.7% M[ J^,W!?I;E55Q,"Z@TX8IJ'RC[0_Z@?*,M:%2H[>2TG*"W$ D9M5[6]1\O\ MV8'X/D1>#GDT!2S-@"YXO.EK(;,^? &S-H)?Q-6^^-%M1'6P>4+0X1G4(2\E M]BH7ZP;*$)19=/62D:5GM*E9\EI,[!JX!1S;=G=5UM"NX_*2=K1V[)V\%H8- MZ$' ^,KU9?T9@"L4D/R%[G$VGR.RO)N,D@2S%X 0>X#&'Z7K+^ZBT0/V,L). MA.,#<:N"*VU]BU],JD::U^"A6<$I^:X# MCCHP"E1Q2P9>,JPS&JZC198F.?1#Y2NLDE85@-O*%BAQ$ZU1N8?5P(,')BWO#=Q7!/^5 MXE&US:W&JM=.%Q@ZJAOQ:WEJ6UTYK#=54)HA8Q<)M*"+83 M#Q>T1FX'C><66%;6YG7DZ=O=*[9N;L4R)9AX;,$PI1 M&0T0XN303+R:T!,HB,F8+378OXD1M"*, MJCT'YR1TJ-9$0UY=NJ$K37\J)'NBETUHYSOP9I+,]H9-M MJ; F>F I [*)9\$0_2HW/T@U_^S0FH&M7!T;H34#\7,A M-9'_LT-KJ JZXKAP. JZ'UK3_!)_X":3MN'LK'>)/Q#GRKH*Z:]_+S"P] 10 M5W=OF1JZ$&/3AC]Y<&2IP$'3BX'!_B,G=:!U(<"F)1Z[LKW:)%2U?]K(>6[E M6F P@YUVXF0'X.0\_SU"2;)79:N M+L':N0NI^N6"\)-N)&+T[EI$KE$3D4T=67(_4QZ[L.RNY*!*'@X^'G33N#,>^&:[(; MN7J]&XP[*C015=>EP;@V9NAQ,G9BEY8_S+7\3SA:M:U017Q@[X;MRF2YCKPP M\[%_'5TB$M%/DL-VAJ]$ *[U?X*9ZDJQ@N&\NEUP$.[Z'QF*TB!%K#[D=32) MR3P'.'J*LY2%PA8E!L<;X:^5UZ6N0V)K90.Q]L7E'_9F4?!7AELKYR;[Z7RX M'!^T:R?:K/!V[*8F>OM\J2ZKY!KJ0HSJ*$PQB?AJL!)[8Z+GBZ%D-(#:%Y / MG=Y?N1X4FHKJ5%RH696U42-0]+/%SOS1?81SZ^.O':T:C($V$/-J\FU-BJ][ ML4^V6-P:00)56 M6-?U()!77TDE=_QW.0G4"_>Z*;"T U(:&7<<6-5&U*F;( M_C._M5[A/!O8JD2I_0IG,6#WE2V0V5KLI$K-Z$6MYLUON,A.+J!UU%PML[70 M1H6:_\3!=)9B?_2,"5(L)97?<@A.;@(TU*Z0O0M5NW9/&(#8;U&3 MC0SM&^ M\U807#N=*.A5):8R9T?[ M M^3P,/?XY"N.'256BIC^D'M"^QG3N_+(3,+QJD"8HOA:KN2L:L@ML/3W6$T MCS/FMH.$@0.[X<_Y'#EZ&[8^D8W!F@C>JDGI+2(_A MJH8YE&!LL>;6KE3Y#64^L/@;M>+S1:U^UD/4;1DNPUR"T'8K9JB-:A1#.PZ4 MWIQF='75V?"J HW>:5::>40*WI"9" :\VG%C[PG OVW)$?WM)]XK;V,XP=2%=^OB26Q?$$H! M6S9JL+53,-'6BV:M4@>'*N!/RT/4HX*);HU90^S61BX@>^5.:B^Q?.3[02'% M1C9YZ]GA%!*^FUS0J1&D5\C+(\AN *G=TG9\=1P<#]L].E0)M?$R51%/=9>E M28HBGYK8FOAD7960G4I %)52;,"6A>>Q=D647GQ5?5YBX %]MT$)P.DEA7(NR([C4DP& M"_**U36XUW@,6MLVO(L7<1BB%!,4CJ94'H%1K6I2P.U"T1<( M(S(7DP2:@2-0/5*$=IFZ42&]K>( 2@L:KEPX*;O #!QWG-'BVF*VSX_*;K81 M^_7OBSG5!XHNV#O7[$X 9J<)FG$D3NY'=.:!A"$E,J?5D\!5Q0XM14G:W6 $ M.%Q53](O6'5HR[]=HR38X;[S4RBRJ\))M33L>B=HHFK5&F^_B%*]6E6'9YTI M"7:X7\]#(K.U8DE6*J\=VBJ%8T[-U3)WHCC1=T0"MKT\T*U?F>&U_6F!Y-". M]NUNFFI(G2A!M"D>(+MG]^,"S9&E54@C#4ND9#4INT Z45'($"VN]V3S_"CS MD=N])>016G?/F$2L.N!5$*'("Z(IDWP<3\CZ7ZXC'[^,?Z$%^Q=EC&FC?E=^ MZY,#IX]]R"99->WF4+=8;.@FCOPXRJ.XGNC!]&XRP12#E&6M]EQI3C/4X536 MA-:)Q]2:1F<4UFT'$M%K&RLR4)TH%V3BNK] Y#IS7*9J"#F[8#I1J\<@/5TQ M7$;J+LM<,D<<$2LZ7F_^B,!?@G7"CJ,]F1!VPG2A0LRF>0NQ$Z4J#%$6%>,C3:8,UND!KK[>8M[$CQ3D8KEI"C><.Y[ M='.^"3W@1@CIA,-T&HXHFS:R'5$/GXE:-%9BZ!1;H:@)1]:!%R=J;WQJ:)VH M+E,EY@V+2"7*-535E"-U_72$F@@X@=7P.E%.I@4BN[(UVF94N2UJ>5* V^(E M2M(_<9+"0[SV6Q0 !D[]P_!I(]G^9- Z4?ZE"B6/;SB/"8E_!='T BWHOZ1+ MS9DGZH8?A9W6IJ\DMTE\N1IL)XK$5*XXQ=M?&\G$17:QKKDCZ(9J8# XMN6; M=D2W&JR)RC&-Z689-M=1DI*,I37DA:S&"X*1?Q=M7G\=2JB&=E$,=+B M61^HB7(S5F;TMXB*YJ^6(%:A(\@+?5QA?$]/#/1/=.QJ3F]0GUPWW=NWF\QU M3>0FBM@T'Q5Q-'W$9,X&]>. I+'5Z,.5\#18*D$ M(Z!CY6BRGK! M83\+<>5OKC6M=D!#>BE.K0^VG\3.=F4"QV] _E&D?_\N,&3U%X2>>2T,M>\15'Z;!F4'U:MMB5 M8C-=WTE-1B&%T-.Z^PD7U54M(*GR]O5<+;GIRDS6E.S:;6U VRX2CV]),(XG MZ2]$,/A:MJH-3[MVDG(L'KV2O4(.HKV*2?>8GILNKN(EBOQ1DL1>0*WLY#I* M,H(B#X\Q>0X\G(#)T>V/9U0[*8-7LSP//!0>)XM,;F. M@ 3*VG(L3L(R:Y$% V,@[1E(S&B!7_@(8<$:$2;PF25K6V Y<7*FK$4,#(R! MY&@@,9^3^E[_^06C,)VM M%E3P B9OS?$XN?&J10P4CHG4:S _2>!=99$&)3L-^!3OS_20(#"15@VUEE%& M./UT@L:$!?T!;69A2QYBUB/+&0#%1$XUD).K.(M\5"R:U B<8W).#4$?OJ\K M.^!#S4D]TEH,:2 RD50-/>F$*$D#+[E%$9KF[C;XH4;("PMIC-_ M1=Z7.&11&LD%G\^!Y%$D<%M^B]&?=0T&QD3B,I"9/V,2^NN#;7G6!4\;90<% M+%N/*EO@2 .1B?1EZ*F2>%D:).=!G,XP00N9*"WQ%JKI9 :%'CFNYY4;L"N*5W>JP,?R40$PF_T#B7.&.V0G1'TEGLL]@A;^66 MKG%B$8=&C6V,@'!,IN4!^ON,D\>)\H*QL=S [LK:%/GH4?@$#TV)*+4LS MP^DM]EF$ ;5BWL-($31;/9E]?- ?CS($BHE\6B AUUXP3^!$['R^EMI-MEPM M F003&2V@D/)_ "E)/"^Q'/\@),\;R,FRQHQ9,".2J3]L9[K@3.1L0JE,8@B MY(7XD6"4QTA?8.:D@/N3E1UP"Z<_/C,-1";R3J'%'*)G3+)DM0V"^1&UXX9- M?S8>-1 3^9[02Y@Y)@&+U,E=>O-\EF-M6PW6RVII..S3K8P^,A-9F]!;:/R2 M)9N270H[/03@%^!EM+J+8F >]^N $--KP+K"S&S5)(P2? M315-UM+;>I[%1C"A H: !"N.!(+"<4:FF"Q70T3;?(#T40ZR_GA]M'$)>+-3 M[1Q[K##-_0R1.?+R:!,4:FQ,R@Y*9/VYWM,#):#+AI?BX27!4:)OF8O:\=OC M_IR:U$ $Z9\VG W7S\LK3-*\ (6VGTC:F,/ISZ4=$(V '"L.!A)@%L%-YW%> M%OHV\%F]1# _JO8<5'_.L'! I9L.!X^AW'\,P9[?W8^YW]>=B01N7@#H;?H)1&(Y3%B@_FC+[7<,?*FK(W4[]<=L D @(L7'B M_R/P/P5T']./)A"WY$#ZXY>!0!%P8L,!,,ZB.?8_DSA;:+,B:\LOI_ISVH>! M$3!CXXA?43=*&;:VWX37$'-B[F[KUUS),RE, 4.K!<)E2<"1[P>%7-?1)";S MHL"D9BW YJ_YL@TA]P!+*@**/RXT?=)NQR]G_F&O CBFL]5".D)E*'F5(3%?O:T[+5S17/[TN:L*!63I1 M@I_!D6DR;@$J+_9L />6W$E3\!8J6K,67K1;6BV@78S>Y_"O;+%2N/!0KVA<;73A=L'>9O,\ MCIA@&X\022BM_#Y7S-&!$[>-4085Z Q8XLW6$\TZ]OMMN0+LS#6="O9Z_-3 M9_ $/&AK@[L*(A1Y 0I9QGG(4OG*!R&NHV><%!']Q=Y6\7'K7B&(4!"'D58_ MQ7S4JR/5"E*5FPGGDML3[95K:E1Y-^Q BY[[ZRQL- D%WPT2?.2/+1Q M\(Q'82['AF=>&)%IX3<+W:U#YSHV:$0\2Q8%NTIJSZVWA^-N@5G1TFAJ9RSI M=<^IXYLX243FA'XG'+Q3WW'3P= $M8$7 M3LQ3SH>M[B+1J+]U?K&;P$[K8T%;!P:>6&D\,KC'B7MX)91O?\B5TU$B:UB3 M(G@&7EXQ^F@U?W)Y-&>>>-C)'-*<#&_2#_&="@^X)2>7W76 MXHUF?!SW_V2O!];$LS#MF%E75%WS6D\+K[B=)0D M./V.P@P#^*_\GBNH6Z=T\SPKL)MX;J>=O:+./)?UP\>TDR 'E_,6.\ BQ58P.P&:HT1NWJ5[[&&FD&1.O#9E?038A M/<:Y-GBH89UU1-T;UX=3JZ$1C<#50T<3)AXY,C\R*C=$^O^#V*?SB6"4X$^X M^/\Z0T2CV](+UJW(@!8VG[I:4CS2U/E(+CKOZ+_/<%Z*J'?)?D.]ZE7.$OV& MECRRNDE^N;ZJ9T25Q*Z"I("7K7]B-H2QS_V(DM#\1.Z1-=!KON ,+$72U<_$ MJ"#<*%AY8%7%ZO>!R?)$5]%__7]02P,$% @ 5($(5YMSP10"8@ ?0$& M !T !C:S P,#$W-#,T,34M,C R,S V,S!?;&%B+GAM;.U];7/D-I+F]XNX M_X#SQ,ZTX]1O[K5W/#.[&]5ZL;6C;FDEM;UWCHL)B$25L,TBRR1++O_O5?_O+?7K[\@<0DQ3D)T=T3.CD[_XC^X_WU!3J/LQS' M 4$G2;#?DCA'+]%]GN_^]/KUER]?7H5K&F=)M,]9]=FK(-F^9G__J?@[-'J5I)O7W[QY\^YU5?"KHN2?'C-Z4/K+ MNZKLV]?_\>'B)K@G6_R2EHK44KP:F=S;[[___K7X*RN:T3]E0OXB"7 N^G"P M74A9@O_TLBKVDO_JY=MO7KY[^^HQ"[]B?8#07](D(M=DC40#_I0_[<@_?Y71 M[2[B#1>_NT_)6MZ**$U?<_G7,=EP2_(O?,^_\/8[_H7?E;^^P'=N;]]MJW:&=GHSX3Q>L!0=M(X\YB4,25JWC MLAI/*JH6'EA4RJM-@H,*(^Z.D[2O;<8J%)5E)'BU21Y>AX2^YH,._X<8?82B M[(>_'2=L7%S=97F*@[RJ2;1?U/\W29G7=7MXL8,6I21+]FE K%0LNN[PR_A. M]F4V:+$2?- F\MAK. VJK[%_#K2P+/$Z M2-BHNTJQ5H'*;XCBC?,R^)KLD55E87=RAL35M M[MJ]CL.:LJ@H[!,!0YW>!H-)CR^(BW_?LZ&5I-&3$2QZI3V@HM]B)2CJHH P MH>AP&20TO;T (E;LDR'_[%F$-PH<=,HXM'ZW=5V;UW]'O(!/0TO[L6U>92J!XM[5*@A<%$2N)>%$(_);VM(S=RFY> :G<4YSYD8V ME <=<#0XHUF H_]!<'K& M?I,-C >]TAY&A'Z+E6-"413QLD@4AC J*'I<-BYHNGMQ2!1CDCDH#LI[@\5A MJX> 4<8,P* AZ7DU.!3=OL2JT#Y-#S"I#R'5Q5VN%:G;W%LV*HH>^ P(P>10 MMQ^L)AGT^7(A1?'Q8H)*X\U-CG.E[]"+N \P5&U7Q1DE6&H!5$@ "#>T5I!$ M'8,F6 PP9S0BZ3&#YR9)]1%HIZ1S>'1;JD"%*(:J[S,:DTSO(3HEG5N^VU*%Y44Q5)7S;WEI!_1)$)0@X+ MNG<1A^U4>0A>"@X*9)TK\0^*GETNADRVVR2^R9/@\\T]9O:ZW.<\.XEG9>DC M2:V@^WA2KXK\/EH&N7QHBQ^R?E^EM\B4V 4B[ MM"]X'+1X"!R\,/82 0,4A1V4:-$886G(7"4L4([^)]T-1C!R 5]PZ;9[""Q%><0$@,0H MNOY7 D79^4MLQ_'/I@1K@'%8Q.6VVV';>EMMPO3L[]YM+>O$@PTU10\N8$]^ MCBJZND]B_4RU7\RA725M[-I6%$&B#("9JJI3VS;6]>B",]6<\)1_^D!.<([+ M7;B!*:I^K?R>NM()N!#IE@,<#E8)BEZWNC4_7WH_9_^4Y7GI"ON"0;N]&BB(;1%1 M#@X>>EVMQ(2TGYW@8I5E),\,AJ%N0<=XZ+6S=\I4%!@8028W,V]=<3&UK;YQ M*C=]%Z-JNSO!YWG\0+*<@NDK)#M/P]'%'XHR4:2JK./S(]%%F&MD(.P:DD3Y=9)1"J)3RA]Q)K2>% ME/<9OCFDN@RPPY,;IYMLM[2(8%A#CI.8WWQ!XH 2W7?HD)8)V>?0B(P3%24[0=U_[YHH!O'K#A!FVG+#C@N([&M&N-<#HXGD %4YP_ ''>".VN\\(N<)/ W-$ M>7''2%:TN0N*IAABY5!9T!^4[9N]9LW>%05;OON==]^M TT7Y$.(<>2M8W*Y M/DY)2/5NNEW,N7\^:&/_S$B\>7E+TFUQV#A9HZ*H3]>L;? U>4BB!WZ[3R"* MH#4.N+>37NSB:D]BQDYV.ZCT\=L?3>3@=4*P$_I 0Q*'6UX2AY?Y/4G-P&HH[SIKR5"K7E)3(8?: M4V*^IB)$T>+P-TIJ':E:H4+440R7"D-93K6"8R^?RA:+,^9>K,(MC<5K%7P( MU4ZL#>5\Y%QHM.A1Y:"HW^GV3#I FWM; 4R::N$,759I%K-8R%=V1]SXEL G# &F2HO"=*<_@/AEU9DI[_N^9U(P_N"BO*N]U,4K>[M M3!3E_H"*DB#V!TW;_BFF^7T2A:+]QWA'-\05NNAVQ_F,N2@(8OG+5(7>FIA09-^F1P"#'J98TVVK#P'- M6295>;6[./NA(4F_J(>*,H[)H>JU5VDL7)(%"P/L+&B MQ4L5_OAATW1Q7+8X/XAVK.F< 8NT?">N\KK)<9HOW?XC=$#4_+_$6C0PTM0D^( MH:84"-H9F'.L7I,>4 M%4*HDD(O6G*H%)2&86Z&V5%:M54(J]P;L51'RFI\\\,J/<\B*>QZ2B9K;V]R4^185J70+[R<]UO7U%W=FY%H^]D#+DZ2+0.N M,3*JXEZQ4;=Y$!U%26#X..QR/4+Z_3UC_L;-[J'Z3C'H#R5N2 1\9&S(VMV[ MGO'JIQ8.BF(>UN^7:[?S9 PE6J19&,M#Q2K]PK3KJ^3]49D6IK3;WV5!2G-1<5A/W9!W$F)RU[@!F1]_1YG%!Z,LO,0/:/=U= MD90GM. -.8]7ZS7[,)L 9(K0V[X*'Q0WTZV7>%M)H48,G<>H$=1$[@YI/Z-V MU% [YZ[ IU2G^ #FE;.8:H1=P=&Q+6@1Y>AG)6-J02@VU#.X$P>>Q1Z^4O?B$;M6 M/F8FJT;2 WH7Y)L XAS:G\;M.+4]07A!A/G?QUF>BLXZPP%9;9.]_NH/I8CKZS[4;>]=D,&*HJ8LOZP^(*@H[O&VC]$* M\,5 @K"R_4[O^1B 4.]N#P/\>,#^IYAU9YK3OY.07_7/6W25DBW=;U=Q*(IF MV1ZS'CE.LCS[2,PI,J)FKTP:TQ.#A&M5BJI:T8NRWJ]%7G8A4]:-1.5'B%4/ MA:!S] M/#4W6:-_JC9"K32NU RX+B]*CF:%G_B1:.#P&PH\?7#9'!G0))O+R M7@Z$]%NM.5UQA%I%?1\),6XYSTMM'^;PFQQNVGA>(E,<1^%/ 0VFB,^DDE$2 MOYU2K/6&.?ONC]@H6"P_9Z.AL.,WOL1D8Y5S%ZAQ/(KRWE[T.FRU^M6H8EI\ MQ('#RT)XO\NTZ0+MP5*-MGZP2]]L5>?Z>8E+@FGU UP*0#L>_XO#DD9#?U74 MVZA?MU4[X,,X_FG27C',4V5S_0PEAX!0CR)]-+BZZ"C9DOIA;*,'?A42[B\\ M4K1<S0%I]"R,?^G:K]77B( MUOCB$VCS/R/ZI:KWS/30M@J0;9&[@8[7[90>CGB%\7>5XV-[J M$,3MKV%W\"-R!U\3(T&LG ,N-0U)KP\AN/S88B MA9"/H4C5?MW:C[C2>LFAR#CYP[3U19.IWQ#+'#?2 <@-:*P&H!'@25J6\#T M%2D?3UV/<<%&RS-FMX_S@RN39I4J[=A;$P/:(Q;5G?4#UG1"U[GUXBS M 375'D&XL&G>[N 3T5)GKMLGQ8U.?H;0T8A7C[*3X.Z$\&43XDWYYJO),Y(: M&<=DU;6^-\Q59:M7AF&\+&FC0E7$>]PYB)HN)8P@XVF*5?U<-LUJKM63]3[I MZFMC-/NJ?[7H$]PFUW>-4:E838'R8(PQQ(:G9QI\N7F*J?76A7@&(!MFB4;& M]9-+FM;K7O4HGIS(_#]'/U:!XEF2;/#=B'T):@A-O1> M?S*A@J]=,+O=+^]#FSSU5+[;!6?T4B?,&JW]>]N7F])HSUMR%EMQ?M\Y'QY* MY<5]OG.N]MN==\Z]CYWVS08U9(YJ/I2!4@=S["CFM[L4;>>/ M5P8F3T8N\SG?>_WS])E)$D#U)3'Z-M]"_&-5/D 2MS=F>,'RFZCZZ-([F-8G MMA;MQX,^VS=]MA%]%E5]UJQ1^=\H79*5@VD',U/RV;DQ1^[K6;LMI^X*PK+\ M(EW&E\93:^_T6W).+IR2C^9-P#H\$S>@RIX_ MXX^+[B.1(B52$9,Z/,\?/%?8A)GFF4(XO)RS0TU3'BT%)QP/GL";] M*T"&A[IEV!&2-65(9AC]84]#?F/0K(IQU@3W[#"5L M#&U7S@>:CPQO29RS5D:\6)V;"F%LG:57SJNU]!#PAM(OO MUFSP,P(?%_81X<%MBN.,M8J;94SX/%R7[]'80%N3,;FLI@B94:LBX19*3IS4 MG(! ^'FZPF[OK/HUK_F!H=X[U4>C?W" MX&^$Z)?X33G+UJ6#5L%XH$)<4_] ME;B6OC)F!5,-T4?4Y9CH8[3MHKNJXP\UO';399 M-R(&<0IG!LI(#^M XHO5F1YX./%S4$CNR(_YFE:UH6(=@G2D0<0?78TL@H\# M46A1QY!>@XWW'W-(P686<"B1YI$[,TV]0<^ZC:>=LJ4RYA][;(,VN396L'JY M0>_[81)OCADUD,ET\59YU38-V;H%7=^>U&UG[P:?HL"RQ+!X'7.PP9\D<#\R M?2-S)DT,GBX=J(JHX$WXBI-'FA(PO=/GS*>/5M? M)%W.S:C1C>5C*G.?T6"OKVQ6*N!858/NGM +7A/BAT.:*]";VD#L8\ZB?(N' M[9<4#K3UOEDY'M:2O(0)F';U8.=!D-AJW07%=_SJ-C/^VE;D_GE/.ST-)TT- M@EO5@"#LC!H?9!DEM<914XUWTH[#L>1!U)$@GO=JLDXC#N\-/R/D"C_Q]*:A MC1.;FCQ=8V:NJ1*>E33?&^G M\$K[<6.]H7*E%IZ]R1C<#0_=>M!Y(M+!5=KJ8=RV N]D4NAE2*?.Q?3>ANS) M^G7N>@?+*QT,AYDUA$%O@U1S)>@8:DGEO3-+KI7Q.-6^ 1@@KXRU:]WB"I95 M&@":#%=:]'GBU"H(TCT)V[/?.!3W=LMFQE9TLZW:.Q.M^\*0I&6]!RM(_(;" MX@YXZ0H3) I/[I9"SZBC/2Y[!SD-AT5^X[V M)/QJ1S;7)^)VJO4)S43V_M#5[7-4"L/+F.EOY'/$9:!57=SQ5+6AR^4O@I_B MA,;U 5<7U^HR#(>5NC NXIT/^(8>RP?J)_JOB>@_S,J+#0'AUL%=DX#0![Z5 M<9:D+;UNDDAV=_&DVF"XM &-C7Q94P>_TKCMO1"O!N!:HJ76+0773,$6/%&F M4!" TS(!LZ&WWR!W6L\01XWJAHW"R M_OWOWG[WYL^[0O@EC5]^9N+%+ZG7JZ[G(X%AH.&# 1/CC8E,:(<=@34PW$Z/ MKM(D("3,^'U&;/ZW2S):Z#QM8=FH5AANS[ 'S):=R[J**]!:M8%?AQ[7";6^ MXBAMV-+W>:Q36X#?=-G:!_*GKF)/9,#!HK8A(OS,MU;A?^[+!O![V3EZJ @R MS^N[VV^3^2X46.9SCN=N"_59_X!A_1G^@$+](=1[?X'_^3E>7^"G(].Z(^-) M3R#SNG@- >_Y7;OG]U7/M])DX%REL"3ENQ/;I?D.[$H5C>>SJ03L%2J*32]+ MW^/O"CL(FL*\-45%X'&P=4)+WB[^O]-?]_0!1]S'7!/^LE20DY#_816'A[]H ME=0P=6*]CLD[M1=DMP$=%3AO%3Q"31VH*,*/@W1^V9;P>XG=[+VRNOD1K6[1 MZ<<3='F&KDZOSR]/?-\XN)22[T]_./_X\?SC#WI573JR6;C>]6VS$1V^NY-? M/GI>O=IV^AC<,R20:YR3T_6::.=PKAORG!SJF'Y>R@/KGNAIO]A7-0KQ5J&B M6?Y"-._=__'T%IV<'E^?KFY.T?E'Q+WBLW9_H[D_J[^<1'R?T[SZ'-<<-V=J M*X,Q[=/K:SDI:DY< EMZFD7Y[LV9,FV]+_>,A[7A7- 0TS-NVI6[C\5UNP=/ MF@]MS.DD?6R^:37IO[Q19 Q/"^&CJ,I-Y+'D8PU&0F+. /AT%#) GA,N79,RVRP;'$CZ M11VS1-+6_LF-JL@R X5=EK=U@^$,$"I<=#&M P6PI8I9EB@ +TW,LR0!;D?: MJ:8P5R.FKT*X?]%IO]M%X@I6'%4O 9W'ZR3=BIF:R>-.IC6X?N?)6+/>DT\M MR>;))]02!K$>.)."_(!OE&3[E-13Z#57ES95>5\0M$1I[[4K>X@Z.CE8W2Q. MPZ&C@9V2SL_^=5NJ/.C&BQSQ';IRKZX^A]$ZXG?D,,G*[+JQ(?6$&Q#W'Q4' M3XOROGFA %#_K)X2/6X&F>">A/OH\(85DZ%%+^=Z0!G0HN=ER_+/K3IFJ6?5U&JQ= MV@FB7,#Y/%'1;DV_-_>^L*(^YX#&31]HK]L9H XH_8G@$$H6&;^.D^T.QT_G M<;AGTX2G6U:U^?@E%?8[?LGUT4"\%. IS(4(XC)@QB]3?8H_ QN\-. :&+Q< M(&ODX&6-L*!"&*T0QMOL>_#Z@/-]2O.G$]/!ZU# V^#5:;>FWZN2Z 3(X#70 M],'V^AF\9$!1#UXJE"PR>-WL4H+#U5WR0!@=R:,B$+.2]CM\*332H+R00$($ M"1E/P=HTC4HU<*,&L+%,A[6!PSR[_!*3\!-K M3AH]T7ASA@.RVO+;D5?,)Z6?2?X3CO9F(YUI5=[&0&-=-684=1PA+HL*80A# MY&C-KG"J48II8L.Q#RRZ?#]@\S!^>("R A 88[ M>BT6;K#%;0,CF\U[_=_V,4%OOSM"')%^+X:8JL6[-VHM//HL"94'O)."QX[] MT"KX=4^+Z_",I[4]&6]>J-]ZM1,Z0JW28":XPQJ8M-H/\!784>-> QS'L.=+ M4*M'JG^:NU_8&]!;[=4,L[P4^H67\[Y+K>YJ-3QD_>P!%\<,FILD+>]'_D"V M=R0UQHE=*+V/RXSX. M4Q)>$6;?.,<;H@23?14^%MW,=),=DB@?XV5RJ!1$C23ZI9#UD'T^KWJ__]T? MOWG[S9_1VS=O7KWY!Q"K<19PE"[)^<"BU;K<>*,5#R>CA&'R?L^7"A@H=[7H MDG?>'R?;;1+SNWGRI^+_JPWL[&>'3L@IE!70R4KH1 (Z53#'?\-OYXS%-U#^)4$[_A6T9I]Q%.6U M)M02O86^8WWLI*K]IFN,Z0O=4D5[2LDM7M2(>$U(U%G^$]QL<]XNN>5W'1P< MS&N\Z+=0O.@,C!C(&_%/AY%))7/30N$("_?GVA->4'Q'(W$J^CP^?0Q(EEVN M+_-[DA93]QD\XBR?\.$9Y^F;+A1:M?)'X(IZ^4$047.U7O5L?.7RG425G53Y MT1?"CWX-PI'.2"BI0X7()BO'Z@0PI 9,(@!3+BAZ=;4&JQ2WK,)"[?])TL36 MT<[P :!+D8/],G:)4E1<.EA>-4 'NWCW&"QKOGM&RYIF'!J[W.F80',O@XY% MRM#R*,H%D0J?^G=.)!CA:Q.ZWY 'UIPG]HO% EG+CT$,:6W[:UQPVUX8*+\C M?O>L ]TYN\X@Y'W[3V^?3%%IS)@:/W5+_S'+K[. M20.^UP3"V:FWX1IU5_$<[F_.+\':\Q_14Y:;_FVOR1?JGXWG=--I^@P!0(YU M?K99I@AXI]I,.0)SH4>=)-#VT)QRRWCI@U,)K &O-LG#ZY#0XD "^T=S#H'] M\+<+LL'1:9S3_$EQ,$5:RI&[E+>P-QO@)5!11',.95DG-6M37;@1C?4K%S!@ M^@7@6'RH. :BP.)A$8= [+2M:]K*J)HS+,LC<'H;74%/9NDV[E1FGC%276U) M2KQH<^0 M"/B9@/;;W0]J61G$"O&7XZ%0WJKAXLW[GOEG:?$#2>^2Y=J,7DF;[6&2J<"W M8JZX-+@MIWRF_;YF(*<2J,P9<@1,7[[OS"9Y%$>; Q*.\ES!C6 MJN>RCZ]/;U C@RHA6*'%W(J!H+,I".6!A&L$VH40(PS&1?C5KY7!MK7!%@X; M5A%EW\0W 27,>)EQ]*"6\T)^M1:]KBZ*HJKL$:288JH>,*@] "DYI5WAR8[* M]O;(:GLL/8Q'T0W3@JPV5SC-+=8*E')^F*O4HM_#$1)ET6J#1&E8X_1D38"P M5P\K!7L=8BH0AO"/LI\!B!!X2]T+G M09UZ/5](H(X(J%%Y+J6 K +,JP\,KV7&);GS M'BW<5[>\'W_5:W6_/T416 [)M-5JC^.!HG* *#BY,#HL26B,DJ59MB./-R1] MH 'A,4W,(&,>^&MEO;!/KTVOCUEQ5)9'E0"H*< ,^@":"1A@34Y>ET"S(_(( M V6E@78MP"VZD9?2<$/8Z'UUC],M-M_/4\IYV=93:]';^!!%682#BK*01MH) M:@ :>H<@)=]"&P^#F[PIDH5.$[2G>&I/T!'0Z;5]$*R"[ M^P/EP.V:Y<5#DE(GZ(+FM[OV>K M4L#X/*+Q4&BKQ(R"JLL#QI*>MGV_, M/XWO,^I_?U+_%,5/C&.]HCB/C93R# M"GPPU$2O_E&00@;50JB4 K6SOX!J(,AM#$4IU=WCT(KXDXRVJXT65$9;.!G@ M ]ZGM$@Q8O. A+^1&YKY YVD#T>@U:3_BGE1&+5+0^']*$V.#E0!P?-A;$D) M[A!85LP>!S#:*KTHD5-ZDZSS+S@USZB7RW@AK[SUO5Z]/D=5.4@C]U_: M&]EN&',$'>+ECL4%W.U?$>*;>*^[#>_3;W.W!H@2D MR;EIFP%-RA70D')M:5Q8T"H_R^S ME<+"'ONGA" 1;X(*(%BH!Y&4C(X09,5)2S-43PTM3E&ZN;_)4T+R M]_LGDIJ35"GGA:9J+7K=RXJBHBP2A4%Q=8(>0);3)JL P^D,T$+N=EQQPL[Q M6!HD*PQR)[BQO/?9T/@NR>_Q]CS.]BE/\UEM2!P\&;NAH0H\^:-!O22=7\N@ M6@@54H :9Q5JY3GE/*FK>+P-+OUG8'V^:?8#S\_/" M2S%I='J#N#SZ=+."M$$PLZJOT._Q=O?GGK8OWD=[_> M?O?FS]O2;,5/"_N%LV0?A[@(C=B4:TO2]VS:%9JG'!A4X,,SF.C5M4HVNAN.23N&&Q!E)8AHT(4\+HP*:23$H;B+I?4$X3LL 2OU(+[0 M:N5'9K%F\Q@9WV\1[XTP:V9VIL'L7\WT])FI-',X]B5(4/ M;V*F6].SY(D%/*LL2P+^_:S>2ZH.9!C/4^SK\^%'1FC=M9JH ATC M5@E?+&UJ:6V&UN>\ ,UKYE/]%=>]7#W5JJ^<_#C=,/*E.) ['\<27>J)O;/< MRBW/R/9U\E2L%_%U9=S8OME'SUJ<7]1QTSC&041N4X)SWA7\HCOF!8QS_0PJ M\.*:#?3J6:>40;40*J4@I0'.JQF0Q, EE(+R"*XQQ>0^TCF_[)SB%,/EM>&" MDF<+IQ3>XGWP <=X0_A7C:-1I9@/SZ;6H=O/MZM/QZ@I"BE\'*T$G!7P 2Q) MR>P*2%84MK3%]@!02[+U.@M:R4#&$8E2S =;U3IT._?ZYO@@O0Q0R#%:"4 ) MO -@DM+5%9*LZ&IGC':&W,*#ZT\DRX+D PT#^Z/P>ED?Q!W0IMO717$DRH,\ M$#^'/G &7Q.L22GM%&A6O!YGH*TPD*OS\%<1SOBU]R-B:*VHEQ4"K2Z].4M9 M&F@\/5D9((NKLZ@!(^ PX(I\PN^0*'93_7'&<3A?^'5[%>TM7O&2"'B9(TC: MW8OE_OT#XH5 G?XQ;/A_5Y_U<3\-4&%$/@%8'"!VH;\A4'8<*$N?A_D)[\1; MU5OCB;E,PDMH+VMY+[ZJ"D&:B-NU'-#L6PT6>92^/%+L8G,[Q"P\T?Y(]FD2 M$ZN7X.0R?I*OI*WOI[/4Q2 QT+[U@%BH XXB5L0,V:(B'[RUT;-KCD86<>'F'7B8L^F%584QUW:A) RW9\U0J2_T M1T\K!SF360-NUEUEUNV 66?-).6YJRD-?DRVY)ID.YKRNIY&I) :5^0G=]1< MSWX:62F+N#!J21_F#$+QIRYT]>Y/72@)PY]:4U21_.F+GY99GW.8]9Z;-6V9 M-=.:=49_^G.21F%SJ5.=:VKL1PTJ\.$_3?3JVD/(M&\9:S)O 7G+>36#X1P7 MT F&+S2FE]0'NN>6E>\;;[76A7 ''%OV@B:&R'W[J*69@U/+^;F"2:E%_^5; M4;1U&1&<=;():I39VR_6GS$Z26G$OK-AOUHW>2@PSB$.X4UQ>Y(CL%E>EV1M MK3KE9.'EM?.'IS.2YC2BN?T<<$#8![^'].GV-RN/:@&01P'GT0A.;ID1XJ3D M=@LW*X:/,=*Z-I*KTV@?5\>E#SHNWWUFJOT;WNQQ:KC--5R!ESTO [UZ6QBK MXVK 0RTI5(A!(?^AW2[:2*N5@SX*6E;[3R&VZ 8; MCF[VZ8:D3]5RMG5^N5D=?K;5C+3K+]7C")5RS?;+X>ME0%S$5^V7@39J4)ZWVR>ZT)YTQU)0]1L *58L MM4?,HNF#^SPC.?]<@"-C]JFDO,Q@5!KT8B91$)4E0;W_/D4'&*34XT@>G+L! MD5TX;FF(;66(I6^.27&!^\-M.IV?R6"A P20N75$(#8/[]B+ZYI)OY&XPV,70E32$I=@G,\6CF% M*>:[$^;;"/-M*_,M&@[0*")/)S1C>*Q:E4;LXJ$A^ M'FU@Q/0&*)./_0XA9C?PCS%.>&"/\.DGB/'X@F;B6/) M1+/>JS9U"D@CA0HQ4'N,$Y5[<7Y[_+5"11">P!R6\O>6W&/2[L&E:>:CC>'N M2\-%T:)N@M]RFY)'IMKM/4GQCNS+$\FO?L8IFZSDF9FS,*_'A\NPT+)KG$84 MM67+W-Y*'(K[6%Q1$$[$%K125^(-L58.91Z#Y@<&%<\O?2G%76W&6?H3K:CO M[;GAON_L=H'S$_-H \(9&(!L<#:[30L_?P72F+.L) '8(#54%X"VOHRA]M](9;NV<;YS#JKFM4=VYF M'V])^$.:['?6>=)Z62_.1*]-K__W\0>^DL_+@[R'>PY]X*Q+F&!-[@I< LV. M_:,,M!$&GL@+4J@'Z/63. ME(9QFL*MNC"V>,8Q6>Y2_=+8SLG.9NJD96K)?66+'\1XS/A3W=:!EEK.RU$+ MM1:]3/5'\38YR-AJHAK>'>#$]L/P:$.,D!_O<$4'N_,<]O9P%@$JYZA3EY!@ MKAQ9KZ) RDF942U V2FF$+1<"H) _"D&ZRS\+'X_3D"WYK3OEO9R TZWQ=VN MI,?G'VY )959-!D&-^6HD%]:LRPD[&ZI,>SGA3EU$Z6K+;U-=D'RGM7SF:3F M:RDZ42]#JE:7GA>[N$:K#^=(E$>E *A,+VM]7LKU 4%3 Z#)1T^'*+,;.$=9 M)Q?6N6M99TEVK[8DI1]P^OF?B#K94KF<>BM&W1@^M94!*346Z&ZY@Q M)86":YS="2WWV5;\1GDAXH?(7?SO]=2]NX0OV*QU30D9B7W@YJ>=P02T[% M%TQ5C5&.9*:"GC'5TV,04R?)%M,8'*KD!AE"E=H:V\,E)*H)]IW5;%) @& MI9U2(;-H)('99S^)@[+4.&R0RGB)$>2M[SE87@S5Y:!0>ESK0;!6!QOY$.X" M,W;CM4WO[ZMR2W+QA#XP[- U)>$9C7$<4!S9!?0F-?C@J9%FW9YO":%:"EP$ MOX!J(!AN#D8IWST@T8K]D\VVKLWF(D:_2=;Y%YP:[CQV2_LYD=%I<3]%NR@ MA!VBON9T7;;W)\_5$]J N&3 M19-!,$H!"\7,8-I=@RX'7<'0'6R M!)W;^8E^>2^#VZGF. MFW1A\EWAX#/>D/",OPS FO:!8-,[]K2B7K(1?I)'D\1C[;6@\ )M42C.8#8-VYZA70,(!V&%4]6;7AY :ONT MUR13!@=@#5NBB\8)#*I)C*/JR5[#$$$AY24Z4&G0\]-EP>:Y:"!.8+P&(-BM MAY!\Y'>#'[M!W]H*U5/5;K:>;DEP'R=1LE&?;#.6]+O-)-%$M_?2%(="V!E4 M <'<87 -[!0MCJR1^T/F9A&[0GE=?$DJ7Q":[5/"#SKNN$XL0+ ;=0TJ\$%L M$[VZO5_*H%I(!#W0!N99-&M'YJ#&;6,\2IV >S!:^8(IIB.'IN/(=#'4MU(P MCY,X8[JFHU.D515XSI!6ZJ5+1ZV$P&TWSZX8"+=@#,.AY&A'&!R;&SW*9$%E M,A?;VA=T36X"2ICMLMLDB>R3SDQJ\!(RF&C6<\],"%522(B!3#>;2SFPJ6;F MN)1'#NY!:1[>+#TI!(?N(IH/@ ML 8N4M*ZP(H52T=T_*+/XN(=S7'$;UXCQD_@2F6\/''@ MN-:#H*$.-O)':%U@QN[!6;O>WQ;E%AT*]U3<=FBWNJ:2\C(@JC3H^;>R(+BE ML_$:@."E'D+R$=(-?NP&26LKN%CHJNX#J0Y$6D]K#2KP>3>/3B_EW2CUF6&( M4]IY- ,XE36&HO:6'GT%)TF MO92"5F%PY)^N"0BJ#T-+GJKB#E=VZ2JCK>*"Q\U6?'L'[F:_VT7&=W&9U>$W ME46KG2X3Y'#CNQ*%0ODY%3Q8QBYK .$0;# ZD ?C$* C,V+&V%'DQI #H&:E MZ,(IJ0%7<$,NU[=)CJ/S^(%D.6]#MLK/,$U_PM&># 8$IM5X2EHUU%&2?5A* MHLLU$K*H)8Q6.>+B2,C[CAS\:>DC"]8&M:JT6"^0MP8+#A-4&2+.1V8VE1.&X/J*O0(C^@OCA4[ ZHC^KZ'?WLYYVP6_SX'F,DR\^2]#P.DBUA):[V MZ2[)B.[E/\MZ()!7HZ4YQ>$J?,!%_NMJO:81?T.T/;D7CF85AI2[%AU[)];KF,U3 M>Z$_R6D 3F.Q@%I5B?($-94>\;6/9D&K'+=17;<_PL_=)0:*N:3V++CO4GTV MT(.E_C7A24(+<+]=\3,@_T$_S,W^IO+G17]MIYBH!MT!]-$_AP>00]^)"S@A M=WQ?L/L$[W4YC_@!T_B"M5##=>,:')/:7+/>J3\F*3A;R*)&^ A5XHC+HQ>\ MAJ_]<72\CJ9ZN"2D)1:[S!L!1)\4:R;KXTDFJP,&S:3:V1"MM8@#F6I&>A[? MLY\(CP3,M0) /#5"#:FGAZ>C$)=9EPW(XDHV?O]_'!93[J:5VCC60-IYL&JB MD733C4F5UR$6;7A88[$>35@#TM[S; M4'VU:Y:>V\O0'TENN]9K6"F$A5]3_E]T M5HA57=&N4M4/WE>+K9AAM'1L30LP&[?M]D[.V714PKH]5 M>FCC=DAE[[0V0/:8C5L5K&=-@:P^7EQ8_-1.Z[S\$C,LW-/=<"JD62U^4B(- M-52OVY;7:S^APW3D6MA[AN1T#8-2P]U!;FZBT]!#SJ0-5A6YDUZ :IE#N;@Y M_61S723QAJ%ZRQ<(;MEW5H]4-]^6%W<\N"O:W+OVB15[> M6)H^[7+ TO5Z=U :ZG(O,#E)MICJ(D25@&>HU.TV TM1'!Q<#GM_"##]KI\Q M5EEM24KYO3%B(00'.7T@%U%@=EIC0-A'9#*D3QU!-#%Q3&4HQJS M*00BW#""FS3*<(LUJ^!BO(EHRT11%"QY+FN5!3\F41@DYNR62'BAM*SEO3Z] M.49%J2-0[!W1=AA$5<)%SDXM5ASG6IUGV9ZD538((_! 4#PHZ2U;2J6)>I9R MA H9U!("$C0;&DB=[S-H'=\X&XRJ#63A8$T9:P^A#4C4;6PH"\2-B\5GQ%R= MXQ86;?O(^B*)<]8O$0F5X_K(>KQAT4Q+'2Z;&DJ('JCP&".#4]4-*"R2K M"6H)8R=DO4PW.*9_%_Z"/X201#0LABO^3@K)JFG%Y?J,QCCF;X;?L-^0XI:' MNRSG,P(-B6>JWS&YY^J5+@O:]1ZA@YK+=X^:NOEZ;5T[:JIG 5+Y >_\F!4\ M7=[,CASX?#JA61 E_.FA6_*8OV0^)K' MP=AQQSUK-Z/AU*P>9X!03IS/*@B2?Y M# OCU=MOMSA]X@/@@*:^:66'S"[%[&$YYY[&)B5E=D)L=2WY]]K><0J0&4-2%2!VG4 \/K3#2W?J/!J9;MMQ?FL MS>/RM+3V3E@[;]6Q[,.K50QWN3922#<6SE:SGZ=:)_1$_]W,>OYTN486O/8Z MJB[7'QVLJWL A#N;3@K%^[!@&&'Y<.PRS&"Q%U[4!TZ>%=2W%#2M-IE?ZL4< MSP &=.C:I[F+H[4(!"'@L+%)-PHV-8@W4)G,, ?D ,!*QWL5KD!,(\U4)>+CX0=INZ2T/[15U,+Y4W_6R2P[T_>X!+R:>4RGA M%3':**D+&1!NTJ[]L, ]Z!0-0.($WL?)=DOS*L0^3L2*'8GY>IV5E[2LQS$5 M;+7LW2C3R(N9PT$-,)WM*,-V43K:JG"P:^*Q;2N"B%Z=?S2'+PC'OZR^SX*8 M@^/'>,BZ.6%(6>M(>$'Q'8UH_E2>L[VX."[2\++B[BJ#@<6Z)M=G$JTU[1U6 M+&I =17U8?@7K):O45G/'ZIKV^",,2.MW#OB.-[$3L!\T(J/26X[O!C*.P:N MJ59=N';A*$3A#2)CU?L4T_P^B4*AXC'>T1Q'OGEF!< NNZS1Y_@,0\GV.N/K M1[JYC]C_C+*?[:KQ=H+!2,?AVU&.6NF3316 !H0Q5E6G\]N9% QL388$RWH M E?G0\V1"V*HF*JN3+7GP,3!H6,T2MTD4>[O,O+KGK7N],'PL(Q:Q'6BI+KM M_=S!JB@JR@+R]T,FZ.4'&O2_%^P8Y=RJ93RC1Y]ZVH,/"*<[20=HN!].C#7! MCMM\@%66D3S[0#"?"(27\36_XCBE\49.BZ4WU;*'SPASKL"H[3NC#M>L6^2CD6Z M,G]A!,PA4?I3G# GE#YPA)['NWW._LQZLKK,8$;&FW\)ID.PZ*EI_H)?.]Q\ M"HEOH<.//4>7,J'_6AXGOR]VMYFC2+RP)1^5[JE9^)J;!DXTA.- MH9\/1[6*ZS5_2F3:L (?DS@]4([+EVH$]S%E,54F"#+"?2WU?;].;;%>U>18 MEE\1*SX"<<6^:UTK:JJ%[,^<=5W+R_VZQW%.>6K\ W^R:)VDV_+T_%W"!@/A M!(O%ES]DAUZO[1&WC0&@.<-E63[@(I>G^(RGHVZ">Q+N(W*Y_A2O]W%(PM8N M_Z"3&U^5C_-/=KKV^%-*\^-.E3QJ9WU <#)SZMOXBWVE;M#(@SC&- *]TG-+ M/J%K=5!I)@@K;+KD,;PV-=C+82O\Y%KY_.K922==(-7(=BJ6/C2J(R M\2BJ$X^J1PWV,7,)VI&,9"5]FVVT)7R)$_9QG--H^ M-)V[C:D,XK;YD!$M]L[]>Z19-6]Y)MI[9^4(K>M.N']>N^Q&\Y9I\)XQ-ICK MCB[>UJ$08MYO^8@T9NXMW25QGYR;'QQUD#MK#^BN^0([.X_CKS?L5U9G"OVWI 8Q_"XF/_:9&L1[PEAS)ED.=C]',&'W/ M=$2[R5FL+ZZS#T_V?(OBBJ0T"6_N,6O]1_)%_$GWGHUI!:YS&$WUZDT3N6#Q MKD&("E%4R!ZA0IH_TOZE*"&=(;J9$T]4D!8*AH6".R&+,B&,8J8>5:KG-!'2 M"IV]K$AK:/I9MRK6]7,2EN?!;):I^K*^5Z4DVI@L0M5BNE-QGI:;[%2J5KF# M6B//2]S6P!MP);;F)XQ:77D8@U9/*YLQJTP6!#QD&:HG';&*]!3P M Y8D:;>O!QW^1R3^ZA'WPRW$+8="J@U0QNM4W2O)QZ#:VF MC*O3QXK)2.V[D*JJ044]J*H(L9I0NRJQ2-*NS'/2P=SZWQ7ZTTK_G.D?MO7G MTW0\H+_S19\I') N[( @@-7BC7<@+)D>U=^++;*[BE"ZE>0UY-@L*O+AS6ST M')XAHK,R#;,0;Z=C>O9:,^E931NK7+U23VAYF-;HE;HD?]"U\D/.3.O4W]3Y MI-,]CJXJ$#Y'JZN!UVG2O^'[G;&Z-FF9S\WW#"/9S/LXA/$T_[.DB9?W081\ MP(]TN]^^3](T^<)#,S./(Q7TYU_D>LB[GQ!4%D9-:1">PU*+;:G%G58+3SY! M@RR-!W !JQ%\GVR8&;>2LS1O+1*RGYH%0O;#WZ[Y^>G5(Y7QN/-W1W3MMJJ_ MF,PLD>4T8,ZO?:[T%U[>6]:'M"\KY"H[B5GCP'-R"U^'(J< M%4(^HF95^[N&;\KQ;,VB)-^T\!PNCVA^LD:D:'XN;[[S.%F+(6F,[ 9 5O'Q M5$LL.<4U>TS2Y-R234U@7X96'0.Q>3X6SG$B>^..?Q :P%&@N2P,\1E4E3KO MG]I_4?)]W!7Z_#2[^VY_N+OWF=NPYTL'YX7[6&[ M$=BLIY<,:"_3D*27ZZN4)BG-F:O,]VE\N:ZWGN(\I7=[X4@5H^6TZOR<6;35 MN7\HC-7 IZ]5':BHA/^JV4-NU>-YE)W#Y(KCA'[M;7E:,!^P,A\AGKK_S> M0BVS4')TM3Y(/;X/>E<*BYK0"(9#BFK:PWUZR76"#G4"*):LB(A**Y9V5%^D:L7(]I=Y#K-F/O&F+O:F 7W MEJ38[3U-0[%\1=)CG ?WGW9FM-((^J"23H]NCXNRJ"R,1>:0>+,H-VD=+$ MG5&LJ&%O'%P:)Q#&V>] ;4Z.VXV$M/UHM-_8*@][[W'$9J/WW<566ZPV&B5R M,"!EN/UX "J 6Y%*NQ@":]$-R@\XQAN1S'%&U GAPR(^!FAYV_O)IE4IQ(K! M&I(UO2\=C%UTO=4P;&V"-1EW#Z+Q?ON6QI0_"LU;;PQII9B?/7B5#OT]XG9) M>/ >L(9BB]Z-*2PWZT>:9&&X=Y9&1^S2@]F)']IUK9?RX>ZFV^Z8@]L5-]WY M=@CI4;O7@':HAWK(;K'=H6=PH8ZG[38MWC2;;&[ -F)K;;J5BG<2%]].FSU!;&RMWC;BYL@" M*C:"^M'>=9V/8)]EXM"S@.X'/]N9\R;) 2&%_4:H3U!\6-P#]NY",UGG4@CY M\%^J]GYQ3@9JM>2C$0(%>NMLA@#FGI M:\ :9E"'L/QE;Q)/<&<#2DBY1K=?$K/PU:@*$#20ZF9 B5H.,4%8D9>%_F+_[:U@;VVJ<+S7NI%E<_70![B'>>_!\K0Y O9SZ=NLN:O,=?J[BIU\Z2UC0?CTO,QB!Z\X]$YG$=? M_>C"SG[.?_0>?+A-6(!3K+%*7).9F.\7@0]U,'D,6$B42\N W@$V5B2H%,F% M(NERBCR0]"Z9796A_G=Y5L*$$H,/%BOX,.M\@(4Z&Q;=7.X(S^Z--Z>/.Q)G M)!-Q$_O9*LZPKL[/C,!6YWY\6-: ZBI050>J*H$5<,RI=%(K32JETTII@&'' M2(PKID%^ 6XY#_)A'R*Z:O9OWS^5.2V?=DE\07_=T]#H MT=WI]?N>.XWL%?U\ZJ#23I0<\4,7JK M9^Z>ZA/:>]XSD;YGO,[(IO!I<)8&@DRC9V[ H.-PU:EN4#%2_#AJN4E5B6]? MJ=-O<(&IEN3#'Y=%/X((]&90L(-%B#&=%4Q-UI <873*XM&,ID2.8S4QD5UM MDWV17VH56%G\BEVKJI* 3FH M.7N#0;U8M\)%;X2MWCCT8&)3!VMZPZL[&\>501_GF2BC'1\ B+CRDL?[-&7_ MGKS#IZ_'MP<+E>D[2U[6"\?6A?L=>-Q!']H-YIZ2VV'U8G MIG)5A?6N(Y3=Q1EZXKJ[+IH5_/S<"7J@8:KQT!SI>00=6D1/F L!#T#L83TT MZYD4C"SU7,,U^Z7$/1E)P7BJH=3 ^*&&(\0E_)W\&*=&[U0C2A5: 'AKH@TJ MPY:TDD1 'M MI8Q2CM\;7BK'(L1=K1Q6*>=U'V4 FX.[**Z .7H/97X;^LFQ+;=^5MDJ/H]Y M&?I SHAL&)U:H6^78JJW11YNLU6+5CSC#=55\4=$ 'F<&727Y'56V>*8)R\A M6NN^ENL.*&5W /66Z;NN(#]3*J\#\WN]I6),:LE 10!\EU;/<9=3 $PSF:"H MYKH"L)FW1O@==R$%O+2396WK9R7B#-/T)QSMR2K+B+C]YX+B.QJQ=I+L \'9 M/B7A97Q->.8,C3>LP,(:\JWI'1SH-HWX1\K\)(AW@9 D6]4#BED+OG^I__DA)RGKX_NF" M/#!#Z=_4-JW %_B']%(C&]7E"V"O?@+RV+:=S918-3:86R"6=!&7(?8;./@D MMV4]OF!IJ*4=.H&\VCW*E$J8VMK1+5K/X]T^SP1MWBHOB#:2\H5$J0:Z\;X0 M.$)"!+WU?@.TA4V4(-,;Q!NDOAD%J6\ 0>J;$9#Z!C2DOK&'E,0@WB#U;A2D MW@&"U+L1D'H'&E+O["$E,8CK^4)K8#Y+R:][$@>JI].MI/W-%#0:]1(VFZ*H M+@MO?C!D(\WDP,1 WF8&=8M&S0=ZT@!F 7V-#"$'..A76,DDU->8R-]TM%Z_ M,1]#M>( 8"?1R6RM#]QX:F HHSFFQDHS[F*_Q_'G$W*7WY"8)ND-_R8)+Q)L M^O#LL+R//6L#K;KHXB*(RZ!"")522(A!>3-VBF*O98J!V(HV!:%T!]HY JTV MGL<:+.1(S J#9:7!(BZVZ+-CR7:;Q*>_[FG^M(K#XA_G,8,GR<1NPL\X33'S M389/D-E6Y^4Y,FN=>Z]:B1I0(2DN*2C_6=89;\1>: MY\-FSX&Y\/^NW*((6V(#7PHOD"04S?T4)W<921]XVH%86&1_9A9A4L*_+9"5 M9O=9X!2U[,/9&"N^>X3:7R[6NM'AMY]Q'ML8>$XE]%AL^N#WR.9;9KI-^XI? M]D[L(0.R3B4GR,2X.8 U0,2Y4/6,>#&/M/QL[U3^85]2D+& MK,/&HSZ#Q2>/4/U1?]=<..K"ZF_\N!-M'DD5R] B;@7CI1:@G\G>W)SR8^J?X@J+[M1B[[-M5I0?7TD.K-XOF=H#H65(]5N.:(]KQ7,[U[ MQ6U7:^9;+O?YY;K(2'432,N__'QC:D5/.@NOZ^^C9"]N^BL3IG\3T;9AY\K[ MX/>_>_O=FS]+.^*9!MTZUBX8?P]1]AF%XC^PH 1".-ZTX[<8DK=ZV6]8SAOR M_T)LKNGP_Q^?*ZCO)49?C/>@XO0A_CN+U07&?Q,!^PV.7"UUEY]ZOB%YU5?. M8G#QP=]$P*WJNOK:.>Z\VW=Y9?\O+'8?D&_!0+O'O.?FI40U;KQ4^:GGZZ6J MOG+DI8HJ%W%2.Y+2)#R-0X>.2M5[QVRT+\(#]NM@27UO-4*PWD<1/N0A.?Q*4[Y,)B]=>/YM UXOAY0 MWZ_.)M1BW?8%;\C7J&H*7]JI&O.;<(IV?TI#1/B[^^O<] MCG/*UW8?V&_62;JU/N)E6)'?Z\&&]33<3BK=#3^1Q?]8K!W?DN ^IK_N"<@[ MPJTL/7##F(6909YOE)W.K.W8F-'%U=_JSP(_WVC9AW,1"^2YJ$4 M\019!.T MC6=LEN8MMK*?&J:R'_[V,Z&;^YR$JP>2X@U1WE6B*>N($[K6=H%\7 M7PUV=04LHWYVXK];'D X@%OVK8&;(M4BCOVFINVZ"_J*$V>\,)!+(8=LT'5' M)@;P!I[!6Q]U0@ 9'3'8QM"0"YY'+:%"8P\7>G8;Y MV85NQM7X2 8UUW'8V;5D42$,Y=8VCUHZSZ2T1*TT$=(79*WR&.@W9U(AES@PZB6QS&]9/QGM_ 7-@G4@EX'@6IFQWM^^;5>_5;I[_%_G,UZBT36!ILQ$NU_KIR(/JUB'#UE-/N0 MA"0R"TF@&RJ /> &EGL^X :6\P M+WMZIW&%VJ;I>E M>P'VYO3%$.@H75<*/R=47D5L.AN7.?_5?1S=T5;#1T-YQZ0RU:K+C)8<:@2/ M^C199&&!3?3NDN'#9%Z4Z2Q8J*T%5+;!(:ZOK97_PM%/5-U.' M &S"4A/T>F-H>4ZSY3@*3V+)4'4U !BJT=&8H=5AW%8EY1 +BZ$C=.T-J;C4 MM36*E@,K1(H.(=B$HB;P=4+1$W*7G\=9GHIE?+%F=[-+"0XOXY]P2OGD[QKG M1'=GE'D5CJEIH5L7JEP4-;)'Y67ZA3A_C;.J /$:_#'2JXHNB6B+TRX)QX#4 MVQCY*=YG)*R&[>-DNZ5B:>^,D"O"8!3GS'=8#IB&=0(8/4VU-QY*BPKKL.\( M-74B5BEJ:H4UM +K"-_CKA4K3 9A:TJX<0A)O+DEZ99[K,[E)NTAG-;SD52!>QQ'J7653U2/&L"/$\PL1K\LCT6=1 M&N5QO63Q]W-!6[ MX2<#(;61-("ANJ^1\5C4B*(3KR'T-+UZK#1N%%0$2WO^VVS*- M<'Q\CS/R'L>?S;+&E6(^(*[6H=NS_W;U091$HBCB96&EC ^80XIT5[:PPKJY M3?ZS+,D?.60VN6-E?5WOT"PF#E[LT"WJ_$1^KZW]4U^M-6 P-S?(N[A_V%[= MO\ZQ8'!/0[^P1SQH[F8X0 28BQA47:U#A:?+%\H3,'QM(N8K%V;SY@G?\+X-G_2;6ZQAM4WNA?V2H."M4BZ&ZQ@*K+VXNSZZ_ M;OU=U(MXQ268O9VD?YY]XI+@LW"FZPMF(\R,L?1%$H=)+-8P>11SN5X3UD0M M_RWE?437!EI)EKF9"*IE4"GDFZO+ZO7BXOS])6.D;]Z-PJ1T9N$44FXPG*,O]Y3?4"5F'>A.9-UE:+V/J\>@D_R>I.*O_-T^Q'Y")0AH#8+B M3L@E)^DWP>XJI0^LS<62;G'?P?LPN-D]7$2!X4%OLTJ\G/HVU*\W1AY?H5*P MVJ4H+[AX?W*,;JY^0A<7Q[#X:&5*^0%Q+W:T.RT^TIY9L$.[TI[E[@PM['D7 M!BC;/: H"OPL#LAV5 86"=0B +;_%(L&%X1%2RGZB+=0E@R&.MXH9=/'$H*L M(47W#BXH#(L"0%!'%^/=XQ)B4)8?3,UD="Y.8:,90X%3G.4_LPC&?*E>)N%C MD)>VO(L:7@CQ4@#7YM5=+QVG'?2[U:!LU/^$]_\7WO^CU^&-8]I[$NXCQJ%/ M,0^X2=AD\2D?/[2NP4\T:Z!9+Y0MA?@QJ$JLE>/I_?'!D;931+#.#6<9ODXQ M(!OS]I4!@T9N22[=TB@B3\?W9$L#'+W?/Y&4A=QFPX->U@=_!K3I=GQ1'%7E MD1#@\T H"TUSZ"-N;@3!?1.L25GO%&A6?!]GH* RT)T ')NH+DGQCSCX,8GX M:;/L.$EW29')9T9QO:P/B@]HTWL>?G6,JO*H)0"%X3.I X+?)D"3\MLIRJSX M/<(\]Y5Y@D9@27KSTZ0D_\ FD\RC,.?SRHS92C$?I%;KT.WAHB0JBXJQ[144 M+D_3 @2%!\ D9:\K)%D1U]H6V\H6"X_&YP'=9N8T[17W0<]^F[N=2(_//]R M(J-AFP%Q3X$,*>>6AH45UXR[>F%J'9,4[SB-+?@EE_&2;2]O?2_9OBX&:_ ; MV7P0S-,!1WY"P 5J[ X(V'?_PFSD8V^>TAB;DU$JXN=U25G;^R\3E*5@,7%4 MXT'P4 ,9Q8N6R^/%\O%*RZY?F(,W.Q+PRT^N[G&ZQ0'9YSS&M1@>#2KPLD]B MH%=OE;V401TA6.2=7S,0S#8&HGS7QSD*[39]IMALU[79PBYA%44W3"V2K397 M.,TSXR1 C: /%Z#3HW\O?(2*PFBU0:+X8'J?0\Y/5.6(ZP*"Y8/8DK+;';"L M6&UKE:RP"MZ@704P;TD0%YI+TT?5 BX9HJVA?4+$A?^;U2<8TSXS8CE+SI<= M8611#QD2DJ8.L4HJXH-"\K9W>U?&$<]#HF7# WW#G?-9@QDI>5T QHJIX_O? M3X[]X46? ]GULL)>+ZE59-1W[FH%DE6O[FK][:M>,ND/F\#/)@QFT*M%O&+D MH.V#M_H6IS" Y,D/&4&/&[D%9AS@K\E#$CW0XF9!B^=/U7(^AGJ-%EVTU$61 MN$03X/.G0R:1#J+.[&$UDHZRB[CG<_SSI]93R*))V>FO>\VK;1:R?J>+4FUT MD\12 !420//EU38:F \Z,-#(6:"=H=C<;UL:B@@)#]P8L;"BD@?$$=/%E"Y/ MX"ZCZ(UF0QAP2R?VEIN'.)-C\>:Q4C:KW.'XJ;QX!4<_TLU]Q"]<49[>&E&' MXVC=1KO^W1*5+"J%CU MCAIYWR/3:$MV(_Q19@0#4MT@,+(>@N19SP (8 M(B:9=@QRI7:=,3:Y2M)\G40TN=VG,;_N_YH/(4,1B4K*1QRBU* +M+H@JDHB M4=3S\O2(]N=5^U-5^YV'2WH<28,D1R"R"HTF&P-:."3:GZWNLCS%@>Z)1/,J MP(PO/=WLAI9"'/U25>#QUL8).I9:Y$G]>DM,\/D;]YR8E]"XE.]MWZKKQ7> 8GOH?J# MJ/FB[R-)KCJQ[#',>JRXA;#S7@U_KD94#2(,69*9\L-3SX&6=B>PG-,S*.E) MS<%6!%L("WK2FIZX_N*BQRZ[/72Y([P]\6893V];/0BG;MTG!OZ[KO/YNNG) MW=+T 6S'.XX39C[6,R&FN=,YB5%YSJ0'BF487Q>VL%TF6J9:@QE3B M>[*JT\]DNMKZ77FG\ M>Q=>^EJYF4?0CX3?JUHH5E^N"FY,.0G-P5FJ$2S^\ M*YV/;: RL3[?;#34VH28955E (+=!B /)+U+1I!TI/ZW28XC[_'&+%@>Y*PM MD)V_Z%V^4;S:)OLXYQ?.Y&RZQ(9^#5O-Q#V^W:W1:>C![NJ=[D(6M81AO-!M MH5JEBGB4.]$KXO1N:@OTZ5[9-H$>G"CTC/5#&:LG<79%TIM[G)(Q.REC:O<] M4H[JD4D!K7CHI*G^"+$/(/$%F%LTL_10H^,)SC&\?9GQQ!@5')NSPH^?^ '3 MF+?S,F[^5+72QB/HZ_'-_0$M35C.JZB(+9ZJJHJT: V(RY8:\_EK2G!$_TY" ML5B]C^L?-T+SB&L.CLTF\!WDK2EVX8SD8QBJK\TG#(.PR2HI<+/=X') MFHZF0'5S1)*RD9K>[<7P_0&'Y#8I4\POTPNZI3D)^?T7,?N%02 ]JC;7!RM' M:=P[<]FN!?%J>$)/=40B25%9%:KJ A$2+Z$[4[N5L>0]()X Z-Y)U&EH]C.< MMAM]FPBG4IIFS*!J4IOOH=5(8Y,!MET1AW6[JL4&V>\+K6.RP0Q/UL/L*.7Y MI V%E:1XV9W@-.;WUONF[P0\#PZ\=F#V0U\6!ZUX)NA/.-J3JEGLOS0)6;3 MYBP9.2'%?VUX;%6M;T+;]8$)LWET*:I$HLZ&RX+6K%Y458Q>5%5+)X.>@NEI M/5+$UJ5^;*Y[D& <% G&;':<[2.1D%"\7UROZ8#S"",H,N@:1O)CQA2UGPD_ M/43"71E.[GI,OT6TBRU^DA(&]T#7;Q7%=4[354L7M=5YZ>) MVOQN02W]U3E/SB3SV-+ M:MEJW=J[6RU9LI4K6XHDS^QN*N6"2*B%F$WV@*0LW53^>P 2_4X !R1( )K9 MJMVUQP0:SWD.W@[.R[_\V_,L>?.$:4ZR].^_[+_=^^4-3J,L)NGT[[^4Q<.O MXU_^[5__ZW_YE__VZZ^?<(HI*G#\YO[ESK!W,'KSO_;&?QN-_W9X_+_?_-_K+__OUU_Y&!*2_KA' M.7[#QISF?_]E[5>>[VGR-J/3=P=[>Z-WBP]_J;_\VW-.-K[^.5I\N__NW[]< MWD:/>(9^)0+(LA7OIJG=_O'Q\;OJ7]FG.?E;7K6_S")45%+4CNN-] O^MU\7 MG_W*_].O^P>_CO;?/N?Q+UP&-$OP#7YX4_W\WXJ7.?[[+SF9S1,^[.J_/5+\ M\/=?HA][#-W1X>AP_WTETKT/HSW>RW\_S1C=UVC*&O#.OMU<;(PXC^;SB-PG M%57\@W=K#=[9&@)7"1)S9;HMV/_E:I-?/4SR'!?Y)(TO";HG"2D(SN&C-.G3 M 9!K1-D_/N*"1"CI ]76#_0)\>KA:L[7 CZG.T'9[*C?(9\^HG2*\XOT6TJ* MQRR)V2)TBN:DZ$B'IN>>0:'\\3S)?G:E8:V?/@;,5LBX3/#5PT7ZA/.BTN)6 M(V[N:*@A[UL;\_YP@^;K0J=U1]^I)2A7=(I2\L]J.8".=+.-I8'?:X.9Z3E)W<"4H^D^ECPOX7OKLT-K6VC-SG^(^2\7'V M9++C[;:S/;_NT'T"UZN=9OVKO-D 1WUIOYF(Y6W[V\J&)(M[Z"';7X2QX3_ M?Y1&/%)80-S]=VPOE$L.ZAOW%XSR MDN)X4BR_N$HG-S@J*66GX(_U#M4!8V]Y[.R$N)7M) MV,#PTF;[(F8T;_%YHX498)N_V-\I=#FFE15)C*;A8\-EQ=*O>0)^PY _K"0: M?[H2RYSBG/U3-6,NF10VY(.?"\R7C(6$^%C KTK5TUX6;728\,>TC&Y*G/>7 MLPZK)[,<1V^GV=.[&)-W7/K\#Q4-%07L+]^K7YC= M;[[O?SCX,'Z_,,WV,:;%&^D=ZU$RI/5/OA_L'QX=C@_VQP<--$SHY@ 1C19] MLC_N<+#YTBB^>#>O&/\U>B3)DKX'FLVT,A*_G %&7N9L)-F\7GE_>9-1MO#\ M_1?6!T/S@"D[Y5[6,I".MAIJ):@!R&'G,%I@FKSPW;_4B M#V=N[7N!_"@X[AHQ-+-W[!M[IR6E&TJH/HO(/J]Q'X6P6NHA2"[4>[YQ)];] M&D]]12'IE+L=2B>?JHD00 @W-!@,"8_>649J-.(TH^J3RL:7 FX( M.YYR]!*RO#.'U"!N9RA)3LJ@E9'EG *E!G,TPG;+U MX1/-?A:/PCRO)*VQA8 _#H8\#0H)B=[92H0F/N(D@7"W_F$-=KP7#&7-@Y

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end

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
5D0XM/A21KK*DL,1>D4L?88&NA"<>D%$VEC=9Z!3YY M57=,E"& H-,^Z!;_"\UI>4\E#CS[U<=,X:,H=6(OM@1'Z"5Z 2.7@;]]F.'!"+\&AD\8I MNN30N$0G)7"\4=2>:"+S1H.-4R9 ;4EJ"J^YZBG=.&I/H 3G;YZ[&]])P"/V M1&PV7V3]]]ARC.($S2Q>L8/SG= /VQ-=03_#D!UF,DR;#94]C1NZ!CA-T,US M!OV9'MCE.5$T:D]T#?!$2Y8#34GQ#02%2:(%I&T&Y4&-&1A\ZK)RHA MM7:P5C*0! F_T&<38X)5648KG\WFKT(>?0FKZ_-$(C,/V1"8;P)J*]&B^Y[I@00^5Y[HLMLL:\_5*:L M+8SKM2>Z@$(J2'=9P5R%U)U*J((.+8T3\X>F1$$ +IJM#]+8-0AIA.ZX9J4Q M>TH>P7V70A2JRU4#D$0NCI(1^B'U2MA,P3,"/?&:2%U1":2D@M%M2K:5F/@I MF @; E/5G?)[A'S78W0Z2FA=M, W3+.Z0;/8+,TI?&BKVPIX\2% MK@%^P+-C?"$V72AWGMUS]\L6LD6(# *K*I)SBF]A5;4S!<^H\:XZ$!?Y+IH_ M;? %E9IQI@_[TI8NA%X^)9N%"=,5)5RO]@A?(!K*[Y/9R_"8_F0\TQ.!CI.: M/F]!^H <.#B$]. 0-FTMGSQ8N@,B+_'1K1VM^TO-$>ZFXA%N1^)K&\=P;W.$ M+'RP^[&":0D3NETB^Z_]"CYI-\\=>;N_@V<>6*4PITM@=8^3:(!ENQ.W+UK4 M=@^]%QK2TSZNX&<$E88 [I="Z.V+$=#_,!G_!U!+ P04 " !4@0A7I)9? MP\P" !W!@ &0 'AL+W=O=77 6)@121CS;]HHT$'=,V%0E1V!ZF/3C);6/AV,%V*/S[V4D:BM3V:2^) MKWW/N>?$]LUT(^2SRA$UO!6,JYF3:UU./$^E.19$78H2N5E9"5D0;4*Y]E0I MD60UJ&!>Z/L#KR"4._&TGKN7\514FE&.]Q)4511$OM\@$YN9$SC;B0>ZSK6= M\.)I2=:X1/U4WDL3>1U+1@ODB@H.$E+;! MCVSF^%80,DRU92#F]8IS9,P2&1DO+:?3E;3 W?&6_5OMW7A)B,*Y8+]IIO.9 M,W(@PQ6IF'X0F^_8^HDL7RJ8JI^P:7*CL0-II;0H6K!14%#>O,E;^QUV "/_ M "!L 6&MNRE4J_Q*-(FG4FQ VFS#9@>UU1IMQ%%N-V6II5FE!J?C)TYU+EB& M4GV!.2FI)@S.'TG"4%U,/6U*V$0O;>EN&KKP -T [@37N8);GF'V&>\9:9V^ M<*OO)CQ*^+/BE]#S70C]L'>$K]?Y[=5\O0-\"UI0C1DL*$DHH_H=YJ(H"7^' M\\5B?@%W6"3UM[A]J>SJG^M$:6G.SM]]'Z.IU=]?R]ZGB2I)BC/'7!B%\A6= M^.PT&/A71YST.R?]8^SQLKE&(%; 6E.L,Y6VIBJSO=#N+Z3-]NXSDH#(976V[8H$0@"E:"F?NN)B>/N42$HCD5N\&)95% -"2X MIIQ3OK9>2I149!!&;C#VW3#J03!T@][0#8=1"Z%*5<9M73J\@L =19$;CD:? MEPG/P'0AIR9*^;=5^#(]K_4 ?U#HPI8;N8.S_ M7[7[CI&WTPP*E.NZY9G-%Q7735_H9KNN>MTTDX_TIB7?$6G<*F"X,E#_YN;/@-(FF/65$'H;V +=OR;^!U!+ P04 " !4 M@0A715&WV/P$ !G"P &0 'AL+W=O#S?.U?/1R.8;47$;ZEHH M_++2IN(.7\UZ9&LC>.&=JG+$HB@;55RJX>+,K]V8Q9EN7"F5N#%@FZKBYO%2 ME'I[/HR'NX5;N=XX6A@MSFJ^%G?"?:EO#+Z->I1"5D)9J148L3H?7L3SRS'9 M>X.O4FSMWC,0DZ76W^GENC@?1A20*$7N"('C[5Y(JE[R$#QA_21PLG'SFRU+8T[.1PRW(<)1W<)TO--/%[R MZU MNA?6854YN-)5S=5C +75W$6O3U"8=Q3&!]#7]RU_0-Z!?*)3;YCL^K9;'HVAR@+XP MN!$&[C;<"* RG\,)/QU\PIG%K<7K/2\; 37:-$JZ )9B+96BR#%67):Z@%\@ MCL(D:>]LZKWW]),*%100A5F$E_',?\2\E@Z5P\K T4%!KHRN .>L MX32I+%!\>$G9X)W$(I3+IEUW>A]O/GA/?L7.A'H6!#?$VX+?C;W=W8^(A0(_ MERF+V_LT&GS6%.NM<(U!RLO3D_P46#B)X36D893!Z\'+%'_&9MDD8"RCIR@- M8A2,O"W@[\(Z%!E#?^[$T&X6!2Q-()X&LQD+TBP9W))47A%^C[JM!:@=04O. M!X*ZZG1'!O,7LI^&4X;$QF$V0V)_M!G!!(D'_ E:82$.,S)@(8O0X%HY@5ET MOCPTEKX!S'PA':QX+DOI'I\\42QT@21D*%VG:O\Q:V'3<$P?+SI&A5BZ?65( MM6D:9''BGZ(@G46#&VT<-JK40!G2Z J^C"!F(25I$HX1$ML%^9=Y4W*']=M8 M@J->W:G7/$\#5 (%+$+XYG]LU ,OFO[?QHXMX$B1C%K#) M+* 6J87_;Y>/X0"K;Y\$MW[3?,/5VO?:IXNO?5E#T9@=QZZ0ZK*Q3]WB&ZH0 M>8DSI=CKAD+>2PI]^>A]GR;)/GH(;0)-VQ:%QAPJ[A YQVLEAJ/ M3[3Q]K]+X6?9*:?'T#OLGZ&X;V2^P\&*"@_]/4=[AY]*F+4_XEG\'Z(H[3FH M7^U/D1?MX>G)O#V"?N0<T96:%K%$[2(9CV6->^.%W[H]12.SR8^<<-GH2% M(0/\OM+:[5YH@_YLO?@74$L#!!0 ( %2!"%=8F,,B;@0 (T7 9 M>&PO=V]R:W-H965T\4>Q!9#H*4VHF#E;*;-+UQ71%E(L>BP#JNZL&4^Q5)=\XXJ, XX+HS1Q M \\;N2DFU)E/B[$[/I^R7":$PAU'(D]3S+]=0\+V,\=W#@.?R68K]8 [GV9X M _<@'[([KJ[<6B4F*5!!&$4G)PC'!;/" A8L^8O$A%+1/&+]M6SGH.B7$B65L;*@Y30\HB?*A G!O[@ MC$%0&02O->A7!OWG!L,S!H/*8%"0*4,I.(18XOF4LSWB^FFEID\*F(6U"I]0 MG?=[R=5=HNSD_)9O,"7_X"()OZ"K.";Z%"?HAI:S2M]X&X+$)'FGGGBX#]'; M-^_0&^0BL<4!&>\&:$E MHW(KT <:0]RT=U5D=7C!(;SKP"BXQ+R'_. ]"CS_HL6?A=G\-I(]Y T+\TE; M.&;SWW+:0WU/FP=]0S3].EG]0J__FF0M&!4L(7%Y=45C=*>2 526 [=K])%0 M3".BFC&W5'?&T)[KIT9M#NC"Y(ER+#$@ZL2R)-8"- M:F"C[P6VPTD._\-K]&)*%+R>T3*ZT)66);$&K7%-:VRFI><0RCB)H(W&^ 4- M_SD*HWY7%);$&B@F-8I)UXJTSO4']%".J@)5? #:8!GENY8FFV+AY.6D'OG# MDUG= '91 [OH"BRGW9 97] 5F4VQ\.)%W1P-SA+SO>,ZT3,R6Q)*TCQ%7Y:0 MKH!_1?^B(T91#[>Q,BMWA655+;2EUJ1ZLOKV?Z057>6-K4S85 MMJ34S$1PS M$;RB)@#HYJJ8Z"O&E8CZ"+?^_\UJG4G:5 LKM6'CX]=8.349'=L/W[BPGG_ MG&H@: 6J-P35[$E0_D@D\9-JMI5O:FZ6[;R:O#AE7%9SNQ6AU?["JEI8J356 MG\/S!(^]@V]N'I;5Y/J>*FJU@;"J%MI2:U(]=AK^\(>JHC9;CH55M="66C,3 MQQ;&-_4UEN9=:C]5[S5;'#ZAX?+S>JEYAO"!4H@;4R]7ICE3]> M[OV6%Y)EQ6[HBDG)TN)T"S@&KA]0]]>,R<.%?D&] S__#U!+ P04 " !4 M@0A7 V&F"34" ##! &0 'AL+W=OR6<6Q8 RTU$]6!M">5TBU%:^HZ M-IT&6GI0*^(T2>9Q2[F,BLSO;721J1X%E[#1Q/1M2_6?-0AUR*.;Z+3QQ.L& MW49<9!VM80OXK=MH:\4C2\E;D(8K2314>;2Z6:YGSM\[?.=P,&=KXC+9*?7L MC(Y[*B!.R5^\!*; M/+J-2 D5[04^J<,7&/+YX/B8$L9_R2'X+A818;U!U0Y@JZ#E,OSI<:C#&<#R M7 :D R#UND,@K_*>(BTRK0Y$.V_+YA8^58^VXKATE[)%;4^YQ6&Q#9=!5$6V MO):\XHQ*)"O&5"^1RYILE.",@R'OR:HLN:LE%>1!AH9PE7US#TBY>)O%:!4Y MWI@-T=OI"]#EY5!(;0S[)$LK_\;'-9$PG/:6S3J\2?NWEA$R3=R1-TND5 MONE8GJGGF[[ =ZD./U<[@]JVTZ]+"0>^V64^-V)+TU$&>61GR(#>0U2\?G4S M3SY>43L;U?SX MK+%:T+4?'T-\34*/C;OCA*Y"8_YS#^/]2'7-I2$"*@M-)@O;WSJ,3#!0=;Y- M=PIMT_ME8U\9T,[!GE=*X&PO=V]R:W-H965T3O7'[$6J+Q2CQ-1@\ !..E/[XU?"Q$) 9),Y M[9ON&*/G!1U9$H<7N+%#M\5O,GXK&WT2>REV6_2X_O(\N1I8\(I[P>2D13/SWR*]XDDB2 M.(X_:NAH&U,6;/[]0J?5R8N3N6,%O\J2_\91N;@834ZGVM$9FOBS);UH7%$2SC=/,_^UY71*. [;Y2P*D+..T"WBL% MW+J VR[@OU+ JPMX^T;PZP+^OA$F=8')OA%.Z@(GE5B;VJVDN68EFYWGV1/) MY=Z")O^H]*U*"T7B5#;%SV4NOHU%N7)V^9!S+II661"61N033UC)(W+#\O*9 M?,E96K"JS13D'^0RBF+Y-TO(^W3S*Y"MZ>=K7K(X^47L\?7S-?GYIU_(3R1. MR9=%MBX$M#@?E^)(9;SQO#ZJZ\U1.:\&\F-1 M0]MJQIW_F8B_][G1X3UY+%';>G>+!_<:>O-OY: M]/#-T;6Z=+=-SJUX[NXF=VEN/UQY&=^%FQ8G-^ M,1*]=,'S1SZ:_?UO]L3Z9Y^"2%B A%$D+ 3!-.6]K?*>B3Y[GS[RHI32DWFV M7+'T^8B462GZDYR7ZSSM.=YW9N*M_>WHUNEM',:"0QL'$A8@870#.ZU@?$/A\_-F7OW#X7:HHY"\GNA8CQ\FZ=%]6/ M6VZ(XJ+,X[OUYM=\]TQ8]!B+,R+KE1@WDOB/=1Q58TB??L;(0_7;P*:-TV]5 M4( ,1W>&"T'A--4F6]4F1M4^L%0H5HETSSGAW\6\MN!]&A@Y0S78P";-2K%. MIBT9NCM-IZ?Z/K2[CV.[DU8%]T0[F5C]S?UD6W$GQHJ[C,0,3+9I)N?/LO(* M4^T984-K;P/SM=KS6Y77W>?4;=5==Q?'MEI5UQ-J:O?7W'1;<],=/;_L)^I* M,]69$3.TSJ;=-N!/G5:E33MG>])N3+0'9/E>J]JZ(!'ME0[V=%MOIP-'3/G_ M,B[EC&G.5K$8//NJ\;1SP*XSL:R6TM?&X$.'-22,(F$A"*8I:%OJ"LLR:DCC MO"B/R-8Z8/_4E :0&41J&T M$$7356]<5]L'NLJI Z$: )(60&D42@M1-+T!.*H!.,:?_4J;&\_7XOO%5 MGLTYCPIQW4/6VQZASR*Y,O,'ZXZD!5 :K6FF^3(JH"ZFLBQLXW7Q[#.?9VET M?$0NZRN8*U;.%^3KRMQU0PT**"V TBB4%J)HNMC*I;"]0W7=4!,"2@N@- JE MA2B:W@"4JV$/L34V#A5;9FO1?V\M#=$@]"Z\\L]K@Z._/XVW^[2?X0'8BL3Q#:[(+K(5_7X?-,8GR]-8D*M$2@M@-)H3=/%G+:U!(74 MM52^C&TV9KXLXCPB'W-Y<27$O,GC+(]%9UU?7DE]-]?*Y"I+&Y:DN=,?I'6&>.LLXT5 M$>J&U33;UG-:+*=]5QP:ENX;-D2%U052'I9C]K N'T1?^R"Z5Y*MN$Q82!]> M[KL7))<=K]RR>T9L#C-8-+][)]WQK;9B4#=JKY@A*J8NEW*C'+,;99P-?7G* MS+,AJ!D%I050&H720A1-UURY5L[)H69#4*\*2@N@- JEA2B:W@"45^7LRHIZ MXVP(ZDQ!:0&41IUN4E7_;.A'>$Z.\IP@9;J*WD=#// MNC%#5$S]^0-E*[E[9&2]W!SX^):; ^8 @Q\]@'I)4!J%TD(431=>>4[NH9*R M7*@!!:4%4!J%TD(436\ RH!RS4E9'4-YE16;.?: Q"QSC,':0[TG*(VZNQ.S M4 %U01O/DNV3F/7FY%HS?;"4V&?(L ^189\B^Q'NDZO<)_=0&5HNU)."T@(H MC4)I(8JF-P#E;KE#,K3>VH]#K2TH+8#2J+O[@3140%U0Y7^Y9O]KD\$S*+O6 M3!PL']3U@M(HE!:B:+K2RO5R#^5ZN5#7"TH+H#0*I84HFMX E.OEFEVO_?IN M4R:M.A@C:&96% :=?LRL3K9 M.JB8^L(-RC+S=EAFV3HO%W6*[<=NBNV;7#1SS*$:0VD!E$:AM!!%T]N"!@@:%V&91&H;001=,;@K++//]0(S;4,X/2 BB-0FDABJ8W &6O>69[ M[0TKKUV9D8.EAOIK4!KU^AYQM-HK2J%BZA(JW\S;M?B4&(JSW-P]0QTQ*"V MTBB4%J)HNK3*$?,.]V4+;?T4^,VBPP-T, ML9XU^7KVZB[*Y_4D?G57Y>L+^.JR?+YRIWRS.S5P83XS;6@EUC3STGP].W76 MYNO9I[LX7U^TUU;G\Y6EXYL?QMM[?3XS9W#5V=V3Z:[05^_5;%K=)?KZ4-TU M^GI0KR_2YRM#Q#<;(I_:*Y]F^0-+XS]9O5RV-+NS>W&9U4P,[:U>J#E2TYIU MXK=39P-H2+I/R! 54E=+61Z^V?+HJK67-%!OHZ8UZ\FUVATO-"3=)V2("JE+ MHQP+W^Q8[/HA&06">A,U35N)UFOK W4<]H@8HB+J\C26>S:GW33F*93SIJ^T MS]6)&3Y8(*AW *51*"U$T731E7?@3PYT=>)#'04H+8#2*)06HFAZ U#.@V]V M'EX47U6*ETIQ(N;;_;-$J \!I050&JUIK87U.S<"4$%U!97!X ])N5FQYZH+ M+S.R2D30ZH/XKO^I;3-ZL)902P%*HWXWV::S;/^/\ E\Y1/X.YXS:USGBI_? M6\9@J'\ I050&H720A1-?V&#,C@FUH'&X G4^X#2 BB-0FDABJ8W &703,P& MS? QV P<+#0TMP9*HS6M-09;G6M;5%1=0FD2Z5N4$3$Q&Q&W]K-2Q*M*X="[B&VQ9EH"LFZ:+UB)^+SA,E; M^2_%CL0.CW$DMMP]5V7O^$.$'2K)0)'\DZXH21@B5B M6Y*QZ/C6^?:K^(ZEZ9HE\9^"?2\&G_Y:VV_ML\"NV<[M<_"ONV7$^>,3OI( M0BWQ3?5JP+$ZI,TK&3^P7-2;/+M[<7C6\8FX),LW;SG>"LXCG<@?Q_7V6E2\?9(#MNR9G_P=02P,$% @ 5($(5TJ]P?\E!0 MW28 !D !X;"]W;W)K&ULS5IM;^(X$/XK5FYU MVI5Z36+SV@.DOMSJ>FKOJG*[^V&U'PR88C6)6=O KG0__IR0QC$$EU C\042 MF'DR\\Q,\LA.;\7XLY@1(L&/.$I$WYM).;_P?3&>D1B+(->MEO#WS08PL9T80\<" 6<8SYSRL2L57?"[V7 M'Q[ITTRF/_B#WAP_D2&1G^8/7)WY!)%)!_9ZD^2)]1,\<8L$MDG6.6V@0?&"R%9 MG#NK"&*:K+_QCYR(DD/8V.$